0000943819-23-000029.txt : 20231027 0000943819-23-000029.hdr.sgml : 20231027 20231026193803 ACCESSION NUMBER: 0000943819-23-000029 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231027 DATE AS OF CHANGE: 20231026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RESMED INC CENTRAL INDEX KEY: 0000943819 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 980152841 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-15317 FILM NUMBER: 231351636 BUSINESS ADDRESS: STREET 1: 9001 SPECTRUM CENTER BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92123 BUSINESS PHONE: 8587462400 MAIL ADDRESS: STREET 1: 9001 SPECTRUM CENTER BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92123 10-Q 1 rmd-20230930.htm 10-Q rmd-20230930
false2024Q106-300000943819http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent00009438192023-07-012023-09-3000009438192023-10-23xbrli:shares00009438192023-09-30iso4217:USD00009438192023-06-30iso4217:USDxbrli:shares0000943819rmd:SleepAndRespiratoryMember2023-07-012023-09-300000943819rmd:SleepAndRespiratoryMember2022-07-012022-09-300000943819rmd:SoftwareAsServiceMember2023-07-012023-09-300000943819rmd:SoftwareAsServiceMember2022-07-012022-09-3000009438192022-07-012022-09-300000943819us-gaap:CommonStockMember2023-06-300000943819us-gaap:AdditionalPaidInCapitalMember2023-06-300000943819us-gaap:TreasuryStockCommonMember2023-06-300000943819us-gaap:RetainedEarningsMember2023-06-300000943819us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000943819us-gaap:CommonStockMember2023-07-012023-09-300000943819us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000943819us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000943819us-gaap:RetainedEarningsMember2023-07-012023-09-300000943819us-gaap:CommonStockMember2023-09-300000943819us-gaap:AdditionalPaidInCapitalMember2023-09-300000943819us-gaap:TreasuryStockCommonMember2023-09-300000943819us-gaap:RetainedEarningsMember2023-09-300000943819us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000943819us-gaap:CommonStockMember2022-06-300000943819us-gaap:AdditionalPaidInCapitalMember2022-06-300000943819us-gaap:TreasuryStockCommonMember2022-06-300000943819us-gaap:RetainedEarningsMember2022-06-300000943819us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000009438192022-06-300000943819us-gaap:CommonStockMember2022-07-012022-09-300000943819us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000943819us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000943819us-gaap:RetainedEarningsMember2022-07-012022-09-300000943819us-gaap:CommonStockMember2022-09-300000943819us-gaap:AdditionalPaidInCapitalMember2022-09-300000943819us-gaap:TreasuryStockCommonMember2022-09-300000943819us-gaap:RetainedEarningsMember2022-09-300000943819us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-3000009438192022-09-30rmd:segment0000943819rmd:DevicesMemberrmd:UsCanadaAndLatinAmericaMember2023-07-012023-09-300000943819rmd:DevicesMemberrmd:UsCanadaAndLatinAmericaMember2022-07-012022-09-300000943819rmd:MasksAndOtherMemberrmd:UsCanadaAndLatinAmericaMember2023-07-012023-09-300000943819rmd:MasksAndOtherMemberrmd:UsCanadaAndLatinAmericaMember2022-07-012022-09-300000943819rmd:UsCanadaAndLatinAmericaMember2023-07-012023-09-300000943819rmd:UsCanadaAndLatinAmericaMember2022-07-012022-09-300000943819rmd:CombinedEuropeAsiaAndOtherMarketsMemberrmd:DevicesMember2023-07-012023-09-300000943819rmd:CombinedEuropeAsiaAndOtherMarketsMemberrmd:DevicesMember2022-07-012022-09-300000943819rmd:CombinedEuropeAsiaAndOtherMarketsMemberrmd:MasksAndOtherMember2023-07-012023-09-300000943819rmd:CombinedEuropeAsiaAndOtherMarketsMemberrmd:MasksAndOtherMember2022-07-012022-09-300000943819rmd:CombinedEuropeAsiaAndOtherMarketsMember2023-07-012023-09-300000943819rmd:CombinedEuropeAsiaAndOtherMarketsMember2022-07-012022-09-300000943819rmd:GlobalMemberrmd:DevicesMember2023-07-012023-09-300000943819rmd:GlobalMemberrmd:DevicesMember2022-07-012022-09-300000943819rmd:GlobalMemberrmd:MasksAndOtherMember2023-07-012023-09-300000943819rmd:GlobalMemberrmd:MasksAndOtherMember2022-07-012022-09-300000943819rmd:GlobalMemberrmd:SleepAndRespiratoryMember2023-07-012023-09-300000943819rmd:GlobalMemberrmd:SleepAndRespiratoryMember2022-07-012022-09-300000943819rmd:GlobalMemberrmd:SoftwareAsServiceMember2023-07-012023-09-300000943819rmd:GlobalMemberrmd:SoftwareAsServiceMember2022-07-012022-09-300000943819rmd:GlobalMember2023-07-012023-09-300000943819rmd:GlobalMember2022-07-012022-09-300000943819srt:MinimumMember2023-07-012023-09-300000943819srt:MaximumMember2023-07-012023-09-300000943819rmd:AccountsReceivableNetMember2023-09-300000943819rmd:AccountsReceivableNetMember2023-06-300000943819us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-09-300000943819us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-06-300000943819rmd:PrepaidTaxesAndOtherNonCurrentAssetsMember2023-09-300000943819rmd:PrepaidTaxesAndOtherNonCurrentAssetsMember2023-06-300000943819rmd:DeferredRevenueCurrentLiabilitiesMember2023-09-300000943819rmd:DeferredRevenueCurrentLiabilitiesMember2023-06-300000943819rmd:DeferredRevenueNonCurrentLiabilitiesMember2023-09-300000943819rmd:DeferredRevenueNonCurrentLiabilitiesMember2023-06-300000943819rmd:SleepAndRespiratoryMember2023-07-012023-09-300000943819rmd:SleepAndRespiratoryMember2022-07-012022-09-300000943819rmd:SoftwareAsServiceMember2023-07-012023-09-300000943819rmd:SoftwareAsServiceMember2022-07-012022-09-300000943819us-gaap:OperatingSegmentsMemberrmd:SleepAndRespiratoryMember2023-07-012023-09-300000943819us-gaap:OperatingSegmentsMemberrmd:SleepAndRespiratoryMember2022-07-012022-09-300000943819us-gaap:OperatingSegmentsMemberrmd:SoftwareAsServiceMember2023-07-012023-09-300000943819us-gaap:OperatingSegmentsMemberrmd:SoftwareAsServiceMember2022-07-012022-09-300000943819us-gaap:CorporateNonSegmentMember2023-07-012023-09-300000943819us-gaap:CorporateNonSegmentMember2022-07-012022-09-300000943819us-gaap:OperatingSegmentsMember2023-07-012023-09-300000943819us-gaap:OperatingSegmentsMember2022-07-012022-09-300000943819us-gaap:MaterialReconcilingItemsMember2023-07-012023-09-300000943819us-gaap:MaterialReconcilingItemsMember2022-07-012022-09-300000943819rmd:DevelopedOrCoreProductTechnologyMember2023-09-300000943819rmd:DevelopedOrCoreProductTechnologyMember2023-06-300000943819us-gaap:CustomerRelationshipsMember2023-09-300000943819us-gaap:CustomerRelationshipsMember2023-06-300000943819us-gaap:OtherIntangibleAssetsMember2023-09-300000943819us-gaap:OtherIntangibleAssetsMember2023-06-300000943819srt:MinimumMember2023-09-300000943819srt:MaximumMember2023-09-300000943819rmd:SleepAndRespiratoryMember2023-06-300000943819rmd:SaasMember2023-06-300000943819rmd:SaasMember2023-07-012023-09-300000943819rmd:SleepAndRespiratoryMember2023-09-300000943819rmd:SaasMember2023-09-300000943819rmd:NonMarketableSecuritiesMember2023-06-300000943819rmd:MarketableSecuritiesMember2023-06-300000943819us-gaap:EquityMethodInvestmentsMember2023-06-300000943819rmd:NonMarketableSecuritiesMember2023-07-012023-09-300000943819rmd:MarketableSecuritiesMember2023-07-012023-09-300000943819us-gaap:EquityMethodInvestmentsMember2023-07-012023-09-300000943819rmd:NonMarketableSecuritiesMember2023-09-300000943819rmd:MarketableSecuritiesMember2023-09-300000943819us-gaap:EquityMethodInvestmentsMember2023-09-300000943819rmd:NonMarketableSecuritiesMember2022-06-300000943819rmd:MarketableSecuritiesMember2022-06-300000943819us-gaap:EquityMethodInvestmentsMember2022-06-300000943819rmd:NonMarketableSecuritiesMember2022-07-012022-09-300000943819rmd:MarketableSecuritiesMember2022-07-012022-09-300000943819us-gaap:EquityMethodInvestmentsMember2022-07-012022-09-300000943819rmd:NonMarketableSecuritiesMember2022-09-300000943819rmd:MarketableSecuritiesMember2022-09-300000943819us-gaap:EquityMethodInvestmentsMember2022-09-300000943819us-gaap:RevolvingCreditFacilityMemberrmd:MufgUnionBankNaAndWestpacBankingCorporationMember2022-06-290000943819us-gaap:RevolvingCreditFacilityMemberrmd:MufgUnionBankNaAndWestpacBankingCorporationMember2022-06-292022-06-29xbrli:pure0000943819us-gaap:RevolvingCreditFacilityMemberrmd:MufgUnionBankMemberrmd:ResmedLimitedMember2022-06-290000943819rmd:TermLoanCreditAgreementMember2022-06-292022-06-290000943819rmd:SecuredOvernightFinancingRateMembersrt:MinimumMemberrmd:TermLoanCreditAgreementMember2022-06-292022-06-290000943819srt:MaximumMemberrmd:SecuredOvernightFinancingRateMemberrmd:TermLoanCreditAgreementMember2022-06-292022-06-290000943819us-gaap:BaseRateMembersrt:MinimumMemberrmd:TermLoanCreditAgreementMember2022-06-292022-06-290000943819srt:MaximumMemberus-gaap:BaseRateMemberrmd:TermLoanCreditAgreementMember2022-06-292022-06-290000943819rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMemberrmd:MufgUnionBankNaAndWestpacBankingCorporationMember2023-09-300000943819us-gaap:RevolvingCreditFacilityMemberrmd:MufgUnionBankNaAndWestpacBankingCorporationMembersrt:MinimumMember2023-07-012023-09-300000943819srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberrmd:MufgUnionBankNaAndWestpacBankingCorporationMember2023-07-012023-09-300000943819us-gaap:RevolvingCreditFacilityMember2023-09-300000943819rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember2023-09-300000943819rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember2023-06-300000943819rmd:SeniorNotesOneMember2019-07-100000943819rmd:SeniorNotesTwoMember2019-07-100000943819us-gaap:SeniorNotesMember2023-09-300000943819us-gaap:SeniorNotesMember2023-06-300000943819rmd:RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember2023-09-3000009438192022-06-16rmd:patent00009438192022-06-302022-06-300000943819us-gaap:CurrencySwapMemberrmd:FairValueAndNetInvestmentHedgingMember2023-09-300000943819us-gaap:CurrencySwapMemberrmd:FairValueAndNetInvestmentHedgingMember2023-06-300000943819us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2023-07-012023-09-300000943819us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2023-09-300000943819us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2023-06-300000943819us-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMember2023-09-300000943819us-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMember2023-06-300000943819us-gaap:ForeignExchangeContractMemberrmd:PrepaidTaxesAndOtherNonCurrentAssetsMemberus-gaap:NondesignatedMember2023-09-300000943819us-gaap:ForeignExchangeContractMemberrmd:PrepaidTaxesAndOtherNonCurrentAssetsMemberus-gaap:NondesignatedMember2023-06-300000943819us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember2023-09-300000943819us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember2023-06-300000943819us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2023-09-300000943819us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2023-06-300000943819us-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2023-09-300000943819us-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2023-06-300000943819us-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:NondesignatedMember2023-09-300000943819us-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:NondesignatedMember2023-06-300000943819us-gaap:CurrencySwapMemberus-gaap:FairValueHedgingMember2023-07-012023-09-300000943819us-gaap:CurrencySwapMemberus-gaap:FairValueHedgingMember2022-07-012022-09-300000943819us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2023-07-012023-09-300000943819us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2022-07-012022-09-300000943819us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMember2023-07-012023-09-300000943819us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMember2022-07-012022-09-300000943819us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2023-07-012023-09-300000943819us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2022-07-012022-09-300000943819us-gaap:OtherNonoperatingIncomeExpenseMemberrmd:OtherForeignExchangeContractsMemberus-gaap:NondesignatedMember2023-07-012023-09-300000943819us-gaap:OtherNonoperatingIncomeExpenseMemberrmd:OtherForeignExchangeContractsMemberus-gaap:NondesignatedMember2022-07-012022-09-300000943819us-gaap:NondesignatedMember2023-07-012023-09-300000943819us-gaap:NondesignatedMember2022-07-012022-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
______________________________________________________________________________________________
FORM 10-Q
______________________________________________________________________________________________
(Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______to _______
Commission File Number: 001-15317
______________________________________________________________________________________________
ResMed Inc.
(Exact name of registrant as specified in its charter)
______________________________________________________________________________________________
Delaware
(State or other jurisdiction of incorporation or organization)
98-0152841
(I.R.S. Employer Identification No.)
9001 Spectrum Center Blvd.
San Diego, CA 92123
United States of America
(Address of principal executive offices, including zip code)
(858) 836-5000
(Registrant’s telephone number, including area code)
______________________________________________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.004 per shareRMDNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated FilerxAccelerated Filero
Non-Accelerated FileroSmaller Reporting Companyo
Emerging Growth Companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
At October 23, 2023 there were 147,091,910 shares of Common Stock ($0.004 par value) outstanding. This number excludes 41,836,234 shares held by the registrant as treasury shares.

RESMED INC. AND SUBSIDIARIES
INDEX
Part I
  
Item 1
  
 
  
 
  
 
  
 
  
 
  
 
  
  
  
  
  
  
  
  
  
  
  
  
 


2
PART I – FINANCIAL INFORMATIONItem 1
Item 1. Financial Statements
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets (Unaudited)
(In US$ and in thousands, except share and per share data)
 September 30,
2023		June 30,
2023
Assets
Current assets:
Cash and cash equivalents$209,100 $227,891 
Accounts receivable, net of allowances of $20,532 and $23,603 at September 30, 2023 and June 30, 2023, respectively
692,388 704,909 
Inventories (note 3)958,233 998,012 
Prepaid expenses and other current assets (note 3)444,864 437,018 
Total current assets2,304,585 2,367,830 
Non-current assets:
Property, plant and equipment, net (note 3)533,985 537,856 
Operating lease right-of-use assets123,416 127,955 
Goodwill (note 4)2,812,142 2,770,299 
Other intangible assets, net (note 3)563,278 552,341 
Deferred income taxes138,271 132,974 
Prepaid taxes and other non-current assets265,109 262,453 
Total non-current assets4,436,201 4,383,878 
Total assets$6,740,786 $6,751,708 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$177,048 $150,756 
Accrued expenses348,263 365,660 
Operating lease liabilities, current21,795 21,919 
Deferred revenue146,718 138,072 
Income taxes payable67,073 72,224 
Short-term debt, net (note 7)9,905 9,902 
Total current liabilities770,802 758,533 
Non-current liabilities:
Deferred revenue121,492 119,186 
Deferred income taxes87,672 90,650 
Operating lease liabilities, non-current 112,448 116,853 
Other long-term liabilities34,328 68,166 
Long-term debt, net (note 7)1,351,511 1,431,234 
Long-term income taxes payable12,157 37,183 
Total non-current liabilities1,719,608 1,863,272 
Total liabilities2,490,410 2,621,805 
Commitments and contingencies (note 9)
Stockholders’ equity:
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued
— — 
Common stock, $0.004 par value, 350,000,000 shares authorized; 188,921,316 issued and 147,085,082 outstanding at September 30, 2023 and 188,900,583 issued and 147,064,349 outstanding at June 30, 2023
588 588 
Additional paid-in capital1,791,351 1,772,083 
Retained earnings4,401,841 4,253,016 
Treasury stock, at cost, 41,836,234 shares at September 30, 2023 and June 30, 2023
(1,623,256)(1,623,256)
Accumulated other comprehensive loss(320,148)(272,528)
Total stockholders’ equity4,250,376 4,129,903 
Total liabilities and stockholders’ equity$6,740,786 $6,751,708 
See the accompanying notes to the unaudited condensed consolidated financial statements.

3
PART I – FINANCIAL INFORMATIONItem 1
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations (Unaudited)
(In US$ and in thousands, except per share data)
 Three Months Ended
September 30,
 20232022
Net revenue - Sleep and Respiratory Care products$963,037 $844,443 
Net revenue - Software as a Service139,284 105,851 
Net revenue1,102,321 950,294 
 
Cost of sales - Sleep and Respiratory Care products444,460 363,844 
Cost of sales - Software as a Service48,893 39,266 
Cost of sales (exclusive of amortization shown separately below)493,353 403,110 
 
Amortization of acquired intangible assets - Sleep and Respiratory Care products1,916 1,228 
Amortization of acquired intangible assets - Software as a Service6,992 5,146 
Amortization of acquired intangible assets8,908 6,374 
Total cost of sales502,261 409,484 
Gross profit600,060 540,810 
 
Selling, general, and administrative222,874 193,933 
Research and development 75,710 63,188 
Amortization of acquired intangible assets12,479 7,950 
Total operating expenses311,063 265,071 
Income from operations288,997 275,739 
Other income (loss), net:
Interest (expense) income, net(14,957)(7,134)
Loss attributable to equity method investments (note 5)(3,895)(2,028)
Gain (loss) on equity investments (note 5)(602)(3,280)
Other, net2,648 (1,504)
Total other income (loss), net(16,806)(13,946)
Income before income taxes272,191 261,793 
Income taxes52,769 51,315 
Net income$219,422 $210,478 
Basic earnings per share (note 8)$1.49 $1.44 
Diluted earnings per share (note 8)$1.49 $1.43 
Dividend declared per share$0.48 $0.44 
Basic shares outstanding (000's)147,075 146,431 
Diluted shares outstanding (000's)147,486 147,134 
See the accompanying notes to the unaudited condensed consolidated financial statements.

4
PART I – FINANCIAL INFORMATIONItem 1
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)
(In US$ and in thousands)
 Three Months Ended
September 30,
 20232022
Net income$219,422 $210,478 
Other comprehensive income (loss), net of taxes:
Unrealized losses on designated hedging instruments(17,093)— 
Foreign currency translation (loss) gain adjustments(30,527)(93,381)
Comprehensive income$171,802 $117,097 
See the accompanying notes to the unaudited condensed consolidated financial statements.

5
PART I – FINANCIAL INFORMATIONItem 1
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Changes in Equity (Unaudited)
(In US$ and in thousands)
 Common Stock
Additional
Paid-in
Capital
Treasury Stock
Retained
Earnings
Accumulated
Other
Comprehensive
Income (Loss)
Total
 SharesAmountSharesAmount
Balance, June 30, 2023
188,901 $588 $1,772,083 (41,836)$(1,623,256)$4,253,016 $(272,528)$4,129,903 
Common stock issued on exercise of options
17 — 983 — — — — 983 
Common stock issued on vesting of restricted stock units, net of shares withheld for tax3 — (225)— — — — (225)
Stock-based compensation costs— — 18,510 — — — — 18,510 
Other comprehensive loss— — — — — — (47,620)(47,620)
Net income— — — — — 219,422 — 219,422 
Dividends declared ($0.48 per common share)
— — — — — (70,597)— (70,597)
Balance, September 30, 2023
188,921 $588 $1,791,351 (41,836)$(1,623,256)$4,401,841 $(320,148)$4,250,376 
See the accompanying notes to the unaudited condensed consolidated financial statements.

6
PART I – FINANCIAL INFORMATIONItem 1
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Changes in Equity (Unaudited)
(In US$ and in thousands)
 Common Stock
Additional
Paid-in
Capital
Treasury Stock
Retained
Earnings
Accumulated
Other
Comprehensive
Income (Loss)
Total
 SharesAmountSharesAmount
Balance, June 30, 2022
188,247 $586 $1,682,432 (41,836)$(1,623,256)$3,613,736 $(312,747)$3,360,751 
Common stock issued on exercise of options
45 — 2,610 — — — — 2,610 
Common stock issued on vesting of restricted stock units, net of shares withheld for tax3 — (59)— — — — (59)
Stock-based compensation costs— — 16,919 — — — — 16,919 
Other comprehensive loss— — — — — — (93,381)(93,381)
Net income— — — — — 210,478 — 210,478 
Dividends declared ($0.44 per common share)
— — — — — (64,431)— (64,431)
Balance, September 30, 2022
188,295 $586 $1,701,902 (41,836)$(1,623,256)$3,759,783 $(406,128)$3,432,887 
See the accompanying notes to the unaudited condensed consolidated financial statements.

7
PART I – FINANCIAL INFORMATIONItem 1
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows (Unaudited)
(In US$ and in thousands)
 Three Months Ended
September 30,
 20232022
Cash flows from operating activities:
Net income $219,422 $210,478 
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization44,934 36,273 
Amortization of right-of-use assets8,508 7,761 
Stock-based compensation costs18,510 16,919 
Loss attributable to equity method investments (note 5)3,895 2,028 
(Gain) loss on equity investments (note 5)602 3,280 
Changes in operating assets and liabilities:
Accounts receivable6,534 (56,238)
Inventories26,911 (147,096)
Prepaid expenses, net deferred income taxes and other current assets(42,015)(36,784)
Accounts payable, accrued expenses, income taxes payable and other(1,018)8,041 
Net cash provided by operating activities
286,283 44,662 
Cash flows from investing activities:
Purchases of property, plant and equipment(30,035)(29,056)
Patent registration and acquisition costs(10,831)(3,317)
Business acquisitions, net of cash acquired(103,183)(19,100)
Purchases of investments (note 5)(3,680)(4,291)
Proceeds from exits of investments (note 5)250 — 
(Payments) / proceeds on maturity of foreign currency contracts(1,501)(3,042)
Net cash used in investing activities(148,980)(58,806)
Cash flows from financing activities:
Proceeds from issuance of common stock, net983 2,610 
Taxes paid related to net share settlement of equity awards(225)(59)
Payments of business combination contingent consideration(1,293)— 
Proceeds from borrowings, net of borrowing costs105,000 50,000 
Repayment of borrowings(185,000)(30,000)
Dividends paid(70,597)(64,431)
Net cash used in financing activities
(151,132)(41,880)
Effect of exchange rate changes on cash(4,962)(10,523)
Net decrease in cash and cash equivalents(18,791)(66,547)
Cash and cash equivalents at beginning of period227,891 273,710 
Cash and cash equivalents at end of period$209,100 $207,163 
Supplemental disclosure of cash flow information:
Income taxes paid, net of refunds$76,749 $53,437 
Interest paid$14,957 $7,134 
Fair value of assets acquired, excluding cash$34,092 $9,506 
Liabilities assumed(5,325)(3,975)
Goodwill on acquisition74,416 19,281 
Deferred payments
— (2,856)
Fair value of contingent consideration
1,293 $(2,856)
Cash paid for acquisitions$104,476 $19,100 
See the accompanying notes to the unaudited condensed consolidated financial statements.

8
PART I – FINANCIAL INFORMATIONItem 1
RESMED INC. AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
(1)    Summary of Significant Accounting Policies
Organization and Basis of Presentation
ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Finland, Norway and Sweden. We also operate a Software as a Service (“SaaS”) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice.
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and the rules of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2024.
The condensed consolidated financial statements for the three months ended September 30, 2023 and September 30, 2022 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K (our “Form 10-K”) for the year ended June 30, 2023.
Revenue Recognition
In accordance with Accounting Standard Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers”, we account for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (“Sleep and Respiratory Care”) and the supply of business management software as a service to out-of-hospital care providers (“SaaS”). Our Sleep and Respiratory Care revenue relates primarily to the sale of our products that are therapy-based equipment. Some contracts include additional performance obligations such as the provision of extended warranties and provision of data for patient monitoring. Our SaaS revenue relates to the provision of software access with ongoing support and maintenance services as well as professional services such as training and consulting.
9
PART I – FINANCIAL INFORMATIONItem 1
RESMED INC. AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
Disaggregation of revenue
The following table summarizes our net revenue disaggregated by segment, product and region (in thousands):
Three Months Ended
September 30,
20232022
U.S., Canada and Latin America
Devices$345,897 $339,545 
Masks and other292,461 238,560 
Total U.S., Canada and Latin America
$638,358 $578,105 
Combined Europe, Asia and other markets
Devices$218,831 $178,032 
Masks and other105,848 88,306 
Total Combined Europe, Asia and other markets
$324,679 $266,338 
Global revenue
Total Devices
$564,728 $517,577 
Total Masks and other
398,309 326,866 
Total Sleep and Respiratory Care$963,037 $844,443 
Software as a Service139,284 105,851 
Total$1,102,321 $950,294 
Performance obligations and contract balances
Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; generally, this occurs with the transfer of risk and/or control of our products at a point in time. For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with cloud-hosted services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of one year to five years. Our contracts do not contain significant financing components.
The following table summarizes our contract balances (in thousands):
 September 30,
2023		June 30,
2023		Balance sheet caption
Contract assets
Accounts receivable, net$692,388 $704,909 Accounts receivable, net
Unbilled revenue, current33,201 31,521 Prepaid expenses and other current assets
Unbilled revenue, non-current10,244 10,078 Prepaid taxes and other non-current assets
 
Contract liabilities
Deferred revenue, current(146,718)(138,072)Deferred revenue (current liabilities)
Deferred revenue, non-current(121,492)(119,186)Deferred revenue (non-current liabilities)
Transaction price determination
Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g. rebates, discounts, free goods) and returns offered to our customers and their
10
PART I – FINANCIAL INFORMATIONItem 1
RESMED INC. AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of our historical experience. However, returns of products, excluding warranty-related returns, have historically been infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed.
We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer’s expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates each quarter based on actual sales results and updated forecasts for the remaining rebate periods.
We participate in programs where we issue credits to our Sleep and Respiratory Care distributors when they are required to sell our products below negotiated list prices if we have preexisting contracts with the distributors' customers. We reduce revenue for future credits at the time of sale to the distributor, which we estimate based on historical experience using the expected value method.
We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs.
When Sleep and Respiratory Care or SaaS contracts have multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each performance obligation. An allocation is not required for many of our Sleep and Respiratory Care contracts that have a single performance obligation, which is the shipment of our therapy-based equipment.
Accounting and practical expedient elections
We have elected to account for shipping and handling activities associated with our Sleep and Respiratory Care segment as a fulfillment cost within cost of sales, and record shipping and handling costs collected from customers in net revenue. We have also elected for all taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, to be excluded from revenue and presented on a net basis. We have elected two practical expedients including the “right to invoice” practical expedient, which is relevant for some of our SaaS contracts as it allows us to recognize revenue in the amount of the invoice when it corresponds directly with the value of performance completed to date. The second practical expedient adopted permits relief from considering a significant financing component when the payment for the good or service is expected to be one year or less.
Lease Revenue
We lease Sleep and Respiratory Care medical devices to customers primarily as a means to comply with local health insurer requirements in certain foreign geographies. Device rental contracts are classified as operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. Operating lease revenue was $22.7 million for the three months ended September 30, 2023 and $23.7 million for the three months ended September 30, 2022.
Provision for Warranty
We provide for the estimated cost of product warranties on our Sleep and Respiratory Care products at the time the related revenue is recognized. We determine the amount of this provision by using a financial model, which takes into consideration actual historical expenses and potential risks associated with our different products. We use this financial model to calculate the future probable expenses related to warranty and the required level of the warranty provision. Although we engage in product improvement programs and processes, our warranty obligation is affected by product failure rates and costs incurred to correct those product failures. Should actual product failure rates or estimated costs to repair those product failures differ from our estimates, we would be required to revise our estimated warranty provision.
11
PART I – FINANCIAL INFORMATIONItem 1
RESMED INC. AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
(2)    Segment Information
We have quantitatively and qualitatively determined that we operate in two operating segments, which are the Sleep and Respiratory Care segment and the SaaS segment.
We evaluate the performance of our segments based on net revenues and income from operations. The accounting policies of the segments are the same as those described in note 2 of our consolidated financial statements included in our Form 10-K for the fiscal year ended June 30, 2023. Segment net revenues and segment income from operations do not include inter-segment profits and revenue is allocated to a geographic area based on where the products are shipped to or where the services are performed.
Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include corporate headquarters costs, stock-based compensation, amortization expense from acquired intangibles, acquisition related expenses, net interest expense (income), loss attributable to equity method investments, gains and losses on equity investments, and other, net. We neither discretely allocate assets to our operating segments, nor does our Chief Operating Decision Maker evaluate the operating segments using discrete asset information.
The table below presents a reconciliation of net revenues and net operating profit by reportable segments (in thousands):
Three Months Ended
September 30,
20232022
Net revenue by segment
Sleep and Respiratory Care
$963,037 $844,443 
Software as a Service139,284 105,851 
Total$1,102,321 $950,294 
Depreciation and amortization by segment
Sleep and Respiratory Care$20,519 $19,767 
Software as a Service2,760 1,913 
Amortization of acquired intangible assets and corporate assets21,655 14,593 
Total$44,934 $36,273 
Net operating profit by segment
Sleep and Respiratory Care$390,415 $352,560 
Software as a Service31,258 24,441 
Total$421,673 $377,001 
Reconciling items
Corporate costs$103,378 $86,938 
Amortization of acquired intangible assets21,387 14,324 
Astral field safety notification expenses (1)
7,911 — 
Interest expense (income), net14,957 7,134 
Loss attributable to equity method investments3,895 2,028 
(Gain) loss on equity investments602 3,280 
Other, net(2,648)1,504 
Income before income taxes$272,191 $261,793 
(1)    The Astral field safety notification expenses relate to estimated costs associated with the replacement of a certain component in some of our Astral ventilation devices that were manufactured between 2013 to 2019.
12
PART I – FINANCIAL INFORMATIONItem 1
RESMED INC. AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
(3)    Supplemental Balance Sheet Information
Components of selected captions in the condensed consolidated balance sheets consisted of the following (in thousands):
InventoriesSeptember 30,
2023		June 30,
2023
Raw materials$427,860 $459,126 
Work in progress5,190 3,956 
Finished goods525,183 534,930 
Total inventories$958,233 $998,012 
Prepaid expenses and other current assetsSeptember 30,
2023		June 30,
2023
Prepaid taxes$104,710 $114,009 
Prepaid inventories178,490 143,084 
Other prepaid expenses and current assets161,664 179,925 
Total prepaid expenses and other current assets$444,864 $437,018 
Property, Plant and EquipmentSeptember 30,
2023		June 30,
2023
Property, plant and equipment, at cost$1,201,818 $1,205,868 
Accumulated depreciation and amortization(667,833)(668,012)
Property, plant and equipment, net$533,985 $537,856 
Other Intangible Assets September 30,
2023		June 30,
2023
Developed/core product technology$415,933 $398,740 
Accumulated amortization(273,912)(265,802)
Developed/core product technology, net142,021 132,938 
Customer relationships448,769 443,652 
Accumulated amortization(133,503)(124,220)
Customer relationships, net315,266 319,432 
Other intangibles251,770 244,373 
Accumulated amortization(145,779)(144,402)
Other intangibles, net105,991 99,971 
Total other intangibles, net$563,278 $552,341 
Intangible assets consist of developed/core product technology, trade names, non-compete agreements, customer relationships, and patents, which we amortize over the estimated useful life of the assets, generally between two years to fifteen years. There are no expected residual values related to these intangible assets.
(4)    Goodwill
A reconciliation of changes in our goodwill by reportable segment is as follows (in thousands):
Three Months Ended September 30, 2023
Sleep and
Respiratory Care		SaaSTotal
Balance at the beginning of the period$670,120 $2,100,180 $2,770,299 
Business acquisitions74,416 — 74,416 
Foreign currency translation adjustments(8,144)(24,429)(32,573)
Balance at the end of the period$736,392 $2,075,751 $2,812,142 
13
PART I – FINANCIAL INFORMATIONItem 1
RESMED INC. AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
(5)    Investments
We have equity investments in privately and publicly held companies that are unconsolidated entities. The following discusses our investments in marketable equity securities, non-marketable equity securities, and investments accounted for under the equity method.
Our marketable equity securities are publicly traded stocks measured at fair value and classified within Level 1 in the fair value hierarchy because we use quoted prices for identical assets in active markets. Marketable equity securities are recorded in prepaid expenses and other current assets on the condensed consolidated balance sheets.
Non-marketable equity securities consist of investments in privately held companies without readily determinable fair values and are recorded in prepaid taxes and other non-current assets on the condensed consolidated balance sheets. Non-marketable equity securities are reported at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. We assess non-marketable equity securities at least quarterly for impairment and consider qualitative and quantitative factors including the investee's financial metrics, product and commercial outlook and cash usage. All gains and losses on marketable and non-marketable equity securities, realized and unrealized, are recognized in gain (loss) on equity investments as a component of other income (loss), net on the condensed consolidated statements of operations.
Equity investments whereby we have significant influence, but not control over the investee and are not the primary beneficiary of the investee’s activities, are accounted for under the equity method. Under this method, we record our share of gains or losses attributable to equity method investments as a component of other income (loss), net on the condensed consolidated statements of operations.
Equity investments by measurement category were as follows (in thousands):
Measurement categorySeptember 30,
2023		June 30,
2023
Fair value$11,821 $12,423 
Measurement alternative69,678 68,748 
Equity method62,161 65,366 
Total$143,660 $146,537 
14
PART I – FINANCIAL INFORMATIONItem 1
RESMED INC. AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
The following tables show a reconciliation of the changes in our equity investments (in thousands):
 Three Months Ended September 30, 2023
 Non-marketable securitiesMarketable securitiesEquity method investmentsTotal
Balance at the beginning of the period$68,748 $12,423 $65,366 $146,537 
Additions to investments1,180 — 2,500 3,680 
Unrealized losses on marketable equity securities— (602)— (602)
Proceeds from exits of investments(250)— — (250)
Loss attributable to equity method investments— — (3,895)(3,895)
Foreign currency translation adjustments— — (1,810)(1,810)
Carrying value at the end of the period$69,678 $11,821 $62,161 $143,660 
Three Months Ended September 30, 2022
Non-marketable securitiesMarketable securitiesEquity method investmentsTotal
Balance at the beginning of the period$39,290 $9,167 $9,918 $58,375 
Additions to investments
4,291 — — 4,291 
Unrealized losses on marketable equity securities
— (3,280)— (3,280)
Loss attributable to equity method investments— — (2,028)(2,028)
Carrying value at the end of the period$43,581 $5,887 $7,890 $57,358 
Net unrealized losses recognized for equity investments in non-marketable and marketable securities held as of September 30, 2023 for the three months ended September 30, 2023 were $0.6 million. Net unrealized losses recognized for equity investments in non-marketable and marketable securities held as of September 30, 2022 for the three months ended September 30, 2022 were $3.3 million.
(6)    Product Warranties
Changes in the liability for warranty costs, which is included in accrued expenses in our condensed consolidated balance sheets, are as follows (in thousands):
Three Months Ended
September 30,
20232022
Balance at the beginning of the period$27,621 $25,889 
Warranty accruals for the period6,025 2,088 
Warranty costs incurred for the period (4,828)(2,612)
Foreign currency translation adjustments(672)(1,272)
Balance at the end of the period$28,146 $24,093 
(7)    Debt
Debt consisted of the following (in thousands):
September 30,
2023		June 30,
2023
Short-term debt $10,000 $10,000 
Deferred borrowing costs(95)(98)
Short-term debt, net$9,905 $9,902 
Long-term debt$1,355,000 $1,435,000 
Deferred borrowing costs(3,489)(3,766)
Long-term debt, net$1,351,511 $1,431,234 
Total debt$1,361,416 $1,441,136 
15
PART I – FINANCIAL INFORMATIONItem 1
RESMED INC. AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
Credit Facility
On June 29, 2022, we entered into a second amended and restated credit agreement (the “Revolving Credit Agreement”), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger, sole book runner, swing line lender and letter of credit issuer, Westpac Banking Corporation, as syndication agent and joint lead arranger, HSBC Bank USA, National Association, as syndication agent and joint lead arranger, and Wells Fargo Bank, National Association, as documentation agent. The Revolving Credit Agreement, among other things, provided a senior unsecured revolving credit facility of $1,500.0 million, with an uncommitted option to increase the revolving credit facility by an additional amount equal to the greater of $1,000.0 million or 1.0 times the EBITDA (as defined in the Revolving Credit Agreement) for the trailing twelve-month measurement period. The Revolving Credit Agreement amends and restates that certain Amended and Restated Credit Agreement, dated as of April 17, 2018, among ResMed, MUFG Union Bank, N.A., Westpac Banking Corporation and the lenders party thereto.
Additionally, on June 29, 2022, ResMed Pty Limited entered into a Second Amendment to the Syndicated Facility Agreement and First Amendment to Unconditional Guaranty Agreement (the “Term Credit Agreement”), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger and joint book runner, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner, which amends that certain Syndicated Facility Agreement dated as of April 17, 2018. The Term Credit Agreement, among other things, provides ResMed Pty Limited a senior unsecured term credit facility of $200.0 million.
Our obligations under the Revolving Credit Agreement are guaranteed by certain of our direct and indirect U.S. subsidiaries, and ResMed Pty Limited’s obligations under the Term Credit Agreement are guaranteed by us and certain of our direct and indirect U.S. subsidiaries. The Revolving Credit Agreement and Term Credit Agreement contain customary covenants, including, in each case, a financial covenant that requires that we maintain a maximum leverage ratio of funded debt to EBITDA (as defined in the Revolving Credit Agreement and Term Credit Agreement, as applicable). The entire principal amounts of the revolving credit facility and term credit facility, and, in each case, any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable. Events of default under the Revolving Credit Agreement and the Term Credit Agreement include, in each case, failure to make payments when due, the occurrence of a default in the performance of any covenants in the respective agreements or related documents, or certain changes of control of us, or the respective guarantors of the obligations borrowed under the Revolving Credit Agreement and Term Credit Agreement.
The Revolving Credit Agreement and Term Credit Agreement each terminate on June 29, 2027, when all unpaid principal and interest under the loans must be repaid. Amounts borrowed under the Term Credit Agreement will also amortize on a semi-annual basis, with a $5.0 million principal payment required on each such semi-annual amortization date. The outstanding principal amounts will bear interest at a rate equal to the Adjusted Term SOFR (as defined in the Revolving Credit Facility) plus 0.75% to 1.50% (depending on the then-applicable leverage ratio) or the Base Rate (as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable) plus 0.0% to 0.50% (depending on the then-applicable leverage ratio). At September 30, 2023, the interest rate that was being charged on the outstanding principal amounts was 6.3%. An applicable commitment fee of 0.075% to 0.150% (depending on the then-applicable leverage ratio) applies on the unused portion of the revolving credit facility. As of September 30, 2023, we had $825.0 million available for draw down under the revolving credit facility.
We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As the Revolving Credit and Term Credit Agreements’ interest rate is calculated as Adjusted Term SOFR plus the spreads described above, its carrying amount is equivalent to its fair value as at September 30, 2023 and June 30, 2023, which was $865.0 million and $945.0 million, respectively.
Senior Notes
On July 10, 2019, we entered into a Note Purchase Agreement with the purchasers to that agreement, in connection with the issuance and sale of $250.0 million principal amount of our 3.24% senior notes due July 10, 2026, and $250.0 million principal amount of our 3.45% senior notes due July 10, 2029 (collectively referred to as the “Senior Notes”). Our obligations under the Note Purchase Agreement and the Senior Notes are unconditionally and irrevocably guaranteed by certain of our direct and indirect U.S. subsidiaries. The net proceeds from this transaction were used to pay down borrowings on our Revolving Credit Agreement.
16
PART I – FINANCIAL INFORMATIONItem 1
RESMED INC. AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
Under the terms of the Note Purchase Agreement, we agreed to customary covenants including with respect to our corporate existence, transactions with affiliates, and mergers and other extraordinary transactions. We also agreed that, subject to limited exceptions, we will maintain a ratio of consolidated funded debt to consolidated EBITDA (as defined in the Note Purchase Agreement) of no more than 3.50 to 1.00 as of the last day of any fiscal quarter, and will not at any time permit the amount of all priority secured and unsecured debt of us and our subsidiaries to exceed 10% of our consolidated tangible assets, determined as of the end of our most recently ended fiscal quarter. This ratio is calculated at the end of each reporting period for which the Note Purchase Agreement requires us to deliver financial statements, using the results of the 12 consecutive month period ending with such reporting period.
We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As of September 30, 2023 and June 30, 2023, the Senior Notes had a carrying amount of $500.0 million, excluding deferred borrowing costs, and an estimated fair value of $451.7 million and $462.2 million, respectively. Quoted market prices in active markets for similar liabilities based inputs (Level 2) were used to estimate fair value.
At September 30, 2023, we were in compliance with our debt covenants and there was $1,365.0 million outstanding under the Revolving Credit Agreement, Term Credit Agreement and Senior Notes.
(8)    Earnings Per Share
Basic earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units.
The weighted average number of outstanding stock options and restricted stock units not included in the computation of diluted earnings per share were 417,364 and 113,167 for the three months ended September 30, 2023 and 2022, respectively, as the effect would have been anti-dilutive.
Basic and diluted earnings per share are calculated as follows (in thousands except per share data):
Three Months Ended
September 30,
20232022
Numerator:
Net income$219,422 $210,478 
Denominator:
Basic weighted-average common shares outstanding147,075 146,431 
Effect of dilutive securities:
Stock options and restricted stock units411 703 
Diluted weighted average shares 147,486 147,134 
Basic earnings per share$1.49 $1.44 
Diluted earnings per share$1.49 $1.43 
(9)    Legal Actions, Contingencies and Commitments
Litigation
In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.
On June 2, 2021, New York University ("NYU") filed a complaint for patent infringement in the United States District Court, District of Delaware against ResMed Inc., case no. 1:21-cv-00813 (JPM). The complaint alleges that the AutoSet or AutoRamp features of ResMed’s AirSense 10 AutoSet flow generators infringe one or more claims of various NYU patents, including U.S. Patent Nos. 6,988,994; 9,108,009; 9,168,344; 9,427,539; 9,533,115; 9,867,955; and 10,384,024. According to the complaint, the NYU patents are directed to systems and methods for diagnosis and treating sleeping
17
PART I – FINANCIAL INFORMATIONItem 1
RESMED INC. AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
disorders during different sleep states. The complaint seeks monetary damages and attorneys’ fees. We answered the complaint on September 30, 2021 and filed a motion to dismiss the complaint on the basis that the patents are invalid because the subject matter of the patents is not patentable under the Supreme Court and Federal Circuit precedent. The motion to dismiss was granted in part and denied in part. We have also requested that the court dismiss the case based on NYU’s license of the patents to Fisher & Paykel and Fisher & Paykel’s prior settlement with us; that request is pending. In December 2022, the Patent Trial and Appeals Board (“PTAB”) of the Patent and Trademark Office granted our request to review the validity of the claims in the patents asserted by NYU against us, determining that there is a reasonable likelihood that we will prevail. The PTAB’s final written decisions on the validity of the asserted claims is expected by December 2023. On April 10, 2023, the district court granted our request to stay the case pending the PTAB’s decision on the validity of the patents asserted by NYU.
On January 27, 2021, the International Trade Commission ("ITC") instituted In Re Certain UMTS and LTE Cellular Communications Modules and Products Containing the Same, Investigation No. 337-TA-1240, by complainants Philips RS North America, LLC and Koninklijke Philips N.V. (collectively “Philips”) against Quectel Wireless Solutions Co., Ltd; Thales DIS AIS USA, LLC, Thales DIS AIS Deutschland GmbH; Telit Wireless Solutions, Inc., Telit Communications PLC, CalAmp. Corp., Xirgo Technologies, LLC, and Laird Connectivity, Inc. (collectively “respondents”). In the ITC investigation, Philips seeks an order excluding communications modules, and products that contain them, from importation into the United States based on alleged infringement of 3G and 4G standard essential patents held by Philips. On October 6-14, 2021, the administrative law judge held a hearing on the merits. The administrative law judge issued an initial determination on April 1, 2022, finding no violation of any of the Philips' patents asserted in the ITC. Philips sought review by the full ITC. On July 6, 2022, the Commission affirmed the administrative law judge’s determination that there was no violation of asserted Philips' patents. The Commission terminated the ITC proceedings. Philips did not appeal the ITC’s decision. On December 17, 2020, Philips filed companion cases for patent infringement against the same defendants in the United States District Court for the District of Delaware, case nos. 1:20-cv-01707, 01708, 01709, 01710, 01711, and 01713 (CFC) seeking damages, an injunction, and a declaration from the court on the amount of a fair reasonable and non-discriminatory license rate for the standard essential patents it is asserting against the communications module defendants. The district court cases were stayed pending the resolution of the ITC proceedings. The parties have returned to the district court for further proceedings. We were not a party to the ITC investigation, and we are not a party to the district court cases, but we sell products that incorporate communications modules at issue in the district court case. The first trial in these cases is set for August 12, 2024.
On June 16, 2022, Cleveland Medical Devices Inc. ("Cleveland Medical") filed suit for patent infringement against ResMed Inc. in the United States District Court for the District of Delaware, case no. 1:22-cv-00794. Cleveland Medical asserts that numerous ResMed connected devices, when combined with certain ResMed data platforms and/or software, including AirView and ResScan, infringe one or more of eight Cleveland Medical patents, including U.S. Patent Nos. 10,076,269; 10,426,399; 10,925,535; 11,064,937; 10,028,698; 10,478,118; 11,202,603; and 11,234,637. We moved to dismiss the action because Cleveland Medical sued the wrong ResMed entity, and to dismiss the indirect and willful infringement allegations by Cleveland Medical. On October 2, 2023, the court granted a portion of the motion, dismissing all Cleveland Medical claims for indirect and willful infringement, and declined the rest of the motion. On March 23, 2023, we filed a petition with the Patent Trial and Appeals Board of the Patent and Trademark Office seeking review of the validity of Cleveland Medical U.S. Patent 10,076,269. On September 25, 2023, the PTAB exercised its discretion to deny our petition challenging the validity of the ‘269 patent in light of the August 2024 trial date in the Delaware District Court case; that decision does not impact the merits of our invalidity challenge in that trial.
On March 23, 2023, ResMed Corp. filed suit in the Southern District of California, case no. 23-cv-00500-TWR-JLB, seeking a declaration that it does not infringe U.S. patent number 11,602,284 recently issued to Cleveland Medical. Cleveland Medical has asked the court to dismiss the California case or to move it to Delaware or Cleveland for the convenience of the parties. We are opposing that request.
Based on currently available information, we are unable to make a reasonable estimate of loss or range of losses, if any, arising from matters that remain open.
Contingent Obligations Under Recourse Provisions
We use independent financing institutions to offer some of our customers financing for the purchase of some of our products. Under these arrangements, if the customer qualifies under the financing institutions’ credit criteria and finances the transaction, the customers repay the financing institution on a fixed payment plan. For some of these arrangements, the
18
PART I – FINANCIAL INFORMATIONItem 1
RESMED INC. AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
customer’s receivable balance is with limited recourse whereby we are responsible for repaying the financing company should the customer default. We record a contingent provision, which is estimated based on historical default rates. This is applied to receivables sold with recourse and is recorded in accrued expenses.
During the three months ended September 30, 2023 and September 30, 2022, receivables sold with limited recourse were $47.7 million and $39.9 million, respectively. As of September 30, 2023, the maximum exposure on outstanding receivables sold with recourse and the associated contingent provision were $28.9 million and $0.8 million, respectively. As of June 30, 2023, the maximum exposure on outstanding receivables sold with recourse and contingent provision were $32.6 million and $0.6 million, respectively.
(10)    Derivative Instruments and Hedging Activities
We may use derivative financial instruments, specifically foreign cross-currency swaps, purchased foreign currency call options, collars and forward contracts to mitigate exposure from certain foreign currency risk. No derivatives are used for trading or speculative purposes. We do not require or are not required to pledge collateral for the derivative instruments.
Fair Value and Net Investment Hedging
On November 17, 2022, we executed foreign cross-currency swaps as net investment hedges and fair value hedges in designated hedging relationships with either the foreign denominated net asset balances or the foreign denominated intercompany loan as the hedged items. All derivatives are recorded at fair value as either an asset or liability. Cash flows associated with derivative instruments are presented in the same category on the consolidated statements of cash flows as the hedged item.
The purpose of the cross-currency swaps for the fair value hedge is to mitigate foreign currency risk associated with changes in spot rates on foreign denominated intercompany debt between USD and EUR. For these hedges, we excluded certain components from the assessment of hedge effectiveness that are not related to spot rates. For fair value hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in the same line item as the hedged item, other, net, in the condensed consolidated statement of operations. The initial fair value of hedge components excluded from the assessment of effectiveness is recognized in the statement of operations under a systematic and rational method over the life of the hedging instrument and is presented in interest (expense) income, net. Any difference between the change in the fair value of the hedge components excluded from the assessment of effectiveness and the amounts recognized in earnings is recorded as a component of other comprehensive income.
The purpose of the cross-currency swaps for the net investment hedge is to mitigate foreign currency risk associated with changes in spot rates on the net asset balances of our foreign functional subsidiaries. For net investment hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in cumulative translation adjustment within other comprehensive loss and reclassified into earnings when the hedged net investment is either sold or substantially liquidated. The initial fair value of components excluded from the assessment of hedge effectiveness will be recognized in interest (expense) income, net.
The notional value of outstanding foreign cross-currency swaps was $1,014.8 million and $1,046.6 million at September 30, 2023 and June 30, 2023, respectively. These contracts mature at various dates prior to December 31, 2029.
Non-Designated Hedges
We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have foreign currency exposure through both our Australian and Singapore manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased foreign currency call options, collars and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed three years. The purpose of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, and Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not designate these foreign currency contracts as hedges. All movements in the fair value of the foreign currency instruments are recorded within other, net in our condensed consolidated statements of income.
19
PART I – FINANCIAL INFORMATIONItem 1
RESMED INC. AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
The notional value of the outstanding non-designated hedges was $1,363.3 million and $954.7 million at September 30, 2023 and June 30, 2023, respectively. These contracts mature at various dates prior to March 15, 2025.
Fair Values of Derivative Instruments
The following table presents our assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets (in thousands):
September 30,
2023		June 30,
2023		Balance Sheet Caption
Derivative Assets
Not Designated as Hedging Instruments
Foreign currency hedging instruments$3,611 $2,126 Prepaid expenses and other current assets
Foreign currency hedging instruments717 279 Prepaid taxes and other non-current assets
Total derivative assets$4,328 $2,405 
Derivative Liabilities
Designated as Hedging Instruments
Foreign cross-currency swaps – Fair Value Hedge$9,883 $19,743 Other long-term liabilities
Foreign cross-currency swaps – Net Investment Hedge17,367 $40,803 Other long-term liabilities
Not Designated as Hedging Instruments
Foreign currency hedging instruments25,005 9,558 Accrued expenses
Foreign currency hedging instruments592 595 Other long-term liabilities
Total derivative liabilities$52,847 $70,699 
Fair Value Hedge Gains (Losses)
We recognized the following gains (losses) on the foreign cross currency swaps designated as fair value hedges (in thousands):
Three Months Ended
September 30,
20232022
Gain (loss) recognized in other comprehensive income (loss)$588 $— 
Gain (loss) recognized on cross-currency swap in interest (expense) income, net (amount excluded from effectiveness testing)1,181 — 
Gain (loss) recognized on cross-currency swap in other, net9,271 — 
Gain (loss) recognized on intercompany debt in other, net(9,271)— 
Net Investment Hedge Gains (Losses)
We recognized the following gains (losses) on the foreign cross currency swaps designated as net investment hedges (in thousands):
Three Months Ended
September 30,
20232022
Gain (loss) recognized in cumulative translation adjustment within other comprehensive income (loss)$23,436 $— 
Gain (loss) recognized from the excluded components in interest (expense) income, net 3,013 — 
Non-designated Derivative Gains (Losses)
We recognized the following gains (losses) in the condensed consolidated statement of operations on derivatives not designated as hedging instruments (in thousands):
20
PART I – FINANCIAL INFORMATIONItem 1
RESMED INC. AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
Three Months Ended
September 30,
20232022
Gain (loss) recognized on foreign currency hedging instruments in other, net$(15,073)$(20,522)
Gain (loss) recognized on other foreign-currency-denominated transactions in other, net17,646 19,089 
Total$2,573 $(1,433)
We classified the fair values of all hedging instruments as Level 2 measurements within the fair value hierarchy.
We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments. We minimize counterparty credit risk by entering into derivative transactions with major financial institutions.
21
PART I – FINANCIAL INFORMATIONItem 2
RESMED INC. AND SUBSIDIARIES
Management’s Discussion and Analysis of Financial Condition and Results of Operations
.
Special Note Regarding Forward-Looking Statements
This report contains or may contain certain forward-looking statements and information that are based on the beliefs of our management as well as estimates and assumptions made by, and information currently available to, our management. All statements other than statements regarding historical facts are forward-looking statements. The words “believe,” “expect,” “intend,” “anticipate,” “will continue,” “will,” “estimate,” “plan,” “future” and other similar expressions, and negative statements of such expressions, generally identify forward-looking statements, including, in particular, statements regarding expectations of future revenue or earnings, expenses, new product development, new product launches, new markets for our products, the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, tax outlook, the impact of COVID-19, its variants, and similar epidemics or pandemics and macroeconomic conditions on our business. These forward-looking statements are made in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements reflect the views of our management at the time the statements are made and are subject to a number of risks, uncertainties, estimates and assumptions, including, without limitation, and in addition to those identified in the text surrounding such statements, those identified in our annual report on Form 10-K for the fiscal year ended June 30, 2023 and elsewhere in this report. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources.
In addition, important factors to consider in evaluating such forward-looking statements include changes or developments in healthcare reform, social, macroeconomic, market, legal or regulatory circumstances, including the public health crises such as COVID-19 and its variants; changes in our business or growth strategy or an inability to execute our strategy due to changes in our industry or the economy generally, the emergence of new or growing competitors, the actions or omissions of third parties, including suppliers, customers, competitors and governmental authorities and various other factors. If any one or more of these risks or uncertainties materialize, or underlying estimates or assumptions prove incorrect, actual results may vary significantly from those expressed in our forward-looking statements, and there can be no assurance that the forward-looking statements contained in this report will in fact occur.
Before deciding to purchase, hold or sell our common stock, you should carefully consider the risks described in our annual report on Form 10-K for the fiscal year ended June 30, 2023, in addition to the other cautionary statements and risks described elsewhere in this report and in our other filings with the Securities and Exchange Commission (“SEC”), including our subsequent reports on Forms 10-Q and 8-K. These risks and uncertainties are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business. If any of these known or unknown risks or uncertainties actually occurs with material adverse effects on us, our business, financial condition and results of operations could be seriously harmed. In that event, the market price for our common stock will likely decline and you may lose all or part of your investment.
22
PART I – FINANCIAL INFORMATIONItem 2
RESMED INC. AND SUBSIDIARIES
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Overview
The following is an overview of our results of operations for the three months ended September 30, 2023. Management’s discussion and analysis of financial condition and results of operations (“MD&A”) is intended to help the reader understand our results of operations and financial condition. Management’s discussion and analysis is provided as a supplement to, and should be read in conjunction with, the condensed consolidated financial statements and notes included in this report.
We are a global leader in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (“SDB”), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. SDB includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Our products and solutions are designed to improve patient quality of life, reduce the impact of chronic disease and lower healthcare costs as global healthcare systems continue to drive a shift in care from hospitals to the home and lower cost settings. Our cloud-based software digital health applications, along with our devices, are designed to provide connected care to improve patient outcomes and efficiencies for our customers.
Since the development of continuous positive airway pressure therapy, we have expanded our business by developing or acquiring a number of products and solutions for a broader range of respiratory disorders including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes and customer and provider business processes. Our growth has been fueled by geographic expansion, our research and product development efforts, acquisitions and an increasing awareness of SDB and respiratory conditions like chronic obstructive pulmonary disease as significant health concerns.
We are committed to ongoing investment in research and development and product enhancements. During the three months ended September 30, 2023, we invested $75.7 million on research and development activities, which represents 6.9% of net revenues, with a continued focus on the development and commercialization of new, innovative products and solutions that improve patient outcomes, create efficiencies for our customers and help physicians and providers better manage chronic disease and lower healthcare costs. During the three months ended September 30, 2023, we continued the launch of AirSense 11, which introduces new features such as a touch screen, algorithms for patients new to therapy and digital enhancements and over-the-air update capabilities. Due to multiple acquisitions, including Brightree in 2016, HEALTHCAREfirst and MatrixCare in 2018, and MEDIFOX DAN in 2022, our operations include out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. These platforms comprise our SaaS business. These products, our cloud-based remote monitoring and therapy management system, and a robust product pipeline, should continue to provide us with a strong platform for future growth.
We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (“Sleep and Respiratory Care”) and the supply of business management software as a service to out-of-hospital health providers (“SaaS”).
Net revenue for the three months ended September 30, 2023 was $1.1 billion, an increase of 16% compared to the three months ended September 30, 2022. Gross margin was 54.4% for the three months ended September 30, 2023 compared to 56.9% for the three months ended September 30, 2022. Diluted earnings per share was $1.49 for the three months ended September 30, 2023, compared to diluted earnings per share of $1.43 for the three months ended September 30, 2022.
At September 30, 2023, our cash and cash equivalents totaled $209.1 million, our total assets were $6.7 billion and our stockholders’ equity was $4.3 billion.
In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with accounting principles generally accepted in the United States (“GAAP”).
23
PART I – FINANCIAL INFORMATIONItem 2
RESMED INC. AND SUBSIDIARIES
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Results of Operations
Three Months Ended September 30, 2023 Compared to the Three Months Ended September 30, 2022
Net Revenue
Net revenue for the three months ended September 30, 2023 increased to $1,102.3 million from $950.3 million for the three months ended September 30, 2022, an increase of $152.0 million or 16% (a 15% increase on a constant currency basis). The following table summarizes our net revenue disaggregated by segment, product and region (in thousands):
Three Months Ended
September 30,		% ChangeConstant Currency*
20232022
U.S., Canada and Latin America      
Devices$345,897 $339,545 2 %
Masks and other292,461 238,560 23 
Total U.S., Canada and Latin America
$638,358 $578,105 10 
Combined Europe, Asia and other markets
Devices$218,831 $178,032 23 %20 %
Masks and other105,848 88,306 20 15 
Total Combined Europe, Asia and other markets
$324,679 $266,338 22 18 
Global revenue
Total Devices$564,728 $517,577 9 %8 %
Total Masks and other398,309 326,866 22 21 
Total Sleep and Respiratory Care$963,037 $844,443 14 13 
Software as a Service139,284 105,851 32 
Total$1,102,321 $950,294 16 15 
*Constant currency numbers exclude the impact of movements in international currencies.
Sleep and Respiratory Care
Net revenue from our Sleep and Respiratory Care business for the three months ended September 30, 2023 was $963.0 million, an increase of 14% compared to net revenue for the three months ended September 30, 2022. Movements in international currencies against the U.S. dollar positively impacted net revenue by approximately $9.6 million for the three months ended September 30, 2023. Excluding the impact of currency movements, total Sleep and Respiratory Care net revenue for the three months ended September 30, 2023 increased by 13% compared to the three months ended September 30, 2022. The increase in net revenue associated with our devices and masks was primarily attributable to increased demand and unit sales.
Net revenue from our Sleep and Respiratory Care business in the U.S., Canada and Latin America for the three months ended September 30, 2023 increased to $638.4 million from $578.1 million for the three months ended September 30, 2022, an increase of $60.3 million or 10%. The increase in net revenue associated with our devices and masks was primarily attributable to increased demand and unit sales.
Net revenue in combined Europe, Asia and other markets increased for the three months ended September 30, 2023 to $324.7 million from $266.3 million for the three months ended September 30, 2022, an increase of $58.3 million or 22% (an 18% increase on a constant currency basis). The constant currency increase in device and mask sales in combined Europe, Asia and other was primarily attributable to increased demand and unit sales.
Net revenue from devices for the three months ended September 30, 2023 increased to $564.7 million from $517.6 million for the three months ended September 30, 2022, an increase of $47.2 million or 9%, including an increase of 2% in the U.S., Canada and Latin America and an increase of 23% in combined Europe, Asia and other markets (a 20% increase on a constant currency basis). Excluding the impact of foreign currency movements, device sales for the three months ended September 30, 2023 increased by 8%.
24
PART I – FINANCIAL INFORMATIONItem 2
RESMED INC. AND SUBSIDIARIES
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Net revenue from masks and other for the three months ended September 30, 2023 increased to $398.3 million from $326.9 million for the three months ended September 30, 2022, an increase of $71.4 million or 22%, including an increase of 23% in the U.S., Canada and Latin America and an increase of 20% in combined Europe, Asia and other markets (a 15% increase on a constant currency basis). Excluding the impact of foreign currency movements, masks and other sales for the three months ended September 30, 2023 increased by 21%.
Software as a Service
Net revenue from our SaaS business for the three months ended September 30, 2023 increased to $139.3 million from $105.9 million for the three months ended September 30, 2022, an increase of $33.4 million or 32%. The increase was predominantly due to our recent acquisition of MEDIFOX DAN, which was acquired on November 21, 2022. Excluding the MEDIFOX DAN acquisition, SaaS revenue increased 7% and was driven by continued growth in the HME vertical within our SaaS business.
Gross Profit and Gross Margin
Gross profit increased for the three months ended September 30, 2023 to $600.1 million from $540.8 million for the three months ended September 30, 2022, an increase of $59.3 million or 11%. Gross margin, which is gross profit as a percentage of net revenue, for the three months ended September 30, 2023 was 54.4% compared to 56.9% for the three months ended September 30, 2022.
The decrease in gross margin for the three months ended September 30, 2023 compared to the three months ended September 30, 2022 was due primarily to a $7.9 million provision of expected costs associated with a field safety notification on Astral devices, in addition to higher component and manufacturing costs, partially offset by a favorable product mix and favorable foreign currency movements. The Astral field safety notification relates to estimated expenses associated with the replacement of a certain component in some of our Astral ventilation devices that were manufactured between 2013 to 2019.
Operating Expenses
The following table summarizes our operating expenses (in thousands):
Three Months Ended
September 30,		Change% ChangeConstant Currency
20232022
Selling, general, and administrative$222,874 $193,933 $28,941 15 %14 %
as a % of net revenue20.2 %20.4 %
Research and development 75,710 63,188 12,522 20 %21 %
as a % of net revenue6.9 %6.6 %
Amortization of acquired intangible assets12,479 7,950 4,529 57 %58 %
Selling, General, and Administrative Expenses
Selling, general, and administrative expenses increased for the three months ended September 30, 2023 to $222.9 million from $193.9 million for the three months ended September 30, 2022, an increase of $28.9 million or 15%. Selling, general, and administrative expenses were unfavorably impacted by the movement of international currencies against the U.S. dollar, which increased our expenses by approximately $2.1 million, as reported in U.S. dollars. Excluding the impact of foreign currency movements, selling, general, and administrative expenses for the three months ended September 30, 2023 increased by 14% compared to the three months ended September 30, 2022. As a percentage of net revenue, selling, general, and administrative expenses were 20.2% for the three months ended September 30, 2023, compared to 20.4% for the three months ended September 30, 2022.
The constant currency increase in selling, general, and administrative expenses during the three months ended September 30, 2023 compared to the three months ended September 30, 2022 was primarily due to increases in employee-related costs and additional expenses associated with the consolidation of recent acquisitions.
25
PART I – FINANCIAL INFORMATIONItem 2
RESMED INC. AND SUBSIDIARIES
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Research and Development Expenses
Research and development expenses increased for the three months ended September 30, 2023 to $75.7 million from $63.2 million for the three months ended September 30, 2022, an increase of $12.5 million, or 20%. Research and development expenses were favorably impacted by the movement of international currencies against the U.S. dollar, which decreased our expenses by approximately $0.6 million for the three months ended September 30, 2023, as reported in U.S. dollars. Excluding the impact of foreign currency movements, research and development expenses increased by 21% compared to the three months ended September 30, 2022. As a percentage of net revenue, research and development expenses were 6.9% for the three months ended September 30, 2023 compared to 6.6% for the three months ended September 30, 2022.
The increase in research and development expenses in constant currency terms was primarily due to increased investment in our digital health technologies and SaaS solutions as well as additional expenses associated with the consolidation of recent acquisitions.
Amortization of Acquired Intangible Assets
Amortization of acquired intangible assets for the three months ended September 30, 2023 totaled $12.5 million compared to $8.0 million for the three months ended September 30, 2022. The increase in amortization expense was primarily attributable to our acquisition of MEDIFOX DAN.
Total Other Income (Loss), Net
The following table summarizes our other income (loss) (in thousands):
Three Months Ended
September 30,
20232022Change
Interest (expense) income, net$(14,957)$(7,134)$(7,823)
Loss attributable to equity method investments(3,895)(2,028)(1,867)
Gain (loss) on equity investments(602)(3,280)2,678 
Other, net2,648 (1,504)4,152 
Total other income (loss), net$(16,806)$(13,946)$(2,860)
Total other income (loss), net for the three months ended September 30, 2023 was a loss of $16.8 million compared to a loss of $13.9 million for the three months ended September 30, 2022. Interest expense, net, increased to $15.0 million for the three months ended September 30, 2023 compared to $7.1 million for the three months ended September 30, 2022 due to higher debt levels associated with the acquisition of MEDIFOX DAN, which was funded by our Revolving Credit Agreement. In addition, we recorded higher losses attributable to equity method investments for the three months ended September 30, 2023 of $3.9 million compared to $2.0 million for the three months ended September 30, 2022. Increases in interest expense, net, and losses attributable to equity method investments were partially offset by foreign exchange net gains for the three months ended September 30, 2023 of $2.6 million compared to foreign exchange net losses of $1.4 million for the three months ended September 30, 2022, as well as lower losses associated with our investments in marketable and non-marketable equity securities, which were a loss of $0.6 million for the three months ended September 30, 2023 compared to a loss of $3.3 million for the three months ended September 30, 2022.
Income Taxes
Our effective income tax rate for the three months ended September 30, 2023 was 19.4% as compared to 19.6% for the three months ended September 30, 2022. Our effective rate of 19.4% for the three months ended September 30, 2023 differs from the statutory rate of 21.0% primarily due to research credits, foreign operations and windfall tax benefits related to the vesting or settlement of employee share-based awards. The decrease in our effective tax rate for the three months ended September 30, 2023 was primarily due to a shift in the geographic mix of earnings.
Our Singapore operations operate under certain tax holidays and tax incentive programs that will expire in whole or in part at various dates through June 30, 2030. As a result of the U.S. Tax Cuts and Jobs Act of 2017, we treated all non-U.S. historical earnings as taxable during the year ended June 30, 2018. Therefore, future repatriation of cash held by our non-U.S. subsidiaries will generally not be subject to U.S. federal tax, if repatriated.
26
PART I – FINANCIAL INFORMATIONItem 2
RESMED INC. AND SUBSIDIARIES
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Net Income and Earnings per Share
As a result of the factors above, our net income for the three months ended September 30, 2023 was $219.4 million compared to $210.5 million for the three months ended September 30, 2022, an increase of $8.9 million, or 4%.
Our diluted earnings per share for the three months ended September 30, 2023 was $1.49 per diluted share compared to $1.43 for the three months ended September 30, 2022, an increase of 4%.
Summary of Non-GAAP Financial Measures
In addition to financial information prepared in accordance with GAAP, our management uses certain non-GAAP financial measures, such as non-GAAP revenue, non-GAAP cost of sales, non-GAAP gross profit, non-GAAP gross margin, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted earnings per share, in evaluating the performance of our business. We believe that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, can provide investors better insight when evaluating our performance from core operations and can provide more consistent financial reporting across periods. For these reasons, we use non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. These non-GAAP financial measures should be considered in addition to, and not superior to or as a substitute for, GAAP financial measures. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. Non-GAAP financial measures as presented herein may not be comparable to similarly titled measures used by other companies.
The measure “non-GAAP cost of sales” is equal to GAAP cost of sales less amortization of acquired intangible assets relating to cost of sales and Astral field safety notification expenses. The Astral field safety notification expenses relate to estimated costs associated with the replacement of a certain component in some of our Astral ventilation devices that were manufactured between 2013 to 2019. The measure “non-GAAP gross profit” is the difference between GAAP net revenue and non-GAAP cost of sales, and “non-GAAP gross margin” is the ratio of non-GAAP gross profit to GAAP net revenue.
These non-GAAP measures are reconciled to their most directly comparable GAAP financial measures below (in thousands, except percentages):
Three Months Ended
September 30,
20232022
GAAP Net revenue$1,102,321 $950,294 
 
GAAP Cost of sales$502,261 $409,484 
Less: Amortization of acquired intangibles
(8,908)(6,374)
Less: Astral field safety notification expenses
(7,911)— 
Non-GAAP cost of sales$485,442 $403,110 
GAAP gross profit$600,060 $540,810 
GAAP gross margin54.4 %56.9 %
Non-GAAP gross profit$616,879 $547,184 
Non-GAAP gross margin56.0 %57.6 %
27
PART I – FINANCIAL INFORMATIONItem 2
RESMED INC. AND SUBSIDIARIES
Management’s Discussion and Analysis of Financial Condition and Results of Operations
The measure “non-GAAP income from operations” is equal to GAAP income from operations once adjusted for amortization of acquired intangibles, acquisition-related expenses, and Astral field safety notification expenses. Non-GAAP income from operations is reconciled with GAAP income from operations below (in thousands):
Three Months Ended
September 30,
20232022
GAAP income from operations$288,997 $275,739 
Amortization of acquired intangibles - cost of sales8,908 6,374 
Amortization of acquired intangibles - operating expenses12,479 7,950 
Acquisition-related expenses483 745 
Astral field safety notification expenses7,911 — 
Non-GAAP income from operations $318,778 $290,808 
The measure “non-GAAP net income” is equal to GAAP net income once adjusted for amortization of acquired intangibles, acquisition related expenses, Astral field safety notification expenses, and associated tax effects. The measure “non-GAAP diluted earnings per share” is the ratio of non-GAAP net income to diluted shares outstanding. These non-GAAP measures are reconciled to their most directly comparable GAAP financial measures below (in thousands, except for per share amounts):
 Three Months Ended
September 30,
 20232022
GAAP net income$219,422 $210,478 
Amortization of acquired intangibles - cost of sales8,908 6,374 
Amortization of acquired intangibles - operating expenses12,479 7,950 
Acquisition related expenses483 745 
Astral field safety notification expenses7,911 — 
Income tax effect on non-GAAP adjustments(8,019)(3,458)
Non-GAAP net income$241,184 $222,089 
Diluted shares outstanding147,486 147,134 
GAAP diluted earnings per share$1.49 $1.43 
Non-GAAP diluted earnings per share$1.64 $1.51 
Liquidity and Capital Resources
Our principal sources of liquidity are our existing cash and cash equivalents, cash generated from operations and access to our revolving credit facility. Our primary uses of cash have been for research and development activities, selling and marketing activities, capital expenditures, strategic acquisitions and investments, dividend payments and repayment of debt obligations. We expect that cash provided by operating activities may fluctuate in future periods as a result of several factors, including fluctuations in our operating results, which include impacts from supply chain disruptions, working capital requirements and capital deployment decisions.
Our future capital requirements will depend on many factors including our growth rate in net revenue, third-party reimbursement of our products for our customers, the timing and extent of spending to support research development efforts, the expansion of selling, general and administrative activities, the timing of introductions of new products, and the expenditures associated with possible future acquisitions, investments or other business combination transactions. As we assess inorganic growth strategies, we may need to supplement our internally generated cash flow with outside sources. If we are required to access the debt market, we believe that we will be able to secure reasonable borrowing rates. As part of our liquidity strategy, we will continue to monitor our current level of earnings and cash flow generation as well as our ability to access the market considering those earning levels.
As of September 30, 2023 and June 30, 2023, we had cash and cash equivalents of $209.1 million and $227.9 million, respectively. Our cash and cash equivalents held within the United States at September 30, 2023 and June 30, 2023 were
28
PART I – FINANCIAL INFORMATIONItem 2
RESMED INC. AND SUBSIDIARIES
Management’s Discussion and Analysis of Financial Condition and Results of Operations
$41.0 million and $49.3 million, respectively. Our remaining cash and cash equivalent balances at September 30, 2023 and June 30, 2023, were $168.1 million and $178.6 million, respectively. Our cash and cash equivalent balances are held at highly rated financial institutions.
As of September 30, 2023, we had $825.0 million available for draw down under the revolver credit facility and a combined total of $1,034.1 million in cash and available liquidity under the revolving credit facility.
As a result of the U.S. Tax Act, we treated all non-U.S. historical earnings as taxable, which resulted in additional tax expense of $126.9 million which was payable over the proceeding eight years. Therefore, future repatriation of cash held by our non-U.S. subsidiaries will generally not be subject to U.S. federal tax if repatriated.
We believe that our current sources of liquidity will be sufficient to fund our operations, including expected capital expenditures, for the next 12 months and beyond.
Revolving Credit Agreement, Term Credit Agreement and Senior Notes
On June 29, 2022, we entered into a second amended and restated credit agreement (as amended from time to time, the “Revolving Credit Agreement”). The Revolving Credit Agreement, among other things, provided a senior unsecured revolving credit facility of $1,500.0 million, with an uncommitted option to increase the revolving credit facility by an additional amount equal to the greater of $1,000.0 million or 1.00 times the EBITDA for the trailing twelve-month measurement period. Additionally, on June 29, 2022, ResMed Pty Limited entered into a Second Amendment to the Syndicated Facility Agreement (the “Term Credit Agreement”). The Term Credit Agreement, among other things, provides ResMed Limited a senior unsecured term credit facility of $200.0 million. The Revolving Credit Agreement and Term Credit Agreement each terminate on June 29, 2027, when all unpaid principal and interest under the loans must be repaid. As of September 30, 2023, we had $825.0 million available for draw down under the revolving credit facility.
On July 10, 2019, we entered into a Note Purchase Agreement with the purchasers to that agreement, in connection with the issuance and sale of $250.0 million principal amount of our 3.24% senior notes due July 10, 2026, and $250.0 million principal amount of our 3.45% senior notes due July 10, 2029 (“Senior Notes”).
On September 30, 2023, there was a total of $1,365.0 million outstanding under the Revolving Credit Agreement, Term Credit Agreement and Senior Notes. We expect to satisfy all of our liquidity and long-term debt requirements through a combination of cash on hand, cash generated from operations and debt facilities.
Cash Flow Summary
The following table summarizes our cash flow activity (in thousands):
 Three Months Ended
September 30,
 20232022
Net cash provided by operating activities$286,283 $44,662 
Net cash used in investing activities(148,980)(58,806)
Net cash used in financing activities(151,132)(41,880)
Effect of exchange rate changes on cash(4,962)(10,523)
Net decrease in cash and cash equivalents$(18,791)$(66,547)
Operating Activities
Cash provided by operating activities was $286.3 million for the three months ended September 30, 2023, compared to cash provided of $44.7 million for the three months ended September 30, 2022. The $241.6 million increase in cash flow from operations was primarily due to lower cash outflows on inventory purchases and greater cash inflows from customer payments during the three months ended September 30, 2023 compared to the three months ended September 30, 2022.
Investing Activities
Cash used in investing activities was $149.0 million for the three months ended September 30, 2023, compared to cash used of $58.8 million for the three months ended September 30, 2022. The $90.2 million increase in cash flow used in
29
PART I – FINANCIAL INFORMATIONItem 2
RESMED INC. AND SUBSIDIARIES
Management’s Discussion and Analysis of Financial Condition and Results of Operations
investing activities was primarily due to cash used to acquire Somnoware, a leader in digital sleep and respiratory care diagnostics software for sleep labs and physicians.
Financing Activities
Cash used in financing activities was $151.1 million for the three months ended September 30, 2023, compared to cash used of $41.9 million for the three months ended September 30, 2022. The $109.3 million increase in cash flow used in financing activities was primarily due to borrowing activity under our Revolving Credit Agreement in order to finance our acquisition of Somnoware.
Dividends
During the three months ended September 30, 2023, we paid cash dividends of $0.48 per common share totaling $70.6 million. On October 26, 2023, our board of directors declared a cash dividend of $0.48 per common share, to be paid on December 14, 2023, to shareholders of record as of the close of business on November 9, 2023. Future dividends are subject to approval by our board of directors.
Common Stock
On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. Since approval of the share repurchase program in 2014 through September 30, 2023, we have repurchased a total of 7.1 million shares under this repurchase program for an aggregate of $413 million. We did not repurchase any shares during the three months ended September 30, 2023 and 2022. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares of common stock outstanding used in calculating earnings (loss) per share. We are authorized to continue repurchasing shares through June 30, 2024, provided that the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. At September 30, 2023, 12.9 million additional shares remain available for us to repurchase under the approved share repurchase program.
Critical Accounting Principles and Estimates
The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, including those related to allowance for doubtful accounts, inventory reserves, warranty obligations, goodwill, potentially impaired assets, intangible assets, income taxes and contingencies.
We state these accounting policies in the notes to the financial statements and at relevant sections in this discussion and analysis. The estimates are based on the information that is currently available to us and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could vary from those estimates under different assumptions or conditions.
For a full discussion of our critical accounting policies, see our Annual Report on Form 10-K for the fiscal year ended June 30, 2023.
Recently Issued Accounting Pronouncements
None
Contractual Obligations and Commitments
There have been no material changes outside the ordinary course of business in our outstanding contractual obligations from those disclosed within “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023.
Off-Balance Sheet Arrangements
As of September 30, 2023, we are not involved in any significant off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated by the SEC.
30
PART I – FINANCIAL INFORMATIONItem 3
RESMED INC. AND SUBSIDIARIES
Quantitative and Qualitative Disclosures About Market Risk

Foreign Currency Market Risk
Our reporting currency is the U.S. dollar, although the financial statements of our non-U.S. subsidiaries are maintained in their respective local currencies. We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through our Australian and Singapore manufacturing activities and our international sales operations.
Net Investment and Fair Value Hedging
On November 17, 2022, we executed foreign cross-currency swaps as net investment hedges and fair value hedges in designated hedging relationships with either the foreign denominated net asset balances or the foreign denominated intercompany loan as the hedged items. All derivatives are recorded at fair value as either an asset or liability. Cash flows associated with derivative instruments are presented in the same category on the consolidated statements of cash flows as the hedged item.
The purpose of the cross-currency swaps for the fair value hedge is to mitigate foreign currency risk associated with changes in spot rates on foreign denominated intercompany debt between USD and EUR. For these hedges, we excluded certain components from the assessment of hedge effectiveness that are not related to spot rates. For fair value hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in the same line item as the hedged item, Other, net, in the condensed consolidated statement of operations. The initial fair value of hedge components excluded from the assessment of effectiveness is recognized in the statement of operations under a systematic and rational method over the life of the hedging instrument and is presented in interest (expense) income, net. Any difference between the change in the fair value of the hedge components excluded from the assessment of effectiveness and the amounts recognized in earnings is recorded as a component of other comprehensive income.
The purpose of the cross-currency swaps for the net investment hedge is to mitigate foreign currency risk associated with changes in spot rates on the net asset balances of our foreign functional subsidiaries. For net investment hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in cumulative translation adjustment within other comprehensive loss and reclassified into earnings when the hedged net investment is either sold or substantially liquidated. The initial fair value of components excluded from the assessment of hedge effectiveness will be recognized in interest (expense) income, net.
The notional value of outstanding foreign cross-currency swaps was $1,014.8 million and $1,046.6 million at September 30, 2023 and June 30, 2023, respectively. These contracts mature at various dates prior to December 31, 2029.
Non-Designated Hedges
We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have foreign currency exposure through both our Australian and Singapore manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased foreign currency call options, collars and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed three years. The purpose of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, and Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not designate these foreign currency contracts as hedges. All movements in the fair value of the foreign currency instruments are recorded within other, net in our condensed consolidated statements of operations.
The notional value of the outstanding non-designated hedges was $1,363.3 million and $954.7 million at September 30, 2023 and June 30, 2023, respectively. These contracts mature at various dates prior to March 15, 2025.
31
PART I – FINANCIAL INFORMATIONItem 3
RESMED INC. AND SUBSIDIARIES
Quantitative and Qualitative Disclosures About Market Risk
Fair Values of Derivative Instruments
The table below provides information (in U.S. dollars) on our foreign currency denominated operating assets and liabilities and after considering our foreign currency hedging activities as of September 30, 2023 (in thousands):
 U.S.
Dollar
(USD)		Euro
(EUR)		Canadian
Dollar
(CAD)		Chinese
Yuan
(CNY)
AUD Functional:
Net Assets/(Liabilities)412,361 (141,366)— 30,193 
Foreign Currency Hedges(415,000)111,160 — (10,996)
Net Total(2,639)(30,206)— 19,197 
USD Functional:    
Net Assets/(Liabilities)— 300,172 26,330 — 
Foreign Currency Hedges— (296,426)(29,445)— 
Net Total— 3,746 (3,115)— 
SGD Functional:    
Net Assets/(Liabilities)493,152 108,853 — 1,319 
Foreign Currency Hedges(495,000)(127,040)— — 
Net Total(1,848)(18,187)— 1,319 
32
PART I – FINANCIAL INFORMATIONItem 3
RESMED INC. AND SUBSIDIARIES
Quantitative and Qualitative Disclosures About Market Risk
The table below provides information about our material foreign currency derivative financial instruments and presents the information in U.S. dollar equivalents. The table summarizes information on instruments and transactions that are sensitive to foreign currency exchange rates, including foreign currency call options, collars, forward contracts and cross-currency swaps held at September 30, 2023. The table presents the notional amounts and weighted average exchange rates by contractual maturity dates for our foreign currency derivative financial instruments, including the forward contracts used to hedge our foreign currency denominated assets and liabilities. These notional amounts generally are used to calculate payments to be exchanged under the contracts (in thousands, except exchange rates).
Fair Value Assets / (Liabilities)
TotalSeptember 30,
2023		June 30,
2023
AUD/USD
Contract amount415,000(11,268)(1,064)
Ave. contractual exchange rateAUD 1 = USD 0.6624
AUD/Euro
Contract amount206,439(861)(915)
Ave. contractual exchange rateAUD 1 = EUR 0.6351
SGD/Euro
Contract amount206,4391,815 (1,760)
Ave. contractual exchange rateSGD 1 = Euro 0.6903
SGD/USD
Contract amount495,000(11,561)(4,133)
Ave. contractual exchange rateSGD 1 = USD 0.7513
AUD/CNY
Contract amount10,996(324)(31)
Ave. contractual exchange rateAUD 1 = CNY 4.7507
USD/EUR
Contract amount1,014,831(27,250)(60,546)
Ave. contractual exchange rateUSD 1 = EUR .9610
USD/CAD
Contract amount29,445929 156 
Ave. contractual exchange rateCAD 1 = USD 0.7594
Interest Rate Risk
We are exposed to risk associated with changes in interest rates affecting the return on our cash and cash equivalents and debt. At September 30, 2023, we held cash and cash equivalents of $209.1 million, principally comprised of bank term deposits and at-call accounts, and are invested at both short-term fixed interest rates and variable interest rates. At September 30, 2023, there was $865.0 million outstanding under the Revolving Credit Agreement and Term Credit Agreement, which are subject to variable interest rates. A hypothetical 10% change in interest rates during the three months ended September 30, 2023, would not have had a material impact on pretax income. We have no interest rate hedging agreements.
Inflation
Inflationary factors such as increases in the cost of our products, freight, overhead costs or wage rates may adversely affect our operating results. Sustained inflationary pressures in the future may have an adverse effect on our ability to maintain current levels of gross margin and operating expenses as a percentage of net revenue if we are unable to offset such higher costs through price increases.

33
PART I – FINANCIAL INFORMATIONItem 4
RESMED INC. AND SUBSIDIARIES
Item 4    Controls and Procedures
We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our reports made pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance management necessarily was required to apply its judgment in evaluating the cost benefit relationship of possible controls and procedures.
As required by Rule 13a-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2023.
There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
34
PART II – OTHER INFORMATIONItem 1-6
RESMED INC. AND SUBSIDIARIES
PART II. OTHER INFORMATION
Item 1    Legal Proceedings
We are involved in various legal proceedings, claims, investigations and litigation that arise in the ordinary course of our business. We investigate these matters as they arise, and accrue estimates for resolution of legal and other contingencies in accordance with Accounting Standard Codification Topic 450, “Contingencies”. See note 9 to the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.
Litigation is inherently uncertain. Accordingly, we cannot predict with certainty the outcome of these matters. But we do not expect the outcome of these matters to have a material adverse effect on our consolidated financial statements when taken as a whole.
Item 1A    Risk Factors
The discussion of our business and operations should be read together with the risk factors contained in our annual report on Form 10-K for the fiscal year ended June 30, 2023, which was filed with the SEC and describe various material risks and uncertainties to which we are or may become subject. As of September 30, 2023, there have been no further material changes to such risk factors.
Item 2    Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities
Purchases of equity securities. On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant and subject to applicable legal requirements. We are authorized to continue repurchasing shares through June 30, 2024, provided that the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. All share repurchases after February 21, 2014 have been executed under this program.
We suspended our share repurchase program in fiscal year 2019. As a result, we did not repurchase any shares during the three months ended September 30, 2023. However, we recently announced in October 2023 that our board of directors has elected to reactivate and resume share repurchases pursuant to the share repurchase program as the circumstances allow. Since approval of the share repurchase program in 2014 through September 30, 2023, we have repurchased a total of 7.1 million shares under this repurchase program for an aggregate of $413 million. At September 30, 2023, 12.9 million additional shares of common stock can be repurchased under the approved share repurchase program.
Item 3    Defaults Upon Senior Securities
None
Item 4    Mine Safety Disclosures
None
Item 5    Other Information
During the quarterly period ended September 30, 2023, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement, and/or any non-Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408(a) of Regulation S-K).
35
PART II – OTHER INFORMATIONItem 1-6
RESMED INC. AND SUBSIDIARIES
Item 6    Exhibits
Exhibits (numbered in accordance with Item 601 of Regulation S-K)
3.1
3.2
31.1
31.2
32*
101
The following financial statements from ResMed Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, filed on October 26, 2023, formatted in Inline XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Comprehensive Income, (iv) Condensed Consolidated Statements of Cash Flows, (v) the Notes to the Condensed Consolidated Financial Statements.
104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).
*In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 33-8238 and 34-47986, Final Rule: Management’s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibit 32 hereto are deemed to accompany this Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.


36
PART II – OTHER INFORMATIONSignatures
RESMED INC. AND SUBSIDIARIES
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
October 26, 2023
ResMed Inc.
/s/ MICHAEL J. FARRELL
Michael J. Farrell
Chief Executive Officer
(Principal Executive Officer)
/s/ BRETT A. SANDERCOCK
Brett A. Sandercock
Chief Financial Officer
(Principal Financial Officer)
37
 EX-31.1 2 rmd-20230930xex311.htm EX-31.1 Document

EXHIBIT 31.1
Certification of Chief Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Michael J. Farrell, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of ResMed Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
October 26, 2023
/s/ MICHAEL J. FARRELL
Michael J. Farrell
Chief Executive Officer
(Principal Executive Officer)

 EX-31.2 3 rmd-20230930xex312.htm EX-31.2 Document

EXHIBIT 31.2
Certification of Chief Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Brett A. Sandercock, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of ResMed Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
October 26, 2023
/s/ BRETT A. SANDERCOCK
Brett A. Sandercock
Chief Financial Officer
(Principal Financial Officer)

 EX-32.1 4 rmd-20230930xex32.htm EX-32.1 Document

EXHIBIT 32.1
The following certifications are being furnished solely to accompany the Quarterly Report pursuant to 18 U.S.C. Section 1350 and in accordance with SEC Release No. 33-8238. These certifications shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be incorporated by reference in any filing made by ResMed Inc. under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Michael J. Farrell, Chief Executive Officer of ResMed Inc., a Delaware corporation (the “Company”), hereby certify that to my knowledge:
(i)the accompanying Quarterly Report on Form 10-Q of the Company for the period ended September 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii) the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
October 26, 2023
/s/ MICHAEL J. FARRELL
Michael J. Farrell
Chief Executive Officer
(Principal Executive Officer)
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Brett A. Sandercock, Chief Financial Officer of the Company, hereby certify that to my knowledge:
(i)the accompanying Quarterly Report on Form 10-Q of the Company for the period ended September 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii)the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
October 26, 2023
/s/ BRETT A. SANDERCOCK
Brett A. Sandercock
Chief Financial Officer
(Principal Financial Officer)
A signed original of this written statement required by Section 906 has been provided to ResMed Inc. and will be retained by ResMed Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-101.SCH 5 rmd-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Supplemental Balance Sheet Information link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Goodwill link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Product Warranties link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Legal Actions, Contingencies and Commitments link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Derivative Instruments and Hedging Activities link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Supplemental Balance Sheet Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Product Warranties (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Derivative Instruments and Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Summary of Significant Accounting Policies - Schedule Of Net Revenue Disaggregated By Product And Region (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Summary of Significant Accounting Policies - Schedule Of Contract Balances (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Segment Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Segment Information - Schedule of Revenue By Segment And Reconciling Items (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Supplemental Balance Sheet Information - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Supplemental Balance Sheet Information - Schedule of Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Supplemental Balance Sheet Information - Schedule of Components of Property, Plant And Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Intangible Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Investments - Schedule of Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Investments - Schedule of Changes in Equity Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Product Warranties (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Debt - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Earnings Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Earnings Per Share - Schedule of Basic And Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Legal Actions, Contingencies and Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Derivative Instruments and Hedging Activities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Fair Values of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Fair Value Hedge Gains (Losses) (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Net Investment Hedge Gains (Losses) (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Non-Designated Derivative Gains (Losses) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 rmd-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 rmd-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 rmd-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate [Domain] Variable Rate [Domain] Pay vs Performance Disclosure [Line Items] Accrued expenses Accrued Liabilities, Current Other long-term liabilities Other Noncurrent Liabilities [Member] Range [Domain] Statistical Measurement [Domain] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent All Award Types Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Debt Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Cash paid for acquisitions Payments to Acquire Businesses, Gross Revolving Credit Facility Revolving Credit Facility [Member] Effect of exchange rate changes on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Fair Value And Net Investment Hedging Fair Value And Net Investment Hedging [Member] Fair Value And Net Investment Hedging Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts payable Accounts Payable, Current Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Restatement Determination Date: Restatement Determination Date [Axis] Purchases of investments (note 5) Payments to Acquire Investments Total other income (loss), net Nonoperating Income (Expense) Commitments and contingencies (note 9) Commitments and Contingencies Amortization of acquired intangible assets Amortization of acquired intangible assets Amortization of acquired intangible assets 1 The aggregate expense charged against earnings to allocate the cost of acquired intangible assets. Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Proceeds from issuance of common stock, net Proceeds from Issuance of Common Stock Schedule of Goodwill [Table] Schedule of Goodwill [Table] Geographical [Axis] Geographical [Axis] Organization and Basis of Presentation Organization And Basis Of Presentation, Policy [Policy Text Block] Organization And Basis Of Presentation, Policy [Policy Text Block] Warranty costs incurred for the period Standard and Extended Product Warranty Accrual, Decrease for Payments Warranty accruals for the period Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Common stock issued on vesting of restricted stock units, net of shares withheld for tax (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Current liabilities: Liabilities, Current [Abstract] Preferred stock, par value per share (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued Preferred Stock, Value, Issued Line of credit facility collateral, maximum percentage of ownership interests held in subsidiary Line of credit facility, collateral, percentage of the company Line of credit facility collateral, percentage of the company Deferred borrowing costs Debt Issuance Costs, Noncurrent, Net Payments of business combination contingent consideration Payment for Contingent Consideration Liability, Financing Activities Diluted earnings per share (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Hedging Relationship [Axis] Hedging Relationship [Axis] Accounts receivable, net of allowances of $20,532 and $23,603 at September 30, 2023 and June 30, 2023, respectively Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Goodwill [Roll Forward] Goodwill [Roll Forward] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current [Abstract] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Treasury stock, shares (in shares) Treasury stock, common, beginning balance (in shares) Treasury stock, common, ending balance (in shares) Treasury Stock, Common, Shares Non-current assets: Assets, Noncurrent [Abstract] Common stock issued on exercise of options Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Long-term debt, fair value Long-Term Debt, Fair Value Net income Net income Net income Net income Net Income (Loss) Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Proceeds from exits of investments Payments for (Proceeds from) Investments Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Prepaid taxes Prepaid Taxes Stockholders’ equity: Equity, Attributable to Parent [Abstract] Common stock issued on exercise of options (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Gain (loss) recognized in other comprehensive income (loss) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Other intangibles Other Intangible Assets [Member] Schedule of Basic and Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Total cost of sales Cost of Goods and Services Sold Executive Category: Executive Category [Axis] Foreign currency hedging instruments Foreign Exchange Contract [Member] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Name Measure Name Available for draw Line of Credit Facility, Current Borrowing Capacity Name Forgone Recovery, Individual Name Goodwill (note 4) Balance at the beginning of the period Balance at the end of the period Goodwill Schedule of Components of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Hedging Relationship [Domain] Hedging Relationship [Domain] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Notional value Derivative, Notional Amount Dividend declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Operating lease liabilities, non-current Operating Lease, Liability, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Accrued expenses Accrued Liabilities [Member] Supplemental Balance Sheet Information Supplemental Balance Sheet Information [Text Block] Supplemental Balance Sheet Information [Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Line of Credit Facility [Table] Line of Credit Facility [Table] Non-marketable securities Non Marketable Securities [Member] Non-marketable Securities [Member] Total Sleep and Respiratory Care Sleep And Respiratory [Member] Sleep And Respiratory [Member] Stock options and restricted stock units (shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Masks and other Masks and Other [Member] Masks and Other [Member] Other Foreign Exchange Contracts Other Foreign Exchange Contracts [Member] Other Foreign Exchange Contracts Income taxes payable Accrued Income Taxes, Current Products and Services [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventories Increase (Decrease) in Inventories Unbilled revenue, current Contract with Customer, Asset, after Allowance for Credit Loss, Current Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Contract liabilities Contract with Customer, Liability [Abstract] Award Type Award Type [Axis] Gain (loss) recognized on cross-currency swap in interest (expense) income, net (amount excluded from effectiveness testing) Derivative, Excluded Component, Gain (Loss), Recognized in Earnings Antidilutive securities excluded from computation of earnings per share, amount (share) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Derivative Instruments and Hedging Activities Disclosure [Abstract] Document Quarterly Report Document Quarterly Report Contract with Customer, Asset and Liability [Table] Contract with Customer, Asset and Liability [Table] Contract with Customer, Asset and Liability [Table] Interest expense (income), net Interest Expense Hedging Designation [Axis] Hedging Designation [Axis] Goodwill [Line Items] Goodwill [Line Items] Property, plant and equipment, at cost Property, Plant and Equipment, Gross Gain (loss) recognized in cumulative translation adjustment within other comprehensive income (loss) Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Trading Arrangement: Trading Arrangement [Axis] Astral field safety notification expenses (1) Astral Field Action Notification Expenses Astral Field Action Notification Expenses PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Operating lease liabilities, current Operating Lease, Liability, Current Derivative, term of contract (in years) Derivative, Term of Contract Liabilities assumed Noncash or Part Noncash Acquisition, Value of Liabilities Assumed Receivables sold with limited recourse Receivables Sold With Limited Recourse Receivables Sold With Limited Recourse Amortization of acquired intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Other intangible assets, net (note 3) Total other intangibles, net Finite-Lived Intangible Assets, Net Restatement Determination Date Restatement Determination Date Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Gain (loss) recognized from the excluded components in interest (expense) income, net Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax Deferred revenue (current liabilities) Deferred Revenue Current Liabilities [Member] Deferred Revenue Current Liabilities [Member] Common stock, shares issued (in shares) Common Stock, Shares, Issued Proceeds from exits of investments (note 5) Proceeds from Sale, Maturity and Collection of Investments Gross profit Gross Profit Commitment fees percentage rate on unused portion of credit facility Line of Credit Facility, Commitment Fee Percentage Deferred revenue Deferred revenue, current Contract with Customer, Liability, Current Treasury stock, at cost, 41,836,234 shares at September 30, 2023 and June 30, 2023 Treasury Stock, Common, Value Security Exchange Name Security Exchange Name Long-term debt, net (note 7) Long-term debt, net Long-Term Debt Selling, general, and administrative Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Employee Stock Option Employee Stock Option [Member] Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Global revenue Global [Member] Global [Member] Maximum Maximum [Member] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Business acquisitions Goodwill, Acquired During Period Tabular List, Table Tabular List [Table Text Block] Currency Swap Currency Swap [Member] Entity Address, Address Line One Entity Address, Address Line One Foreign currency translation adjustments Temporary Equity, Foreign Currency Translation Adjustments Cost of sales (exclusive of amortization shown separately below) Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Short-term debt Short-Term Debt, Gross Short-Term Debt, Gross Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration] Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration] Schedule of Changes in Equity Investments Schedule Of Changes In Equity Investments [Table Text Block] Schedule Of Changes In Equity Investments [Table Text Block] Accounts receivable, allowance for credit loss, current Accounts Receivable, Allowance for Credit Loss, Current Uncommitted option to increase credit facility Uncommitted option to increase credit facility Uncommitted option to increase credit facility Revolving Credit Agreement, Term Credit Agreement, and Senior Notes Revolving Credit Agreement Term Credit Agreement And Senior Notes [Member] Revolving Credit Agreement, Term Credit Agreement, And Senior Notes [Member] Derivative [Table] Derivative [Table] Deferred payments Deferred Payment Obligations For Acquisitions Deferred Payment Obligations For Acquisitions Schedule of Other Intangible Assets, Net Schedule of Finite-Lived Intangible Assets [Table Text Block] Variable Rate [Axis] Variable Rate [Axis] Accounts payable, accrued expenses, income taxes payable and other Increase (Decrease) in Accounts Payable and Accrued Liabilities Deferred revenue recognized, term Term Of Contract Under Revenue Recognition Term Of Contract Under Revenue Recognition Income Statement [Abstract] Income Statement [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Derivative Liabilities Derivative Liability Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Operating Segments Operating Segments [Member] Other prepaid expenses and current assets Other Assets, Current Stock-based compensation costs Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Entity Tax Identification Number Entity Tax Identification Number Foreign currency translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) Equity method Equity Method Investments Total debt Outstanding debt Debt, Long-Term and Short-Term, Combined Amount Inventories (note 3) Total inventories Inventory, Net Statistical Measurement [Axis] Statistical Measurement [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Total Shareholder Return Amount Total Shareholder Return Amount Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Deferred income taxes Deferred Income Taxes and Other Tax Liabilities, Noncurrent (Payments) / proceeds on maturity of foreign currency contracts Payments for (Proceeds from) Derivative Instrument, Investing Activities Segments [Domain] Segments [Domain] Total Equity Investments, Total by Measurement Category Equity Investments, Total by Measurement Category Consolidation Items [Domain] Consolidation Items [Domain] Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Contingent provision Loss Contingency Accrual, Provision Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Principal amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Product Warranties Disclosures [Abstract] Product Warranties Disclosures [Abstract] Lease Revenue Lease Revenue [Policy Text Block] Lease Revenue [Policy Text Block] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Fair value of contingent consideration Business Acquisition, Contingent Consideration, Recognized Liability Business Acquisition, Contingent Consideration, Recognized Liability Deferred borrowing costs Debt Issuance Costs, Current, Net 3.45% Senior Notes Due July 10, 2029 Senior Notes Two [Member] Senior Notes Two [Member] Common stock, shares outstanding (in shares) Common stock, shares outstanding, beginning balance (in shares) Common stock, shares outstanding, ending balance (in shares) Common Stock, Shares, Outstanding Dividends declared Dividends PEO PEO [Member] Maximum potential contingent liability Loss Contingency, Estimate of Possible Loss Unbilled revenue, non-current Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent Total non-current assets Assets, Noncurrent Accounts receivable, net Accounts Receivable Net [Member] Accounts Receivable Net [Member] Common stock, par value per share (in dollars per share) Common Stock, Par or Stated Value Per Share Prepaid taxes and other non-current assets Prepaid Taxes And Other Non Current Assets [Member] Prepaid Taxes And Other Non Current Assets [Member] Term Loan Credit Agreement Term Loan Credit Agreement [Member] Term Loan Credit Agreement [Member] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount (Gain) loss on equity investments (note 5) (Gain) loss on equity investments Debt and Equity Securities, Unrealized Gain (Loss) Credit Facility [Axis] Credit Facility [Axis] Total liabilities Liabilities Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] EBITDA multiple of trailing twelve-month measurement period Debt Instrument, EBITDA Multiple of Trailing Twelve-Month Measurement Period Debt Instrument, EBITDA Multiple of Trailing Twelve-Month Measurement Period Prepaid expenses, net deferred income taxes and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated ‎Other ‎Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount All Executive Categories All Executive Categories [Member] Deferred revenue Deferred revenue, non-current Contract with Customer, Liability, Noncurrent Non-current liabilities: Liabilities, Noncurrent [Abstract] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Gain (loss) recognized on intercompany debt in other, net Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Effect of dilutive securities: Earnings Per Share, Diluted, Other Disclosure [Abstract] Mufg Union Bank Mufg Union Bank [Member] Mufg Union Bank Amortization of right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Equity method investments Equity Method Investments [Member] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Senior Notes Senior Notes [Member] Total current assets Assets, Current All Individuals All Individuals [Member] Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Other, net Other, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Mufg Union Bank Na and Westpac Banking Corporation Mufg Union Bank Na And Westpac Banking Corporation [Member] Mufg Union Bank Na And Westpac Banking Corporation PEO Name PEO Name Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Base Rate Base Rate [Member] Schedule of Changes in Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Schedule of Prepaid Expenses and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Schedule of Investments Schedule Of Investments [Table Text Block] Schedule Of Investments [Table Text Block] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Corporate Costs Corporate, Non-Segment [Member] Deferred income taxes Deferred Income Taxes and Other Assets, Noncurrent Depreciation and amortization Depreciation and amortization by segment Depreciation, Depletion and Amortization Interest rate Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Balance at the beginning of the period Balance at the end of the period Standard and Extended Product Warranty Accrual Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Consolidation Items [Axis] Consolidation Items [Axis] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Foreign currency translation (loss) gain adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Measurement alternative Equity Securities without Readily Determinable Fair Value, Amount Patent registration and acquisition costs Payments to Acquire Intangible Assets Numerator: Income Amounts Attributable to Parent, Disclosures [Abstract] Secured Overnight Financing Rate Secured Overnight Financing Rate [Member] Secured Overnight Financing Rate Not Designated as Hedging Instruments Not Designated as Hedging Instrument [Member] Contract with Customer, Asset and Liability [Line Items] Contract with Customer, Asset and Liability [Line Items] Contract with Customer, Asset and Liability [Line Items] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Hedging Designation [Domain] Hedging Designation [Domain] Net Investment Hedging Net Investment Hedging [Member] Entity Emerging Growth Company Entity Emerging Growth Company Schedule of Changes in Liability for Warranty Costs Schedule of Product Warranty Liability [Table Text Block] Interest rate on outstanding principal amount Debt Instrument, Interest Rate, Effective Percentage Schedule of Derivative Gains (Losses) Derivative Instruments, Gain (Loss) [Table Text Block] Provision For Warranty Standard Product Warranty, Policy [Policy Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Intangible assets, estimated useful life Finite-Lived Intangible Asset, Useful Life Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Title Trading Arrangement, Individual Title 3.24% Senior Notes Due July 10, 2026 Senior Notes One [Member] Senior Notes One [Member] Stock-based compensation costs Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Long-term income taxes payable Accrued Income Taxes, Noncurrent Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Earnings Per Share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Segment, Geographical [Domain] Geographical [Domain] Minimum Minimum [Member] Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property, plant and equipment, net (note 3) Property, plant and equipment, net Property, Plant and Equipment, Net Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Total Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Proceeds from borrowings, net of borrowing costs Proceeds from Issuance of Long-Term Debt Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Income taxes paid, net of refunds Income Taxes Paid, Net Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Legal Actions, Contingencies and Commitments Commitments and Contingencies Disclosure [Text Block] Retained Earnings Retained Earnings [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Other income (loss), net: Nonoperating Income (Expense) [Abstract] Prepaid taxes and other non-current assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Number of patents Number of Patents Number of Patents Unrealized losses on designated hedging instruments Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Basic earnings per share (in dollars per share) Earnings Per Share, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Contract assets Contract with Customer, Asset, after Allowance for Credit Loss [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Derivative Asset, Current, Statement of Financial Position [Extensible Enumeration] Derivative Asset, Current, Statement of Financial Position [Extensible Enumeration] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Product Warranties Product Warranty Disclosure [Text Block] Corporate costs Unallocated Corporate Costs Unallocated corporate costs. Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Debt to consolidated EBITDA ratio Debt To Consolidated EBITDA Ratio Debt To Consolidated EBITDA Ratio Schedule of Revenue by Segment and Reconciling Items Schedule of Segment Reporting Information, by Segment [Table Text Block] Total non-current liabilities Liabilities, Noncurrent Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Interest Expense Interest Expense [Member] Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Termination Date Trading Arrangement Termination Date Goodwill on acquisition Goodwill, Acquired During Period, Increase (Decrease) Goodwill, Acquired During Period, Increase (Decrease) Common stock, shares authorized (shares) Common Stock, Shares Authorized Short-term debt, net (note 7) Short-term debt, net Short-Term Debt Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Fair value Marketable Equity Investments, Fair Value Marketable Equity Investments, Fair Value Gain (loss) on equity investments (note 5) Equity Securities, FV-NI, Gain (Loss) Entity Address, Country Entity Address, Country Derivative Instrument [Axis] Derivative Instrument [Axis] Long-term debt Long-Term Debt, Gross Adjustment to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Additions to investments Additional Equity Investments Additional Equity Investments All Trading Arrangements All Trading Arrangements [Member] Revolving Credit Facility and Term Credit Agreement Revolving Credit Facility And Term Loan Credit Agreement [Member] Revolving Credit Facility And Term Loan Credit Agreement [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Derivative [Line Items] Derivative [Line Items] Common stock, $0.004 par value, 350,000,000 shares authorized; 188,921,316 issued and 147,085,082 outstanding at September 30, 2023 and 188,900,583 issued and 147,064,349 outstanding at June 30, 2023 Common Stock, Value, Outstanding Award Timing Disclosures [Line Items] Investments Investment [Text Block] Compensation Amount Outstanding Recovery Compensation Amount Equity Method Investments [Roll Forward] Equity Method Investments [Roll Forward] Equity Method Investments Other comprehensive income (loss), net of taxes: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Derivative Assets Derivative Asset Schedule of Fair Values of Derivative Instruments Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Prepaid expenses and other current assets (note 3) Total prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Developed/core product technology Developed Or Core Product Technology [Member] Developed/ Core Product Technology [Member] Insider Trading Arrangements [Line Items] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Movement in Standard Product Warranty Accrual [Roll Forward] Movement in Standard Product Warranty Accrual [Roll Forward] Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Equity securities, unrealized loss Equity Securities, FV-NI, Unrealized Gain (Loss) Adjustment to Compensation, Amount Adjustment to Compensation Amount Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Common stock issued on vesting of restricted stock units, net of shares withheld for tax Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Repayment of borrowings Repayments of Long-Term Debt Treasury Stock Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Gain (loss) recognized on cross-currency swap in other, net Derivative, Gain (Loss) on Derivative, Net Devices Devices [Member] Devices [Member] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Other intangibles, gross Finite-Lived Intangible Assets, Gross Income taxes Income Tax Expense (Benefit) Software as a Service Software As Service [Member] Software As A Service [Member] Finished goods Inventory, Finished Goods, Net of Reserves Designated as Hedging Instruments Designated as Hedging Instrument [Member] Number of operating segments Number of Operating Segments Name Trading Arrangement, Individual Name Schedule of Net Revenue Disaggregated by Product and Region Disaggregation of Revenue [Table Text Block] Lender Name [Axis] Lender Name [Axis] Marketable securities Marketable Securities [Member] Marketable Securities [Member] SaaS Saas [Member] Saas [Member] Net revenue Net revenue by segment Revenue from Contract with Customer, Excluding Assessed Tax Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] Fair Value Hedging Fair Value Hedging [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Business acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Senior notes, carrying amount Senior Notes Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Interest (expense) income, net Interest Income (Expense), Net Credit Facility [Domain] Credit Facility [Domain] Balance at the beginning of the period Carrying value at the end of the period Equity Investments Equity Investments U.S., Canada and Latin America Us Canada And Latin America [Member] US Canada And Latin America [Member] Credit facility interest rate equal to reference rate plus Debt Instrument, Basis Spread on Variable Rate Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Goodwill Goodwill Disclosure [Text Block] Diluted shares outstanding (000's) (in shares) Diluted weighted average shares (shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Schedule of Contract Balances Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Prepaid inventories Prepaid Inventory Prepaid Inventory Operating Expenses Operating Expenses [Abstract] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock Additional ‎Paid-in Capital Additional Paid-in Capital [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Loss attributable to equity method investments (note 5) Loss attributable to equity method investments (note 5) Loss attributable to equity method investments Loss attributable to equity method investments Income (Loss) from Equity Method Investments Cover [Abstract] Cover [Abstract] Foreign currency translation adjustments Standard and Extended Product Warranty Accrual, Foreign Currency Translation Gain (Loss) Reconciling items Segment Reconciling Items [Member] Dividends paid Payments of Dividends Other long-term liabilities Other Liabilities, Noncurrent Deferred revenue (non-current liabilities) Deferred Revenue Non Current Liabilities [Member] Deferred Revenue Non Current Liabilities [Member] Non-NEOs Non-NEOs [Member] Other Nonoperating Income (Expense) Other Nonoperating Income (Expense) [Member] Non-Designated Hedges Cash Flow Hedging [Member] Total operating expenses Operating Expenses Segment Information Segment Reporting Disclosure [Text Block] Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Work in progress Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Principal payment Line of Credit Facility, Periodic Payment, Principal Debt Instrument [Line Items] Debt Instrument [Line Items] Basic shares outstanding (000's) (in shares) Basic weighted-average common shares outstanding (shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Unrealized losses on marketable equity securities Marketable Security, Unrealized Gain (Loss) Income from operations Net operating profit by segment Operating Income (Loss) Combined Europe, Asia and other markets Combined Europe Asia And Other Markets [Member] Combined Europe Asia And Other Markets [Member] Supplemental Balance Sheet Information [Abstract] Supplemental Balance Sheet Information [Abstract] Supplemental Balance Sheet Information [Abstract] Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Operating lease revenue Operating Lease, Lease Income Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Segments [Axis] Segments [Axis] Statement [Line Items] Statement [Line Items] ResMed Limited Resmed Limited [Member] ResMed Limited [Member] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Schedule of Debt Schedule of Debt [Table Text Block] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Customer relationships Customer Relationships [Member] Fair value of assets acquired, excluding cash Noncash Part Of Acquisition, Fair Value of Assets Acquired The fair value of an asset or business acquired in a noncash acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. EX-101.PRE 9 rmd-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
 3 Months Ended
Sep. 30, 2023
Oct. 23, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 001-15317  
Entity Registrant Name ResMed Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 98-0152841  
Entity Address, Address Line One 9001 Spectrum Center Blvd.  
Entity Address, City or Town San Diego  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92123  
Entity Address, Country US  
City Area Code 858  
Local Phone Number 836-5000  
Title of 12(b) Security Common Stock, par value $0.004 per share  
Trading Symbol RMD  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   147,091,910
Amendment Flag false  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Current Fiscal Year End Date --06-30  
Entity Central Index Key 0000943819  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Jun. 30, 2023
Current assets:    
Cash and cash equivalents $ 209,100 $ 227,891
Accounts receivable, net of allowances of $20,532 and $23,603 at September 30, 2023 and June 30, 2023, respectively 692,388 704,909
Inventories (note 3) 958,233 998,012
Prepaid expenses and other current assets (note 3) 444,864 437,018
Total current assets 2,304,585 2,367,830
Non-current assets:    
Property, plant and equipment, net (note 3) 533,985 537,856
Operating lease right-of-use assets 123,416 127,955
Goodwill (note 4) 2,812,142 2,770,299
Other intangible assets, net (note 3) 563,278 552,341
Deferred income taxes 138,271 132,974
Prepaid taxes and other non-current assets 265,109 262,453
Total non-current assets 4,436,201 4,383,878
Total assets 6,740,786 6,751,708
Current liabilities:    
Accounts payable 177,048 150,756
Accrued expenses 348,263 365,660
Operating lease liabilities, current 21,795 21,919
Deferred revenue 146,718 138,072
Income taxes payable 67,073 72,224
Short-term debt, net (note 7) 9,905 9,902
Total current liabilities 770,802 758,533
Non-current liabilities:    
Deferred revenue 121,492 119,186
Deferred income taxes 87,672 90,650
Operating lease liabilities, non-current 112,448 116,853
Other long-term liabilities 34,328 68,166
Long-term debt, net (note 7) 1,351,511 1,431,234
Long-term income taxes payable 12,157 37,183
Total non-current liabilities 1,719,608 1,863,272
Total liabilities 2,490,410 2,621,805
Commitments and contingencies (note 9)
Stockholders’ equity:    
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued 0 0
Common stock, $0.004 par value, 350,000,000 shares authorized; 188,921,316 issued and 147,085,082 outstanding at September 30, 2023 and 188,900,583 issued and 147,064,349 outstanding at June 30, 2023 588 588
Additional paid-in capital 1,791,351 1,772,083
Retained earnings 4,401,841 4,253,016
Treasury stock, at cost, 41,836,234 shares at September 30, 2023 and June 30, 2023 (1,623,256) (1,623,256)
Accumulated other comprehensive loss (320,148) (272,528)
Total stockholders’ equity 4,250,376 4,129,903
Total liabilities and stockholders’ equity $ 6,740,786 $ 6,751,708
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2023
Jun. 30, 2023
Statement of Financial Position [Abstract]    
Accounts receivable, allowance for credit loss, current $ 20,532 $ 23,603
Preferred stock, par value per share (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 2,000,000 2,000,000
Preferred stock, shares issued (in shares) 0 0
Common stock, par value per share (in dollars per share) $ 0.004 $ 0.004
Common stock, shares authorized (shares) 350,000,000 350,000,000
Common stock, shares issued (in shares) 188,921,316 188,900,583
Common stock, shares outstanding (in shares) 147,085,082 147,064,349
Treasury stock, shares (in shares) 41,836,234 41,836,234
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Net revenue $ 1,102,321 $ 950,294
Cost of sales (exclusive of amortization shown separately below) 493,353 403,110
Amortization of acquired intangible assets 8,908 6,374
Total cost of sales 502,261 409,484
Gross profit 600,060 540,810
Operating Expenses    
Selling, general, and administrative 222,874 193,933
Research and development 75,710 63,188
Amortization of acquired intangible assets 12,479 7,950
Total operating expenses 311,063 265,071
Income from operations 288,997 275,739
Other income (loss), net:    
Interest (expense) income, net (14,957) (7,134)
Loss attributable to equity method investments (note 5) (3,895) (2,028)
Gain (loss) on equity investments (note 5) (602) (3,280)
Other, net 2,648 (1,504)
Total other income (loss), net (16,806) (13,946)
Income before income taxes 272,191 261,793
Income taxes 52,769 51,315
Net income $ 219,422 $ 210,478
Basic earnings per share (in dollars per share) $ 1.49 $ 1.44
Diluted earnings per share (in dollars per share) 1.49 1.43
Dividend declared per share (in dollars per share) $ 0.48 $ 0.44
Basic shares outstanding (000's) (in shares) 147,075 146,431
Diluted shares outstanding (000's) (in shares) 147,486 147,134
Total Sleep and Respiratory Care    
Net revenue $ 963,037 $ 844,443
Cost of sales (exclusive of amortization shown separately below) 444,460 363,844
Amortization of acquired intangible assets 1,916 1,228
Software as a Service    
Net revenue 139,284 105,851
Cost of sales (exclusive of amortization shown separately below) 48,893 39,266
Amortization of acquired intangible assets $ 6,992 $ 5,146
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]    
Net income $ 219,422 $ 210,478
Other comprehensive income (loss), net of taxes:    
Unrealized losses on designated hedging instruments (17,093) 0
Foreign currency translation (loss) gain adjustments (30,527) (93,381)
Comprehensive income $ 171,802 $ 117,097
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional ‎Paid-in Capital
Treasury Stock
Retained Earnings
Accumulated ‎Other ‎Comprehensive Income (Loss)
Common stock, shares outstanding, beginning balance (in shares) at Jun. 30, 2022   188,247,000        
Beginning balance at Jun. 30, 2022 $ 3,360,751 $ 586 $ 1,682,432 $ (1,623,256) $ 3,613,736 $ (312,747)
Treasury stock, common, beginning balance (in shares) at Jun. 30, 2022       (41,836,000)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Common stock issued on exercise of options (shares)   45,000        
Common stock issued on exercise of options 2,610   2,610      
Common stock issued on vesting of restricted stock units, net of shares withheld for tax (in shares)   3,000        
Common stock issued on vesting of restricted stock units, net of shares withheld for tax (59)   (59)      
Stock-based compensation costs 16,919   16,919      
Other comprehensive loss (93,381)         (93,381)
Net income 210,478       210,478  
Dividends declared (64,431)       (64,431)  
Common stock, shares outstanding, ending balance (in shares) at Sep. 30, 2022   188,295,000        
Treasury stock, common, ending balance (in shares) at Sep. 30, 2022       (41,836,000)    
Ending balance at Sep. 30, 2022 $ 3,432,887 $ 586 1,701,902 $ (1,623,256) 3,759,783 (406,128)
Common stock, shares outstanding, beginning balance (in shares) at Jun. 30, 2023 147,064,349 188,901,000        
Beginning balance at Jun. 30, 2023 $ 4,129,903 $ 588 1,772,083 $ (1,623,256) 4,253,016 (272,528)
Treasury stock, common, beginning balance (in shares) at Jun. 30, 2023 (41,836,234)     (41,836,000)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Common stock issued on exercise of options (shares)   17,000        
Common stock issued on exercise of options $ 983   983      
Common stock issued on vesting of restricted stock units, net of shares withheld for tax (in shares)   3,000        
Common stock issued on vesting of restricted stock units, net of shares withheld for tax (225)   (225)      
Stock-based compensation costs 18,510   18,510      
Other comprehensive loss (47,620)         (47,620)
Net income 219,422       219,422  
Dividends declared $ (70,597)       (70,597)  
Common stock, shares outstanding, ending balance (in shares) at Sep. 30, 2023 147,085,082 188,921,000        
Treasury stock, common, ending balance (in shares) at Sep. 30, 2023 (41,836,234)     (41,836,000)    
Ending balance at Sep. 30, 2023 $ 4,250,376 $ 588 $ 1,791,351 $ (1,623,256) $ 4,401,841 $ (320,148)
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parenthetical) - $ / shares
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Statement of Stockholders' Equity [Abstract]    
Dividend declared per share (in dollars per share) $ 0.48 $ 0.44
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net income $ 219,422 $ 210,478
Adjustment to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 44,934 36,273
Amortization of right-of-use assets 8,508 7,761
Stock-based compensation costs 18,510 16,919
Loss attributable to equity method investments (note 5) 3,895 2,028
(Gain) loss on equity investments (note 5) 602 3,280
Changes in operating assets and liabilities:    
Accounts receivable 6,534 (56,238)
Inventories 26,911 (147,096)
Prepaid expenses, net deferred income taxes and other current assets (42,015) (36,784)
Accounts payable, accrued expenses, income taxes payable and other (1,018) 8,041
Net cash provided by operating activities 286,283 44,662
Cash flows from investing activities:    
Purchases of property, plant and equipment (30,035) (29,056)
Patent registration and acquisition costs (10,831) (3,317)
Business acquisitions, net of cash acquired (103,183) (19,100)
Purchases of investments (note 5) (3,680) (4,291)
Proceeds from exits of investments (note 5) 250 0
(Payments) / proceeds on maturity of foreign currency contracts (1,501) (3,042)
Net cash used in investing activities (148,980) (58,806)
Cash flows from financing activities:    
Proceeds from issuance of common stock, net 983 2,610
Taxes paid related to net share settlement of equity awards (225) (59)
Payments of business combination contingent consideration (1,293) 0
Proceeds from borrowings, net of borrowing costs 105,000 50,000
Repayment of borrowings (185,000) (30,000)
Dividends paid (70,597) (64,431)
Net cash used in financing activities (151,132) (41,880)
Effect of exchange rate changes on cash (4,962) (10,523)
Net decrease in cash and cash equivalents (18,791) (66,547)
Cash and cash equivalents at beginning of period 227,891 273,710
Cash and cash equivalents at end of period 209,100 207,163
Supplemental disclosure of cash flow information:    
Income taxes paid, net of refunds 76,749 53,437
Interest paid 14,957 7,134
Fair value of assets acquired, excluding cash 34,092 9,506
Liabilities assumed (5,325) (3,975)
Goodwill on acquisition 74,416 19,281
Deferred payments 0 (2,856)
Fair value of contingent consideration 1,293 (2,856)
Cash paid for acquisitions $ 104,476 $ 19,100
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies
 3 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Organization and Basis of Presentation
ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Finland, Norway and Sweden. We also operate a Software as a Service (“SaaS”) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice.
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and the rules of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2024.
The condensed consolidated financial statements for the three months ended September 30, 2023 and September 30, 2022 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K (our “Form 10-K”) for the year ended June 30, 2023.
Revenue Recognition
In accordance with Accounting Standard Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers”, we account for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (“Sleep and Respiratory Care”) and the supply of business management software as a service to out-of-hospital care providers (“SaaS”). Our Sleep and Respiratory Care revenue relates primarily to the sale of our products that are therapy-based equipment. Some contracts include additional performance obligations such as the provision of extended warranties and provision of data for patient monitoring. Our SaaS revenue relates to the provision of software access with ongoing support and maintenance services as well as professional services such as training and consulting.
Disaggregation of revenue
The following table summarizes our net revenue disaggregated by segment, product and region (in thousands):
Three Months Ended
September 30,
20232022
U.S., Canada and Latin America
Devices$345,897 $339,545 
Masks and other292,461 238,560 
Total U.S., Canada and Latin America
$638,358 $578,105 
Combined Europe, Asia and other markets
Devices$218,831 $178,032 
Masks and other105,848 88,306 
Total Combined Europe, Asia and other markets
$324,679 $266,338 
Global revenue
Total Devices
$564,728 $517,577 
Total Masks and other
398,309 326,866 
Total Sleep and Respiratory Care$963,037 $844,443 
Software as a Service139,284 105,851 
Total$1,102,321 $950,294 
Performance obligations and contract balances
Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; generally, this occurs with the transfer of risk and/or control of our products at a point in time. For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with cloud-hosted services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of one year to five years. Our contracts do not contain significant financing components.
The following table summarizes our contract balances (in thousands):
 September 30,
2023		June 30,
2023		Balance sheet caption
Contract assets
Accounts receivable, net$692,388 $704,909 Accounts receivable, net
Unbilled revenue, current33,201 31,521 Prepaid expenses and other current assets
Unbilled revenue, non-current10,244 10,078 Prepaid taxes and other non-current assets
 
Contract liabilities
Deferred revenue, current(146,718)(138,072)Deferred revenue (current liabilities)
Deferred revenue, non-current(121,492)(119,186)Deferred revenue (non-current liabilities)
Transaction price determination
Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g. rebates, discounts, free goods) and returns offered to our customers and their
customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of our historical experience. However, returns of products, excluding warranty-related returns, have historically been infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed.
We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer’s expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates each quarter based on actual sales results and updated forecasts for the remaining rebate periods.
We participate in programs where we issue credits to our Sleep and Respiratory Care distributors when they are required to sell our products below negotiated list prices if we have preexisting contracts with the distributors' customers. We reduce revenue for future credits at the time of sale to the distributor, which we estimate based on historical experience using the expected value method.
We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs.
When Sleep and Respiratory Care or SaaS contracts have multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each performance obligation. An allocation is not required for many of our Sleep and Respiratory Care contracts that have a single performance obligation, which is the shipment of our therapy-based equipment.
Accounting and practical expedient elections
We have elected to account for shipping and handling activities associated with our Sleep and Respiratory Care segment as a fulfillment cost within cost of sales, and record shipping and handling costs collected from customers in net revenue. We have also elected for all taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, to be excluded from revenue and presented on a net basis. We have elected two practical expedients including the “right to invoice” practical expedient, which is relevant for some of our SaaS contracts as it allows us to recognize revenue in the amount of the invoice when it corresponds directly with the value of performance completed to date. The second practical expedient adopted permits relief from considering a significant financing component when the payment for the good or service is expected to be one year or less.
Lease Revenue
We lease Sleep and Respiratory Care medical devices to customers primarily as a means to comply with local health insurer requirements in certain foreign geographies. Device rental contracts are classified as operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. Operating lease revenue was $22.7 million for the three months ended September 30, 2023 and $23.7 million for the three months ended September 30, 2022.
Provision for Warranty
We provide for the estimated cost of product warranties on our Sleep and Respiratory Care products at the time the related revenue is recognized. We determine the amount of this provision by using a financial model, which takes into consideration actual historical expenses and potential risks associated with our different products. We use this financial model to calculate the future probable expenses related to warranty and the required level of the warranty provision. Although we engage in product improvement programs and processes, our warranty obligation is affected by product failure rates and costs incurred to correct those product failures. Should actual product failure rates or estimated costs to repair those product failures differ from our estimates, we would be required to revise our estimated warranty provision.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Information
 3 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Segment Information Segment Information
We have quantitatively and qualitatively determined that we operate in two operating segments, which are the Sleep and Respiratory Care segment and the SaaS segment.
We evaluate the performance of our segments based on net revenues and income from operations. The accounting policies of the segments are the same as those described in note 2 of our consolidated financial statements included in our Form 10-K for the fiscal year ended June 30, 2023. Segment net revenues and segment income from operations do not include inter-segment profits and revenue is allocated to a geographic area based on where the products are shipped to or where the services are performed.
Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include corporate headquarters costs, stock-based compensation, amortization expense from acquired intangibles, acquisition related expenses, net interest expense (income), loss attributable to equity method investments, gains and losses on equity investments, and other, net. We neither discretely allocate assets to our operating segments, nor does our Chief Operating Decision Maker evaluate the operating segments using discrete asset information.
The table below presents a reconciliation of net revenues and net operating profit by reportable segments (in thousands):
Three Months Ended
September 30,
20232022
Net revenue by segment
Sleep and Respiratory Care
$963,037 $844,443 
Software as a Service139,284 105,851 
Total$1,102,321 $950,294 
Depreciation and amortization by segment
Sleep and Respiratory Care$20,519 $19,767 
Software as a Service2,760 1,913 
Amortization of acquired intangible assets and corporate assets21,655 14,593 
Total$44,934 $36,273 
Net operating profit by segment
Sleep and Respiratory Care$390,415 $352,560 
Software as a Service31,258 24,441 
Total$421,673 $377,001 
Reconciling items
Corporate costs$103,378 $86,938 
Amortization of acquired intangible assets21,387 14,324 
Astral field safety notification expenses (1)
7,911 — 
Interest expense (income), net14,957 7,134 
Loss attributable to equity method investments3,895 2,028 
(Gain) loss on equity investments602 3,280 
Other, net(2,648)1,504 
Income before income taxes$272,191 $261,793 
(1)    The Astral field safety notification expenses relate to estimated costs associated with the replacement of a certain component in some of our Astral ventilation devices that were manufactured between 2013 to 2019.
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Balance Sheet Information
 3 Months Ended
Sep. 30, 2023
Supplemental Balance Sheet Information [Abstract]  
Supplemental Balance Sheet Information Supplemental Balance Sheet Information
Components of selected captions in the condensed consolidated balance sheets consisted of the following (in thousands):
InventoriesSeptember 30,
2023		June 30,
2023
Raw materials$427,860 $459,126 
Work in progress5,190 3,956 
Finished goods525,183 534,930 
Total inventories$958,233 $998,012 
Prepaid expenses and other current assetsSeptember 30,
2023		June 30,
2023
Prepaid taxes$104,710 $114,009 
Prepaid inventories178,490 143,084 
Other prepaid expenses and current assets161,664 179,925 
Total prepaid expenses and other current assets$444,864 $437,018 
Property, Plant and EquipmentSeptember 30,
2023		June 30,
2023
Property, plant and equipment, at cost$1,201,818 $1,205,868 
Accumulated depreciation and amortization(667,833)(668,012)
Property, plant and equipment, net$533,985 $537,856 
Other Intangible Assets September 30,
2023		June 30,
2023
Developed/core product technology$415,933 $398,740 
Accumulated amortization(273,912)(265,802)
Developed/core product technology, net142,021 132,938 
Customer relationships448,769 443,652 
Accumulated amortization(133,503)(124,220)
Customer relationships, net315,266 319,432 
Other intangibles251,770 244,373 
Accumulated amortization(145,779)(144,402)
Other intangibles, net105,991 99,971 
Total other intangibles, net$563,278 $552,341 
Intangible assets consist of developed/core product technology, trade names, non-compete agreements, customer relationships, and patents, which we amortize over the estimated useful life of the assets, generally between two years to fifteen years. There are no expected residual values related to these intangible assets.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Goodwill
 3 Months Ended
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill Goodwill
A reconciliation of changes in our goodwill by reportable segment is as follows (in thousands):
Three Months Ended September 30, 2023
Sleep and
Respiratory Care		SaaSTotal
Balance at the beginning of the period$670,120 $2,100,180 $2,770,299 
Business acquisitions74,416 — 74,416 
Foreign currency translation adjustments(8,144)(24,429)(32,573)
Balance at the end of the period$736,392 $2,075,751 $2,812,142 
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Investments
 3 Months Ended
Sep. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]  
Investments Investments
We have equity investments in privately and publicly held companies that are unconsolidated entities. The following discusses our investments in marketable equity securities, non-marketable equity securities, and investments accounted for under the equity method.
Our marketable equity securities are publicly traded stocks measured at fair value and classified within Level 1 in the fair value hierarchy because we use quoted prices for identical assets in active markets. Marketable equity securities are recorded in prepaid expenses and other current assets on the condensed consolidated balance sheets.
Non-marketable equity securities consist of investments in privately held companies without readily determinable fair values and are recorded in prepaid taxes and other non-current assets on the condensed consolidated balance sheets. Non-marketable equity securities are reported at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. We assess non-marketable equity securities at least quarterly for impairment and consider qualitative and quantitative factors including the investee's financial metrics, product and commercial outlook and cash usage. All gains and losses on marketable and non-marketable equity securities, realized and unrealized, are recognized in gain (loss) on equity investments as a component of other income (loss), net on the condensed consolidated statements of operations.
Equity investments whereby we have significant influence, but not control over the investee and are not the primary beneficiary of the investee’s activities, are accounted for under the equity method. Under this method, we record our share of gains or losses attributable to equity method investments as a component of other income (loss), net on the condensed consolidated statements of operations.
Equity investments by measurement category were as follows (in thousands):
Measurement categorySeptember 30,
2023		June 30,
2023
Fair value$11,821 $12,423 
Measurement alternative69,678 68,748 
Equity method62,161 65,366 
Total$143,660 $146,537 
The following tables show a reconciliation of the changes in our equity investments (in thousands):
 Three Months Ended September 30, 2023
 Non-marketable securitiesMarketable securitiesEquity method investmentsTotal
Balance at the beginning of the period$68,748 $12,423 $65,366 $146,537 
Additions to investments1,180 — 2,500 3,680 
Unrealized losses on marketable equity securities— (602)— (602)
Proceeds from exits of investments(250)— — (250)
Loss attributable to equity method investments— — (3,895)(3,895)
Foreign currency translation adjustments— — (1,810)(1,810)
Carrying value at the end of the period$69,678 $11,821 $62,161 $143,660 
Three Months Ended September 30, 2022
Non-marketable securitiesMarketable securitiesEquity method investmentsTotal
Balance at the beginning of the period$39,290 $9,167 $9,918 $58,375 
Additions to investments
4,291 — — 4,291 
Unrealized losses on marketable equity securities
— (3,280)— (3,280)
Loss attributable to equity method investments— — (2,028)(2,028)
Carrying value at the end of the period$43,581 $5,887 $7,890 $57,358 
Net unrealized losses recognized for equity investments in non-marketable and marketable securities held as of September 30, 2023 for the three months ended September 30, 2023 were $0.6 million. Net unrealized losses recognized for equity investments in non-marketable and marketable securities held as of September 30, 2022 for the three months ended September 30, 2022 were $3.3 million.
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Product Warranties
 3 Months Ended
Sep. 30, 2023
Product Warranties Disclosures [Abstract]  
Product Warranties Product Warranties
Changes in the liability for warranty costs, which is included in accrued expenses in our condensed consolidated balance sheets, are as follows (in thousands):
Three Months Ended
September 30,
20232022
Balance at the beginning of the period$27,621 $25,889 
Warranty accruals for the period6,025 2,088 
Warranty costs incurred for the period (4,828)(2,612)
Foreign currency translation adjustments(672)(1,272)
Balance at the end of the period$28,146 $24,093 
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Debt
 3 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Debt Debt
Debt consisted of the following (in thousands):
September 30,
2023		June 30,
2023
Short-term debt $10,000 $10,000 
Deferred borrowing costs(95)(98)
Short-term debt, net$9,905 $9,902 
Long-term debt$1,355,000 $1,435,000 
Deferred borrowing costs(3,489)(3,766)
Long-term debt, net$1,351,511 $1,431,234 
Total debt$1,361,416 $1,441,136 
Credit Facility
On June 29, 2022, we entered into a second amended and restated credit agreement (the “Revolving Credit Agreement”), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger, sole book runner, swing line lender and letter of credit issuer, Westpac Banking Corporation, as syndication agent and joint lead arranger, HSBC Bank USA, National Association, as syndication agent and joint lead arranger, and Wells Fargo Bank, National Association, as documentation agent. The Revolving Credit Agreement, among other things, provided a senior unsecured revolving credit facility of $1,500.0 million, with an uncommitted option to increase the revolving credit facility by an additional amount equal to the greater of $1,000.0 million or 1.0 times the EBITDA (as defined in the Revolving Credit Agreement) for the trailing twelve-month measurement period. The Revolving Credit Agreement amends and restates that certain Amended and Restated Credit Agreement, dated as of April 17, 2018, among ResMed, MUFG Union Bank, N.A., Westpac Banking Corporation and the lenders party thereto.
Additionally, on June 29, 2022, ResMed Pty Limited entered into a Second Amendment to the Syndicated Facility Agreement and First Amendment to Unconditional Guaranty Agreement (the “Term Credit Agreement”), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger and joint book runner, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner, which amends that certain Syndicated Facility Agreement dated as of April 17, 2018. The Term Credit Agreement, among other things, provides ResMed Pty Limited a senior unsecured term credit facility of $200.0 million.
Our obligations under the Revolving Credit Agreement are guaranteed by certain of our direct and indirect U.S. subsidiaries, and ResMed Pty Limited’s obligations under the Term Credit Agreement are guaranteed by us and certain of our direct and indirect U.S. subsidiaries. The Revolving Credit Agreement and Term Credit Agreement contain customary covenants, including, in each case, a financial covenant that requires that we maintain a maximum leverage ratio of funded debt to EBITDA (as defined in the Revolving Credit Agreement and Term Credit Agreement, as applicable). The entire principal amounts of the revolving credit facility and term credit facility, and, in each case, any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable. Events of default under the Revolving Credit Agreement and the Term Credit Agreement include, in each case, failure to make payments when due, the occurrence of a default in the performance of any covenants in the respective agreements or related documents, or certain changes of control of us, or the respective guarantors of the obligations borrowed under the Revolving Credit Agreement and Term Credit Agreement.
The Revolving Credit Agreement and Term Credit Agreement each terminate on June 29, 2027, when all unpaid principal and interest under the loans must be repaid. Amounts borrowed under the Term Credit Agreement will also amortize on a semi-annual basis, with a $5.0 million principal payment required on each such semi-annual amortization date. The outstanding principal amounts will bear interest at a rate equal to the Adjusted Term SOFR (as defined in the Revolving Credit Facility) plus 0.75% to 1.50% (depending on the then-applicable leverage ratio) or the Base Rate (as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable) plus 0.0% to 0.50% (depending on the then-applicable leverage ratio). At September 30, 2023, the interest rate that was being charged on the outstanding principal amounts was 6.3%. An applicable commitment fee of 0.075% to 0.150% (depending on the then-applicable leverage ratio) applies on the unused portion of the revolving credit facility. As of September 30, 2023, we had $825.0 million available for draw down under the revolving credit facility.
We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As the Revolving Credit and Term Credit Agreements’ interest rate is calculated as Adjusted Term SOFR plus the spreads described above, its carrying amount is equivalent to its fair value as at September 30, 2023 and June 30, 2023, which was $865.0 million and $945.0 million, respectively.
Senior Notes
On July 10, 2019, we entered into a Note Purchase Agreement with the purchasers to that agreement, in connection with the issuance and sale of $250.0 million principal amount of our 3.24% senior notes due July 10, 2026, and $250.0 million principal amount of our 3.45% senior notes due July 10, 2029 (collectively referred to as the “Senior Notes”). Our obligations under the Note Purchase Agreement and the Senior Notes are unconditionally and irrevocably guaranteed by certain of our direct and indirect U.S. subsidiaries. The net proceeds from this transaction were used to pay down borrowings on our Revolving Credit Agreement.
Under the terms of the Note Purchase Agreement, we agreed to customary covenants including with respect to our corporate existence, transactions with affiliates, and mergers and other extraordinary transactions. We also agreed that, subject to limited exceptions, we will maintain a ratio of consolidated funded debt to consolidated EBITDA (as defined in the Note Purchase Agreement) of no more than 3.50 to 1.00 as of the last day of any fiscal quarter, and will not at any time permit the amount of all priority secured and unsecured debt of us and our subsidiaries to exceed 10% of our consolidated tangible assets, determined as of the end of our most recently ended fiscal quarter. This ratio is calculated at the end of each reporting period for which the Note Purchase Agreement requires us to deliver financial statements, using the results of the 12 consecutive month period ending with such reporting period.
We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As of September 30, 2023 and June 30, 2023, the Senior Notes had a carrying amount of $500.0 million, excluding deferred borrowing costs, and an estimated fair value of $451.7 million and $462.2 million, respectively. Quoted market prices in active markets for similar liabilities based inputs (Level 2) were used to estimate fair value.
At September 30, 2023, we were in compliance with our debt covenants and there was $1,365.0 million outstanding under the Revolving Credit Agreement, Term Credit Agreement and Senior Notes.
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings Per Share
 3 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
Basic earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units.
The weighted average number of outstanding stock options and restricted stock units not included in the computation of diluted earnings per share were 417,364 and 113,167 for the three months ended September 30, 2023 and 2022, respectively, as the effect would have been anti-dilutive.
Basic and diluted earnings per share are calculated as follows (in thousands except per share data):
Three Months Ended
September 30,
20232022
Numerator:
Net income$219,422 $210,478 
Denominator:
Basic weighted-average common shares outstanding147,075 146,431 
Effect of dilutive securities:
Stock options and restricted stock units411 703 
Diluted weighted average shares 147,486 147,134 
Basic earnings per share$1.49 $1.44 
Diluted earnings per share$1.49 $1.43 
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Legal Actions, Contingencies and Commitments
 3 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Legal Actions, Contingencies and Commitments Legal Actions, Contingencies and Commitments
Litigation
In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.
On June 2, 2021, New York University ("NYU") filed a complaint for patent infringement in the United States District Court, District of Delaware against ResMed Inc., case no. 1:21-cv-00813 (JPM). The complaint alleges that the AutoSet or AutoRamp features of ResMed’s AirSense 10 AutoSet flow generators infringe one or more claims of various NYU patents, including U.S. Patent Nos. 6,988,994; 9,108,009; 9,168,344; 9,427,539; 9,533,115; 9,867,955; and 10,384,024. According to the complaint, the NYU patents are directed to systems and methods for diagnosis and treating sleeping
disorders during different sleep states. The complaint seeks monetary damages and attorneys’ fees. We answered the complaint on September 30, 2021 and filed a motion to dismiss the complaint on the basis that the patents are invalid because the subject matter of the patents is not patentable under the Supreme Court and Federal Circuit precedent. The motion to dismiss was granted in part and denied in part. We have also requested that the court dismiss the case based on NYU’s license of the patents to Fisher & Paykel and Fisher & Paykel’s prior settlement with us; that request is pending. In December 2022, the Patent Trial and Appeals Board (“PTAB”) of the Patent and Trademark Office granted our request to review the validity of the claims in the patents asserted by NYU against us, determining that there is a reasonable likelihood that we will prevail. The PTAB’s final written decisions on the validity of the asserted claims is expected by December 2023. On April 10, 2023, the district court granted our request to stay the case pending the PTAB’s decision on the validity of the patents asserted by NYU.
On January 27, 2021, the International Trade Commission ("ITC") instituted In Re Certain UMTS and LTE Cellular Communications Modules and Products Containing the Same, Investigation No. 337-TA-1240, by complainants Philips RS North America, LLC and Koninklijke Philips N.V. (collectively “Philips”) against Quectel Wireless Solutions Co., Ltd; Thales DIS AIS USA, LLC, Thales DIS AIS Deutschland GmbH; Telit Wireless Solutions, Inc., Telit Communications PLC, CalAmp. Corp., Xirgo Technologies, LLC, and Laird Connectivity, Inc. (collectively “respondents”). In the ITC investigation, Philips seeks an order excluding communications modules, and products that contain them, from importation into the United States based on alleged infringement of 3G and 4G standard essential patents held by Philips. On October 6-14, 2021, the administrative law judge held a hearing on the merits. The administrative law judge issued an initial determination on April 1, 2022, finding no violation of any of the Philips' patents asserted in the ITC. Philips sought review by the full ITC. On July 6, 2022, the Commission affirmed the administrative law judge’s determination that there was no violation of asserted Philips' patents. The Commission terminated the ITC proceedings. Philips did not appeal the ITC’s decision. On December 17, 2020, Philips filed companion cases for patent infringement against the same defendants in the United States District Court for the District of Delaware, case nos. 1:20-cv-01707, 01708, 01709, 01710, 01711, and 01713 (CFC) seeking damages, an injunction, and a declaration from the court on the amount of a fair reasonable and non-discriminatory license rate for the standard essential patents it is asserting against the communications module defendants. The district court cases were stayed pending the resolution of the ITC proceedings. The parties have returned to the district court for further proceedings. We were not a party to the ITC investigation, and we are not a party to the district court cases, but we sell products that incorporate communications modules at issue in the district court case. The first trial in these cases is set for August 12, 2024.
On June 16, 2022, Cleveland Medical Devices Inc. ("Cleveland Medical") filed suit for patent infringement against ResMed Inc. in the United States District Court for the District of Delaware, case no. 1:22-cv-00794. Cleveland Medical asserts that numerous ResMed connected devices, when combined with certain ResMed data platforms and/or software, including AirView and ResScan, infringe one or more of eight Cleveland Medical patents, including U.S. Patent Nos. 10,076,269; 10,426,399; 10,925,535; 11,064,937; 10,028,698; 10,478,118; 11,202,603; and 11,234,637. We moved to dismiss the action because Cleveland Medical sued the wrong ResMed entity, and to dismiss the indirect and willful infringement allegations by Cleveland Medical. On October 2, 2023, the court granted a portion of the motion, dismissing all Cleveland Medical claims for indirect and willful infringement, and declined the rest of the motion. On March 23, 2023, we filed a petition with the Patent Trial and Appeals Board of the Patent and Trademark Office seeking review of the validity of Cleveland Medical U.S. Patent 10,076,269. On September 25, 2023, the PTAB exercised its discretion to deny our petition challenging the validity of the ‘269 patent in light of the August 2024 trial date in the Delaware District Court case; that decision does not impact the merits of our invalidity challenge in that trial.
On March 23, 2023, ResMed Corp. filed suit in the Southern District of California, case no. 23-cv-00500-TWR-JLB, seeking a declaration that it does not infringe U.S. patent number 11,602,284 recently issued to Cleveland Medical. Cleveland Medical has asked the court to dismiss the California case or to move it to Delaware or Cleveland for the convenience of the parties. We are opposing that request.
Based on currently available information, we are unable to make a reasonable estimate of loss or range of losses, if any, arising from matters that remain open.
Contingent Obligations Under Recourse Provisions
We use independent financing institutions to offer some of our customers financing for the purchase of some of our products. Under these arrangements, if the customer qualifies under the financing institutions’ credit criteria and finances the transaction, the customers repay the financing institution on a fixed payment plan. For some of these arrangements, the
customer’s receivable balance is with limited recourse whereby we are responsible for repaying the financing company should the customer default. We record a contingent provision, which is estimated based on historical default rates. This is applied to receivables sold with recourse and is recorded in accrued expenses.
During the three months ended September 30, 2023 and September 30, 2022, receivables sold with limited recourse were $47.7 million and $39.9 million, respectively. As of September 30, 2023, the maximum exposure on outstanding receivables sold with recourse and the associated contingent provision were $28.9 million and $0.8 million, respectively. As of June 30, 2023, the maximum exposure on outstanding receivables sold with recourse and contingent provision were $32.6 million and $0.6 million, respectively.
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Derivative Instruments and Hedging Activities
 3 Months Ended
Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities
We may use derivative financial instruments, specifically foreign cross-currency swaps, purchased foreign currency call options, collars and forward contracts to mitigate exposure from certain foreign currency risk. No derivatives are used for trading or speculative purposes. We do not require or are not required to pledge collateral for the derivative instruments.
Fair Value and Net Investment Hedging
On November 17, 2022, we executed foreign cross-currency swaps as net investment hedges and fair value hedges in designated hedging relationships with either the foreign denominated net asset balances or the foreign denominated intercompany loan as the hedged items. All derivatives are recorded at fair value as either an asset or liability. Cash flows associated with derivative instruments are presented in the same category on the consolidated statements of cash flows as the hedged item.
The purpose of the cross-currency swaps for the fair value hedge is to mitigate foreign currency risk associated with changes in spot rates on foreign denominated intercompany debt between USD and EUR. For these hedges, we excluded certain components from the assessment of hedge effectiveness that are not related to spot rates. For fair value hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in the same line item as the hedged item, other, net, in the condensed consolidated statement of operations. The initial fair value of hedge components excluded from the assessment of effectiveness is recognized in the statement of operations under a systematic and rational method over the life of the hedging instrument and is presented in interest (expense) income, net. Any difference between the change in the fair value of the hedge components excluded from the assessment of effectiveness and the amounts recognized in earnings is recorded as a component of other comprehensive income.
The purpose of the cross-currency swaps for the net investment hedge is to mitigate foreign currency risk associated with changes in spot rates on the net asset balances of our foreign functional subsidiaries. For net investment hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in cumulative translation adjustment within other comprehensive loss and reclassified into earnings when the hedged net investment is either sold or substantially liquidated. The initial fair value of components excluded from the assessment of hedge effectiveness will be recognized in interest (expense) income, net.
The notional value of outstanding foreign cross-currency swaps was $1,014.8 million and $1,046.6 million at September 30, 2023 and June 30, 2023, respectively. These contracts mature at various dates prior to December 31, 2029.
Non-Designated Hedges
We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have foreign currency exposure through both our Australian and Singapore manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased foreign currency call options, collars and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed three years. The purpose of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, and Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not designate these foreign currency contracts as hedges. All movements in the fair value of the foreign currency instruments are recorded within other, net in our condensed consolidated statements of income.
The notional value of the outstanding non-designated hedges was $1,363.3 million and $954.7 million at September 30, 2023 and June 30, 2023, respectively. These contracts mature at various dates prior to March 15, 2025.
Fair Values of Derivative Instruments
The following table presents our assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets (in thousands):
September 30,
2023		June 30,
2023		Balance Sheet Caption
Derivative Assets
Not Designated as Hedging Instruments
Foreign currency hedging instruments$3,611 $2,126 Prepaid expenses and other current assets
Foreign currency hedging instruments717 279 Prepaid taxes and other non-current assets
Total derivative assets$4,328 $2,405 
Derivative Liabilities
Designated as Hedging Instruments
Foreign cross-currency swaps – Fair Value Hedge$9,883 $19,743 Other long-term liabilities
Foreign cross-currency swaps – Net Investment Hedge17,367 $40,803 Other long-term liabilities
Not Designated as Hedging Instruments
Foreign currency hedging instruments25,005 9,558 Accrued expenses
Foreign currency hedging instruments592 595 Other long-term liabilities
Total derivative liabilities$52,847 $70,699 
Fair Value Hedge Gains (Losses)
We recognized the following gains (losses) on the foreign cross currency swaps designated as fair value hedges (in thousands):
Three Months Ended
September 30,
20232022
Gain (loss) recognized in other comprehensive income (loss)$588 $— 
Gain (loss) recognized on cross-currency swap in interest (expense) income, net (amount excluded from effectiveness testing)1,181 — 
Gain (loss) recognized on cross-currency swap in other, net9,271 — 
Gain (loss) recognized on intercompany debt in other, net(9,271)— 
Net Investment Hedge Gains (Losses)
We recognized the following gains (losses) on the foreign cross currency swaps designated as net investment hedges (in thousands):
Three Months Ended
September 30,
20232022
Gain (loss) recognized in cumulative translation adjustment within other comprehensive income (loss)$23,436 $— 
Gain (loss) recognized from the excluded components in interest (expense) income, net 3,013 — 
Non-designated Derivative Gains (Losses)
We recognized the following gains (losses) in the condensed consolidated statement of operations on derivatives not designated as hedging instruments (in thousands):
Three Months Ended
September 30,
20232022
Gain (loss) recognized on foreign currency hedging instruments in other, net$(15,073)$(20,522)
Gain (loss) recognized on other foreign-currency-denominated transactions in other, net17,646 19,089 
Total$2,573 $(1,433)
We classified the fair values of all hedging instruments as Level 2 measurements within the fair value hierarchy.
We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments. We minimize counterparty credit risk by entering into derivative transactions with major financial institutions.
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Pay vs Performance Disclosure    
Net income $ 219,422 $ 210,478
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Organization and Basis of Presentation
Organization and Basis of Presentation
ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Finland, Norway and Sweden. We also operate a Software as a Service (“SaaS”) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice.
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and the rules of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2024.
The condensed consolidated financial statements for the three months ended September 30, 2023 and September 30, 2022 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K (our “Form 10-K”) for the year ended June 30, 2023.
Revenue Recognition
Revenue Recognition
In accordance with Accounting Standard Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers”, we account for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (“Sleep and Respiratory Care”) and the supply of business management software as a service to out-of-hospital care providers (“SaaS”). Our Sleep and Respiratory Care revenue relates primarily to the sale of our products that are therapy-based equipment. Some contracts include additional performance obligations such as the provision of extended warranties and provision of data for patient monitoring. Our SaaS revenue relates to the provision of software access with ongoing support and maintenance services as well as professional services such as training and consulting.
Disaggregation of revenue
The following table summarizes our net revenue disaggregated by segment, product and region (in thousands):
Three Months Ended
September 30,
20232022
U.S., Canada and Latin America
Devices$345,897 $339,545 
Masks and other292,461 238,560 
Total U.S., Canada and Latin America
$638,358 $578,105 
Combined Europe, Asia and other markets
Devices$218,831 $178,032 
Masks and other105,848 88,306 
Total Combined Europe, Asia and other markets
$324,679 $266,338 
Global revenue
Total Devices
$564,728 $517,577 
Total Masks and other
398,309 326,866 
Total Sleep and Respiratory Care$963,037 $844,443 
Software as a Service139,284 105,851 
Total$1,102,321 $950,294 
Performance obligations and contract balances
Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; generally, this occurs with the transfer of risk and/or control of our products at a point in time. For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with cloud-hosted services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of one year to five years. Our contracts do not contain significant financing components.
The following table summarizes our contract balances (in thousands):
 September 30,
2023		June 30,
2023		Balance sheet caption
Contract assets
Accounts receivable, net$692,388 $704,909 Accounts receivable, net
Unbilled revenue, current33,201 31,521 Prepaid expenses and other current assets
Unbilled revenue, non-current10,244 10,078 Prepaid taxes and other non-current assets
 
Contract liabilities
Deferred revenue, current(146,718)(138,072)Deferred revenue (current liabilities)
Deferred revenue, non-current(121,492)(119,186)Deferred revenue (non-current liabilities)
Transaction price determination
Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g. rebates, discounts, free goods) and returns offered to our customers and their
customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of our historical experience. However, returns of products, excluding warranty-related returns, have historically been infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed.
We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer’s expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates each quarter based on actual sales results and updated forecasts for the remaining rebate periods.
We participate in programs where we issue credits to our Sleep and Respiratory Care distributors when they are required to sell our products below negotiated list prices if we have preexisting contracts with the distributors' customers. We reduce revenue for future credits at the time of sale to the distributor, which we estimate based on historical experience using the expected value method.
We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs.
When Sleep and Respiratory Care or SaaS contracts have multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each performance obligation. An allocation is not required for many of our Sleep and Respiratory Care contracts that have a single performance obligation, which is the shipment of our therapy-based equipment.
Accounting and practical expedient elections
We have elected to account for shipping and handling activities associated with our Sleep and Respiratory Care segment as a fulfillment cost within cost of sales, and record shipping and handling costs collected from customers in net revenue. We have also elected for all taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, to be excluded from revenue and presented on a net basis. We have elected two practical expedients including the “right to invoice” practical expedient, which is relevant for some of our SaaS contracts as it allows us to recognize revenue in the amount of the invoice when it corresponds directly with the value of performance completed to date. The second practical expedient adopted permits relief from considering a significant financing component when the payment for the good or service is expected to be one year or less.
Lease Revenue Lease RevenueWe lease Sleep and Respiratory Care medical devices to customers primarily as a means to comply with local health insurer requirements in certain foreign geographies. Device rental contracts are classified as operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer.
Provision For Warranty
Provision for Warranty
We provide for the estimated cost of product warranties on our Sleep and Respiratory Care products at the time the related revenue is recognized. We determine the amount of this provision by using a financial model, which takes into consideration actual historical expenses and potential risks associated with our different products. We use this financial model to calculate the future probable expenses related to warranty and the required level of the warranty provision. Although we engage in product improvement programs and processes, our warranty obligation is affected by product failure rates and costs incurred to correct those product failures. Should actual product failure rates or estimated costs to repair those product failures differ from our estimates, we would be required to revise our estimated warranty provision.
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Schedule of Net Revenue Disaggregated by Product and Region
The following table summarizes our net revenue disaggregated by segment, product and region (in thousands):
Three Months Ended
September 30,
20232022
U.S., Canada and Latin America
Devices$345,897 $339,545 
Masks and other292,461 238,560 
Total U.S., Canada and Latin America
$638,358 $578,105 
Combined Europe, Asia and other markets
Devices$218,831 $178,032 
Masks and other105,848 88,306 
Total Combined Europe, Asia and other markets
$324,679 $266,338 
Global revenue
Total Devices
$564,728 $517,577 
Total Masks and other
398,309 326,866 
Total Sleep and Respiratory Care$963,037 $844,443 
Software as a Service139,284 105,851 
Total$1,102,321 $950,294 
Schedule of Contract Balances
The following table summarizes our contract balances (in thousands):
 September 30,
2023		June 30,
2023		Balance sheet caption
Contract assets
Accounts receivable, net$692,388 $704,909 Accounts receivable, net
Unbilled revenue, current33,201 31,521 Prepaid expenses and other current assets
Unbilled revenue, non-current10,244 10,078 Prepaid taxes and other non-current assets
 
Contract liabilities
Deferred revenue, current(146,718)(138,072)Deferred revenue (current liabilities)
Deferred revenue, non-current(121,492)(119,186)Deferred revenue (non-current liabilities)
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Information (Tables)
 3 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Schedule of Revenue by Segment and Reconciling Items
The table below presents a reconciliation of net revenues and net operating profit by reportable segments (in thousands):
Three Months Ended
September 30,
20232022
Net revenue by segment
Sleep and Respiratory Care
$963,037 $844,443 
Software as a Service139,284 105,851 
Total$1,102,321 $950,294 
Depreciation and amortization by segment
Sleep and Respiratory Care$20,519 $19,767 
Software as a Service2,760 1,913 
Amortization of acquired intangible assets and corporate assets21,655 14,593 
Total$44,934 $36,273 
Net operating profit by segment
Sleep and Respiratory Care$390,415 $352,560 
Software as a Service31,258 24,441 
Total$421,673 $377,001 
Reconciling items
Corporate costs$103,378 $86,938 
Amortization of acquired intangible assets21,387 14,324 
Astral field safety notification expenses (1)
7,911 — 
Interest expense (income), net14,957 7,134 
Loss attributable to equity method investments3,895 2,028 
(Gain) loss on equity investments602 3,280 
Other, net(2,648)1,504 
Income before income taxes$272,191 $261,793 
(1)    The Astral field safety notification expenses relate to estimated costs associated with the replacement of a certain component in some of our Astral ventilation devices that were manufactured between 2013 to 2019.
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Balance Sheet Information (Tables)
 3 Months Ended
Sep. 30, 2023
Supplemental Balance Sheet Information [Abstract]  
Schedule of Inventories
Components of selected captions in the condensed consolidated balance sheets consisted of the following (in thousands):
InventoriesSeptember 30,
2023		June 30,
2023
Raw materials$427,860 $459,126 
Work in progress5,190 3,956 
Finished goods525,183 534,930 
Total inventories$958,233 $998,012 
Schedule of Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assetsSeptember 30,
2023		June 30,
2023
Prepaid taxes$104,710 $114,009 
Prepaid inventories178,490 143,084 
Other prepaid expenses and current assets161,664 179,925 
Total prepaid expenses and other current assets$444,864 $437,018 
Schedule of Components of Property, Plant and Equipment
Property, Plant and EquipmentSeptember 30,
2023		June 30,
2023
Property, plant and equipment, at cost$1,201,818 $1,205,868 
Accumulated depreciation and amortization(667,833)(668,012)
Property, plant and equipment, net$533,985 $537,856 
Schedule of Other Intangible Assets, Net
Other Intangible Assets September 30,
2023		June 30,
2023
Developed/core product technology$415,933 $398,740 
Accumulated amortization(273,912)(265,802)
Developed/core product technology, net142,021 132,938 
Customer relationships448,769 443,652 
Accumulated amortization(133,503)(124,220)
Customer relationships, net315,266 319,432 
Other intangibles251,770 244,373 
Accumulated amortization(145,779)(144,402)
Other intangibles, net105,991 99,971 
Total other intangibles, net$563,278 $552,341 
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Goodwill (Tables)
 3 Months Ended
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Changes in Carrying Amount of Goodwill
A reconciliation of changes in our goodwill by reportable segment is as follows (in thousands):
Three Months Ended September 30, 2023
Sleep and
Respiratory Care		SaaSTotal
Balance at the beginning of the period$670,120 $2,100,180 $2,770,299 
Business acquisitions74,416 — 74,416 
Foreign currency translation adjustments(8,144)(24,429)(32,573)
Balance at the end of the period$736,392 $2,075,751 $2,812,142 
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Investments (Tables)
 3 Months Ended
Sep. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]  
Schedule of Investments
Equity investments by measurement category were as follows (in thousands):
Measurement categorySeptember 30,
2023		June 30,
2023
Fair value$11,821 $12,423 
Measurement alternative69,678 68,748 
Equity method62,161 65,366 
Total$143,660 $146,537 
Schedule of Changes in Equity Investments
The following tables show a reconciliation of the changes in our equity investments (in thousands):
 Three Months Ended September 30, 2023
 Non-marketable securitiesMarketable securitiesEquity method investmentsTotal
Balance at the beginning of the period$68,748 $12,423 $65,366 $146,537 
Additions to investments1,180 — 2,500 3,680 
Unrealized losses on marketable equity securities— (602)— (602)
Proceeds from exits of investments(250)— — (250)
Loss attributable to equity method investments— — (3,895)(3,895)
Foreign currency translation adjustments— — (1,810)(1,810)
Carrying value at the end of the period$69,678 $11,821 $62,161 $143,660 
Three Months Ended September 30, 2022
Non-marketable securitiesMarketable securitiesEquity method investmentsTotal
Balance at the beginning of the period$39,290 $9,167 $9,918 $58,375 
Additions to investments
4,291 — — 4,291 
Unrealized losses on marketable equity securities
— (3,280)— (3,280)
Loss attributable to equity method investments— — (2,028)(2,028)
Carrying value at the end of the period$43,581 $5,887 $7,890 $57,358 
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Product Warranties (Tables)
 3 Months Ended
Sep. 30, 2023
Product Warranties Disclosures [Abstract]  
Schedule of Changes in Liability for Warranty Costs
Changes in the liability for warranty costs, which is included in accrued expenses in our condensed consolidated balance sheets, are as follows (in thousands):
Three Months Ended
September 30,
20232022
Balance at the beginning of the period$27,621 $25,889 
Warranty accruals for the period6,025 2,088 
Warranty costs incurred for the period (4,828)(2,612)
Foreign currency translation adjustments(672)(1,272)
Balance at the end of the period$28,146 $24,093 
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Debt (Tables)
 3 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Schedule of Debt
Debt consisted of the following (in thousands):
September 30,
2023		June 30,
2023
Short-term debt $10,000 $10,000 
Deferred borrowing costs(95)(98)
Short-term debt, net$9,905 $9,902 
Long-term debt$1,355,000 $1,435,000 
Deferred borrowing costs(3,489)(3,766)
Long-term debt, net$1,351,511 $1,431,234 
Total debt$1,361,416 $1,441,136 
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings Per Share (Tables)
 3 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Earnings Per Share
Basic and diluted earnings per share are calculated as follows (in thousands except per share data):
Three Months Ended
September 30,
20232022
Numerator:
Net income$219,422 $210,478 
Denominator:
Basic weighted-average common shares outstanding147,075 146,431 
Effect of dilutive securities:
Stock options and restricted stock units411 703 
Diluted weighted average shares 147,486 147,134 
Basic earnings per share$1.49 $1.44 
Diluted earnings per share$1.49 $1.43 
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Derivative Instruments and Hedging Activities (Tables)
 3 Months Ended
Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Fair Values of Derivative Instruments
The following table presents our assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets (in thousands):
September 30,
2023		June 30,
2023		Balance Sheet Caption
Derivative Assets
Not Designated as Hedging Instruments
Foreign currency hedging instruments$3,611 $2,126 Prepaid expenses and other current assets
Foreign currency hedging instruments717 279 Prepaid taxes and other non-current assets
Total derivative assets$4,328 $2,405 
Derivative Liabilities
Designated as Hedging Instruments
Foreign cross-currency swaps – Fair Value Hedge$9,883 $19,743 Other long-term liabilities
Foreign cross-currency swaps – Net Investment Hedge17,367 $40,803 Other long-term liabilities
Not Designated as Hedging Instruments
Foreign currency hedging instruments25,005 9,558 Accrued expenses
Foreign currency hedging instruments592 595 Other long-term liabilities
Total derivative liabilities$52,847 $70,699 
Schedule of Derivative Gains (Losses)
We recognized the following gains (losses) on the foreign cross currency swaps designated as fair value hedges (in thousands):
Three Months Ended
September 30,
20232022
Gain (loss) recognized in other comprehensive income (loss)$588 $— 
Gain (loss) recognized on cross-currency swap in interest (expense) income, net (amount excluded from effectiveness testing)1,181 — 
Gain (loss) recognized on cross-currency swap in other, net9,271 — 
Gain (loss) recognized on intercompany debt in other, net(9,271)— 
We recognized the following gains (losses) on the foreign cross currency swaps designated as net investment hedges (in thousands):
Three Months Ended
September 30,
20232022
Gain (loss) recognized in cumulative translation adjustment within other comprehensive income (loss)$23,436 $— 
Gain (loss) recognized from the excluded components in interest (expense) income, net 3,013 — 
We recognized the following gains (losses) in the condensed consolidated statement of operations on derivatives not designated as hedging instruments (in thousands):
Three Months Ended
September 30,
20232022
Gain (loss) recognized on foreign currency hedging instruments in other, net$(15,073)$(20,522)
Gain (loss) recognized on other foreign-currency-denominated transactions in other, net17,646 19,089 
Total$2,573 $(1,433)
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies - Narrative (Details)
$ in Millions
 3 Months Ended
Sep. 30, 2023
USD ($)
segment
Sep. 30, 2022
USD ($)
Summary Of Significant Accounting Policies [Line Items]    
Number of operating segments | segment 2  
Operating lease revenue | $ $ 22.7 $ 23.7
Minimum    
Summary Of Significant Accounting Policies [Line Items]    
Deferred revenue recognized, term 1 year  
Maximum    
Summary Of Significant Accounting Policies [Line Items]    
Deferred revenue recognized, term 5 years  
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies - Schedule Of Net Revenue Disaggregated By Product And Region (Details) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Disaggregation of Revenue [Line Items]    
Net revenue by segment $ 1,102,321 $ 950,294
Total Sleep and Respiratory Care    
Disaggregation of Revenue [Line Items]    
Net revenue by segment 963,037 844,443
Software as a Service    
Disaggregation of Revenue [Line Items]    
Net revenue by segment 139,284 105,851
U.S., Canada and Latin America    
Disaggregation of Revenue [Line Items]    
Net revenue by segment 638,358 578,105
U.S., Canada and Latin America | Devices    
Disaggregation of Revenue [Line Items]    
Net revenue by segment 345,897 339,545
U.S., Canada and Latin America | Masks and other    
Disaggregation of Revenue [Line Items]    
Net revenue by segment 292,461 238,560
Combined Europe, Asia and other markets    
Disaggregation of Revenue [Line Items]    
Net revenue by segment 324,679 266,338
Combined Europe, Asia and other markets | Devices    
Disaggregation of Revenue [Line Items]    
Net revenue by segment 218,831 178,032
Combined Europe, Asia and other markets | Masks and other    
Disaggregation of Revenue [Line Items]    
Net revenue by segment 105,848 88,306
Global revenue    
Disaggregation of Revenue [Line Items]    
Net revenue by segment 1,102,321 950,294
Global revenue | Devices    
Disaggregation of Revenue [Line Items]    
Net revenue by segment 564,728 517,577
Global revenue | Masks and other    
Disaggregation of Revenue [Line Items]    
Net revenue by segment 398,309 326,866
Global revenue | Total Sleep and Respiratory Care    
Disaggregation of Revenue [Line Items]    
Net revenue by segment 963,037 844,443
Global revenue | Software as a Service    
Disaggregation of Revenue [Line Items]    
Net revenue by segment $ 139,284 $ 105,851
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies - Schedule Of Contract Balances (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Jun. 30, 2023
Contract assets    
Accounts receivable, net $ 692,388 $ 704,909
Contract liabilities    
Deferred revenue, current (146,718) (138,072)
Deferred revenue, non-current (121,492) (119,186)
Accounts receivable, net    
Contract assets    
Accounts receivable, net 692,388 704,909
Prepaid expenses and other current assets    
Contract assets    
Unbilled revenue, current 33,201 31,521
Prepaid taxes and other non-current assets    
Contract assets    
Unbilled revenue, non-current 10,244 10,078
Deferred revenue (current liabilities)    
Contract liabilities    
Deferred revenue, current (146,718) (138,072)
Deferred revenue (non-current liabilities)    
Contract liabilities    
Deferred revenue, non-current $ (121,492) $ (119,186)
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Information - Narrative (Details)
 3 Months Ended
Sep. 30, 2023
segment
Segment Reporting [Abstract]  
Number of operating segments 2
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Information - Schedule of Revenue By Segment And Reconciling Items (Details) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Segment Reporting Information [Line Items]    
Net revenue by segment $ 1,102,321 $ 950,294
Depreciation and amortization by segment 44,934 36,273
Net operating profit by segment 288,997 275,739
Amortization of acquired intangible assets 12,479 7,950
Loss attributable to equity method investments 3,895 2,028
(Gain) loss on equity investments 602 3,280
Other, net 2,648 (1,504)
Income before income taxes 272,191 261,793
Operating Segments    
Segment Reporting Information [Line Items]    
Net operating profit by segment 421,673 377,001
Corporate Costs    
Segment Reporting Information [Line Items]    
Depreciation and amortization by segment 21,655 14,593
Reconciling items    
Segment Reporting Information [Line Items]    
Corporate costs 103,378 86,938
Amortization of acquired intangible assets 21,387 14,324
Astral field safety notification expenses (1) 7,911 0
Interest expense (income), net 14,957 7,134
Loss attributable to equity method investments 3,895 2,028
(Gain) loss on equity investments 602 3,280
Other, net (2,648) 1,504
Income before income taxes 272,191 261,793
Total Sleep and Respiratory Care    
Segment Reporting Information [Line Items]    
Net revenue by segment 963,037 844,443
Total Sleep and Respiratory Care | Operating Segments    
Segment Reporting Information [Line Items]    
Depreciation and amortization by segment 20,519 19,767
Net operating profit by segment 390,415 352,560
Software as a Service    
Segment Reporting Information [Line Items]    
Net revenue by segment 139,284 105,851
Software as a Service | Operating Segments    
Segment Reporting Information [Line Items]    
Depreciation and amortization by segment 2,760 1,913
Net operating profit by segment $ 31,258 $ 24,441
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Balance Sheet Information - Schedule of Inventories (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Jun. 30, 2023
Supplemental Balance Sheet Information [Abstract]    
Raw materials $ 427,860 $ 459,126
Work in progress 5,190 3,956
Finished goods 525,183 534,930
Total inventories $ 958,233 $ 998,012
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Balance Sheet Information - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Jun. 30, 2023
Prepaid expenses and other current assets    
Prepaid taxes $ 104,710 $ 114,009
Prepaid inventories 178,490 143,084
Other prepaid expenses and current assets 161,664 179,925
Total prepaid expenses and other current assets $ 444,864 $ 437,018
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Balance Sheet Information - Schedule of Components of Property, Plant And Equipment (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Jun. 30, 2023
Supplemental Balance Sheet Information [Abstract]    
Property, plant and equipment, at cost $ 1,201,818 $ 1,205,868
Accumulated depreciation and amortization (667,833) (668,012)
Property, plant and equipment, net $ 533,985 $ 537,856
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Balance Sheet Information - Schedule of Other Intangible Assets, Net (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Jun. 30, 2023
Finite-Lived Intangible Assets [Line Items]    
Total other intangibles, net $ 563,278 $ 552,341
Developed/core product technology    
Finite-Lived Intangible Assets [Line Items]    
Other intangibles, gross 415,933 398,740
Accumulated amortization (273,912) (265,802)
Total other intangibles, net 142,021 132,938
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Other intangibles, gross 448,769 443,652
Accumulated amortization (133,503) (124,220)
Total other intangibles, net 315,266 319,432
Other intangibles    
Finite-Lived Intangible Assets [Line Items]    
Other intangibles, gross 251,770 244,373
Accumulated amortization (145,779) (144,402)
Total other intangibles, net $ 105,991 $ 99,971
Minimum    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, estimated useful life 2 years  
Maximum    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, estimated useful life 15 years  
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Goodwill (Details)
$ in Thousands
 3 Months Ended
Sep. 30, 2023
USD ($)
Goodwill [Roll Forward]  
Balance at the beginning of the period $ 2,770,299
Business acquisitions 74,416
Foreign currency translation adjustments (32,573)
Balance at the end of the period 2,812,142
Total Sleep and Respiratory Care  
Goodwill [Roll Forward]  
Balance at the beginning of the period 670,120
Business acquisitions 74,416
Foreign currency translation adjustments (8,144)
Balance at the end of the period 736,392
SaaS  
Goodwill [Roll Forward]  
Balance at the beginning of the period 2,100,180
Business acquisitions 0
Foreign currency translation adjustments (24,429)
Balance at the end of the period $ 2,075,751
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Investments - Schedule of Investments (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Jun. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]    
Fair value $ 11,821 $ 12,423
Measurement alternative 69,678 68,748
Equity method 62,161 65,366
Total $ 143,660 $ 146,537
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Investments - Schedule of Changes in Equity Investments (Details) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Equity Method Investments [Roll Forward]    
Balance at the beginning of the period $ 146,537 $ 58,375
Additions to investments 3,680 4,291
Unrealized losses on marketable equity securities (602) (3,280)
Proceeds from exits of investments (250)  
Loss attributable to equity method investments (3,895) (2,028)
Foreign currency translation adjustments (1,810)  
Carrying value at the end of the period 143,660 57,358
Non-marketable securities    
Equity Method Investments [Roll Forward]    
Balance at the beginning of the period 68,748 39,290
Additions to investments 1,180 4,291
Unrealized losses on marketable equity securities 0 0
Proceeds from exits of investments (250)  
Loss attributable to equity method investments 0 0
Foreign currency translation adjustments 0  
Carrying value at the end of the period 69,678 43,581
Marketable securities    
Equity Method Investments [Roll Forward]    
Balance at the beginning of the period 12,423 9,167
Additions to investments 0 0
Unrealized losses on marketable equity securities (602) (3,280)
Proceeds from exits of investments 0  
Loss attributable to equity method investments 0 0
Foreign currency translation adjustments 0  
Carrying value at the end of the period 11,821 5,887
Equity method investments    
Equity Method Investments [Roll Forward]    
Balance at the beginning of the period 65,366 9,918
Additions to investments 2,500 0
Unrealized losses on marketable equity securities 0 0
Proceeds from exits of investments 0  
Loss attributable to equity method investments (3,895) (2,028)
Foreign currency translation adjustments (1,810)  
Carrying value at the end of the period $ 62,161 $ 7,890
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Investments - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]    
Equity securities, unrealized loss $ 0.6 $ 3.3
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Product Warranties (Details) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Movement in Standard Product Warranty Accrual [Roll Forward]    
Balance at the beginning of the period $ 27,621 $ 25,889
Warranty accruals for the period 6,025 2,088
Warranty costs incurred for the period (4,828) (2,612)
Foreign currency translation adjustments (672) (1,272)
Balance at the end of the period $ 28,146 $ 24,093
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Debt - Schedule of Debt (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Jun. 30, 2023
Debt Disclosure [Abstract]    
Short-term debt $ 10,000 $ 10,000
Deferred borrowing costs (95) (98)
Short-term debt, net 9,905 9,902
Long-term debt 1,355,000 1,435,000
Deferred borrowing costs (3,489) (3,766)
Long-term debt, net 1,351,511 1,431,234
Total debt $ 1,361,416 $ 1,441,136
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Debt - Narrative (Details)
 3 Months Ended
Jun. 29, 2022
USD ($)
Sep. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
Jul. 10, 2019
USD ($)
Debt Instrument [Line Items]        
Debt to consolidated EBITDA ratio   3.50    
Line of credit facility collateral, maximum percentage of ownership interests held in subsidiary   10.00%    
Senior notes, carrying amount   $ 500,000,000 $ 500,000,000  
Outstanding debt   1,361,416,000 1,441,136,000  
3.24% Senior Notes Due July 10, 2026        
Debt Instrument [Line Items]        
Principal amount       $ 250,000,000
Interest rate       3.24%
3.45% Senior Notes Due July 10, 2029        
Debt Instrument [Line Items]        
Principal amount       $ 250,000,000
Interest rate       3.45%
Senior Notes        
Debt Instrument [Line Items]        
Long-term debt, fair value   451,700,000 462,200,000  
Revolving Credit Agreement, Term Credit Agreement, and Senior Notes        
Debt Instrument [Line Items]        
Outstanding debt   1,365,000,000    
Revolving Credit Facility and Term Credit Agreement        
Debt Instrument [Line Items]        
Long-term debt, fair value   $ 865,000,000 $ 945,000,000  
Revolving Credit Facility and Term Credit Agreement | Mufg Union Bank Na and Westpac Banking Corporation        
Debt Instrument [Line Items]        
Interest rate on outstanding principal amount   6.30%    
Revolving Credit Facility        
Debt Instrument [Line Items]        
Available for draw   $ 825,000,000    
Revolving Credit Facility | Mufg Union Bank Na and Westpac Banking Corporation        
Debt Instrument [Line Items]        
Maximum borrowing capacity $ 1,500,000,000      
Uncommitted option to increase credit facility $ 1,000,000,000      
EBITDA multiple of trailing twelve-month measurement period 1.0      
Revolving Credit Facility | Mufg Union Bank Na and Westpac Banking Corporation | Minimum        
Debt Instrument [Line Items]        
Commitment fees percentage rate on unused portion of credit facility   0.075%    
Revolving Credit Facility | Mufg Union Bank Na and Westpac Banking Corporation | Maximum        
Debt Instrument [Line Items]        
Commitment fees percentage rate on unused portion of credit facility   0.15%    
Revolving Credit Facility | Mufg Union Bank | ResMed Limited        
Debt Instrument [Line Items]        
Maximum borrowing capacity $ 200,000,000      
Term Loan Credit Agreement        
Debt Instrument [Line Items]        
Principal payment $ 5,000,000      
Term Loan Credit Agreement | Minimum | Secured Overnight Financing Rate        
Debt Instrument [Line Items]        
Credit facility interest rate equal to reference rate plus 0.75%      
Term Loan Credit Agreement | Minimum | Base Rate        
Debt Instrument [Line Items]        
Credit facility interest rate equal to reference rate plus 0.00%      
Term Loan Credit Agreement | Maximum | Secured Overnight Financing Rate        
Debt Instrument [Line Items]        
Credit facility interest rate equal to reference rate plus 1.50%      
Term Loan Credit Agreement | Maximum | Base Rate        
Debt Instrument [Line Items]        
Credit facility interest rate equal to reference rate plus 0.50%      
XML 56 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings Per Share - Narrative (Details) - shares
shares in Thousands
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Earnings Per Share [Abstract]    
Antidilutive securities excluded from computation of earnings per share, amount (share) 417,364 113,167
XML 57 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings Per Share - Schedule of Basic And Diluted Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Numerator:    
Net income $ 219,422 $ 210,478
Denominator:    
Basic weighted-average common shares outstanding (shares) 147,075 146,431
Effect of dilutive securities:    
Stock options and restricted stock units (shares) 411 703
Diluted weighted average shares (shares) 147,486 147,134
Basic earnings per share (in dollars per share) $ 1.49 $ 1.44
Diluted earnings per share (in dollars per share) $ 1.49 $ 1.43
XML 58 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Legal Actions, Contingencies and Commitments (Details)
$ in Millions
 3 Months Ended
Jun. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 16, 2022
patent
Commitments and Contingencies Disclosure [Abstract]          
Number of patents | patent         8
Receivables sold with limited recourse   $ 47.7 $ 39.9    
Maximum potential contingent liability   28.9   $ 32.6  
Contingent provision $ 0.6 $ 0.8      
XML 59 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Derivative Instruments and Hedging Activities - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Currency Swap | Fair Value And Net Investment Hedging    
Derivative [Line Items]    
Notional value $ 1,014.8 $ 1,046.6
Foreign currency hedging instruments | Non-Designated Hedges    
Derivative [Line Items]    
Notional value $ 1,363.3 $ 954.7
Derivative, term of contract (in years) 3 years  
XML 60 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Derivative Instruments and Hedging Activities - Schedule of Fair Values of Derivative Instruments (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Jun. 30, 2023
Derivatives, Fair Value [Line Items]    
Derivative Assets $ 4,328 $ 2,405
Derivative Liabilities $ 52,847 $ 70,699
Derivative Asset, Current, Statement of Financial Position [Extensible Enumeration] Prepaid expenses and other current assets (note 3) Prepaid expenses and other current assets (note 3)
Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration] Prepaid taxes and other non-current assets Prepaid taxes and other non-current assets
Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other long-term liabilities Other long-term liabilities
Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration] Accrued expenses Accrued expenses
Foreign currency hedging instruments | Designated as Hedging Instruments | Fair Value Hedging    
Derivatives, Fair Value [Line Items]    
Derivative Liabilities $ 9,883 $ 19,743
Foreign currency hedging instruments | Designated as Hedging Instruments | Net Investment Hedging    
Derivatives, Fair Value [Line Items]    
Derivative Liabilities 17,367 40,803
Prepaid expenses and other current assets | Foreign currency hedging instruments | Not Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Derivative Assets 3,611 2,126
Prepaid taxes and other non-current assets | Foreign currency hedging instruments | Not Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Derivative Assets 717 279
Accrued expenses | Foreign currency hedging instruments | Not Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Derivative Liabilities 25,005 9,558
Other long-term liabilities | Foreign currency hedging instruments | Not Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Derivative Liabilities $ 592 $ 595
XML 61 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Derivative Instruments and Hedging Activities - Schedule of Fair Value Hedge Gains (Losses) (Details) - Currency Swap - Fair Value Hedging - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Gain (loss) recognized in other comprehensive income (loss) $ 588 $ 0
Gain (loss) recognized on cross-currency swap in interest (expense) income, net (amount excluded from effectiveness testing) 1,181 0
Gain (loss) recognized on cross-currency swap in other, net 9,271 0
Gain (loss) recognized on intercompany debt in other, net $ (9,271) $ 0
XML 62 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Derivative Instruments and Hedging Activities - Schedule of Net Investment Hedge Gains (Losses) (Details) - Currency Swap - Net Investment Hedging - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Gain (loss) recognized in cumulative translation adjustment within other comprehensive income (loss) $ 23,436 $ 0
Interest Expense    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Gain (loss) recognized from the excluded components in interest (expense) income, net $ 3,013 $ 0
XML 63 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Derivative Instruments and Hedging Activities - Schedule of Non-Designated Derivative Gains (Losses) (Details) - Not Designated as Hedging Instruments - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Total $ 2,573 $ (1,433)
Foreign currency hedging instruments | Other Nonoperating Income (Expense)    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Total (15,073) (20,522)
Other Foreign Exchange Contracts | Other Nonoperating Income (Expense)    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Total $ 17,646 $ 19,089
XML 64 rmd-20230930_htm.xml IDEA: XBRL DOCUMENT 0000943819 2023-07-01 2023-09-30 0000943819 2023-10-23 0000943819 2023-09-30 0000943819 2023-06-30 0000943819 rmd:SleepAndRespiratoryMember 2023-07-01 2023-09-30 0000943819 rmd:SleepAndRespiratoryMember 2022-07-01 2022-09-30 0000943819 rmd:SoftwareAsServiceMember 2023-07-01 2023-09-30 0000943819 rmd:SoftwareAsServiceMember 2022-07-01 2022-09-30 0000943819 2022-07-01 2022-09-30 0000943819 us-gaap:CommonStockMember 2023-06-30 0000943819 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000943819 us-gaap:TreasuryStockCommonMember 2023-06-30 0000943819 us-gaap:RetainedEarningsMember 2023-06-30 0000943819 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000943819 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000943819 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000943819 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0000943819 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000943819 us-gaap:CommonStockMember 2023-09-30 0000943819 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000943819 us-gaap:TreasuryStockCommonMember 2023-09-30 0000943819 us-gaap:RetainedEarningsMember 2023-09-30 0000943819 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000943819 us-gaap:CommonStockMember 2022-06-30 0000943819 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000943819 us-gaap:TreasuryStockCommonMember 2022-06-30 0000943819 us-gaap:RetainedEarningsMember 2022-06-30 0000943819 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000943819 2022-06-30 0000943819 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000943819 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000943819 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000943819 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000943819 us-gaap:CommonStockMember 2022-09-30 0000943819 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000943819 us-gaap:TreasuryStockCommonMember 2022-09-30 0000943819 us-gaap:RetainedEarningsMember 2022-09-30 0000943819 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000943819 2022-09-30 0000943819 rmd:DevicesMember rmd:UsCanadaAndLatinAmericaMember 2023-07-01 2023-09-30 0000943819 rmd:DevicesMember rmd:UsCanadaAndLatinAmericaMember 2022-07-01 2022-09-30 0000943819 rmd:MasksAndOtherMember rmd:UsCanadaAndLatinAmericaMember 2023-07-01 2023-09-30 0000943819 rmd:MasksAndOtherMember rmd:UsCanadaAndLatinAmericaMember 2022-07-01 2022-09-30 0000943819 rmd:UsCanadaAndLatinAmericaMember 2023-07-01 2023-09-30 0000943819 rmd:UsCanadaAndLatinAmericaMember 2022-07-01 2022-09-30 0000943819 rmd:DevicesMember rmd:CombinedEuropeAsiaAndOtherMarketsMember 2023-07-01 2023-09-30 0000943819 rmd:DevicesMember rmd:CombinedEuropeAsiaAndOtherMarketsMember 2022-07-01 2022-09-30 0000943819 rmd:MasksAndOtherMember rmd:CombinedEuropeAsiaAndOtherMarketsMember 2023-07-01 2023-09-30 0000943819 rmd:MasksAndOtherMember rmd:CombinedEuropeAsiaAndOtherMarketsMember 2022-07-01 2022-09-30 0000943819 rmd:CombinedEuropeAsiaAndOtherMarketsMember 2023-07-01 2023-09-30 0000943819 rmd:CombinedEuropeAsiaAndOtherMarketsMember 2022-07-01 2022-09-30 0000943819 rmd:DevicesMember rmd:GlobalMember 2023-07-01 2023-09-30 0000943819 rmd:DevicesMember rmd:GlobalMember 2022-07-01 2022-09-30 0000943819 rmd:MasksAndOtherMember rmd:GlobalMember 2023-07-01 2023-09-30 0000943819 rmd:MasksAndOtherMember rmd:GlobalMember 2022-07-01 2022-09-30 0000943819 rmd:SleepAndRespiratoryMember rmd:GlobalMember 2023-07-01 2023-09-30 0000943819 rmd:SleepAndRespiratoryMember rmd:GlobalMember 2022-07-01 2022-09-30 0000943819 rmd:SoftwareAsServiceMember rmd:GlobalMember 2023-07-01 2023-09-30 0000943819 rmd:SoftwareAsServiceMember rmd:GlobalMember 2022-07-01 2022-09-30 0000943819 rmd:GlobalMember 2023-07-01 2023-09-30 0000943819 rmd:GlobalMember 2022-07-01 2022-09-30 0000943819 srt:MinimumMember 2023-07-01 2023-09-30 0000943819 srt:MaximumMember 2023-07-01 2023-09-30 0000943819 rmd:AccountsReceivableNetMember 2023-09-30 0000943819 rmd:AccountsReceivableNetMember 2023-06-30 0000943819 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2023-09-30 0000943819 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2023-06-30 0000943819 rmd:PrepaidTaxesAndOtherNonCurrentAssetsMember 2023-09-30 0000943819 rmd:PrepaidTaxesAndOtherNonCurrentAssetsMember 2023-06-30 0000943819 rmd:DeferredRevenueCurrentLiabilitiesMember 2023-09-30 0000943819 rmd:DeferredRevenueCurrentLiabilitiesMember 2023-06-30 0000943819 rmd:DeferredRevenueNonCurrentLiabilitiesMember 2023-09-30 0000943819 rmd:DeferredRevenueNonCurrentLiabilitiesMember 2023-06-30 0000943819 rmd:SleepAndRespiratoryMember 2023-07-01 2023-09-30 0000943819 rmd:SleepAndRespiratoryMember 2022-07-01 2022-09-30 0000943819 rmd:SoftwareAsServiceMember 2023-07-01 2023-09-30 0000943819 rmd:SoftwareAsServiceMember 2022-07-01 2022-09-30 0000943819 us-gaap:OperatingSegmentsMember rmd:SleepAndRespiratoryMember 2023-07-01 2023-09-30 0000943819 us-gaap:OperatingSegmentsMember rmd:SleepAndRespiratoryMember 2022-07-01 2022-09-30 0000943819 us-gaap:OperatingSegmentsMember rmd:SoftwareAsServiceMember 2023-07-01 2023-09-30 0000943819 us-gaap:OperatingSegmentsMember rmd:SoftwareAsServiceMember 2022-07-01 2022-09-30 0000943819 us-gaap:CorporateNonSegmentMember 2023-07-01 2023-09-30 0000943819 us-gaap:CorporateNonSegmentMember 2022-07-01 2022-09-30 0000943819 us-gaap:OperatingSegmentsMember 2023-07-01 2023-09-30 0000943819 us-gaap:OperatingSegmentsMember 2022-07-01 2022-09-30 0000943819 us-gaap:MaterialReconcilingItemsMember 2023-07-01 2023-09-30 0000943819 us-gaap:MaterialReconcilingItemsMember 2022-07-01 2022-09-30 0000943819 rmd:DevelopedOrCoreProductTechnologyMember 2023-09-30 0000943819 rmd:DevelopedOrCoreProductTechnologyMember 2023-06-30 0000943819 us-gaap:CustomerRelationshipsMember 2023-09-30 0000943819 us-gaap:CustomerRelationshipsMember 2023-06-30 0000943819 us-gaap:OtherIntangibleAssetsMember 2023-09-30 0000943819 us-gaap:OtherIntangibleAssetsMember 2023-06-30 0000943819 srt:MinimumMember 2023-09-30 0000943819 srt:MaximumMember 2023-09-30 0000943819 rmd:SleepAndRespiratoryMember 2023-06-30 0000943819 rmd:SaasMember 2023-06-30 0000943819 rmd:SaasMember 2023-07-01 2023-09-30 0000943819 rmd:SleepAndRespiratoryMember 2023-09-30 0000943819 rmd:SaasMember 2023-09-30 0000943819 rmd:NonMarketableSecuritiesMember 2023-06-30 0000943819 rmd:MarketableSecuritiesMember 2023-06-30 0000943819 us-gaap:EquityMethodInvestmentsMember 2023-06-30 0000943819 rmd:NonMarketableSecuritiesMember 2023-07-01 2023-09-30 0000943819 rmd:MarketableSecuritiesMember 2023-07-01 2023-09-30 0000943819 us-gaap:EquityMethodInvestmentsMember 2023-07-01 2023-09-30 0000943819 rmd:NonMarketableSecuritiesMember 2023-09-30 0000943819 rmd:MarketableSecuritiesMember 2023-09-30 0000943819 us-gaap:EquityMethodInvestmentsMember 2023-09-30 0000943819 rmd:NonMarketableSecuritiesMember 2022-06-30 0000943819 rmd:MarketableSecuritiesMember 2022-06-30 0000943819 us-gaap:EquityMethodInvestmentsMember 2022-06-30 0000943819 rmd:NonMarketableSecuritiesMember 2022-07-01 2022-09-30 0000943819 rmd:MarketableSecuritiesMember 2022-07-01 2022-09-30 0000943819 us-gaap:EquityMethodInvestmentsMember 2022-07-01 2022-09-30 0000943819 rmd:NonMarketableSecuritiesMember 2022-09-30 0000943819 rmd:MarketableSecuritiesMember 2022-09-30 0000943819 us-gaap:EquityMethodInvestmentsMember 2022-09-30 0000943819 us-gaap:RevolvingCreditFacilityMember rmd:MufgUnionBankNaAndWestpacBankingCorporationMember 2022-06-29 0000943819 us-gaap:RevolvingCreditFacilityMember rmd:MufgUnionBankNaAndWestpacBankingCorporationMember 2022-06-29 2022-06-29 0000943819 us-gaap:RevolvingCreditFacilityMember rmd:MufgUnionBankMember rmd:ResmedLimitedMember 2022-06-29 0000943819 rmd:TermLoanCreditAgreementMember 2022-06-29 2022-06-29 0000943819 srt:MinimumMember rmd:TermLoanCreditAgreementMember rmd:SecuredOvernightFinancingRateMember 2022-06-29 2022-06-29 0000943819 srt:MaximumMember rmd:TermLoanCreditAgreementMember rmd:SecuredOvernightFinancingRateMember 2022-06-29 2022-06-29 0000943819 srt:MinimumMember rmd:TermLoanCreditAgreementMember us-gaap:BaseRateMember 2022-06-29 2022-06-29 0000943819 srt:MaximumMember rmd:TermLoanCreditAgreementMember us-gaap:BaseRateMember 2022-06-29 2022-06-29 0000943819 rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember rmd:MufgUnionBankNaAndWestpacBankingCorporationMember 2023-09-30 0000943819 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember rmd:MufgUnionBankNaAndWestpacBankingCorporationMember 2023-07-01 2023-09-30 0000943819 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember rmd:MufgUnionBankNaAndWestpacBankingCorporationMember 2023-07-01 2023-09-30 0000943819 us-gaap:RevolvingCreditFacilityMember 2023-09-30 0000943819 rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember 2023-09-30 0000943819 rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember 2023-06-30 0000943819 rmd:SeniorNotesOneMember 2019-07-10 0000943819 rmd:SeniorNotesTwoMember 2019-07-10 0000943819 us-gaap:SeniorNotesMember 2023-09-30 0000943819 us-gaap:SeniorNotesMember 2023-06-30 0000943819 rmd:RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember 2023-09-30 0000943819 2022-06-16 0000943819 2022-06-30 2022-06-30 0000943819 us-gaap:CurrencySwapMember rmd:FairValueAndNetInvestmentHedgingMember 2023-09-30 0000943819 us-gaap:CurrencySwapMember rmd:FairValueAndNetInvestmentHedgingMember 2023-06-30 0000943819 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2023-07-01 2023-09-30 0000943819 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2023-09-30 0000943819 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2023-06-30 0000943819 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-09-30 0000943819 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-06-30 0000943819 rmd:PrepaidTaxesAndOtherNonCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-09-30 0000943819 rmd:PrepaidTaxesAndOtherNonCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-06-30 0000943819 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000943819 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000943819 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000943819 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000943819 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-09-30 0000943819 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-06-30 0000943819 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-09-30 0000943819 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-06-30 0000943819 us-gaap:CurrencySwapMember us-gaap:FairValueHedgingMember 2023-07-01 2023-09-30 0000943819 us-gaap:CurrencySwapMember us-gaap:FairValueHedgingMember 2022-07-01 2022-09-30 0000943819 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember 2023-07-01 2023-09-30 0000943819 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember 2022-07-01 2022-09-30 0000943819 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:InterestExpenseMember 2023-07-01 2023-09-30 0000943819 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:InterestExpenseMember 2022-07-01 2022-09-30 0000943819 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-07-01 2023-09-30 0000943819 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-07-01 2022-09-30 0000943819 rmd:OtherForeignExchangeContractsMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-07-01 2023-09-30 0000943819 rmd:OtherForeignExchangeContractsMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-07-01 2022-09-30 0000943819 us-gaap:NondesignatedMember 2023-07-01 2023-09-30 0000943819 us-gaap:NondesignatedMember 2022-07-01 2022-09-30 shares iso4217:USD iso4217:USD shares rmd:segment pure rmd:patent false 2024 Q1 --06-30 0000943819 http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent 10-Q true 2023-09-30 false 001-15317 ResMed Inc. DE 98-0152841 9001 Spectrum Center Blvd. San Diego CA 92123 US 858 836-5000 Common Stock, par value $0.004 per share RMD NYSE Yes Yes Large Accelerated Filer false false false 147091910 209100000 227891000 20532000 23603000 692388000 704909000 958233000 998012000 444864000 437018000 2304585000 2367830000 533985000 537856000 123416000 127955000 2812142000 2770299000 563278000 552341000 138271000 132974000 265109000 262453000 4436201000 4383878000 6740786000 6751708000 177048000 150756000 348263000 365660000 21795000 21919000 146718000 138072000 67073000 72224000 9905000 9902000 770802000 758533000 121492000 119186000 87672000 90650000 112448000 116853000 34328000 68166000 1351511000 1431234000 12157000 37183000 1719608000 1863272000 2490410000 2621805000 0.01 0.01 2000000 2000000 0 0 0 0 0.004 0.004 350000000 350000000 188921316 147085082 188900583 147064349 588000 588000 1791351000 1772083000 4401841000 4253016000 41836234 41836234 1623256000 1623256000 -320148000 -272528000 4250376000 4129903000 6740786000 6751708000 963037000 844443000 139284000 105851000 1102321000 950294000 444460000 363844000 48893000 39266000 493353000 403110000 1916000 1228000 6992000 5146000 8908000 6374000 502261000 409484000 600060000 540810000 222874000 193933000 75710000 63188000 12479000 7950000 311063000 265071000 288997000 275739000 -14957000 -7134000 -3895000 -2028000 -602000 -3280000 2648000 -1504000 -16806000 -13946000 272191000 261793000 52769000 51315000 219422000 210478000 1.49 1.44 1.49 1.43 0.48 0.44 147075000 146431000 147486000 147134000 219422000 210478000 -17093000 0 -30527000 -93381000 171802000 117097000 188901000 588000 1772083000 41836000 -1623256000 4253016000 -272528000 4129903000 17000 983000 983000 3000 -225000 -225000 18510000 18510000 -47620000 -47620000 219422000 219422000 0.48 70597000 70597000 188921000 588000 1791351000 41836000 -1623256000 4401841000 -320148000 4250376000 188247000 586000 1682432000 41836000 -1623256000 3613736000 -312747000 3360751000 45000 2610000 2610000 3000 -59000 -59000 16919000 16919000 -93381000 -93381000 210478000 210478000 0.44 64431000 64431000 188295000 586000 1701902000 41836000 -1623256000 3759783000 -406128000 3432887000 219422000 210478000 44934000 36273000 8508000 7761000 18510000 16919000 -3895000 -2028000 -602000 -3280000 -6534000 56238000 -26911000 147096000 42015000 36784000 -1018000 8041000 286283000 44662000 30035000 29056000 10831000 3317000 103183000 19100000 3680000 4291000 250000 0 1501000 3042000 -148980000 -58806000 983000 2610000 225000 59000 1293000 0 105000000 50000000 185000000 30000000 70597000 64431000 -151132000 -41880000 -4962000 -10523000 -18791000 -66547000 227891000 273710000 209100000 207163000 76749000 53437000 14957000 7134000 34092000 9506000 5325000 3975000 74416000 19281000 0 -2856000 -1293000 2856000 104476000 19100000 Summary of Significant Accounting Policies<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Finland, Norway and Sweden. We also operate a Software as a Service (“SaaS”) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and the rules of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2024. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements for the three months ended September 30, 2023 and September 30, 2022 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K (our “Form 10-K”) for the year ended June 30, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standard Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers”, we account for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (“Sleep and Respiratory Care”) and the supply of business management software as a service to out-of-hospital care providers (“SaaS”). Our Sleep and Respiratory Care revenue relates primarily to the sale of our products that are therapy-based equipment. Some contracts include additional performance obligations such as the provision of extended warranties and provision of data for patient monitoring. Our SaaS revenue relates to the provision of software access with ongoing support and maintenance services as well as professional services such as training and consulting. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregation of revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net revenue disaggregated by segment, product and region (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S., Canada and Latin America</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">339,545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292,461 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total U.S., Canada and Latin America</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638,358 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">578,105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Combined Europe, Asia and other markets </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178,032 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Combined Europe, Asia and other markets </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">324,679 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266,338 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Devices</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">564,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">517,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Masks and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398,309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">326,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">963,037</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">844,443</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">139,284</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">105,851</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,102,321</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">950,294</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Performance obligations and contract balances</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; generally, this occurs with the transfer of risk and/or control of our products at a point in time. For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with cloud-hosted services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of one year to five years. Our contracts do not contain significant financing components.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract balances (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance sheet caption</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692,388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">704,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,078 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes and other non-current assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146,718)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(138,072)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (current liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(121,492)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (non-current liabilities)</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction price determination</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g. rebates, discounts, free goods) and returns offered to our customers and their </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of our historical experience. However, returns of products, excluding warranty-related returns, have historically been infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer’s expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates each quarter based on actual sales results and updated forecasts for the remaining rebate periods. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in programs where we issue credits to our Sleep and Respiratory Care distributors when they are required to sell our products below negotiated list prices if we have preexisting contracts with the distributors' customers. We reduce revenue for future credits at the time of sale to the distributor, which we estimate based on historical experience using the expected value method. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When Sleep and Respiratory Care or SaaS contracts have multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each performance obligation. An allocation is not required for many of our Sleep and Respiratory Care contracts that have a single performance obligation, which is the shipment of our therapy-based equipment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting and practical expedient elections</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to account for shipping and handling activities associated with our Sleep and Respiratory Care segment as a fulfillment cost within cost of sales, and record shipping and handling costs collected from customers in net revenue. We have also elected for all taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, to be excluded from revenue and presented on a net basis. We have elected two practical expedients including the “right to invoice” practical expedient, which is relevant for some of our SaaS contracts as it allows us to recognize revenue in the amount of the invoice when it corresponds directly with the value of performance completed to date. The second practical expedient adopted permits relief from considering a significant financing component when the payment for the good or service is expected to be one year or less.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease Sleep and Respiratory Care medical devices to customers primarily as a means to comply with local health insurer requirements in certain foreign geographies. Device rental contracts are classified as operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. Operating lease revenue was $22.7 million for the three months ended September 30, 2023 and $23.7 million for the three months ended September 30, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for Warranty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for the estimated cost of product warranties on our Sleep and Respiratory Care products at the time the related revenue is recognized. We determine the amount of this provision by using a financial model, which takes into consideration actual historical expenses and potential risks associated with our different products. We use this financial model to calculate the future probable expenses related to warranty and the required level of the warranty provision. Although we engage in product improvement programs and processes, our warranty obligation is affected by product failure rates and costs incurred to correct those product failures. Should actual product failure rates or estimated costs to repair those product failures differ from our estimates, we would be required to revise our estimated warranty provision.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Finland, Norway and Sweden. We also operate a Software as a Service (“SaaS”) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and the rules of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2024. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements for the three months ended September 30, 2023 and September 30, 2022 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K (our “Form 10-K”) for the year ended June 30, 2023.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standard Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers”, we account for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (“Sleep and Respiratory Care”) and the supply of business management software as a service to out-of-hospital care providers (“SaaS”). Our Sleep and Respiratory Care revenue relates primarily to the sale of our products that are therapy-based equipment. Some contracts include additional performance obligations such as the provision of extended warranties and provision of data for patient monitoring. Our SaaS revenue relates to the provision of software access with ongoing support and maintenance services as well as professional services such as training and consulting. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregation of revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net revenue disaggregated by segment, product and region (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S., Canada and Latin America</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">339,545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292,461 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total U.S., Canada and Latin America</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638,358 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">578,105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Combined Europe, Asia and other markets </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178,032 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Combined Europe, Asia and other markets </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">324,679 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266,338 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Devices</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">564,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">517,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Masks and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398,309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">326,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">963,037</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">844,443</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">139,284</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">105,851</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,102,321</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">950,294</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Performance obligations and contract balances</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; generally, this occurs with the transfer of risk and/or control of our products at a point in time. For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with cloud-hosted services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of one year to five years. Our contracts do not contain significant financing components.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract balances (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance sheet caption</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692,388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">704,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,078 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes and other non-current assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146,718)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(138,072)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (current liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(121,492)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (non-current liabilities)</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction price determination</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g. rebates, discounts, free goods) and returns offered to our customers and their </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of our historical experience. However, returns of products, excluding warranty-related returns, have historically been infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer’s expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates each quarter based on actual sales results and updated forecasts for the remaining rebate periods. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in programs where we issue credits to our Sleep and Respiratory Care distributors when they are required to sell our products below negotiated list prices if we have preexisting contracts with the distributors' customers. We reduce revenue for future credits at the time of sale to the distributor, which we estimate based on historical experience using the expected value method. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When Sleep and Respiratory Care or SaaS contracts have multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each performance obligation. An allocation is not required for many of our Sleep and Respiratory Care contracts that have a single performance obligation, which is the shipment of our therapy-based equipment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting and practical expedient elections</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to account for shipping and handling activities associated with our Sleep and Respiratory Care segment as a fulfillment cost within cost of sales, and record shipping and handling costs collected from customers in net revenue. We have also elected for all taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, to be excluded from revenue and presented on a net basis. We have elected two practical expedients including the “right to invoice” practical expedient, which is relevant for some of our SaaS contracts as it allows us to recognize revenue in the amount of the invoice when it corresponds directly with the value of performance completed to date. The second practical expedient adopted permits relief from considering a significant financing component when the payment for the good or service is expected to be one year or less.</span></div> 2 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net revenue disaggregated by segment, product and region (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S., Canada and Latin America</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">339,545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292,461 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total U.S., Canada and Latin America</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638,358 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">578,105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Combined Europe, Asia and other markets </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178,032 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Combined Europe, Asia and other markets </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">324,679 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266,338 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Devices</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">564,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">517,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Masks and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398,309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">326,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">963,037</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">844,443</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">139,284</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">105,851</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,102,321</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">950,294</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 345897000 339545000 292461000 238560000 638358000 578105000 218831000 178032000 105848000 88306000 324679000 266338000 564728000 517577000 398309000 326866000 963037000 844443000 139284000 105851000 1102321000 950294000 P1Y P5Y <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract balances (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance sheet caption</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692,388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">704,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,078 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes and other non-current assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146,718)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(138,072)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (current liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(121,492)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (non-current liabilities)</span></td></tr></table></div> 692388000 704909000 33201000 31521000 10244000 10078000 146718000 138072000 121492000 119186000 Lease RevenueWe lease Sleep and Respiratory Care medical devices to customers primarily as a means to comply with local health insurer requirements in certain foreign geographies. Device rental contracts are classified as operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. 22700000 23700000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for Warranty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for the estimated cost of product warranties on our Sleep and Respiratory Care products at the time the related revenue is recognized. We determine the amount of this provision by using a financial model, which takes into consideration actual historical expenses and potential risks associated with our different products. We use this financial model to calculate the future probable expenses related to warranty and the required level of the warranty provision. Although we engage in product improvement programs and processes, our warranty obligation is affected by product failure rates and costs incurred to correct those product failures. Should actual product failure rates or estimated costs to repair those product failures differ from our estimates, we would be required to revise our estimated warranty provision.</span></div> Segment Information<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have quantitatively and qualitatively determined that we operate in two operating segments, which are the Sleep and Respiratory Care segment and the SaaS segment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate the performance of our segments based on net revenues and income from operations. The accounting policies of the segments are the same as those described in note 2 of our consolidated financial statements included in our Form 10-K for the fiscal year ended June 30, 2023. Segment net revenues and segment income from operations do not include inter-segment profits and revenue is allocated to a geographic area based on where the products are shipped to or where the services are performed. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include corporate headquarters costs, stock-based compensation, amortization expense from acquired intangibles, acquisition related expenses, net interest expense (income), loss attributable to equity method investments, gains and losses on equity investments, and other, net. We neither discretely allocate assets to our operating segments, nor does our Chief Operating Decision Maker evaluate the operating segments using discrete asset information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents a reconciliation of net revenues and net operating profit by reportable segments (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net revenue by segment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">963,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">844,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139,284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,102,321 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">950,294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Depreciation and amortization by segment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,519 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,913 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets and corporate assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,934 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,273 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net operating profit by segment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">352,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">421,673 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">377,001 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reconciling items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Astral field safety notification expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span id="i8835a331fb104f4e9e2bc0b2056ce711_22-1-1-1-123894"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,911 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense (income), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,895 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,028 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,648)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,504 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">272,191 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261,793 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    The Astral field safety notification expenses relate to estimated costs associated with the replacement of a certain component in some of our Astral ventilation devices that were manufactured between 2013 to 2019.</span></div> 2 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents a reconciliation of net revenues and net operating profit by reportable segments (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net revenue by segment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">963,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">844,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139,284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,102,321 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">950,294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Depreciation and amortization by segment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,519 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,913 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets and corporate assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,934 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,273 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net operating profit by segment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">352,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">421,673 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">377,001 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reconciling items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Astral field safety notification expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span id="i8835a331fb104f4e9e2bc0b2056ce711_22-1-1-1-123894"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,911 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense (income), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,895 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,028 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,648)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,504 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">272,191 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261,793 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    The Astral field safety notification expenses relate to estimated costs associated with the replacement of a certain component in some of our Astral ventilation devices that were manufactured between 2013 to 2019.</span></div> 963037000 844443000 139284000 105851000 1102321000 950294000 20519000 19767000 2760000 1913000 21655000 14593000 44934000 36273000 390415000 352560000 31258000 24441000 421673000 377001000 103378000 86938000 21387000 14324000 7911000 0 14957000 7134000 -3895000 -2028000 -602000 -3280000 -2648000 1504000 272191000 261793000 Supplemental Balance Sheet Information<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of selected captions in the condensed consolidated balance sheets consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inventories</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">427,860 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">459,126 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">525,183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534,930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">958,233 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">998,012 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104,710 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114,009 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178,490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,084 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid expenses and current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161,664 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444,864 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">437,018 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, Plant and Equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, at cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,201,818 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,205,868 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(667,833)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(668,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533,985 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537,856 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Intangible Assets </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed/core product technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415,933 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(273,912)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(265,802)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed/core product technology, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142,021 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132,938 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448,769 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443,652 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(133,503)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(124,220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">315,266 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319,432 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangibles</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251,770 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244,373 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(145,779)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144,402)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,991 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,971 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other intangibles, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563,278 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552,341 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of developed/core product technology, trade names, non-compete agreements, customer relationships, and patents, which we amortize over the estimated useful life of the assets, generally between two years to fifteen years. There are no expected residual values related to these intangible assets.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of selected captions in the condensed consolidated balance sheets consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inventories</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">427,860 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">459,126 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">525,183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534,930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">958,233 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">998,012 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 427860000 459126000 5190000 3956000 525183000 534930000 958233000 998012000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104,710 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114,009 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178,490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,084 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid expenses and current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161,664 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444,864 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">437,018 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 104710000 114009000 178490000 143084000 161664000 179925000 444864000 437018000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, Plant and Equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, at cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,201,818 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,205,868 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(667,833)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(668,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533,985 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537,856 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1201818000 1205868000 667833000 668012000 533985000 537856000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Intangible Assets </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed/core product technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415,933 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(273,912)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(265,802)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed/core product technology, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142,021 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132,938 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448,769 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443,652 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(133,503)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(124,220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">315,266 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319,432 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangibles</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251,770 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244,373 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(145,779)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144,402)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,991 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,971 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other intangibles, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563,278 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552,341 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 415933000 398740000 273912000 265802000 142021000 132938000 448769000 443652000 133503000 124220000 315266000 319432000 251770000 244373000 145779000 144402000 105991000 99971000 563278000 552341000 P2Y P15Y Goodwill <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of changes in our goodwill by reportable segment is as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sleep and <br/>Respiratory Care</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SaaS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">670,120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,100,180 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,770,299 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,573)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">736,392 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,075,751 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,812,142 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of changes in our goodwill by reportable segment is as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sleep and <br/>Respiratory Care</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SaaS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">670,120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,100,180 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,770,299 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,573)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">736,392 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,075,751 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,812,142 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 670120000 2100180000 2770299000 74416000 0 74416000 -8144000 -24429000 -32573000 736392000 2075751000 2812142000 Investments<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have equity investments in privately and publicly held companies that are unconsolidated entities. The following discusses our investments in marketable equity securities, non-marketable equity securities, and investments accounted for under the equity method.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities are publicly traded stocks measured at fair value and classified within Level 1 in the fair value hierarchy because we use quoted prices for identical assets in active markets. Marketable equity securities are recorded in prepaid expenses and other current assets on the condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-marketable equity securities consist of investments in privately held companies without readily determinable fair values and are recorded in prepaid taxes and other non-current assets on the condensed consolidated balance sheets. Non-marketable equity securities are reported at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. We assess non-marketable equity securities at least quarterly for impairment and consider qualitative and quantitative factors including the investee's financial metrics, product and commercial outlook and cash usage. All gains and losses on marketable and non-marketable equity securities, realized and unrealized, are recognized in gain (loss) on equity investments as a component of other income (loss), net on the condensed consolidated statements of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments whereby we have significant influence, but not control over the investee and are not the primary beneficiary of the investee’s activities, are accounted for under the equity method. Under this method, we record our share of gains or losses attributable to equity method investments as a component of other income (loss), net on the condensed consolidated statements of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments by measurement category were as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Measurement category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,821 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,423 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Measurement alternative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,366 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,660 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,537 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show a reconciliation of the changes in our equity investments (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity method investments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,748 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,423 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,366 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,537 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized losses on marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(602)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(602)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exits of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,895)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,895)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,810)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,810)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying value at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,678 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,821 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,161 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,660 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity method investments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,290 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,918 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,375 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized losses on marketable equity securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,028)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,028)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying value at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,581 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,887 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,890 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,358 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net unrealized losses recognized for equity investments in non-marketable and marketable securities held as of September 30, 2023 for the three months ended September 30, 2023 were $0.6 million. Net unrealized losses recognized for equity investments in non-marketable and marketable securities held as of September 30, 2022 for the three months ended September 30, 2022 were $3.3 million.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments by measurement category were as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Measurement category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,821 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,423 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Measurement alternative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,366 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,660 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,537 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 11821000 12423000 69678000 68748000 62161000 65366000 143660000 146537000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show a reconciliation of the changes in our equity investments (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity method investments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,748 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,423 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,366 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,537 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized losses on marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(602)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(602)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exits of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,895)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,895)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,810)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,810)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying value at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,678 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,821 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,161 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,660 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity method investments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,290 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,918 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,375 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized losses on marketable equity securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,028)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,028)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying value at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,581 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,887 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,890 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,358 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 68748000 12423000 65366000 146537000 1180000 0 2500000 3680000 0 -602000 0 -602000 -250000 0 0 -250000 0 0 -3895000 -3895000 0 0 -1810000 -1810000 69678000 11821000 62161000 143660000 39290000 9167000 9918000 58375000 4291000 0 0 4291000 0 -3280000 0 -3280000 0 0 -2028000 -2028000 43581000 5887000 7890000 57358000 -600000 -3300000 Product Warranties<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the liability for warranty costs, which is included in accrued expenses in our condensed consolidated balance sheets, are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,621 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,889 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warranty accruals for the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,025 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,088 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warranty costs incurred for the period </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,828)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,146 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,093 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the liability for warranty costs, which is included in accrued expenses in our condensed consolidated balance sheets, are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,621 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,889 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warranty accruals for the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,025 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,088 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warranty costs incurred for the period </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,828)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,146 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,093 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 27621000 25889000 6025000 2088000 4828000 2612000 672000 1272000 28146000 24093000 Debt<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consisted of the following (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred borrowing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,905 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,902 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,355,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,435,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred borrowing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,766)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,351,511 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,431,234 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,361,416 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,441,136 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2022, we entered into a second amended and restated credit agreement (the “Revolving Credit Agreement”), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger, sole book runner, swing line lender and letter of credit issuer, Westpac Banking Corporation, as syndication agent and joint lead arranger, HSBC Bank USA, National Association, as syndication agent and joint lead arranger, and Wells Fargo Bank, National Association, as documentation agent. The Revolving Credit Agreement, among other things, provided a senior unsecured revolving credit facility of $1,500.0 million, with an uncommitted option to increase the revolving credit facility by an additional amount equal to the greater of $1,000.0 million or 1.0 times the EBITDA (as defined in the Revolving Credit Agreement) for the trailing twelve-month measurement period. The Revolving Credit Agreement amends and restates that certain Amended and Restated Credit Agreement, dated as of April 17, 2018, among ResMed, MUFG Union Bank, N.A., Westpac Banking Corporation and the lenders party thereto.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on June 29, 2022, ResMed Pty Limited entered into a Second Amendment to the Syndicated Facility Agreement and First Amendment to Unconditional Guaranty Agreement (the “Term Credit Agreement”), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger and joint book runner, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner, which amends that certain Syndicated Facility Agreement dated as of April 17, 2018. The Term Credit Agreement, among other things, provides ResMed Pty Limited a senior unsecured term credit facility of $200.0 million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Revolving Credit Agreement are guaranteed by certain of our direct and indirect U.S. subsidiaries, and ResMed Pty Limited’s obligations under the Term Credit Agreement are guaranteed by us and certain of our direct and indirect U.S. subsidiaries. The Revolving Credit Agreement and Term Credit Agreement contain customary covenants, including, in each case, a financial covenant that requires that we maintain a maximum leverage ratio of funded debt to EBITDA (as defined in the Revolving Credit Agreement and Term Credit Agreement, as applicable). The entire principal amounts of the revolving credit facility and term credit facility, and, in each case, any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable. Events of default under the Revolving Credit Agreement and the Term Credit Agreement include, in each case, failure to make payments when due, the occurrence of a default in the performance of any covenants in the respective agreements or related documents, or certain changes of control of us, or the respective guarantors of the obligations borrowed under the Revolving Credit Agreement and Term Credit Agreement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Agreement and Term Credit Agreement each terminate on June 29, 2027, when all unpaid principal and interest under the loans must be repaid. Amounts borrowed under the Term Credit Agreement will also amortize on a semi-annual basis, with a $5.0 million principal payment required on each such semi-annual amortization date. The outstanding principal amounts will bear interest at a rate equal to the Adjusted Term SOFR (as defined in the Revolving Credit Facility) plus 0.75% to 1.50% (depending on the then-applicable leverage ratio) or the Base Rate (as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable) plus 0.0% to 0.50% (depending on the then-applicable leverage ratio). At September 30, 2023, the interest rate that was being charged on the outstanding principal amounts was 6.3%. An applicable commitment fee of 0.075% to 0.150% (depending on the then-applicable leverage ratio) applies on the unused portion of the revolving credit facility. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, we had $825.0 million available for draw down under the revolving credit facility.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As the Revolving Credit and Term Credit Agreements’ interest rate is calculated as Adjusted Term SOFR plus the spreads described above, its carrying amount is equivalent to its fair value as at September 30, 2023 and June 30, 2023, which was $865.0 million and $945.0 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 10, 2019, we entered into a Note Purchase Agreement with the purchasers to that agreement, in connection with the issuance and sale of $250.0 million principal amount of our 3.24% senior notes due July 10, 2026, and $250.0 million principal amount of our 3.45% senior notes due July 10, 2029 (collectively referred to as the “Senior Notes”). Our obligations under the Note Purchase Agreement and the Senior Notes are unconditionally and irrevocably guaranteed by certain of our direct and indirect U.S. subsidiaries. The net proceeds from this transaction were used to pay down borrowings on our Revolving Credit Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Note Purchase Agreement, we agreed to customary covenants including with respect to our corporate existence, transactions with affiliates, and mergers and other extraordinary transactions. We also agreed that, subject to limited exceptions, we will maintain a ratio of consolidated funded debt to consolidated EBITDA (as defined in the Note Purchase Agreement) of no more than 3.50 to 1.00 as of the last day of any fiscal quarter, and will not at any time permit the amount of all priority secured and unsecured debt of us and our subsidiaries to exceed 10% of our consolidated tangible assets, determined as of the end of our most recently ended fiscal quarter. This ratio is calculated at the end of each reporting period for which the Note Purchase Agreement requires us to deliver financial statements, using the results of the 12 consecutive month period ending with such reporting period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As of September 30, 2023 and June 30, 2023, the Senior Notes had a carrying amount of $500.0 million, excluding deferred borrowing costs, and an estimated fair value of $451.7 million and $462.2 million, respectively. Quoted market prices in active markets for similar liabilities based inputs (Level 2) were used to estimate fair value.</span></div>At September 30, 2023, we were in compliance with our debt covenants and there was $1,365.0 million outstanding under the Revolving Credit Agreement, Term Credit Agreement and Senior Notes. <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consisted of the following (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred borrowing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,905 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,902 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,355,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,435,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred borrowing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,766)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,351,511 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,431,234 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,361,416 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,441,136 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10000000 10000000 95000 98000 9905000 9902000 1355000000 1435000000 3489000 3766000 1351511000 1431234000 1361416000 1441136000 1500000000 1000000000 1.0 200000000 5000000 0.0075 0.0150 0.000 0.0050 0.063 0.00075 0.00150 825000000 865000000 945000000 250000000 0.0324 250000000 0.0345 3.50 0.10 500000000 500000000 451700000 462200000 1365000000 Earnings Per Share<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average number of outstanding stock options and restricted stock units not included in the computation of diluted earnings per share were 417,364 and 113,167 for the three months ended September 30, 2023 and 2022, respectively, as the effect would have been anti-dilutive.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings per share are calculated as follows (in thousands except per share data):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210,478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options and restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">411 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">703 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted average shares </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,134 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.49 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.44 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.49 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.43 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 417364000 113167000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings per share are calculated as follows (in thousands except per share data):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210,478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options and restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">411 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">703 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted average shares </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,134 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.49 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.44 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.49 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.43 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 219422000 210478000 147075000 146431000 411000 703000 147486000 147134000 1.49 1.44 1.49 1.43 Legal Actions, Contingencies and Commitments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, New York University ("NYU") filed a complaint for patent infringement in the United States District Court, District of Delaware against ResMed Inc., case no. 1:21-cv-00813 (JPM). The complaint alleges that the AutoSet or AutoRamp features of ResMed’s AirSense 10 AutoSet flow generators infringe one or more claims of various NYU patents, including U.S. Patent Nos. 6,988,994; 9,108,009; 9,168,344; 9,427,539; 9,533,115; 9,867,955; and 10,384,024. According to the complaint, the NYU patents are directed to systems and methods for diagnosis and treating sleeping </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disorders during different sleep states. The complaint seeks monetary damages and attorneys’ fees. We answered the complaint on September 30, 2021 and filed a motion to dismiss the complaint on the basis that the patents are invalid because the subject matter of the patents is not patentable under the Supreme Court and Federal Circuit precedent. The motion to dismiss was granted in part and denied in part. We have also requested that the court dismiss the case based on NYU’s license of the patents to Fisher &amp; Paykel and Fisher &amp; Paykel’s prior settlement with us; that request is pending. In December 2022, the Patent Trial and Appeals Board (“PTAB”) of the Patent and Trademark Office granted our request to review the validity of the claims in the patents asserted by NYU against us, determining that there is a reasonable likelihood that we will prevail. The PTAB’s final written decisions on the validity of the asserted claims is expected by December 2023. On April 10, 2023, the district court granted our request to stay the case pending the PTAB’s decision on the validity of the patents asserted by NYU. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2021, the International Trade Commission ("ITC") instituted In Re Certain UMTS and LTE Cellular Communications Modules and Products Containing the Same, Investigation No. 337-TA-1240, by complainants Philips RS North America, LLC and Koninklijke Philips N.V. (collectively “Philips”) against Quectel Wireless Solutions Co., Ltd; Thales DIS AIS USA, LLC, Thales DIS AIS Deutschland GmbH; Telit Wireless Solutions, Inc., Telit Communications PLC, CalAmp. Corp., Xirgo Technologies, LLC, and Laird Connectivity, Inc. (collectively “respondents”). In the ITC investigation, Philips seeks an order excluding communications modules, and products that contain them, from importation into the United States based on alleged infringement of 3G and 4G standard essential patents held by Philips. On October 6-14, 2021, the administrative law judge held a hearing on the merits. The administrative law judge issued an initial determination on April 1, 2022, finding no violation of any of the Philips' patents asserted in the ITC. Philips sought review by the full ITC. On July 6, 2022, the Commission affirmed the administrative law judge’s determination that there was no violation of asserted Philips' patents. The Commission terminated the ITC proceedings. Philips did not appeal the ITC’s decision. On December 17, 2020, Philips filed companion cases for patent infringement against the same defendants in the United States District Court for the District of Delaware, case nos. 1:20-cv-01707, 01708, 01709, 01710, 01711, and 01713 (CFC) seeking damages, an injunction, and a declaration from the court on the amount of a fair reasonable and non-discriminatory license rate for the standard essential patents it is asserting against the communications module defendants. The district court cases were stayed pending the resolution of the ITC proceedings. The parties have returned to the district court for further proceedings. We were not a party to the ITC investigation, and we are not a party to the district court cases, but we sell products that incorporate communications modules at issue in the district court case. The first trial in these cases is set for August 12, 2024. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2022, Cleveland Medical Devices Inc. ("Cleveland Medical") filed suit for patent infringement against ResMed Inc. in the United States District Court for the District of Delaware, case no. 1:22-cv-00794. Cleveland Medical asserts that numerous ResMed connected devices, when combined with certain ResMed data platforms and/or software, including AirView and ResScan, infringe one or more of eight Cleveland Medical patents, including U.S. Patent Nos. 10,076,269; 10,426,399; 10,925,535; 11,064,937; 10,028,698; 10,478,118; 11,202,603; and 11,234,637. We moved to dismiss the action because Cleveland Medical sued the wrong ResMed entity, and to dismiss the indirect and willful infringement allegations by Cleveland Medical. On October 2, 2023, the court granted a portion of the motion, dismissing all Cleveland Medical claims for indirect and willful infringement, and declined the rest of the motion. On March 23, 2023, we filed a petition with the Patent Trial and Appeals Board of the Patent and Trademark Office seeking review of the validity of Cleveland Medical U.S. Patent 10,076,269. On September 25, 2023, the PTAB exercised its discretion to deny our petition challenging the validity of the ‘269 patent in light of the August 2024 trial date in the Delaware District Court case; that decision does not impact the merits of our invalidity challenge in that trial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2023, ResMed Corp. filed suit in the Southern District of California, case no. 23-cv-00500-TWR-JLB, seeking a declaration that it does not infringe U.S. patent number 11,602,284 recently issued to Cleveland Medical. Cleveland Medical has asked the court to dismiss the California case or to move it to Delaware or Cleveland for the convenience of the parties. We are opposing that request. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on currently available information, we are unable to make a reasonable estimate of loss or range of losses, if any, arising from matters that remain open.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Obligations Under Recourse Provisions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use independent financing institutions to offer some of our customers financing for the purchase of some of our products. Under these arrangements, if the customer qualifies under the financing institutions’ credit criteria and finances the transaction, the customers repay the financing institution on a fixed payment plan. For some of these arrangements, the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customer’s receivable balance is with limited recourse whereby we are responsible for repaying the financing company should the customer default. We record a contingent provision, which is estimated based on historical default rates. This is applied to receivables sold with recourse and is recorded in accrued expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2023 and September 30, 2022, receivables sold with limited recourse were $47.7 million and $39.9 million, respectively. As of September 30, 2023, the maximum exposure on outstanding receivables sold with recourse and the associated contingent provision were $28.9 million and $0.8 million, respectively. As of June 30, 2023, the maximum exposure on outstanding receivables sold with recourse and contingent provision were $32.6 million and $0.6 million, respectively.</span></div> 8 47700000 39900000 28900000 800000 32600000 600000 Derivative Instruments and Hedging Activities<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may use derivative financial instruments, specifically foreign cross-currency swaps, purchased foreign currency call options, collars and forward contracts to mitigate exposure from certain foreign currency risk. No derivatives are used for trading or speculative purposes. We do not require or are not required to pledge collateral for the derivative instruments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value and Net Investment Hedging</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2022, we executed foreign cross-currency swaps as net investment hedges and fair value hedges in designated hedging relationships with either the foreign denominated net asset balances or the foreign denominated intercompany loan as the hedged items. All derivatives are recorded at fair value as either an asset or liability. Cash flows associated with derivative instruments are presented in the same category on the consolidated statements of cash flows as the hedged item.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the cross-currency swaps for the fair value hedge is to mitigate foreign currency risk associated with changes in spot rates on foreign denominated intercompany debt between USD and EUR. For these hedges, we excluded certain components from the assessment of hedge effectiveness that are not related to spot rates. For fair value hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in the same line item as the hedged item, other, net, in the condensed consolidated statement of operations. The initial fair value of hedge components excluded from the assessment of effectiveness is recognized in the statement of operations under a systematic and rational method over the life of the hedging instrument and is presented in interest (expense) income, net. Any difference between the change in the fair value of the hedge components excluded from the assessment of effectiveness and the amounts recognized in earnings is recorded as a component of other comprehensive income. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the cross-currency swaps for the net investment hedge is to mitigate foreign currency risk associated with changes in spot rates on the net asset balances of our foreign functional subsidiaries. For net investment hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in cumulative translation adjustment within other comprehensive loss and reclassified into earnings when the hedged net investment is either sold or substantially liquidated. The initial fair value of components excluded from the assessment of hedge effectiveness will be recognized in interest (expense) income, net. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of outstanding foreign cross-currency swaps was $1,014.8 million and $1,046.6 million at September 30, 2023 and June 30, 2023, respectively. These contracts mature at various dates prior to December 31, 2029.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Designated Hedges</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have foreign currency exposure through both our Australian and Singapore manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased foreign currency call options, collars and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed three years. The purpose of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, and Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not designate these foreign currency contracts as hedges. All movements in the fair value of the foreign currency instruments are recorded within other, net in our condensed consolidated statements of income. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of the outstanding non-designated hedges was $1,363.3 million and $954.7 million at September 30, 2023 and June 30, 2023, respectively. These contracts mature at various dates prior to March 15, 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Values of Derivative Instruments </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,611 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-619"><span style="-sec-ix-hidden:f-620">Prepaid expenses and other current assets</span></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">717 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-623"><span style="-sec-ix-hidden:f-624">Prepaid taxes and other non-current assets</span></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,328 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign cross-currency swaps – Fair Value Hedge</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,743 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-629"><span style="-sec-ix-hidden:f-630">Other long-term liabilities</span></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign cross-currency swaps – Net Investment Hedge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,005 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-635"><span style="-sec-ix-hidden:f-636">Accrued expenses</span></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,847 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,699 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Hedge Gains (Losses)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the following gains (losses) on the foreign cross currency swaps designated as fair value hedges (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized in other comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on cross-currency swap in interest (expense) income, net (amount excluded from effectiveness testing)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on cross-currency swap in other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on intercompany debt in other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Investment Hedge Gains (Losses)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the following gains (losses) on the foreign cross currency swaps designated as net investment hedges (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized in cumulative translation adjustment within other comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,436 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized from the excluded components in interest (expense) income, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-designated Derivative Gains (Losses)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the following gains (losses) in the condensed consolidated statement of operations on derivatives not designated as hedging instruments (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on foreign currency hedging instruments in other, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,073)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,522)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on other foreign-currency-denominated transactions in other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,089 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,573 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,433)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classified the fair values of all hedging instruments as Level 2 measurements within the fair value hierarchy.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments. We minimize counterparty credit risk by entering into derivative transactions with major financial institutions. 1014800000 1046600000 P3Y 1363300000 954700000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,611 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-619"><span style="-sec-ix-hidden:f-620">Prepaid expenses and other current assets</span></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">717 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-623"><span style="-sec-ix-hidden:f-624">Prepaid taxes and other non-current assets</span></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,328 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign cross-currency swaps – Fair Value Hedge</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,743 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-629"><span style="-sec-ix-hidden:f-630">Other long-term liabilities</span></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign cross-currency swaps – Net Investment Hedge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,005 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-635"><span style="-sec-ix-hidden:f-636">Accrued expenses</span></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,847 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,699 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div> 3611000 2126000 717000 279000 4328000 2405000 9883000 19743000 17367000 40803000 25005000 9558000 592000 595000 52847000 70699000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the following gains (losses) on the foreign cross currency swaps designated as fair value hedges (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized in other comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on cross-currency swap in interest (expense) income, net (amount excluded from effectiveness testing)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on cross-currency swap in other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on intercompany debt in other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the following gains (losses) on the foreign cross currency swaps designated as net investment hedges (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized in cumulative translation adjustment within other comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,436 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized from the excluded components in interest (expense) income, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>We recognized the following gains (losses) in the condensed consolidated statement of operations on derivatives not designated as hedging instruments (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on foreign currency hedging instruments in other, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,073)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,522)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on other foreign-currency-denominated transactions in other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,089 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,573 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,433)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 588000 0 1181000 0 9271000 0 -9271000 0 23436000 0 3013000 0 -15073000 -20522000 17646000 19089000 2573000 -1433000 false false false false EXCEL 65 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
  •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�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�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end

    •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end XML 66 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 67 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 168 251 1 false 56 0 false 6 false false R1.htm 0000001 - Document - Cover Sheet http://investor.resmed.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Sheet http://investor.resmed.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited) Sheet http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited Condensed Consolidated Statements of Changes in Equity (Unaudited) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parenthetical) Sheet http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnauditedParenthetical Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 8 false false R9.htm 0000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://investor.resmed.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Segment Information Sheet http://investor.resmed.com/role/SegmentInformation Segment Information Notes 10 false false R11.htm 0000011 - Disclosure - Supplemental Balance Sheet Information Sheet http://investor.resmed.com/role/SupplementalBalanceSheetInformation Supplemental Balance Sheet Information Notes 11 false false R12.htm 0000012 - Disclosure - Goodwill Sheet http://investor.resmed.com/role/Goodwill Goodwill Notes 12 false false R13.htm 0000013 - Disclosure - Investments Sheet http://investor.resmed.com/role/Investments Investments Notes 13 false false R14.htm 0000014 - Disclosure - Product Warranties Sheet http://investor.resmed.com/role/ProductWarranties Product Warranties Notes 14 false false R15.htm 0000015 - Disclosure - Debt Sheet http://investor.resmed.com/role/Debt Debt Notes 15 false false R16.htm 0000016 - Disclosure - Earnings Per Share Sheet http://investor.resmed.com/role/EarningsPerShare Earnings Per Share Notes 16 false false R17.htm 0000017 - Disclosure - Legal Actions, Contingencies and Commitments Sheet http://investor.resmed.com/role/LegalActionsContingenciesandCommitments Legal Actions, Contingencies and Commitments Notes 17 false false R18.htm 0000018 - Disclosure - Derivative Instruments and Hedging Activities Sheet http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivities Derivative Instruments and Hedging Activities Notes 18 false false R19.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 19 false false R20.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 20 false false R21.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://investor.resmed.com/role/SummaryofSignificantAccountingPolicies 21 false false R22.htm 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://investor.resmed.com/role/SummaryofSignificantAccountingPolicies 22 false false R23.htm 9954473 - Disclosure - Segment Information (Tables) Sheet http://investor.resmed.com/role/SegmentInformationTables Segment Information (Tables) Tables http://investor.resmed.com/role/SegmentInformation 23 false false R24.htm 9954474 - Disclosure - Supplemental Balance Sheet Information (Tables) Sheet http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables Supplemental Balance Sheet Information (Tables) Tables http://investor.resmed.com/role/SupplementalBalanceSheetInformation 24 false false R25.htm 9954475 - Disclosure - Goodwill (Tables) Sheet http://investor.resmed.com/role/GoodwillTables Goodwill (Tables) Tables http://investor.resmed.com/role/Goodwill 25 false false R26.htm 9954476 - Disclosure - Investments (Tables) Sheet http://investor.resmed.com/role/InvestmentsTables Investments (Tables) Tables http://investor.resmed.com/role/Investments 26 false false R27.htm 9954477 - Disclosure - Product Warranties (Tables) Sheet http://investor.resmed.com/role/ProductWarrantiesTables Product Warranties (Tables) Tables http://investor.resmed.com/role/ProductWarranties 27 false false R28.htm 9954478 - Disclosure - Debt (Tables) Sheet http://investor.resmed.com/role/DebtTables Debt (Tables) Tables http://investor.resmed.com/role/Debt 28 false false R29.htm 9954479 - Disclosure - Earnings Per Share (Tables) Sheet http://investor.resmed.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://investor.resmed.com/role/EarningsPerShare 29 false false R30.htm 9954480 - Disclosure - Derivative Instruments and Hedging Activities (Tables) Sheet http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesTables Derivative Instruments and Hedging Activities (Tables) Tables http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivities 30 false false R31.htm 9954481 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 31 false false R32.htm 9954482 - Disclosure - Summary of Significant Accounting Policies - Schedule Of Net Revenue Disaggregated By Product And Region (Details) Sheet http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfNetRevenueDisaggregatedByProductAndRegionDetails Summary of Significant Accounting Policies - Schedule Of Net Revenue Disaggregated By Product And Region (Details) Details 32 false false R33.htm 9954483 - Disclosure - Summary of Significant Accounting Policies - Schedule Of Contract Balances (Details) Sheet http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfContractBalancesDetails Summary of Significant Accounting Policies - Schedule Of Contract Balances (Details) Details 33 false false R34.htm 9954484 - Disclosure - Segment Information - Narrative (Details) Sheet http://investor.resmed.com/role/SegmentInformationNarrativeDetails Segment Information - Narrative (Details) Details 34 false false R35.htm 9954485 - Disclosure - Segment Information - Schedule of Revenue By Segment And Reconciling Items (Details) Sheet http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails Segment Information - Schedule of Revenue By Segment And Reconciling Items (Details) Details 35 false false R36.htm 9954486 - Disclosure - Supplemental Balance Sheet Information - Schedule of Inventories (Details) Sheet http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails Supplemental Balance Sheet Information - Schedule of Inventories (Details) Details 36 false false R37.htm 9954487 - Disclosure - Supplemental Balance Sheet Information - Schedule of Prepaid Expenses and Other Current Assets (Details) Sheet http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails Supplemental Balance Sheet Information - Schedule of Prepaid Expenses and Other Current Assets (Details) Details 37 false false R38.htm 9954488 - Disclosure - Supplemental Balance Sheet Information - Schedule of Components of Property, Plant And Equipment (Details) Sheet http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofComponentsofPropertyPlantAndEquipmentDetails Supplemental Balance Sheet Information - Schedule of Components of Property, Plant And Equipment (Details) Details 38 false false R39.htm 9954489 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Intangible Assets, Net (Details) Sheet http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails Supplemental Balance Sheet Information - Schedule of Other Intangible Assets, Net (Details) Details 39 false false R40.htm 9954490 - Disclosure - Goodwill (Details) Sheet http://investor.resmed.com/role/GoodwillDetails Goodwill (Details) Details http://investor.resmed.com/role/GoodwillTables 40 false false R41.htm 9954491 - Disclosure - Investments - Schedule of Investments (Details) Sheet http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails Investments - Schedule of Investments (Details) Details 41 false false R42.htm 9954492 - Disclosure - Investments - Schedule of Changes in Equity Investments (Details) Sheet http://investor.resmed.com/role/InvestmentsScheduleofChangesinEquityInvestmentsDetails Investments - Schedule of Changes in Equity Investments (Details) Details 42 false false R43.htm 9954493 - Disclosure - Investments - Narrative (Details) Sheet http://investor.resmed.com/role/InvestmentsNarrativeDetails Investments - Narrative (Details) Details 43 false false R44.htm 9954494 - Disclosure - Product Warranties (Details) Sheet http://investor.resmed.com/role/ProductWarrantiesDetails Product Warranties (Details) Details http://investor.resmed.com/role/ProductWarrantiesTables 44 false false R45.htm 9954495 - Disclosure - Debt - Schedule of Debt (Details) Sheet http://investor.resmed.com/role/DebtScheduleofDebtDetails Debt - Schedule of Debt (Details) Details 45 false false R46.htm 9954496 - Disclosure - Debt - Narrative (Details) Sheet http://investor.resmed.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 46 false false R47.htm 9954497 - Disclosure - Earnings Per Share - Narrative (Details) Sheet http://investor.resmed.com/role/EarningsPerShareNarrativeDetails Earnings Per Share - Narrative (Details) Details 47 false false R48.htm 9954498 - Disclosure - Earnings Per Share - Schedule of Basic And Diluted Earnings Per Share (Details) Sheet http://investor.resmed.com/role/EarningsPerShareScheduleofBasicAndDilutedEarningsPerShareDetails Earnings Per Share - Schedule of Basic And Diluted Earnings Per Share (Details) Details 48 false false R49.htm 9954499 - Disclosure - Legal Actions, Contingencies and Commitments (Details) Sheet http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsDetails Legal Actions, Contingencies and Commitments (Details) Details http://investor.resmed.com/role/LegalActionsContingenciesandCommitments 49 false false R50.htm 9954500 - Disclosure - Derivative Instruments and Hedging Activities - Narrative (Details) Sheet http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails Derivative Instruments and Hedging Activities - Narrative (Details) Details 50 false false R51.htm 9954501 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Fair Values of Derivative Instruments (Details) Sheet http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails Derivative Instruments and Hedging Activities - Schedule of Fair Values of Derivative Instruments (Details) Details 51 false false R52.htm 9954502 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Fair Value Hedge Gains (Losses) (Details) Sheet http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails Derivative Instruments and Hedging Activities - Schedule of Fair Value Hedge Gains (Losses) (Details) Details 52 false false R53.htm 9954503 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Net Investment Hedge Gains (Losses) (Details) Sheet http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails Derivative Instruments and Hedging Activities - Schedule of Net Investment Hedge Gains (Losses) (Details) Details 53 false false R54.htm 9954504 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Non-Designated Derivative Gains (Losses) (Details) Sheet http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNonDesignatedDerivativeGainsLossesDetails Derivative Instruments and Hedging Activities - Schedule of Non-Designated Derivative Gains (Losses) (Details) Details 54 false false All Reports Book All Reports rmd-20230930.htm rmd-20230930.xsd rmd-20230930_cal.xml rmd-20230930_def.xml rmd-20230930_lab.xml rmd-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 70 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "rmd-20230930.htm": { "nsprefix": "rmd", "nsuri": "http://investor.resmed.com/20230930", "dts": { "inline": { "local": [ "rmd-20230930.htm" ] }, "schema": { "local": [ "rmd-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "rmd-20230930_cal.xml" ] }, "definitionLink": { "local": [ "rmd-20230930_def.xml" ] }, "labelLink": { "local": [ "rmd-20230930_lab.xml" ] }, "presentationLink": { "local": [ "rmd-20230930_pre.xml" ] } }, "keyStandard": 226, "keyCustom": 25, "axisStandard": 18, "axisCustom": 0, "memberStandard": 28, "memberCustom": 26, "hidden": { "total": 13, "http://fasb.org/us-gaap/2023": 8, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 168, "entityCount": 1, "segmentCount": 56, "elementCount": 495, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 567, "http://xbrl.sec.gov/dei/2023": 30, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://investor.resmed.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R3": { "role": "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R4": { "role": "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "unique": true } }, "R5": { "role": "http://investor.resmed.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "unique": true } }, "R6": { "role": "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited", "longName": "0000006 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Changes in Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-24", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-24", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R7": { "role": "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnauditedParenthetical", "longName": "0000007 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "unique": true } }, "R9": { "role": "http://investor.resmed.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://investor.resmed.com/role/SegmentInformation", "longName": "0000010 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://investor.resmed.com/role/SupplementalBalanceSheetInformation", "longName": "0000011 - Disclosure - Supplemental Balance Sheet Information", "shortName": "Supplemental Balance Sheet Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "rmd:SupplementalBalanceSheetInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "rmd:SupplementalBalanceSheetInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://investor.resmed.com/role/Goodwill", "longName": "0000012 - Disclosure - Goodwill", "shortName": "Goodwill", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://investor.resmed.com/role/Investments", "longName": "0000013 - Disclosure - Investments", "shortName": "Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://investor.resmed.com/role/ProductWarranties", "longName": "0000014 - Disclosure - Product Warranties", "shortName": "Product Warranties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://investor.resmed.com/role/Debt", "longName": "0000015 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://investor.resmed.com/role/EarningsPerShare", "longName": "0000016 - Disclosure - Earnings Per Share", "shortName": "Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://investor.resmed.com/role/LegalActionsContingenciesandCommitments", "longName": "0000017 - Disclosure - Legal Actions, Contingencies and Commitments", "shortName": "Legal Actions, Contingencies and Commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivities", "longName": "0000018 - Disclosure - Derivative Instruments and Hedging Activities", "shortName": "Derivative Instruments and Hedging Activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true }, "uniqueAnchor": null }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "rmd:OrganizationAndBasisOfPresentationPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "rmd:OrganizationAndBasisOfPresentationPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://investor.resmed.com/role/SegmentInformationTables", "longName": "9954473 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables", "longName": "9954474 - Disclosure - Supplemental Balance Sheet Information (Tables)", "shortName": "Supplemental Balance Sheet Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://investor.resmed.com/role/GoodwillTables", "longName": "9954475 - Disclosure - Goodwill (Tables)", "shortName": "Goodwill (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://investor.resmed.com/role/InvestmentsTables", "longName": "9954476 - Disclosure - Investments (Tables)", "shortName": "Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "rmd:ScheduleOfInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "rmd:ScheduleOfInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://investor.resmed.com/role/ProductWarrantiesTables", "longName": "9954477 - Disclosure - Product Warranties (Tables)", "shortName": "Product Warranties (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://investor.resmed.com/role/DebtTables", "longName": "9954478 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://investor.resmed.com/role/EarningsPerShareTables", "longName": "9954479 - Disclosure - Earnings Per Share (Tables)", "shortName": "Earnings Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesTables", "longName": "9954480 - Disclosure - Derivative Instruments and Hedging Activities (Tables)", "shortName": "Derivative Instruments and Hedging Activities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "9954481 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "unique": true } }, "R32": { "role": "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfNetRevenueDisaggregatedByProductAndRegionDetails", "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies - Schedule Of Net Revenue Disaggregated By Product And Region (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule Of Net Revenue Disaggregated By Product And Region (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-44", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "unique": true } }, "R33": { "role": "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfContractBalancesDetails", "longName": "9954483 - Disclosure - Summary of Significant Accounting Policies - Schedule Of Contract Balances (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule Of Contract Balances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-64", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "unique": true } }, "R34": { "role": "http://investor.resmed.com/role/SegmentInformationNarrativeDetails", "longName": "9954484 - Disclosure - Segment Information - Narrative (Details)", "shortName": "Segment Information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true }, "uniqueAnchor": null }, "R35": { "role": "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails", "longName": "9954485 - Disclosure - Segment Information - Schedule of Revenue By Segment And Reconciling Items (Details)", "shortName": "Segment Information - Schedule of Revenue By Segment And Reconciling Items (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-84", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "unique": true } }, "R36": { "role": "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails", "longName": "9954486 - Disclosure - Supplemental Balance Sheet Information - Schedule of Inventories (Details)", "shortName": "Supplemental Balance Sheet Information - Schedule of Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R37": { "role": "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails", "longName": "9954487 - Disclosure - Supplemental Balance Sheet Information - Schedule of Prepaid Expenses and Other Current Assets (Details)", "shortName": "Supplemental Balance Sheet Information - Schedule of Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PrepaidTaxes", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PrepaidTaxes", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R38": { "role": "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofComponentsofPropertyPlantAndEquipmentDetails", "longName": "9954488 - Disclosure - Supplemental Balance Sheet Information - Schedule of Components of Property, Plant And Equipment (Details)", "shortName": "Supplemental Balance Sheet Information - Schedule of Components of Property, Plant And Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R39": { "role": "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails", "longName": "9954489 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Intangible Assets, Net (Details)", "shortName": "Supplemental Balance Sheet Information - Schedule of Other Intangible Assets, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-88", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "unique": true } }, "R40": { "role": "http://investor.resmed.com/role/GoodwillDetails", "longName": "9954490 - Disclosure - Goodwill (Details)", "shortName": "Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "unique": true } }, "R41": { "role": "http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails", "longName": "9954491 - Disclosure - Investments - Schedule of Investments (Details)", "shortName": "Investments - Schedule of Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "rmd:MarketableEquityInvestmentsFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "rmd:ScheduleOfInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "rmd:MarketableEquityInvestmentsFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "rmd:ScheduleOfInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R42": { "role": "http://investor.resmed.com/role/InvestmentsScheduleofChangesinEquityInvestmentsDetails", "longName": "9954492 - Disclosure - Investments - Schedule of Changes in Equity Investments (Details)", "shortName": "Investments - Schedule of Changes in Equity Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-4", "name": "rmd:EquityInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "rmd:ScheduleOfChangesInEquityInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "rmd:EquityInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "rmd:ScheduleOfChangesInEquityInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R43": { "role": "http://investor.resmed.com/role/InvestmentsNarrativeDetails", "longName": "9954493 - Disclosure - Investments - Narrative (Details)", "shortName": "Investments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R44": { "role": "http://investor.resmed.com/role/ProductWarrantiesDetails", "longName": "9954494 - Disclosure - Product Warranties (Details)", "shortName": "Product Warranties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ProductWarrantyAccrual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ProductWarrantyAccrual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R45": { "role": "http://investor.resmed.com/role/DebtScheduleofDebtDetails", "longName": "9954495 - Disclosure - Debt - Schedule of Debt (Details)", "shortName": "Debt - Schedule of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "rmd:ShortTermDebtGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "rmd:ShortTermDebtGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R46": { "role": "http://investor.resmed.com/role/DebtNarrativeDetails", "longName": "9954496 - Disclosure - Debt - Narrative (Details)", "shortName": "Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "rmd:DebtToConsolidatedEbitdaRatio", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "rmd:DebtToConsolidatedEbitdaRatio", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R47": { "role": "http://investor.resmed.com/role/EarningsPerShareNarrativeDetails", "longName": "9954497 - Disclosure - Earnings Per Share - Narrative (Details)", "shortName": "Earnings Per Share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R48": { "role": "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicAndDilutedEarningsPerShareDetails", "longName": "9954498 - Disclosure - Earnings Per Share - Schedule of Basic And Diluted Earnings Per Share (Details)", "shortName": "Earnings Per Share - Schedule of Basic And Diluted Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "unique": true } }, "R49": { "role": "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsDetails", "longName": "9954499 - Disclosure - Legal Actions, Contingencies and Commitments (Details)", "shortName": "Legal Actions, Contingencies and Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-138", "name": "rmd:NumberOfPatents", "unitRef": "patent", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-138", "name": "rmd:NumberOfPatents", "unitRef": "patent", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R50": { "role": "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "longName": "9954500 - Disclosure - Derivative Instruments and Hedging Activities - Narrative (Details)", "shortName": "Derivative Instruments and Hedging Activities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-140", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-140", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R51": { "role": "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails", "longName": "9954501 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Fair Values of Derivative Instruments (Details)", "shortName": "Derivative Instruments and Hedging Activities - Schedule of Fair Values of Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R52": { "role": "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails", "longName": "9954502 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Fair Value Hedge Gains (Losses) (Details)", "shortName": "Derivative Instruments and Hedging Activities - Schedule of Fair Value Hedge Gains (Losses) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-157", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-157", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R53": { "role": "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails", "longName": "9954503 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Net Investment Hedge Gains (Losses) (Details)", "shortName": "Derivative Instruments and Hedging Activities - Schedule of Net Investment Hedge Gains (Losses) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-159", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-159", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } }, "R54": { "role": "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNonDesignatedDerivativeGainsLossesDetails", "longName": "9954504 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Non-Designated Derivative Gains (Losses) (Details)", "shortName": "Derivative Instruments and Hedging Activities - Schedule of Non-Designated Derivative Gains (Losses) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-167", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-167", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rmd-20230930.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r175", "r177", "r178" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current liabilities:", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://investor.resmed.com/role/Debt" ], "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r122", "r181", "r351", "r357", "r358", "r359", "r360", "r361", "r362", "r367", "r374", "r375", "r377" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofComponentsofPropertyPlantAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofComponentsofPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, plant and equipment, at cost", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r120", "r146", "r522" ] }, "rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "BusinessAcquisitionContingentConsiderationRecognizedLiability", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Fair value of contingent consideration", "label": "Business Acquisition, Contingent Consideration, Recognized Liability", "documentation": "Business Acquisition, Contingent Consideration, Recognized Liability" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r83", "r429", "r854" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 }, "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofComponentsofPropertyPlantAndEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofComponentsofPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, plant and equipment, net (note 3)", "totalLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r9", "r514", "r522", "r690" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r7" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization", "terseLabel": "Depreciation and amortization by segment", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r8", "r220" ] }, "us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromDerivativeInstrumentInvestingActivities", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "(Payments) / proceeds on maturity of foreign currency contracts", "label": "Payments for (Proceeds from) Derivative Instrument, Investing Activities", "documentation": "The net cash outflow or inflow from derivative instruments during the period, which are classified as investing activities, excluding those designated as hedging instruments." } } }, "auth_ref": [] }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyEstimateOfPossibleLoss", "crdr": "debit", "presentation": [ "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum potential contingent liability", "label": "Loss Contingency, Estimate of Possible Loss", "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date." } } }, "auth_ref": [ "r320", "r321", "r324", "r325" ] }, "rmd_SleepAndRespiratoryMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "SleepAndRespiratoryMember", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://investor.resmed.com/role/GoodwillDetails", "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails", "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfNetRevenueDisaggregatedByProductAndRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Sleep and Respiratory Care", "label": "Sleep And Respiratory [Member]", "documentation": "Sleep And Respiratory [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r56" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicAndDilutedEarningsPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicAndDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted shares outstanding (000's) (in shares)", "totalLabel": "Diluted weighted average shares (shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r199", "r204" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicAndDilutedEarningsPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicAndDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "netLabel": "Stock options and restricted stock units (shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r805" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r716", "r727", "r737", "r762" ] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/InvestmentsScheduleofChangesinEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized losses on marketable equity securities", "label": "Marketable Security, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": [ "r105" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicAndDilutedEarningsPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicAndDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic shares outstanding (000's) (in shares)", "verboseLabel": "Basic weighted-average common shares outstanding (shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r198", "r204" ] }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseMember", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNonDesignatedDerivativeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Nonoperating Income (Expense)", "label": "Other Nonoperating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/DebtScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r16", "r129", "r378" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://investor.resmed.com/role/SegmentInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r211", "r212", "r213", "r214", "r215", "r227", "r232", "r236", "r237", "r238", "r239", "r240", "r241", "r244" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r102", "r132", "r215", "r229", "r235", "r238", "r513", "r524", "r669" ] }, "us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Asset, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative asset classified as current." } } }, "auth_ref": [ "r439" ] }, "us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative asset classified as noncurrent." } } }, "auth_ref": [ "r439" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNonDesignatedDerivativeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r66", "r68", "r70", "r72", "r571", "r573", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r595", "r596", "r597", "r598", "r609", "r610", "r611", "r612", "r615", "r616", "r617", "r618", "r631", "r632", "r635", "r637", "r666", "r693", "r695" ] }, "us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative liability classified as current." } } }, "auth_ref": [ "r439" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets (note 3)", "totalLabel": "Total prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r793" ] }, "us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative liability classified as noncurrent." } } }, "auth_ref": [ "r439" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses, net deferred income taxes and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r91", "r517", "r690" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://investor.resmed.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue by Segment and Reconciling Items", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r42", "r43", "r44", "r46" ] }, "rmd_ContractWithCustomerAssetAndLiabilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "ContractWithCustomerAssetAndLiabilityLineItems", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfContractBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Asset and Liability [Line Items]", "label": "Contract with Customer, Asset and Liability [Line Items]", "documentation": "Contract with Customer, Asset and Liability [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r11", "r27", "r140", "r167", "r168", "r169", "r184", "r185", "r186", "r188", "r194", "r196", "r210", "r284", "r285", "r383", "r426", "r427", "r428", "r431", "r432", "r448", "r449", "r450", "r451", "r452", "r453", "r455", "r461", "r463", "r464", "r465", "r466", "r467", "r474", "r551", "r552", "r553", "r561", "r621" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r42", "r43", "r44", "r46" ] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available for draw", "label": "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r19" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r174" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional \u200ePaid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r426", "r427", "r428", "r561", "r802", "r803", "r804", "r844", "r861" ] }, "rmd_SeniorNotesOneMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "SeniorNotesOneMember", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.24% Senior Notes Due July 10, 2026", "label": "Senior Notes One [Member]", "documentation": "Senior Notes One [Member]" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on equity investments (note 5)", "label": "Equity Securities, FV-NI, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r531", "r813" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "rmd_SupplementalBalanceSheetInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "SupplementalBalanceSheetInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Balance Sheet Information [Abstract]", "label": "Supplemental Balance Sheet Information [Abstract]", "documentation": "Supplemental Balance Sheet Information [Abstract]" } } }, "auth_ref": [] }, "rmd_LineOfCreditFacilityCollateralPercentageOfCompany": { "xbrltype": "percentItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "LineOfCreditFacilityCollateralPercentageOfCompany", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Line of credit facility collateral, maximum percentage of ownership interests held in subsidiary", "label": "Line of credit facility, collateral, percentage of the company", "documentation": "Line of credit facility collateral, percentage of the company" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash paid for acquisitions", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r33", "r434" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "rmd_ReceivablesSoldWithLimitedRecourse": { "xbrltype": "monetaryItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "ReceivablesSoldWithLimitedRecourse", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables sold with limited recourse", "label": "Receivables Sold With Limited Recourse", "documentation": "Receivables Sold With Limited Recourse" } } }, "auth_ref": [] }, "rmd_DebtToConsolidatedEbitdaRatio": { "xbrltype": "pureItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "DebtToConsolidatedEbitdaRatio", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt to consolidated EBITDA ratio", "label": "Debt To Consolidated EBITDA Ratio", "documentation": "Debt To Consolidated EBITDA Ratio" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Credit facility interest rate equal to reference rate plus", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r778" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r454" ] }, "rmd_PrepaidInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "PrepaidInventory", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid inventories", "label": "Prepaid Inventory", "documentation": "Prepaid Inventory" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, accrued expenses, income taxes payable and other", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r7" ] }, "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Taxes and Other Assets, Noncurrent", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Taxes and Other Tax Liabilities, Noncurrent", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other tax liabilities expected to be paid after one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r7" ] }, "rmd_AstralFieldActionNotificationExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "AstralFieldActionNotificationExpenses", "crdr": "debit", "presentation": [ "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Astral field safety notification expenses (1)", "label": "Astral Field Action Notification Expenses", "documentation": "Astral Field Action Notification Expenses" } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BaseRateMember", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "rmd_SeniorNotesTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "SeniorNotesTwoMember", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.45% Senior Notes Due July 10, 2029", "label": "Senior Notes Two [Member]", "documentation": "Senior Notes Two [Member]" } } }, "auth_ref": [] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r12", "r57", "r58", "r59", "r63", "r67", "r70", "r73", "r74", "r76", "r454" ] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends paid", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r35" ] }, "us-gaap_EquityMethodInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsMember", "presentation": [ "http://investor.resmed.com/role/InvestmentsScheduleofChangesinEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investments", "label": "Equity Method Investments [Member]", "documentation": "Investment in the stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r715", "r726", "r736", "r761" ] }, "rmd_FairValueAndNetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "FairValueAndNetInvestmentHedgingMember", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value And Net Investment Hedging", "label": "Fair Value And Net Investment Hedging [Member]", "documentation": "Fair Value And Net Investment Hedging" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) recognized from the excluded components in interest (expense) income, net", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax", "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r160", "r161", "r442", "r444", "r447" ] }, "us-gaap_SeniorNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotes", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior notes, carrying amount", "label": "Senior Notes", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders." } } }, "auth_ref": [ "r81", "r856" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r93" ] }, "rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "RevolvingCreditFacilityAndTermLoanCreditAgreementMember", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility and Term Credit Agreement", "label": "Revolving Credit Facility And Term Loan Credit Agreement [Member]", "documentation": "Revolving Credit Facility And Term Loan Credit Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r703" ] }, "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Values of Derivative Instruments", "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]", "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position." } } }, "auth_ref": [ "r64" ] }, "rmd_DeferredRevenueNonCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "DeferredRevenueNonCurrentLiabilitiesMember", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfContractBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue (non-current liabilities)", "label": "Deferred Revenue Non Current Liabilities [Member]", "documentation": "Deferred Revenue Non Current Liabilities [Member]" } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "rmd_AmortizationOfAcquiredIntangibleAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "AmortizationOfAcquiredIntangibleAssets1", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of acquired intangible assets", "verboseLabel": "Amortization of acquired intangible assets", "label": "Amortization of acquired intangible assets 1", "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired intangible assets." } } }, "auth_ref": [] }, "rmd_MufgUnionBankNaAndWestpacBankingCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "MufgUnionBankNaAndWestpacBankingCorporationMember", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mufg Union Bank Na and Westpac Banking Corporation", "label": "Mufg Union Bank Na And Westpac Banking Corporation [Member]", "documentation": "Mufg Union Bank Na And Westpac Banking Corporation" } } }, "auth_ref": [] }, "rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "GoodwillAcquiredDuringPeriodIncreaseDecrease", "crdr": "debit", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill on acquisition", "label": "Goodwill, Acquired During Period, Increase (Decrease)", "documentation": "Goodwill, Acquired During Period, Increase (Decrease)" } } }, "auth_ref": [] }, "rmd_AdditionalEquityInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "AdditionalEquityInvestments", "crdr": "debit", "presentation": [ "http://investor.resmed.com/role/InvestmentsScheduleofChangesinEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions to investments", "label": "Additional Equity Investments", "documentation": "Additional Equity Investments" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from borrowings, net of borrowing costs", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r34", "r558" ] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails", "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfContractBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r48", "r49", "r507" ] }, "rmd_LeaseRevenuePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "LeaseRevenuePolicyTextBlock", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Revenue", "label": "Lease Revenue [Policy Text Block]", "documentation": "Lease Revenue [Policy Text Block]" } } }, "auth_ref": [] }, "rmd_EquityInvestmentsTotalByMeasurementCategory": { "xbrltype": "monetaryItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "EquityInvestmentsTotalByMeasurementCategory", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Equity Investments, Total by Measurement Category", "documentation": "Equity Investments, Total by Measurement Category" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_CurrencySwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrencySwapMember", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency Swap", "label": "Currency Swap [Member]", "documentation": "Swap involving the exchange of principal and interest in one currency for another currency." } } }, "auth_ref": [] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Intangible Assets, Net", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r48", "r49" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r705" ] }, "rmd_ResmedLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "ResmedLimitedMember", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ResMed Limited", "label": "Resmed Limited [Member]", "documentation": "ResMed Limited [Member]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicAndDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic earnings per share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r173", "r189", "r190", "r191", "r192", "r193", "r198", "r200", "r202", "r203", "r204", "r208", "r456", "r457", "r512", "r529", "r667" ] }, "rmd_SaasMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "SaasMember", "presentation": [ "http://investor.resmed.com/role/GoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SaaS", "label": "Saas [Member]", "documentation": "Saas [Member]" } } }, "auth_ref": [] }, "rmd_AccountsReceivableNetMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "AccountsReceivableNetMember", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfContractBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable Net [Member]", "documentation": "Accounts Receivable Net [Member]" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, fair value", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r22", "r144", "r182", "r283", "r338", "r339", "r341", "r342", "r343", "r345", "r347", "r349", "r350", "r436", "r437", "r438", "r459", "r690", "r835", "r846", "r847" ] }, "rmd_OtherForeignExchangeContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "OtherForeignExchangeContractsMember", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNonDesignatedDerivativeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Foreign Exchange Contracts", "label": "Other Foreign Exchange Contracts [Member]", "documentation": "Other Foreign Exchange Contracts" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails", "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfContractBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "rmd_MasksAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "MasksAndOtherMember", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfNetRevenueDisaggregatedByProductAndRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Masks and other", "label": "Masks and Other [Member]", "documentation": "Masks and Other [Member]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Contract Balances", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r838" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited", "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r184", "r185", "r186", "r210", "r506", "r557", "r562", "r574", "r575", "r576", "r577", "r578", "r579", "r582", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r595", "r596", "r597", "r598", "r599", "r601", "r603", "r604", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r621", "r696" ] }, "rmd_ContractWithCustomerAssetAndLiabilityTable": { "xbrltype": "stringItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "ContractWithCustomerAssetAndLiabilityTable", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfContractBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Asset and Liability [Table]", "label": "Contract with Customer, Asset and Liability [Table]", "documentation": "Contract with Customer, Asset and Liability [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://investor.resmed.com/role/EarningsPerShareTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Basic and Diluted Earnings Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r805" ] }, "us-gaap_GoodwillDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillDisclosureTextBlock", "presentation": [ "http://investor.resmed.com/role/Goodwill" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill." } } }, "auth_ref": [ "r295", "r297", "r307", "r673" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities, current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r471" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r706" ] }, "us-gaap_StandardProductWarrantyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StandardProductWarrantyPolicy", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Provision For Warranty", "label": "Standard Product Warranty, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability." } } }, "auth_ref": [ "r833" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillLineItems", "presentation": [ "http://investor.resmed.com/role/GoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r308", "r673" ] }, "rmd_NonMarketableSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "NonMarketableSecuritiesMember", "presentation": [ "http://investor.resmed.com/role/InvestmentsScheduleofChangesinEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-marketable securities", "label": "Non Marketable Securities [Member]", "documentation": "Non-marketable Securities [Member]" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": [ "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate Costs", "label": "Corporate, Non-Segment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r13", "r229", "r230", "r231", "r232", "r238", "r807" ] }, "rmd_OrganizationAndBasisOfPresentationPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "OrganizationAndBasisOfPresentationPolicyPolicyTextBlock", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Organization and Basis of Presentation", "label": "Organization And Basis Of Presentation, Policy [Policy Text Block]", "documentation": "Organization And Basis Of Presentation, Policy [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "rmd_SummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Significant Accounting Policies [Line Items]", "label": "Summary Of Significant Accounting Policies [Line Items]", "documentation": "Summary Of Significant Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r20", "r182", "r283", "r338", "r339", "r341", "r342", "r343", "r345", "r347", "r349", "r350", "r436", "r437", "r438", "r459", "r580", "r668", "r702", "r835", "r846", "r847" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://investor.resmed.com/role/GoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r308", "r673" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNonDesignatedDerivativeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r739" ] }, "rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "PrepaidTaxesAndOtherNonCurrentAssetsMember", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails", "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfContractBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid taxes and other non-current assets", "label": "Prepaid Taxes And Other Non Current Assets [Member]", "documentation": "Prepaid Taxes And Other Non Current Assets [Member]" } } }, "auth_ref": [] }, "rmd_SoftwareAsServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "SoftwareAsServiceMember", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails", "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfNetRevenueDisaggregatedByProductAndRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Software as a Service", "label": "Software As Service [Member]", "documentation": "Software As A Service [Member]" } } }, "auth_ref": [] }, "rmd_TermOfContractUnderRevenueRecognition": { "xbrltype": "durationItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "TermOfContractUnderRevenueRecognition", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue recognized, term", "label": "Term Of Contract Under Revenue Recognition", "documentation": "Term Of Contract Under Revenue Recognition" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Equity securities, unrealized loss", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r530", "r813" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r309", "r310", "r311", "r312", "r507", "r508" ] }, "rmd_MarketableSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "MarketableSecuritiesMember", "presentation": [ "http://investor.resmed.com/role/InvestmentsScheduleofChangesinEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Marketable Securities [Member]", "documentation": "Marketable Securities [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r507" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, non-current", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r471" ] }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "presentation": [ "http://investor.resmed.com/role/ProductWarrantiesTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Changes in Liability for Warranty Costs", "label": "Schedule of Product Warranty Liability [Table Text Block]", "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability." } } }, "auth_ref": [ "r333" ] }, "rmd_MufgUnionBankMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "MufgUnionBankMember", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mufg Union Bank", "label": "Mufg Union Bank [Member]", "documentation": "Mufg Union Bank" } } }, "auth_ref": [] }, "rmd_DeferredPaymentObligationsForAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "DeferredPaymentObligationsForAcquisitions", "crdr": "debit", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred payments", "label": "Deferred Payment Obligations For Acquisitions", "documentation": "Deferred Payment Obligations For Acquisitions" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r48", "r49" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Dividends", "crdr": "debit", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends declared", "label": "Dividends", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r6", "r123" ] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/DebtScheduleofDebtDetails": { "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": 1.0, "order": 1.0 }, "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://investor.resmed.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term debt, net (note 7)", "totalLabel": "Short-term debt, net", "label": "Short-Term Debt", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r87", "r127", "r690", "r855" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "netLabel": "Other, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r110" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property, plant and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r112" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r53" ] }, "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract", "presentation": [ "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicAndDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities:", "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Liabilities assumed", "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed", "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r39", "r40", "r41" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares (in shares)", "negatedPeriodStartLabel": "Treasury stock, common, beginning balance (in shares)", "negatedPeriodEndLabel": "Treasury stock, common, ending balance (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r53" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total cost of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r107", "r506" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other prepaid expenses and current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r155", "r690" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://investor.resmed.com/role/SegmentInformationNarrativeDetails", "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r806" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, at cost, 41,836,234 shares at September\u00a030, 2023 and June\u00a030, 2023", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r28", "r53", "r54" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://investor.resmed.com/role/InvestmentsScheduleofChangesinEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r376", "r382", "r454", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r527", "r671", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r809", "r810", "r811", "r812" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation (loss) gain adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r3" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r11", "r15", "r163", "r166", "r171", "r461", "r462", "r467", "r510", "r526", "r794", "r795" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation costs", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r55", "r91", "r92", "r123" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r116", "r180" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssets", "crdr": "debit", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Assets", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r157", "r158", "r458", "r563", "r564", "r565", "r566", "r567", "r569", "r570", "r571", "r572", "r573", "r588", "r589", "r631", "r634", "r635", "r636", "r637", "r638", "r666", "r695", "r859" ] }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]", "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r183", "r352", "r353", "r354", "r355", "r356", "r358", "r363", "r364", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r373", "r376", "r469", "r674", "r675", "r676", "r677", "r678", "r800" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnauditedParenthetical", "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend declared per share (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r123" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Patent registration and acquisition costs", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r112" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock issued on vesting of restricted stock units, net of shares withheld for tax", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r11", "r123" ] }, "us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityForeignCurrencyTranslationAdjustments", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/InvestmentsScheduleofChangesinEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Temporary Equity, Foreign Currency Translation Adjustments", "documentation": "Adjustments to temporary equity resulting from foreign currency translation adjustments." } } }, "auth_ref": [] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://investor.resmed.com/role/GoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business acquisitions", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r299", "r673" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock issued on exercise of options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r11", "r27", "r123" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of investments (note 5)", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r111" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r715", "r726", "r736", "r761" ] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://investor.resmed.com/role/InvestmentsScheduleofChangesinEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r376", "r382", "r454", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r527", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r809", "r810", "r811", "r812" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails", "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfContractBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r65", "r69" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited", "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r184", "r185", "r186", "r210", "r506", "r557", "r562", "r574", "r575", "r576", "r577", "r578", "r579", "r582", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r595", "r596", "r597", "r598", "r599", "r601", "r603", "r604", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r621", "r696" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "lang": { "en-us": { "role": { "terseLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesFairValueLineItems", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) recognized on intercompany debt in other, net", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement." } } }, "auth_ref": [ "r125" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivities" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r124", "r446", "r454" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNonDesignatedDerivativeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": [ "r71", "r779" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": [ "http://investor.resmed.com/role/InvestmentsScheduleofChangesinEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Table]", "label": "Schedule of Equity Method Investments [Table]", "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available." } } }, "auth_ref": [ "r142", "r182", "r280", "r281", "r282", "r283", "r459" ] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangibles", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": [ "http://investor.resmed.com/role/InvestmentsScheduleofChangesinEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Line Items]", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r182", "r280", "r281", "r282", "r283", "r459" ] }, "us-gaap_LossContingencyAccrualProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualProvision", "crdr": "debit", "presentation": [ "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent provision", "label": "Loss Contingency Accrual, Provision", "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges." } } }, "auth_ref": [ "r830" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtAndEquitySecuritiesUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails" ], "lang": { "en-us": { "role": { "negatedNetLabel": "(Gain) loss on equity investments (note 5)", "negatedTerseLabel": "(Gain) loss on equity investments", "label": "Debt and Equity Securities, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in debt and equity securities." } } }, "auth_ref": [ "r613", "r614", "r640", "r641", "r642", "r797", "r798" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://investor.resmed.com/role/InvestmentsScheduleofChangesinEquityInvestmentsDetails", "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Loss attributable to equity method investments (note 5)", "negatedLabel": "Loss attributable to equity method investments (note 5)", "negatedNetLabel": "Loss attributable to equity method investments", "terseLabel": "Loss attributable to equity method investments", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r8", "r103", "r131", "r222", "r279", "r523" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r106", "r182", "r215", "r229", "r235", "r238", "r283", "r338", "r339", "r341", "r342", "r343", "r345", "r347", "r349", "r350", "r459", "r669", "r835" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r77", "r79", "r352", "r469", "r675", "r676" ] }, "rmd_NumberOfPatents": { "xbrltype": "integerItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "NumberOfPatents", "presentation": [ "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of patents", "label": "Number of Patents", "documentation": "Number of Patents" } } }, "auth_ref": [] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r764" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r92", "r95", "r96", "r117", "r584", "r600", "r622", "r623", "r690", "r702", "r801", "r815", "r845", "r861" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r704" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (loss), net:", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "rmd_SummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "documentation": "Summary Of Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r704" ] }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNoncurrentNet", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/DebtScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred borrowing costs", "label": "Debt Issuance Costs, Noncurrent, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r78" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r37", "r145", "r660" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/DebtScheduleofDebtDetails": { "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": 1.0, "order": 2.0 }, "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://investor.resmed.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term debt, net (note 7)", "totalLabel": "Long-term debt, net", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r16", "r129", "r364", "r379", "r675", "r676", "r856" ] }, "rmd_DeferredRevenueCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "DeferredRevenueCurrentLiabilitiesMember", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfContractBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue (current liabilities)", "label": "Deferred Revenue Current Liabilities [Member]", "documentation": "Deferred Revenue Current Liabilities [Member]" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (loss), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r109" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r704" ] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r182", "r283", "r338", "r339", "r341", "r342", "r343", "r345", "r347", "r349", "r350", "r435", "r437", "r459", "r835", "r836", "r846" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r715", "r726", "r736", "r761" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r704" ] }, "rmd_UnallocatedCorporateCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "UnallocatedCorporateCosts", "crdr": "debit", "presentation": [ "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate costs", "label": "Unallocated Corporate Costs", "documentation": "Unallocated corporate costs." } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsCurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsCurrentNet", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/DebtScheduleofDebtDetails": { "parentTag": "us-gaap_ShortTermBorrowings", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred borrowing costs", "label": "Debt Issuance Costs, Current, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r78" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r143", "r156", "r182", "r283", "r338", "r339", "r341", "r342", "r343", "r345", "r347", "r349", "r350", "r435", "r437", "r459", "r690", "r835", "r836", "r846" ] }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityAbstract", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfContractBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Contract with Customer, Liability [Abstract]" } } }, "auth_ref": [] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r746" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r704" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfContractBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "negatedLabel": "Deferred revenue, current", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r384", "r385", "r397" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 4.0 }, "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets, net (note 3)", "totalLabel": "Total other intangibles, net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r119", "r507" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfContractBalancesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "negatedLabel": "Deferred revenue, non-current", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r384", "r385", "r397" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r748" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://investor.resmed.com/role/GoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill (note 4)", "periodStartLabel": "Balance at the beginning of the period", "periodEndLabel": "Balance at the end of the period", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r148", "r296", "r509", "r673", "r690", "r818", "r825" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r718", "r726", "r736", "r753", "r761", "r765", "r773" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other intangibles, gross", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r119", "r508" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r704" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest (expense) income, net", "label": "Interest Income (Expense), Net", "documentation": "The net amount of operating interest income (expense)." } } }, "auth_ref": [ "r134" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited", "http://investor.resmed.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicAndDilutedEarningsPerShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "netLabel": "Net income", "verboseLabel": "Net income", "terseLabel": "Net income", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r104", "r115", "r133", "r142", "r162", "r165", "r169", "r182", "r187", "r189", "r190", "r191", "r192", "r195", "r196", "r201", "r215", "r229", "r235", "r238", "r283", "r338", "r339", "r341", "r342", "r343", "r345", "r347", "r349", "r350", "r457", "r459", "r525", "r602", "r619", "r620", "r669", "r701", "r835" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://investor.resmed.com/role/GoodwillTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Changes in Carrying Amount of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r673", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://investor.resmed.com/role/EarningsPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r197", "r205", "r206", "r207" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r747" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://investor.resmed.com/role/GoodwillDetails", "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r141", "r212", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r238", "r244", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r314", "r316", "r317", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r673", "r780", "r857" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r740" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r12" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate on outstanding principal amount", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r23", "r77", "r380", "r469" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r704" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r708", "r719", "r729", "r754" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r23", "r353" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails", "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r398", "r399", "r422", "r423", "r424", "r481", "r505", "r550", "r572", "r573", "r624", "r626", "r628", "r629", "r639", "r655", "r656", "r670", "r679", "r688", "r692", "r695", "r828", "r837", "r849", "r850", "r851", "r852", "r853" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets:", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r741" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r746" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails", "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r399", "r505", "r550", "r572", "r573", "r624", "r626", "r628", "r629", "r639", "r655", "r656", "r670", "r679", "r688", "r692", "r837", "r848", "r849", "r850", "r851", "r852", "r853" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicAndDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r741" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails", "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r398", "r399", "r422", "r423", "r424", "r481", "r505", "r550", "r572", "r573", "r624", "r626", "r628", "r629", "r639", "r655", "r656", "r670", "r679", "r688", "r692", "r695", "r828", "r837", "r849", "r850", "r851", "r852", "r853" ] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r16", "r84", "r85", "r86", "r89", "r182", "r283", "r338", "r339", "r341", "r342", "r343", "r345", "r347", "r349", "r350", "r436", "r437", "r438", "r459", "r835", "r846", "r847" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r741" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r708", "r719", "r729", "r754" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails", "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r399", "r505", "r550", "r572", "r573", "r624", "r626", "r628", "r629", "r639", "r655", "r656", "r670", "r679", "r688", "r692", "r837", "r848", "r849", "r850", "r851", "r852", "r853" ] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Income taxes payable", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r88", "r128" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid taxes and other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r150" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments of business combination contingent consideration", "label": "Payment for Contingent Consideration Liability, Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r5" ] }, "us-gaap_AccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesMember", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Liabilities [Member]", "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered." } } }, "auth_ref": [ "r21" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r91", "r582" ] }, "us-gaap_CommonStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValueOutstanding", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, $0.004 par value, 350,000,000 shares authorized; 188,921,316 issued and 147,085,082 outstanding at September\u00a030, 2023 and 188,900,583 issued and 147,064,349 outstanding at June\u00a030, 2023", "label": "Common Stock, Value, Outstanding", "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares." } } }, "auth_ref": [ "r92", "r582" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation costs", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r7" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r773" ] }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesNoncurrent", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term income taxes payable", "label": "Accrued Income Taxes, Noncurrent", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent." } } }, "auth_ref": [ "r90", "r128" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r139", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r657" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r774" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r91", "r381" ] }, "us-gaap_StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/ProductWarrantiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign currency translation adjustments", "label": "Standard and Extended Product Warranty Accrual, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the standard and extended product warranty accrual." } } }, "auth_ref": [ "r834" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r713", "r724", "r734", "r759" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r715", "r726", "r736", "r761" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNonDesignatedDerivativeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r12", "r445" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r773" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r470" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r775" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r774" ] }, "us-gaap_DebtLongtermAndShorttermCombinedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtLongtermAndShorttermCombinedAmount", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/DebtScheduleofDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails", "http://investor.resmed.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total debt", "terseLabel": "Outstanding debt", "label": "Debt, Long-Term and Short-Term, Combined Amount", "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt." } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfContractBalancesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts receivable, net of allowances of $20,532 and $23,603 at September\u00a030, 2023 and June\u00a030, 2023, respectively", "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r245", "r246" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r18", "r690" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value per share (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r91", "r381" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general, and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r108" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "netLabel": "Income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r137", "r138", "r195", "r196", "r223", "r430", "r433", "r532" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillRollForward", "presentation": [ "http://investor.resmed.com/role/GoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r776" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r707", "r777" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrualWarrantiesIssued", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/ProductWarrantiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Warranty accruals for the period", "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued", "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued." } } }, "auth_ref": [ "r336" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock, net", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ProductWarrantyAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrual", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/ProductWarrantiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at the beginning of the period", "periodEndLabel": "Balance at the end of the period", "label": "Standard and Extended Product Warranty Accrual", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers." } } }, "auth_ref": [ "r80", "r330", "r334", "r337" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r460" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Other comprehensive income (loss), net of taxes:", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNonDesignatedDerivativeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "documentation": "Disclosure of information about derivatives and hedging activities." } } }, "auth_ref": [] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r707", "r777" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r712", "r723", "r733", "r758" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r113" ] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTermOfContract", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, term of contract (in years)", "label": "Derivative, Term of Contract", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r707", "r777" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r37", "r113", "r179" ] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails", "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfNetRevenueDisaggregatedByProductAndRegionDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net revenue", "terseLabel": "Net revenue by segment", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r216", "r217", "r228", "r233", "r234", "r240", "r242", "r244", "r395", "r396", "r506" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNonDesignatedDerivativeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ProductWarrantyAccrualPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrualPayments", "crdr": "debit", "presentation": [ "http://investor.resmed.com/role/ProductWarrantiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Warranty costs incurred for the period", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty." } } }, "auth_ref": [ "r335" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicAndDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted earnings per share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r173", "r189", "r190", "r191", "r192", "r193", "r200", "r202", "r203", "r204", "r208", "r456", "r457", "r512", "r529", "r667" ] }, "us-gaap_ContractWithCustomerAssetNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNetAbstract", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfContractBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract assets", "label": "Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]" } } }, "auth_ref": [] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r717", "r728", "r738", "r763" ] }, "us-gaap_ProductWarrantiesDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantiesDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Product Warranties Disclosures [Abstract]", "label": "Product Warranties Disclosures [Abstract]" } } }, "auth_ref": [] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r711", "r722", "r732", "r757" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r24", "r52" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425" ] }, "us-gaap_ProductWarrantyDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyDisclosureTextBlock", "presentation": [ "http://investor.resmed.com/role/ProductWarranties" ], "lang": { "en-us": { "role": { "terseLabel": "Product Warranties", "label": "Product Warranty Disclosure [Text Block]", "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period." } } }, "auth_ref": [ "r326", "r327", "r328", "r329", "r331", "r332" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r714", "r725", "r735", "r760" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Commitments and contingencies (note 9)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r26", "r82", "r516", "r581" ] }, "us-gaap_ContractWithCustomerAssetNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNetNoncurrent", "crdr": "debit", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfContractBalancesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Unbilled revenue, non-current", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent." } } }, "auth_ref": [ "r384", "r386", "r397" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories (note 3)", "totalLabel": "Total inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r154", "r661", "r690" ] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfContractBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unbilled revenue, current", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": [ "r384", "r386", "r397" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://investor.resmed.com/role/EarningsPerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (share)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r205" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNonDesignatedDerivativeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r315", "r605" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r745" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedging", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r62" ] }, "rmd_CombinedEuropeAsiaAndOtherMarketsMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "CombinedEuropeAsiaAndOtherMarketsMember", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfNetRevenueDisaggregatedByProductAndRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Combined Europe, Asia and other markets", "label": "Combined Europe Asia And Other Markets [Member]", "documentation": "Combined Europe Asia And Other Markets [Member]" } } }, "auth_ref": [] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://investor.resmed.com/role/GoodwillDetails", "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r212", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r238", "r244", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r316", "r317", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r673", "r780", "r857" ] }, "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInStandardProductWarrantyAccrualRollForward", "presentation": [ "http://investor.resmed.com/role/ProductWarrantiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Movement in Standard Product Warranty Accrual [Roll Forward]", "label": "Movement in Standard Product Warranty Accrual [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r97", "r130", "r520", "r690", "r801", "r815", "r845" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NondesignatedMember", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNonDesignatedDerivativeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Not Designated as Hedging Instruments", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r12" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r12", "r66", "r70" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r764" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r31", "r164", "r166", "r172", "r511", "r528" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNonDesignatedDerivativeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r313", "r315", "r605" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNonDesignatedDerivativeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r571", "r573", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r595", "r596", "r597", "r598", "r609", "r610", "r611", "r612", "r615", "r616", "r617", "r618", "r631", "r632", "r635", "r637", "r693", "r695" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r764" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock issued on vesting of restricted stock units, net of shares withheld for tax (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r11", "r91", "r92", "r123" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued on exercise of options (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r11", "r91", "r92", "r123", "r408" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Stockholders\u2019 Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r746" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "presentation": [ "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest expense (income), net", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r78", "r135", "r170", "r219", "r468", "r606", "r701", "r860" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r183", "r217", "r228", "r229", "r230", "r231", "r232", "r234", "r238", "r338", "r339", "r340", "r341", "r343", "r344", "r346", "r348", "r349", "r835", "r836" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r228", "r229", "r230", "r231", "r232", "r238" ] }, "rmd_DevicesMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "DevicesMember", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfNetRevenueDisaggregatedByProductAndRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Devices", "label": "Devices [Member]", "documentation": "Devices [Member]" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r746" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Lender [Domain]", "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r19", "r800" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r19" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r746" ] }, "us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityPeriodicPaymentPrincipal", "crdr": "debit", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal payment", "label": "Line of Credit Facility, Periodic Payment, Principal", "documentation": "Amount of the required periodic payment applied to principal." } } }, "auth_ref": [ "r19" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r183", "r217", "r228", "r229", "r230", "r231", "r232", "r234", "r238", "r338", "r339", "r340", "r341", "r343", "r344", "r346", "r348", "r349", "r835", "r836" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r746" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liabilities", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r157", "r158", "r458", "r563", "r564", "r565", "r566", "r569", "r570", "r571", "r572", "r573", "r595", "r597", "r598", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r666", "r859" ] }, "us-gaap_MaterialReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MaterialReconcilingItemsMember", "presentation": [ "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciling items", "label": "Segment Reconciling Items [Member]", "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity." } } }, "auth_ref": [ "r45" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r746" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_CostOfGoodsAndServicesSold", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortization of acquired intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r8", "r47", "r50" ] }, "rmd_MarketableEquityInvestmentsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "MarketableEquityInvestmentsFairValue", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails": { "parentTag": "rmd_EquityInvestmentsTotalByMeasurementCategory", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Marketable Equity Investments, Fair Value", "documentation": "Marketable Equity Investments, Fair Value" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lender Name [Axis]", "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r19", "r800" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r94", "r123", "r519", "r554", "r556", "r560", "r583", "r690" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instruments", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r12" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails": { "parentTag": "rmd_EquityInvestmentsTotalByMeasurementCategory", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails" ], "lang": { "en-us": { "role": { "netLabel": "Measurement alternative", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r278" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r766" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r764" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Table]", "label": "Line of Credit Facility [Table]", "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r19", "r800" ] }, "rmd_EquityMethodInvestmentsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "EquityMethodInvestmentsRollForward", "presentation": [ "http://investor.resmed.com/role/InvestmentsScheduleofChangesinEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investments [Roll Forward]", "label": "Equity Method Investments [Roll Forward]", "documentation": "Equity Method Investments" } } }, "auth_ref": [] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r716", "r727", "r737", "r762" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r764" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Revenue Disaggregated by Product and Region", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r839" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets, estimated useful life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r65", "r67", "r75" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) recognized on cross-currency swap in other, net", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r842" ] }, "rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod": { "xbrltype": "pureItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EBITDA multiple of trailing twelve-month measurement period", "label": "Debt Instrument, EBITDA Multiple of Trailing Twelve-Month Measurement Period", "documentation": "Debt Instrument, EBITDA Multiple of Trailing Twelve-Month Measurement Period" } } }, "auth_ref": [] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r764" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "NoncashPartOfAcquisitionFairValueOfAssetsAcquired", "crdr": "debit", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of assets acquired, excluding cash", "label": "Noncash Part Of Acquisition, Fair Value of Assets Acquired", "documentation": "The fair value of an asset or business acquired in a noncash acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r118", "r663" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in progress", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r118", "r664" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r176" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r765" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r118", "r665" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r176" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of borrowings", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r36", "r559" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "rmd_ShortTermDebtGross": { "xbrltype": "monetaryItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "ShortTermDebtGross", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/DebtScheduleofDebtDetails": { "parentTag": "us-gaap_ShortTermBorrowings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term debt", "label": "Short-Term Debt, Gross", "documentation": "Short-Term Debt, Gross" } } }, "auth_ref": [] }, "rmd_ScheduleOfInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "ScheduleOfInvestmentsTableTextBlock", "presentation": [ "http://investor.resmed.com/role/InvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investments", "label": "Schedule Of Investments [Table Text Block]", "documentation": "Schedule Of Investments [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r113", "r114", "r115" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r764" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfNetRevenueDisaggregatedByProductAndRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r396", "r680", "r681", "r682", "r683", "r684", "r685", "r686" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r715", "r726", "r736", "r761" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Gains (Losses)", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r66", "r70", "r445" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfNetRevenueDisaggregatedByProductAndRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r396", "r680", "r681", "r682", "r683", "r684", "r685", "r686" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r765" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional value", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r840", "r841" ] }, "rmd_SecuredOvernightFinancingRateMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "SecuredOvernightFinancingRateMember", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate", "label": "Secured Overnight Financing Rate [Member]", "documentation": "Secured Overnight Financing Rate" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r140", "r184", "r185", "r186", "r188", "r194", "r196", "r284", "r285", "r426", "r427", "r428", "r431", "r432", "r448", "r450", "r451", "r453", "r455", "r551", "r553", "r561", "r861" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r17", "r98", "r99", "r100" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeContractMember", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNonDesignatedDerivativeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency hedging instruments", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r666", "r687", "r689" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value per share (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r92" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseMember", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Expense", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r14" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r715", "r726", "r736", "r753", "r761" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) recognized in other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r159", "r161", "r440", "r441", "r447" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r11", "r140", "r167", "r168", "r169", "r184", "r185", "r186", "r188", "r194", "r196", "r210", "r284", "r285", "r383", "r426", "r427", "r428", "r431", "r432", "r448", "r449", "r450", "r451", "r452", "r453", "r455", "r461", "r463", "r464", "r465", "r466", "r467", "r474", "r551", "r552", "r553", "r561", "r621" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated \u200eOther \u200eComprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r10", "r30", "r449", "r452", "r474", "r551", "r552", "r794", "r795", "r796", "r802", "r803", "r804" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized losses on designated hedging instruments", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r159", "r161" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r24" ] }, "rmd_UsCanadaAndLatinAmericaMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "UsCanadaAndLatinAmericaMember", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfNetRevenueDisaggregatedByProductAndRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S., Canada and Latin America", "label": "Us Canada And Latin America [Member]", "documentation": "US Canada And Latin America [Member]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Commitment fees percentage rate on unused portion of credit facility", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Business acquisitions, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r33" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://investor.resmed.com/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://investor.resmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_FairValueHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueHedgingMember", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails", "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hedging", "label": "Fair Value Hedging [Member]", "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk." } } }, "auth_ref": [ "r60" ] }, "rmd_SupplementalBalanceSheetInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "SupplementalBalanceSheetInformationTextBlock", "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Balance Sheet Information", "label": "Supplemental Balance Sheet Information [Text Block]", "documentation": "Supplemental Balance Sheet Information [Text Block]" } } }, "auth_ref": [] }, "rmd_TermLoanCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "TermLoanCreditAgreementMember", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Credit Agreement", "label": "Term Loan Credit Agreement [Member]", "documentation": "Term Loan Credit Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) recognized on cross-currency swap in interest (expense) income, net (amount excluded from effectiveness testing)", "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings", "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method." } } }, "auth_ref": [ "r136", "r843" ] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidTaxes", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid taxes", "label": "Prepaid Taxes", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r662", "r672", "r816" ] }, "rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "ScheduleOfChangesInEquityInvestmentsTableTextBlock", "presentation": [ "http://investor.resmed.com/role/InvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Equity Investments", "label": "Schedule Of Changes In Equity Investments [Table Text Block]", "documentation": "Schedule Of Changes In Equity Investments [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) recognized in cumulative translation adjustment within other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r443" ] }, "rmd_DevelopedOrCoreProductTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "DevelopedOrCoreProductTechnologyMember", "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed/core product technology", "label": "Developed Or Core Product Technology [Member]", "documentation": "Developed/ Core Product Technology [Member]" } } }, "auth_ref": [] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "rmd_UncommittedOptionToIncreaseCreditFacility": { "xbrltype": "monetaryItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "UncommittedOptionToIncreaseCreditFacility", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Uncommitted option to increase credit facility", "label": "Uncommitted option to increase credit facility", "documentation": "Uncommitted option to increase credit facility" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r126", "r151", "r182", "r215", "r230", "r236", "r283", "r338", "r339", "r341", "r342", "r343", "r345", "r347", "r349", "r350", "r435", "r437", "r459", "r515", "r594", "r690", "r702", "r835", "r836", "r846" ] }, "rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember", "presentation": [ "http://investor.resmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Agreement, Term Credit Agreement, and Senior Notes", "label": "Revolving Credit Agreement Term Credit Agreement And Senior Notes [Member]", "documentation": "Revolving Credit Agreement, Term Credit Agreement, And Senior Notes [Member]" } } }, "auth_ref": [] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [ "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Designated Hedges", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r61" ] }, "rmd_GlobalMember": { "xbrltype": "domainItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "GlobalMember", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfNetRevenueDisaggregatedByProductAndRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Global revenue", "label": "Global [Member]", "documentation": "Global [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://investor.resmed.com/role/SegmentInformationScheduleofRevenueBySegmentAndReconcilingItemsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income from operations", "netLabel": "Net operating profit by segment", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r215", "r229", "r235", "r238", "r669" ] }, "rmd_EquityInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://investor.resmed.com/20230930", "localname": "EquityInvestments", "crdr": "debit", "presentation": [ "http://investor.resmed.com/role/InvestmentsScheduleofChangesinEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at the beginning of the period", "periodEndLabel": "Carrying value at the end of the period", "label": "Equity Investments", "documentation": "Equity Investments" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLeaseIncome", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease revenue", "label": "Operating Lease, Lease Income", "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable." } } }, "auth_ref": [ "r209", "r472", "r473" ] }, "us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeAmountsAttributableToReportingEntityDisclosuresAbstract", "presentation": [ "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicAndDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Income Amounts Attributable to Parent, Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r25" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r768" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r771" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r743" ] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exits of investments (note 5)", "label": "Proceeds from Sale, Maturity and Collection of Investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": [ "r32" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://investor.resmed.com/role/LegalActionsContingenciesandCommitments" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Actions, Contingencies and Commitments", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r121", "r318", "r319", "r645", "r829" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r744" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r745" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r767" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r693", "r694", "r695", "r697", "r698", "r699", "r700", "r802", "r803", "r844", "r858", "r861" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r742" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes paid, net of refunds", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r38" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofOtherIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r149", "r311" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfNetRevenueDisaggregatedByProductAndRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r242", "r243", "r565", "r568", "r570", "r625", "r627", "r630", "r643", "r644", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r659", "r681", "r695", "r839", "r857" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r772" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r742" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r29", "r30", "r101", "r152", "r518", "r555", "r556" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r743" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r769" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Components of Property, Plant and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PaymentsForProceedsFromInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromInvestments", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/InvestmentsScheduleofChangesinEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exits of investments", "label": "Payments for (Proceeds from) Investments", "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r770" ] }, "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_CostOfGoodsAndServicesSold", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales (exclusive of amortization shown separately below)", "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization", "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization." } } }, "auth_ref": [ "r781", "r782" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r753" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofComponentsofPropertyPlantAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofComponentsofPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r51", "r147", "r521" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r771" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r745" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r751" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r744" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r718", "r726", "r736", "r753", "r761", "r765", "r773" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use assets", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r799" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r751" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/GoodwillDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency translation adjustments", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r303" ] }, "us-gaap_InvestmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTextBlock", "presentation": [ "http://investor.resmed.com/role/Investments" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investment [Text Block]", "documentation": "The entire disclosure for investment." } } }, "auth_ref": [ "r783", "r784", "r808" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r750" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r771" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r744" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfNetRevenueDisaggregatedByProductAndRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment, Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r242", "r243", "r565", "r568", "r570", "r625", "r627", "r630", "r643", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r659", "r681", "r695", "r839", "r857" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r752" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r744" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r772" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r710", "r721", "r731", "r756" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r745" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r772" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r749" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r711", "r722", "r732", "r757" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfNetRevenueDisaggregatedByProductAndRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r240", "r506", "r544", "r545", "r546", "r547", "r548", "r549", "r658", "r680", "r691", "r780", "r831", "r832", "r839", "r857" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r92" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r772" ] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r745" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails": { "parentTag": "rmd_EquityInvestmentsTotalByMeasurementCategory", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Equity method", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r225", "r279", "r792", "r814" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r709", "r720", "r730", "r755" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, allowance for credit loss, current", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r153", "r247", "r286" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r753" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r745" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r772" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesScheduleOfNetRevenueDisaggregatedByProductAndRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Products and Services [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r240", "r506", "r544", "r545", "r546", "r547", "r548", "r549", "r658", "r680", "r691", "r780", "r831", "r832", "r839", "r857" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r753" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r92", "r582" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r773" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://investor.resmed.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://investor.resmed.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Common stock, shares outstanding, beginning balance (in shares)", "periodEndLabel": "Common stock, shares outstanding, ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r11", "r92", "r582", "r600", "r861", "r862" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r753" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.16)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "25", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-1A" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(dd)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-20/tableOfContent" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479016/842-30-45-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column D)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column D)(Footnote 6)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CC" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org//321/tableOfContent" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "325", "Publisher": "FASB", "URI": "https://asc.fasb.org//325/tableOfContent" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 71 0000943819-23-000029-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000943819-23-000029-xbrl.zip M4$L#!!0 ( ,"<6ER]:7?B2I8H^KU_13SJW.[,M036Q"!G'NXB/9RF.M-V&V=5]_M2*Y "HTHA M41IL2@%^('MN?^7E%J<@7] MW_;7_Z]:_9]OC]_1M6=&(^*&Z,HG."06>K7#(0J'!/W=\W_9+Q@].#@<>/ZH M6F6_NO+&$]]^'H9(E54MO2NYZ%\V&_* 8(*K6E,?5'5=U:K]?M^JFI:FZ!96 M5%GO2\^7FFD.ZK*&JU9#;U5UV9*K6*NWJH9L6'+?U/I-TI>L2],8&'A@Z;HR M4'2XP>CKAM'H$\.P!J9A6?2UPQ#V!WMT@]\KPS <7UYFL4 M5)\Q'B\_,[FP\%R+O'MH0,S:L_=R 1<6;K3?%G8SMP!%N[!=QW8)Q5]Z.WS^ MM>X'LG9!+_=Q0&9/#U??/7OR1>AC-Z"(QR%0#EV<7)75JJ).8;3TT@68TZOI MK?[(FMYHNR\D"#V_YI-@1*R:Z8W8SF5#D^?65P7(+#P\A=1'2U3J5;E5U91Y M--H?P,5V@Q"[YA0NQ+16HPQ6HX%;EXG]^?.^9 M0S+"U87U7#K8??Z]0MSJSUX%Z)Q@J_UU1$*,Z'.JY%^1_?)[YD.&%J62[M0,3._]+L'\+WP33-S0K;0"%GM<+'N!VSUI\1:O2 M_F]E]Q=<1;Z_L($;U[H&(;T(/0N^J8[@*<.JA2?3=QN5MMRH4C3O^OH;%PAD M<@4K\+'3=2WR]E]D^GS@U;8,_S-TK:48F5ZBI2])!.3E-=ST BS\0CI!0,)D MV[T0-D;A>S^XM5W@"AN [ 4V9?6;-Z#RP.X[Y,:E[V#\GRZMH<#>/Q+&?WGP MR1C;ULW;&)Y".JYU#PK/9R\/DK=GVI%^Z!VI,F<[NO-<<^]-:1LV-;>'V?MR M);5WE8M$8\6:F^!!4^X6'Q$_/K9.Y,E!%[DLT_,_KQ, M ,PV3W5L^CUA"C;]9%OT\\ F/F+/)RNMWZON?RTJWO<_;J=?+3Y]S,R3]!-8 MF7Y(30EJ FE5N5F5E?1WLVO395ISMQK,IEB\DGY.7W*QL._58% Y $-L;H?Q MSA2YJFK3!R57MMM9Y-KQMH(A!NQ/=S8B.(A\TDX RRZFCTBOI9_I,U9#2N,- M4@LTL".D(L9.BZ!(7*;+G[WK[%#2N8-2(QJP>*/%KSL;>S8 MIAW^(*,^O,*R1U2-T7#[YG169X[_>(_V*;I/-F [>#GKCL.82,P>Y^ M),'89L"K'RR5,(3!=0#K'=$&CY&"WJ]FA1\T-+LV1H\0;A*XB/3I!< M.DE>:0FD\,B#/U-Z=>YJ.QY\+'(*;4]#;X?N2Y MO= S?^5/IWD9VU76O\-@.L5,:^!_2-;.%N !2P?WE,NLK/)*B+Q+BI7=*R_(0\P-_F7WT OP$'.#?=F]\V-[ MB+D!ONRN.0<>8FZX*+NW?BREJ^;GE:ME]\J+4+IYPK_L3O>QE6Z>L"^[#WU4 MI9LGX,ON Q>M=//$!0\YX<-L32N[0WF\B',Q>7BM[!YG,1'G@I!5=A>U^(AS M08@KNXM[Y(AS05@2SN_6!D)> 0=-.+_%PE\XO\7!7CB_!0%>.+_\X((_YS>' MXV4)7)>.F-$Z]^1:^H@,1\RX5%",KZ)S%PKXF I^X.!7D/8% M.5E:*$@BD$-I[*5^S_(F$NYM>^-EY)&9:[*(V@AT+E W?!(_[I(8O%5U(IP=UI!4$5 MQL3NCI'8M# :$$AP\X;<9 NX\MYR\P)U[7AXY\Y.UP<$UG%?K$>B0OQ(U( ONY.8ME88(F=TYQ21"0&P=PYP7OA("9 "HC M$W#G")<'![GQ ;>^\#1"]RT*;)<$02]^1'!^&(NFL$]99R%NF]Q%V01=,&%O. N]K,-75QY_M@#RJ#Q MA@1SI\FUW$6%^,1.0;S#7;SH$#*UI)S#79B(1]P4Q#?<18>VP1 MP&Y,VP$LL;M.DWVXBPYQC**"N(B[Z%"*AEO;M4/RW7XA5M<-L?ML]QT2%P5\ MF_S __3\*P<'P7P2Z84XWIA8]S[8#B2IVG\BYM#U'._Y )[Z89)X+>[",J5% M25XY/8.[>,A.*)F:UE$0>B/B/Q*'"<%@:(]+D^,VN(M!E \7N?$%=W[_7KA@ M%6CO;R\-7W#GY9ZW(/#NDZ\%>;ICS['BNAGEZ0SS5[0<) MAQZXIB\D" ^4+SL4Z+GS,_F2,AS8.HK,G=_*D4CB D'<.L'\R"\N\,2MT\R' ML#N4)?&<%]M]7KPIKQ.JWVV7W ]6+8"Q M6C1X_NG"#[YA]]<=G57W=T#[&)OT,UU3<@0/[CB\9:T:N9"!RJW_+LA@&P-E MGA V&"CSMV8S4"+7C@G&C>C"IQ0S(CB(?-).G@%_I@](KZ2?Z1/642"WH8QR M4."^K[2(??F=/&/GAD%_]I9'$HR(]=T>V2&QRB/0N(W2K,/F$_%'WSWLQM<[ MSSYAE3TG(CO>HX?;2,[?L&]3,_H1]C97146-:F+=OQ#?M9^'86(7NL_TMGU9 M;^?7AM> 9T7E)JU,XHK,Z/1M)*%4H^A+G"$2Y*%X?E#A>YE<]IW 9= MOWONGMV>@;L\TIR[6!-WL,Y/6G,;=%DO0M[ISJF*I)KSW5>@3TO) M 0>/=F3;&POS*8W=]C8MZ!B#A^.&2P4=%*7QI?0!&0HZM(-[XCM%3V=TL#%Z MFI,3J'/K!%[#-E[ _7XAL_+&1SOX];[7(ATJ:$YZKWB<5]Q@U9N#/[#M?O>" MX-OD/XGU3-.1<]T=9T+F%MO^W[ 3$1 A=R2<55TFORJ-+-&Y]5,%812J^G5N MG>;M"./6\XG][-Z\F4,:^+R"W?G8S"W'LBN-3.D6!\-;QWL]&%GP$'K4N77V M!0T5J7.X#4P(LBA2XW ;1.&"+-;/X4[O>/#)&-O6S=L8?DL"L$!8*^9D(/=6 M?9BW7DU"7-$WV:T!V1P^N27GP3DMI)*D!^_Y)>?]..N=&I;>%]/@=T)DGMG='I(UZ!T M_LDT1%8VO[7.;1!=$&=9B3,WR5GG-I#/+7%FH8L=8OE<, Y'TI/;A((@T#(3 M:'X2E-MLQ>:X2\5![C2X33((ZN%?]C2XS0*<%?5LO;:N:WHC,AVAN]KX M[P**?7A_4E5UHG*/V_2 H-R24&Y1,I?;O $7P8VM""6-;W@ >;A,$VST5]O1 MS=9+*3C&P868Y3;G((B57V(M2K)RFZ_@B$X^YAM:ELK6L89Q3B5^S(5LY3;+ M(?PG'-AOUV"!^M%ODF"^..08(LMWK)? MVE_A'X8SVS0&!AY8NJX,%!UK=:.O&T:C3PS#&IB&9?V#AN9FOPG"B0.X&]EN M=4CH (1+1:VI^CC\\FI;X?!2D>7_4UF\%?L ^&KHC2\;%7\=_S&Y?>N?9A)J-.>/"N]O8_-7\^^%[E6U?0&0[D\O_> +:"= =>46/W@B[_R$%V VJ 0!Z$-\8 MV'^22Z4%KV=9]NKE'OJ?-TTUOWUNO=W/.Y-WFIO?^_T_K-[]\?3 M_9V$KJ^0*M=U8^?=[+WHQKLUZRO7_(^#_F_M[LO&?;?WCS_05Y!]KN?>@A5H2_X"\+&IM%/X>3XH< H[ M!X\#VRU[&?O0E>5;?"T-O=$GA\T+\T#:QDY GH]3XTRD;2&V/+ JOP4AV_(651I#EDL PS;[P]/_\='DP?'NQ, M+G*+;C"S_/KO".Q)XCN31S+V_+""!IX_PB$8>V_AYU M\BT!_ J8'A)T>2EX!L#__MEY?+IY_/Z_Z/'FX?[Q"3W\?.S][-P]H:=[!);- M$Y@O2-'0_2-2ZI^N/Z/[6_3TGS=HSNB9&CR=JR=Z63$T?0%$C/XN&.=M%(M% MZLWM3*);ST?AD*!_I82$8C\#@?M!K!TTZ@/[^4WLO"S2HP7?5$?PB"']6=7" MD^J$8+]*W)0^-; _R3ADOM>__T5IR%\T64+4<=U:*V_C@PA9*V3M#K:B#Z^S M:3AAO; =8">82EN]TO9.6=H^/7;N>ETF4SD0MP6[*=G$;3BEI53>#GQOA!*C M._10!O.[%!N_\D8C.Z!Q.G1K@_"]8\.Q+S,HF!L6CA2 M:6[4$D>#RI[N@? MN2!N%NW<3-Q9B?B1/-L!%0'A'5Q)";E1:3_2TS(6ZKIF M+;FX,Y8.OH+5A_[DRK,6W0E8D4GS*2$9^]X+?<[,CVA6VM?$P:_8 M)R7@H^68UAI&8O! 8$)X- &-_AGY=F#9)C,C@+/L>=BQV_QG[-I_LL^[,U3I M:.@)OW63-&)<1;!H,+0J;:-5E96ZVM*54R*/;NVQUJNAF]'8\29 'XM 0'=> MK4"IFC5B>F2'9B="ZUB63X(@^0^=\JBD1&8 D8%9BGJ@WV@-";IB4$7?G![#^:YL\+_G&4F9O('D/DXOW_@/H 9"!LX2. M GY'Y_U;=GW)@P?*QOG_[7&LB9)7J(!G5]$9< E%N+Y 0X='=C'VC3'F,'D3=B1K2^#+X&Z4P" MB:IN)Z)1'_2G/0:86Z3$^OK3]B1$)43')WB!I_1*NU5OO2>#SQD8EY8/.@]# MSWT7*U#J\&BM4:T# $Z)S&8.Y;__I:4JS2\!"HE#QA0"R&4@F*9\?ZENG=YVS+B9)W(+XH++&D1]$-( 1>@CN8-:U MHG[J?Z9RGH9W.V9XR6WJOU%K:?(NZ2A-KQF-]9<_RD=]?*U>;^:>Y5+K-;6A ME62Q#++;+79#2NZ#Y%',8>\))*:-O(70=D5;3W;HL)@@P>80F0X.@@SY,9EN ML++5K5NFTJ:P.*:\WA)4/J8[*4ZM;%PF2PGV)J.^YWP*WAD6!\6QO16?*-^)HO:9I)A:\8TXGPC [(6>^4M"8^RC%]JV!_TFUV19ITE5% P_ M"O_F0I$YXN,PM)HW2A(Q%+/Y%!_-2OOQQ[4 ]4&H/SU@%J<*WT=7J&1Y%UII M@?"!M?ZOY_^*^0.EC_@00UD*+8HSTU=#M>M:-,I-4'^"S"&!+8]H^>_KD+!$ M"37)Y]*.GY3/:(@#-+ =,.:QX\!%6M!#;?Q_13:U\,&P[Y/D!GCFU,C7:%I% MJ7^RIJ;^G(>0@IF:__0RK65!%EP%EYO>.O:)29@#KJB(U<$%Z!,\#W"*@@B4 M0C#T:.XS+0D)ASA\O_97O+A*NL3XQ\D>/B/L6NB3&F^Q#X0!E_O_A W0V]F= M\!NZB.0QK&4'6P-;(PY"9,C(PI.@ECE4FLR1B>NCJ)P(<1@%4\HT*NW_)<%R M0'9%R'\7DMJ_,HP1TUM>Z\DW,7+G\08HC[?HT4&D!64CX*"1'=)H-7%H/L=S MJ3IQ)HB :ID@UD0&FRRD>XU#')([A3E^M47CR2YRANE(-Z MU2?TB5; -K^HFEI+;@B'-BN0&-,"B4-+EGB]4XE!@L_9Y<$<8"A<$O$PK4:7 MA3P0\J!X4&:3!\""&#FP(8*P:8(\\.DQ8L8BO@3*=^6W".B[NO)", )! F_Q M4YT)7#4"Z$PD:FK XT!!4^ ](X#1:SA,+]? \B!L;189V"ZK)65Y)IH!4&&; M:U;(+BM?TMLVWK!^?>F-U-Y(;EZSUO1.VXWE'3AT534UH.:MIAK'0=-&2]^I MAK]>:]9;N4<,6S5#J1\B:*K4=PN,%@2#[9ZZ>]#TPS#AD0MD,IY;F!5,^U? MW\\>SIM+\S =&9XW]VZPY>?%['0++"-:>3(&]\Q)R+(*85V#]U;'M9 MXJUEPN4=6!AGAD]Y"9]GQ;V]Q#2;AEO056QOG3;6=]&"#%3?H@ >% 0;#^ZI MZJ:3>R9T/1::BX+8OP:BB _#KSBT"2XZ?9'5\%KD MPMX\ZC*_V 'SJUWLFC9VJ#M.JV'IS71DD(5]*T#T^(IMK2LKTC[ASRM=96ZC M/US11X8.+%RM>X>85# DCI.2/OH$!,TB0_'1NH_C+I]KZ']A[8*BRAEXS6P- M44K96H'I'S6-R<15QT)1)T3W9NA-FXBH6MQ$A-*]3] K_2>!V2U+3X"@C5P[ MAA@K&P$;<1&*:@6XR;3!C Q^KW3O;E?D/EE%"DNX]]@C[J.0"7G [R*0W6A4 MM;RPFCP0E#/80O L>0KR>J6MZ$U)-A3)4*:5ZNE:VW%I"XOVSM?!H$]I]4M: M#@.:8[:(&GJB^:.X')R6)#F1!0_1%:FE-215T]/' G6PK/<[(0,")?0)#B)_ MDMQ96R]=$WQ0?(V]6&E>^FP,Q M9VS\RB! 2_Q([KW@25"[6==+4ZSFTT5S!5H/!P=@J7@?0 M;'+ ]!(D'?'I7; J M47^\Z?VXN4;=NZL::]G9^_FMU[WN=AZ[[_N0?K0C]C)>MM2]N[[YGVWP0)]W M]&00<"R(V9U*Z)LUP]BM@O[#1(A6:^KYYU=H4;I:0'XE+DU=.M-S!.)C<8$' M[(>HF[F .;?-Y20W5VVN*!F><2W;RW!ZGOAVZEYWW=C,@J]0VQ_QHKML8^VR[M[7!9 M9=V1R[O9Y3!D^93(:E!T0S)"RM$D4/+[*KTY;IF]1";'=QH*5#@9U[*KPIG. MJUGA. A](_3-,8^7"'53O+HI$<:%BN%9Q5S1$44N31["7^RL&ZOI^88=T#P$ M]8:$A 'Z]-/%D46[Z'P6^D?HGQ)+HSWT3Z'%,T(%'5 %K6K'(+30L;20ME8+ MS;P>FCJYCX=QTM,G0A^52Q\!BG6ACX0_)# N_"&.-5%C2TU$*YI\,J3C8%\( MBF=#S^LD))12"9028+LNE))02@+C0BEQK)2,;942*[(.: WVS;\B.YP(+ZED M"@DPW1 *Z9@*Z?96*"0^,2X4$J\*B9Y9W4XAX6"(;AWO-1"^4/I%2\+]\0ZK8<+*ZN8^]SU[EN MN8X%GX6F9$C[;]I+RPY9RQ&F]> +)_U,E:;C!1'M=]+I>U&(?F#_%PG1HQW\ M$IJP)'RI*4(5GOJ.A"KDAN4:=<<5 M?:!*IN( 8]:@Z 0UW)JX<(.T[><9.[,.QB9_"B2L+ MNPD-=_H[$AJ.'Y8S4@W7$2JN/"H.L$93<.@6FZ'G'U2[K>HO(Q3<[MPF%-SI M[T@H.&Y8KJD>M=Q3Z+<\]!M%VD\WGJI#?'HX#SOQ))_D='B/F)%OAS8))/0S M8,-)$F' M5J$5\M(*S4J[!W#%H3B'71:E "C3FA\IA8L0]QV2?C\'\F09>AW6.?8"UH?M MTB<.:T7SY=6VPB&L4?X_BXB*-?JE//L)[@>>$X7K?S+"_K/M5@'GE\U%TC") M&Q(_P77[:]^_>+>-U4]I'/PI1Z0"E8)+?8>]N7_IXFWK]\IVDUR3'PW]&6,^ MDVK?)_A7%0]@@Y?8><63H'*Q"!: 2;*@>JM&*6(+9+*]S4'PGU$0VH/)\=LJ M @BY$<8?KV5[S@:^?J*,&X\0 ])T5UGJ61'#9,&,E7U85Q6 XN!Q0"[3/[Y8 M=C!V\.32=MG6V(^^),]/^)^2R'N93E\87YY13TV.*2BQ89(W)Y=K[%*J51:N MZ:V:(:^_+->4M==R>NP&TRL!7@(.VE>7M9!&E+B^%&^7;:%]*!@>.H]/J(M8 MUT[E"[KMWG7NKKJ=[ZA[=WO_^*/SU+V_V\)LVQ483-7S XWTZ.GHT$V< M=_#%+S4K4&>+KZWL7[Y6:!Q?_ZU>_.--[\?--5#=50UU[JY1[^>W7O>ZVWGL MWO0X6OQJY;VFD?PW[ B".H-"7G?0I[S'7WJNNAG[S=6V6V[*!QZ$3R.UGJ3 M-Y-0]AYB/VY?."9^\@EVC==O;8Y)]#6&5VF44U.I&5K^RDE1:W)K_4\_>NS' MUW2Y<9C%:GEHTHS*0U0D Y*^12];#HHSDO'J?G2 @<\;!1ON.63BKC;L,)+#%K1G? MEPTC; !&G3FY7.!FM:BYBGP?& -AAJ/+PW#CKK=N\HVP^>O9]\#MK2;0,DU" MP.,N)R;H:#IJZICT#_*OR'[!SH)5O:@ M]J]C+B2#ZMW_MM>.]SHZ!6YM:_V M&XVUWOK89/,G(M<.'VEH)@JL"M"T2Q?/OC"K0-@6,>T1=H+?*_23BT>$WEE] MQGA\2>FCXUKT/S+2UUCA.S">AE0])&PWO3*]U)&\,EI\HE> M )^H=/)(4VH9"D=\DED]#MC_LH8-IR]=-_9H.N0KG7JD4UU;#"%U3!-V' ;( M)R8!Y(/7+B&7A#2^C1W'>Z6Q$G9L_+<<97,G??*MYU][43\<1$ZZDL?I0A); M*ROM:51&2W5-72(]9BYDVL<&WCGH/G38AR8U9&W%/D(T]0YC?@*W"%&7B&V1 M.DJ+7TN WV!,3)I#="8;TL=J-I98J0M*+3$W4>\2AN](N".2ZY5VPU EK=7: M5U"N%E8'-2C>O7*MVW+V!+5)C.1(4(U*NRGKDB$;'!'463FF7?<%\.;Y-CSQ MD^N%!&F?U\8)/F*-;>WN4K/&!EF; G,"')&5%9J5ME%O2:JVK$%+[ZP) MI2 MMNY#0"T@(*,ERUV%&[.!>QHRUB5-JZKDNMALZ1+2*,V^,*X/SI2I>!KK0F MR&6>G*:<;%R>I?&3%V+GG>#=Q[+=G$\\38[9%%_8AS=HAD+2P .LM^HY62W; MH:E$!O&YTMVF,,0^=*![8UC-1$)C!U." $^*5DV,:2ERG/,1T:J]?:@8Q@\4PF#J MWJ3PS1Y\T+5*NZYIDI&;&B^ILCYM@MKH/.5'4#HE*-#/]09'!'56T:Q[P"4. M8=G((3@@B,&GZ@VJ$7S8PYTZBS##!M$[A>UW"MI'^I+[P<^ ,*,V*ZO4*VU% MU21=V9M51."*7XK:('MSI:@&I:BF9-3WUN;\A:S*(7S_\#SKU7:4JH"9OVN')U5_)I4?)I-F5)-?:N;1$6[(X6+$N] MVFZ(W6>;'@N-K=8Y?U"RMV-]*X)@/BTU%PMFMZ(X)"_$;VRL&> M-G=L$+@I-+L,F$\4EHL%"G>>:^Z4#ZLKX/!I+9"^/)V $:;N<:7O >E+I?2E M2D9S[]HJ80OO5YO(1/!<8:*[E'45!O&N0=T\.(6>!VO4)86K$Q'"#CYR,#WA[BQ2K[1U2=<:DBKG9?B* M\L,3(;VMR@]W)[T&)3VMI4FM_2->H@(Q3\F]6EKO7\QW@IU(LNW]9$3#5EHI MJT!H5MH-J:G+4K.55QT''[IH@U,@&$LP5B:=FY6Q6HRQZHK4E//*+7&F:7GV MD58WC?QNX[[ML/GV+!;5"SWSU]!S *H!ZR/>_()H]6@XV>D(P+)!I $N+"^B M2>#]SP!L:UT?8(EG8(6E32N=&8WL=1"$E^,>XE#'M'W7&$]HWQC1^_(\>OIM MV:'J(::*W8[TU8U*6VDV)5G/RYWF*%XC&.,T&6/+3EM[,49#!L:H@ULI3M(4 MJ/?\B,SZPH@,Z^Z:@@)RSGO8D2?HA&^]):D-GG)C(LMZ=/&:#S6I=*9N76HT M]NXEP%^FM1P2]OU9Q3G?44I;P(BZPUP.*Z;L,MF166B!BR(U#7%0_(0I*M-A MQ7TI2F<492CBG$W19=X^>2%NM!37$1;)ME- X&;ZF+_;X? J"D)O1/Q]N8.> M#M<;4I.K]G/"U#VNP#T$837B,P-R<^_CL<+JW;5W]^Q4S;J8NK!)LL46Y@X_ M[,@7M)"C"6PA^GB?,#%M%UK8GYA:E793E515G)LIB"AZ0\\/JR'Q1X#P_D+K MN:8X.[ZKL&50?0*@?O-\WWL%.&0MZVD8E;8A&3)/'6J$57M<*;L_%37EF(I. MT(3E6:@NMN:>"]:*,S*YB]J]TQM-!6R0IBRU]N<2<4;FM$AO@WS>G_14(+UZ M2ZKG-A2)L\K=\E5GSG?ISJM"4[3J+G,4*I?H_UD$#?:)_N]\TK"IT6:>BJ0; MHHWA"=/6/@F W6E+!]I2#$G9_\B:B$\5W6+K+"(*N[?8@@]S]NSN+%.OM%M- MJ<%5UDP$KHXKC8] 9HU*VY"E1EV4)/)8DCC?'4;8R_G6)>[.,TUJS:B2?HI' MB 15[5>;N#M5M2A5-:36_GVXA(V\3Q]PQW.?XT3NO@F'LS!AMFEVF(NE8M"S M.)*FBOK$$Z:F;1H>YD%-+;G2;K0DI<'3+*2SLGN_3\5L3O4R9V&4;$KB E!I MH<,U@#0K1]#>WI)65Z2Z(KI[GS );4K&[D%"M'VWI&N*I&JB$+%PN6KG5?9] M%I9'YK+OW6T/EFF3E'J3(]M#6+)%5W[O3D\Z>$9-26GQU*3@;*H3W=6%+J)" M\9 5BKOS"CWF*#450VKLW^51E"F>%OUM7Z:X._W1TY!2BTVP*T>9[!G4*L:" M/*=H[[DRS_;".RO+L F[NB%+NI)7EIH/D9VC+7VN5+>]R,Y*=6PP;T,%89W; MV3'.!'69H\=7WFADAR-"N\32QM"4*F 3Q#5IJ^@XCFRLCR-GZ[B\H90[FY!\ M"^Q+UW9^KX3@_RV77TZWU7&MJ_E-30G3H A_1X\\]*7.#TKZ_E RY+50.@.# M9E6;=,+:I%^N+R,2+;*SX=6R7])G)X^HTOLO=2H[B\'[@Y]6^0:4 B3TVT=L M]T#\WA#[Y$.=VKV[?<]^T[7S;@[KL^VH)- A:@_[\%V.,E(SQ]WY=C@+\;!-'[K0WL-V)5_R2^ MMV)7]:- /?.R&I4V+(EL 6>;/7JJ&4"RB<1I9@]W$6=,]FQ$UM3=,,#)99I: M_<)1XE3DWH_KKNY'0BT>2>C8UO8ZJ\Q(GV&[%C@.E]4"S33JOWCN06VT^!59 M#2+C, ;:3HL!4#'S3%ZN),G3/LNP]CV-'T7^R/[=S7S)!$(ILS;H*=H]:8DM^KP M_\O9(^3-GHUPB'ID'))1G_BQ]-=D":FRJNVRS9**7%F_T/*@;#$2)?]4=7YKTX'.07QJC94'&=='0C^.N>4: MYBFMF.Q[8>B-+C5 A.5%?8?$2-J# MUW@#Y&^%0.9DI,_V9\\[KI6#+%(J[8;4U&6IN?] BQP16K!O([A9K9"/R[">X#\N.PO4_&6'_V7;9)IN+[&H2P+:?-QTJ\B9"5-G1 M:$)0."0(FS0LB-T)K<&E[0("%'KL2N3BR+)I^!#(TB)N$/_%L,2BB@/;Q:YI M,P\6OF#GT&N+J9S5<&@LPN&?41#:@TD"B/;7OG_1WN$QA8+S?0IK[E^Z>,IB MMFD,##RP=%T9*#K6ZD9?-XQ&GQB&-3 -R_H'RP7&/QKZL\SJ,ZGV?8)_5?$ M-GB)G5<\"2H7BV !F"0+:JJPXBVHD>UL+1I6 ' P.!@ XW6 ;/+H+ %@*Q E MQ*=WP7(P-VM!0Y^*YK]L1F43G (J>9 W0+0Q ^6-KQ=X*[I>CQ@FS&:RB$E/ M (J#QP&Y3/_X8MG!V,&32]ME6V,_^I(\/Q%@-'?Q3GBR%\:79]13DV,*2MRW MY,W)Y1J[]$X5Q-?T5LV0UU^6:\K::SD]=I/7N:"8/M8^FTPLP-GQI4[%#;#$><=7(][G8>NS>]M6*#%_UW M-341KN9-A-[4,*"",!D5 S>@3S]3Z^(S]WO[U'71S]YO+*9CNV ;>1$\S@HD M1-Y, MP"VXI+7Q#L&J_?T#L97R:!WE1KJJ;E+M 5I69HN^F)CZ_IUI!/BP#(8G 3] M@/N& ;H!$6LQ[VA:781SG/VN)I^%VLI]=KM- MD[*3 9EZ<(XJ@$M/Z^SC'0F13UZ(&Q%413V'D#$SSQY),+;!QO3\";JB!MG8 M]ZS(#)-HBGUC[:MVN-&K*W)K66+F]4UG01C-W/K>:-6$]YLW MTXDH5#I!0.#_K!WJJ%2MTC8:FB1K>X\UV:OT=8JQ/$M !-N<)MLTBF<;O=)N MZ;JDZ\4>9MV&;4Y ^9>YLOV=\O<&X2M5]3A &/6(_V*;!8SW*@NG-XOG='K( M2#,DM;7W;+R]JHUW4Y"%U[67A=!:Q1,:/8$DUZ76_ITW#DYH)Z!2RE=^/Z=( M1*5]=@Y7BN?P)CUCJ,BJI*EY==?AH\10E.+O39Y&\>39JK2-NBRI1EY3@(L@ MSA-03>4[4;!]IF+W(4M%3R_)984G0)UE#L1?>4%(2SL"$'W!;J'X++KLM#76 MAN UA?7]X _/LUC!=QSIF.JI:S+VX<>LO@;^=@C] ^[KC#P QI_L^\P*C!YU MI$&YQMX#!T5+$'[I;D/T]_ATI\F5MM;0I):>E^$DS*,3#08O*2 ^PL%E8?T- MX> "6)]V;6Q)+6/O-)!H>L(OV6T(#A= =G3JAR&I#9[Z.9ZLPBE?J'A1S7PB ME!99&RWX#L_1'0J&WBO\2\88?!_B3%"?.-[K^@F\(H"W:WRY "&A@6XR-$FK MEZ/SA@@V\Q)L+H!6:>]669,4)2_77<2>1>Q9Q)Y/C#H_"(^\/X;,R'1Y="1/ ME#LO,)EE9OXKLND8<-L-L?MLT\-V. A(*$+5APU5SR/B?M"=0K_#@)]9E[&V MU,;^O?9%$)I?BMH0A,Z9HEAS:G5%JU/>*.H$=$R9P\O9-(J(/><8>\Z9XYNT MNY5A+(^+Y2V^)\+*APHKYTQ1=/REI.@B8BPBQGMI#A$;SCTVG#.G&Y4V'<:= ME[4HHKXG0H4;HK[Y4J$N4PM&:XI:8@Z]&9XU4=R=W)S/8.[CE)PKL^^2C@QZ MGF-E9G0%#$M9E=1&7N?6^% X.;HQYTJ#NZ09=Z-!.N)4-B0]MT.Z0MV/S MA^\% 4VA#.Q0N#:YZQD&W@<&WTZ:M#6;-@6B+ M%I<8FF1HQ;:R.VN[IAR:XY$$!/OFD"D,B[P0QQO3<0E(5(WLW'4HAB@P\_4, MGKMRB-C8*RI.B6I5V0Y.45EX3]H1J.%&GXCCU(Z?- MV6MTA3^RWN7F.PEPW^?HE]!-N1=X:XX!T59?!$I&,.O]] M>$JG-OA;<%GN%( 5@"W7G6>0-(FKO;QXU*+[C$CLJ(B2K_QC#?1&7MV.^$C(BTJO0P>$CAD!GU>RYM->UE RX>_WFNF%,"Q8DH+"^*PSBFKNUUR"&HJP4>M"2OZ%/'$76=@$(IL[_Q M![;=Q$5&0,N)*LE-AYR'I;BM#HGYND?,R+=#FP2W+WN%WN M.<>1.2C\B\/KAH^I)IM*:-#96)+:6JX$XXBH3D EE-G'8-'3W<--I37L\LR] M41#>>:ZWF ;9L>R_H5 [KJ'S7_4O7(7#JX.<:4NEO:SK\CY!)^$CG&*A1E(* MN":5)@HV#N@GY,?=&G!W0VK)RVV&,]M[HG3C5,AP6TV3'QGJ0(::9*SH=ET* M,CP!_5.^(HZD4+!/@-9(JH%"_":*T0_@L"S&GZ_@I[8; 33NIQ6:WQ@>XON> M*!9NWD(? S1M%_N3;DA& <@+^E+?8WTQTK1H9F%!FZLT54DQREQ;+,K:CU]T MR!,1-VB!O"(UF?A=W7TU76FCY[GK,V#QQ&+]1ERR0_O)1K/2KJM2 MLR$.Y)\P+6VE5O:G)3KQ1Y$T9;G8@S=:.@&Y7SY_YXZ$B9=S&--@)=_R!H3? M#K3WDY%5&_0>$-'N)VX:!ABMBB'I:EYS[DKA>0GV$NRUI2FP%WLU9LJ0W M\TKD"I_P3'S";SBP342P[\*" S0F/@J&=%9L7)S7VB>*K@%Y6%Y$:\E/7:AE MW'QII=H#\7N4/#XT'M2E.K.$O-)?,Z*;RC%Y)L>42ENIZ0" TZ; [+IY \X0&<D_+(K^T7VR)L[H;I M8-I9?:I[]\GCG)C 6;7#DQ,X'ZO<*V\T\MQ>Z)F_4IJ9"9^$=E9)GWJE+=?V M/_+!7]Y9L,-IL\/'^G=7=F@P=N!_W-H)*./R^<%Q>)PIWP!Y41B$V*5K1Y_@ MM?\1G%G[D[5,&P,H8T;Y[^S1Q.K #O$SN8M&?>+?#QC#!O13'\.9J"RK9/K!Z6REJ4RAJ2KN5542[TQXDYF;N-6(?HK>739;Q9AZ)(]_@Z)"\Z:\DQG:UJT,@;G7&J12Y8RT+X MKV6_M+_"/^DO$JJHZT V8R^P*5 O?>*P0KOA>&WNA2GOT$ M]P./8GOM3T;8?[9=EAMM+C*'2>A1G[SY0)$W,8(:SX G*!P2A$W3&\'[)U3U MT Q>0/L[TBN1BR/+IDH*>,*B9>CL+U;RA>G7 ]O%KFEC!]8.7[#>7;4I1;X' M^!P<&HMP^&<4A/9@D@"B_;7O7[1W>$RAX-07%SS_+UT\96C;- 8&'EBZK@P4 M'6MUHZ\;1J-/#,,:F(9E_4-I5-(?#?UT!V,0+-6^3_"O*A[ !B^Q\XHG0>5B M$2P DV1!3156O 4ULIVM1<,* X&!P-@O Z0A%Y\;.X21!?QZ5VP',S-6M#0 MIWKA+YM1"5[F$VN6Z@T0/19(>>/K!=Z*KMEK)O\",#9\:4. \-#Y_$)==&__Z6E*LH7 M=-N]Z]Q==3O?4??N]O[Q1^>I>W^WS0""'8&QTE@H#AKT,"U2%O:[P@98XKSC MJY#F2A7R>-/[<7,-J+NJH<[=->K]_-;K7G<[C]V;WEJQP8O^NYJ:"%?S)D)O M:AC$@G T]LD0[@,;"R6G3C]]9YU /_U,S8W/W&_V4]=%/WN_(;#JD>V"L>1% M\#@K6+_R=]*]3**\J=0,+7]1KJ@UN;7^IQ\]]N-KNMPXS&*U;1];'N]HO7[, MJ )C8BO&I5_M"4_W9&RSIUB<%+.K)6T0]T(#4Y.@'W#?,$ W(%PMYA?UR!@$ M:I_X2).E+52[()*MB&3)%MI\P&DS^1PGSK6:?%19U7+9[3;3H4X&9.K!.:K$ MZ9(BV7>'D^K[M]SC#0C[')+9ZRAMD9OFY:1Z2\GMI/J!V@I.L530(33!7B?. M7H<\J=Y2-1=B2\O=HVG\B34XVVLB*R]S5\5T MU81O%8UOXOSI^@16\2>Q$*5%6NKC@A2E[8]9@'1(K&>:>;7=(/2C49PF.G;A M3Y$ .D@W.]_B= GJ1#;3HTL_I(B\&#P!X :.A2.J[U MA-\R:S)ZC+$IR2O:Z93^K!% M:P]VUTI[E9J?E59*4'*58.2)(B1^-94$,_1TIA@!=^M^L(M^JE?:FBS5U7VF MB.]5E+Z;?BK\Z$-IZ#'36*?BZ;%1:1N:I+663TIP1(\GH++*%_6_6N'3[Q@& M2HHEWGP0DSN+/#H"<2F(K56S-G=*]2Y%R;+D6<0;"S8 M>!_G/$\VID<\6:!GV9 ^%3;FU.H1AWK$H9YC@+.>RZ$>0QSJ$8=ZQ*$><:A' M'.H1AWI.\%#/$+O/\$[;13?_BNQP4HNT]5FK=EJY2[3Q5/%4P_V5&.[ M UZ)L?#.-U3U^/A='@=:BFQDLN% 2Z.#WES H'B\1OW.GO?/;;&7F1&Y[/?@5^CU5N-I5:3!<4L/5O MV,&N223TU\@EL1S39 DM]%-8K:>V.!BQECR6"C(X:Z:Z#*O61X49:YKVRAN+ M,])!#?NW3J4M>ELMR9"7RTI3/!Y9,;;6*L;^E M[9>38U=51&Y@5\:H0\\!N 1QYF<%'QIRI5UO+9_I%CPH>%#PX&8>W%"6O(H' MLRE*@X[6EII-59);RR=6!9M^U/W\_"R^]>>0UIA\ZL?TF\:N&1TG]E_RH(QD MK%;:NB*UM.6)#)E/70M1+T3]H=EEE:Q?XI4UY_9R$/JT1X'44#5)K0N&$0S# MS;XS\8MV<-M(!Z4"+*))LK+,)L(V$FQZIFR:3:_IQ]-K]4I;!5>FKBY''(16 M*YQLSI5=LG#+$K/DSB,-JM04U9 ,63C\F[GTV,.,YXHUDD=4Z?V7K*M087T8 M:%5F0&D/V4$0$8NVL2-OQ#?M@!V'\L:4?#85-9W<6-I=LF#U+3B\RX!\'?D MB@=8E9<,$V07[V-8WR3@MU8Q.>LQP.GHV9.D@J3WFH#P\?ELEZ]Q#U]($-+^,^ =@N<2^K9)#X_'=U&"":9]^6-'";W:X7!('(L&-&BO_N,W M0N>2IP[@1CY.\<%NZ[QBWV)]L&X]?T#L,&(O?,]GJBQ7VGMSV8$FT9\D3>RF MR02$MX=PMDS&DE?Y429CC5+;E??H_"FU7M1,@3,C"\%X L("P@+" L)E4L\% M:F>5(^V-3$=CX@;Q'!/3"XJ86E(^>20"7P+"_$#X:%D^ M&@CY1L7&U9S4R%A,H\JTD+HEU169H^#CR=.(X$(!80%A 6$!X1+IZL)5M"+,LXJ>P9(6S-7^;0C%R(V)" L("P@+" L('S: M$,YD!K8^#M*#M3"S]S+;>W?[00/]Z3O39UTG MKYX2CCPC'*/2EFOZQT'WW(IE$])QE)$6%, 6$!80%A 6$!X=.& M<+:?&5PA=?%=!8L]B) MXPDC*C*M?9.#Q#D;2Z4.;'3/R=CR6;=8B>NL$CS&N(GJK4]0TXM4I9'/5#[!@5R1F^# _6R^#2-D<^"[)IV(I,N@ M^71A\PF^%WS/A^9=FN]Y.,W;JK0U59:4%4500N\*_CL5_LO"?H>>KJLJ1CQ= M5Y:T9IFGZW+ ]AM2J98=C!T\H?!=&9T1=^Y_IT!!X7<*%!1^IT!!X7<*%!1^ MIT!!X7<*%!1^IT!!X7<*%!1^IT!!X7<*%!1^IT!!X7<*%!1^IT!!X7<*%!1^ M)T/!18C[#ED,[^\0T%?D31%]E1[!63QG,]M_,L+^L^VR^']S,6UF$C6 M@.D1@L(A0=BD;=FQ.Z$#FUTOA#>$'KL2N3BR[)!-UW(MXL9SMER6P,#TZX'M M8M>TL0-KAR]&L)V@MA;@HF=5SP)*A>+.X3M)<]NJO#R+0B++7(M1%? M8C X&"SB=5C$]'PVK>$R N+QZ5VP',S-6M#0I]G.O]BF,3#PP-)U9:#H6*L; M?=TP&GUB&-; -"SK'\U*^XF*+#JO_(HF2ETZ70YO1:+K$<.DX$RLL!PA ,7! MXX!7:[&L M3,3YPC6]53/D]9?EFK+V6DZ/W71<="']^G&.=5/5 N#L^ *$@>&A\_B$NHB= MR%:^H-ON7>?NJMOYCKIWM_>//SI/W?N[M9U:]P?&RE1S<=#H@CI!RL)^%XR' M>?DZQWG'UP9+U19,&SS>]'[<7 /JKFJH->C^_];K7W!(^S@DR;V<(X*8W<5YNU9JN5N]P73Q5//=A3C486@^*=*ZCJK$W@ M:KVZ:^N)7$79=DT'5Q>Q3??4V&9/L;AZOZM8M!QZ5ZM[:<2GVQ K/OS(#O*] MU_AO=5?<37=Y3-V\'1 ZL!'JQV"G."MBNY4^8-NJVB[OR[S"8SM\#\U389GT M=.B9,\TC"3%\:?%.BS?8=P'BP09B/'5T=4PS&D4.]3EXQQ@;BL/[(A>&]B#> M5QLWP4:?:!OL33V'3YT3GKS5JFFU^:JH9V&^+H6Z-A^LX%M+QPT;SF>_G9$7 MN>'Y[%?@=V, _P"3 (KM]_C7R"6Q'$OZ/:K[M\\_E3XX+("3L0V.?KR.CJH< M=W14]>5FJ06=3%RO%?.AF4,<.=Z?:'DZ5$PQL/VAXFQ[+R>CKCJUOX%+M^J[ MJ"JT[R(WAX(%Z_% A8+U-K%>_=!']E65=:AJJ9*N+0^9$MRY3U?[4[+L,GB&_: 3L3 MY8TI[6PJ6SJY ? [Y+&T;8:8=!F0KR,?0/$ J_*L..#!+M['L+Y)P&^MXO!6 MI:W7.9H#?_)4L-L430'A'/AL5??:#3-3UC#9W[ 3D34\EE'%&I6V"FZB+'A0 M\*" L("P@+" \+E .(NFWL;9/:2B!G.<.T6=4ZDD>W>=NHU\Q(,R.9-'.>>4[2R'Z\FP5.WCN*GI:$S<@'6(A ]!N/ZTYDG&;$143$"X[! ^6H:0 MAD&^4;%Q-2:9UU0S*49=$O:$1PH8"P@+" L(#PB4+X6#G"?%1UG4-5 M?5990M9EC3EILS9FCA?LYJ25-J(A8D8"P@+" L("P@+" L("PL>K75"W3(\P M.VVAVVS6S:J* H7#2V#9Q=A#*:/)%&6>5 M/0.D(9NA4&3*1&Q(0%A 6$!80%A ^'0@G,E#T#X.TH.U,+/W,MMYK4I;561) M;[8X"L"?//X%A_'$81NR8/LQF,$C@Q4P,B!]-B^M5Z[M%]LBKA50W#O8)Q;Z M]-M'5/- ?);S_)!ZNG>W'[3/G[XS?=9U\NHIXG$FR-%':*+]J$)OKP] MMO.$3#E%P"KS-(\A=KI>]B%V@JFYHF#!U/LQ]<''X^GTE)#4E!7)D,L\'H\/ MOA>6;!ZC];1CC=;3&SF,UN.#\H3&$1HGEW%'R\QWL'%'>C.?H7V" [DB-\&! M^]E\!Q\'J+?H**5FW9":K>7FML+F$WPO^+X(S7N\08.Z 8:OW) 4=;ET3NA= MP7^GPG^9V._@(PSK,M6[NJ9*K=;R@$^A=_/+I5IV,';PA,)W97A&W+G_G0(% MA=\I4%#XG0(%A=\I4%#XG0(%A=\I4%#XG0(%A=\I4%#XG0(%A=\I4%#XG0(% MA=\I4%#XG0(%A=\I4%#XG0P%%R'N.Z2=''V9Z]J01.+K^CC\,O8"FR8#+GWB MX-!^(5]>;2L/25 MRU(*F'X]L%WLFC9V8.WPQ0BV$]06SQJMAD-C$0[_C(+0'DP20+2_]OV+]@Z/ M*125B$2P DV1!3156O 4ULIVM1<,* X& M!P-@O Z+F)[/IBY<1D!Q/KT+EH.Y60L:^C1K^9?-J&Q6VD]4\M"IXUG2 M*7%X*[I>CQ@FS&:RB*7Z "@.'@?D,OWC2RH,;9=MC?WH2_+\1(#1?J'O,GWL MA?'E&?74Y)B"$DV6O#FY7&.74JF\<$UOU0QY_66YIJR]EM-C-QW[7,BB?IPJ MW51] #@[OM1A8'CH/#ZA+F(GJY4OZ+9[U[F[ZG:^H^[=[?WCC\Y3]_YN;=SN/W9O>6K'!B_Z[FIH(5_,F0F]J&#!!B(,ANG6\UP!]^IE:%Y^YW]NG MKHM^]GY#V+60[8)MY$7P."M8O_)%(Z5,@KNIU PM?\&MJ#6YM?ZG'SWVXVNZ MW#C,8K4\M$Q&11(C,6\JWZ<8:;HG8YL]Q5Q:S*Y65Z(]@<%&T ^X;QB@&Q!1 M%O,N%EHD+"N,G/N,:-WGBQW:)+@\%KGD2ED+#SE2V],BY=AL=@3:IWW0UK7D M1>YU^UKR53O$;YFWOU;ZXKM#VQ8:DJ\OG[H_9FFR*BX^$P:97 MOA*0B2:%CT1 O#9/0W(M/ /FF[1#DSE0? M?$\_F=2L&?L>[+G5.SFU3> MUI(Z>QK;()4/3F.-2KLI-1O+S:Z+H[&SLI)9?X!J'\?5:2.*Q%A8FUZPHVP^ M"VMF@VQFG?V^4:A>S0$U,W?05F,@@A69(_M%&,;'%<$YD5(+2*DA&8K!$2F= ME2E,@XL(AZ%O]Z.XGB7T$&$M6="(A$./5L>\D#B0%:!/M)@8U9?Z&@G39:T( M7M-X:A;;O?6]4=P$YP<#>'<&[\S\9-"N.*T5HP2$<7PR%+8DF8])80VYTE8E M>46O,V$:'V<L2,?):* M^>GZ!#;\)[$H+N+TW#*CT$ED*]K "Q/Y9,AH6T&<@8PR"F.5JGNUQ9,C5KHS MDJ>VX-/R3ZZ&V'V&I]GN?%:A9^M2Q<=]V1(;\= R4I+BNA>X0)W'Y)J M5-J*WI1D(X>902*4EY$L'GPRQK:%2%RE$$BL&M@B ^+[Q)H6">,W$OLZ7C@D M/C(CN.J&^]0IG8?ELB$9OLQ("3ZN$P0DQ2,=U[JG@&?%)=DYK%EIZZHD*\LI MF4)L&6$@%RZO#T)F+593VFPM.V/"9#Y:Q&*,)]3?D6C_+3\B\Y)]09@G]\V$ M^GE9VOM)\RBO,=2EX7'-A\$IWT>'A+X?YO\ M#(C5=:S%6XK7ZN-+GY+/:A:%)EIPP; MC;PJ10Y+DCG9]7Q8\]LUF8E+JW(\C)U/LZ)#)J&+Z5=3#F?O(?+-(9A^K/C/==>@2(Z;^N]Q=K"TH8^#"N6N&V+WV:91CYUBULUZI:W(4DM;CG.(8-I) M4%166;PW135H/;2F+ \$%\GL0Q/&MRB [^AAPIG(33+:8"BSD!J.L6P)PS@W M&9Q"G01W)+P?4-\UN6)E9AYZK%O6)&5%=$S8QB=!75GE<9[414]Z&Q(LF@_B M.B_K>#YF(8YS']@JWOEL;9.=WFZL.,XE[.&3H*7L]O#.M-22*VU=4@U.?*NS M,H4?? ]6;R7Y _)FA_D*WM(:*WG*W03&M+5!#VC_!P[IL=I)Q[6N/,G# :HH@2\>*]+>-;SY]G MLFM8V N;Q]MU@]"/Z#W=-,6^>QU%2Z.%F769$WM'V,X%V6B MG3);USR+\6E=9A2PHU$KRW+VL:9/J?+M( 7V:VK@\N FF@C46Y*Q5^1#E&2> M&&%NVU[I@(39J+3K+:DEYU#2(>HRP@B( Z",L] M>Z.11Y?CF;]80EH$W7((NG43"-\/KAA\6%10,+0(6ST')I>\?3'F.(/WF A;_;X7#H.10JMYZ_KB?_,@,9P$#J/B7P(E3& M,2%M&2K+@9 ,&1RDY=D-90Z"E4,"ISBD\K6?5EZ"H=L'IR@I=G>I[TM%,/P9 M@&/LG^&(R0/(7V"/JRELK^9!FY[XG]RFGNGND0=#H>D,U1"EF.4AMOQ%=!ZT M]F%^VA#YZ:*I9C%NT?=\WWN%3,!IH,'+[Y[[O,3\4>T1W]F(4US MSG)=DE<4-8N.G"=#5SN%-_:B*]K_6.:,K,[*O'XDXU@#+PA@T6QS9^$[!6BP M)VO05'%KM<@5EO%)4-(&<9L;)37B3A"\$-)9&;W7-DW5NU8<1#XOD_80,>'[ MP12BF?F@66DW9:EN<')H6IBO!86#]Z&A5J7=T"6=ETX.9]>L,BV*7%43(QI5 M%E4:F4<;^S Q+$Z MJ;E7EQ'AG)P8;6^K<3BG;;W2;C2D MNKY/7%0X.#E-@5^G?! .49\\VZY+@UZT(SNCB_/**&1A3OWC8/!Q[3TZT%9M M2JT5^D/4SYP,R:D;$A#'I;D&T%Q3DYK[GQXJ<<*"-Q%.Z"#$=<+[@(86;T#Z M[4![/QE9HO$D2IH@2N35/6UYG-V4DP\DV%&PXY0=N5+M]%BPW)241CG&^YV4 MW[:Z9T83ECG@0>@ MDCN2/:)G5-K-AM34EP\LE[X9B6"*TV2*S?/(]V0*A9[@UR1=6PYSE_X *,_T MW04L^V#YKBR WSM>R-MNM^?F53L\&6[>J.)BFMB5E6G/ %TRZGNS,G_1=,$1 MI\D1&_7;?ARA@L4G*9K.$4.<@4MWBVT?O6 G8HX^9J,=N]PXD?8X]R5% QX3@RX1D$?AP'U2MN0ZBNZ;W/)?V?@ MM:9MIVQX(NCU:+3C,-_2UKWD>7@[X9][GW)0\F&.C1(6F@-Y)X:XDIF/ZI5V M7=)$P\]3);0-7M3Q"(W-7S>:G!#:&;A:?WB>]6H[#CWB-S=X_;P:%>7D4*2P M3,V5Z\@'.*PN-,_,&;3+AB[I2EZV#$<.@R"N+8SE@Q)7/%M=;>U=1GV\'(YE M!V,'3^ABR*P[CVV^%]4TY)H,B \4B-(^6GLT""FM>963RDAAF?30N>_# MQE@A$YU#.&=B9>C)JRE&;CUYA=%>)J/]W3&Y/>AKL\I093I"I57?9[!9B2WU MHF3O8F9D8X_^G3LVE8]U\CP\33GG6S(488Y)UK12?R2F]^S"2JUI4_7,W+2V M6W_IC7M16%:>N'X>,:/C\XZZOR82I6>93^*QX5V J?FHT?:EUHOE[/%FEG(J M9WD0*$_(<"UL#M#%]LE+HB.I "+!'[X79#=NV5P&7=*;>T?;[%*OF3S->T7 M\N75ML)ABJ^Y7R4;D6<_P7U8=A2N_\D(^\^VRS;97.15D]""R[R)4)$W4:'* M#@L2@L(A 8O$]$;P_@DM$72]$-X0>NQ*Y.+(LNFX4:!)B[A!_!?#$IM"FO0_ MQ@ZL';Y@E%A;=*=7PZ&Q"(=_1D%H#R8)(-I?^_Y%>X?'% K.UKLPPMR_=/&4 MOVS3&!AX8.FZ,E!TK-6-OFX8C3XQ#&M@&I;U#[5>27\T]-,=C/$SJ?9]@G]5 M\0 V>(F=5SP)*A>+8 &8) LR#%CQ%M3(=K86#2L .!@<#(#Q.D P>;&KBZ_6(8<)L)HN8] 2@ M.'@V%\>48]-3FFH,1'2]Z<7*ZQ M2^]407Q-;]4,>?UEN::LO9;38S>XEAD]2$#+\05+/+&N\_B$NHCE*)0OZ+9[ MU[F[ZG:^H^[=[?WCC\Y3]_YNBW/<'^QWI2HM;L-=T"1(6=C2"DW^$?]HA>B% MI3/Y3"\\WO1^W%P#LJYJJ'-WC7H_O_6ZU]W.8_>FMU86\++XNWESX&IJ!%S- M&P&W4R.@-S4"N-_8IY^I;?-Y>:U;ZNI690LIGK!=E1BR:^0 D8]HD M>((??G,\\]?,ZZA7DNQ,1*Q.F'Q''TO 0QE3NO$C0OM;C "^$ZI2Y]Z 9J] MZ3M2[R59[SNM"]>2U\73FZ?+H*]>HJ$( QWM M[9@<>\6/)/@! K;KFC7TR4_K2$ :#XE/; !SP*P"5?[R2M@?RAQ^Y=<_(P ;1A=@R/\BGT"E.Z/$SN8Q1+BR3<_L&\.D6(8 M.ET%1LDP>Y2XDBS435^1;.$/WXO&-?0TA/\^#Q$L!051/[ M&_O K1)Z)<@B M-*\H(0!;-,!F2!O74$("[/PB(6MA-V8S(M-GPX^?78]2&;TM! .P27$/WL/[9,MFMXR1% XN!=0-#,]T(D.H "?E 35@"F>4^8P FD0!^ M8)\'],M;GTXPE= 5K ['.X&]_729W\TT:E"#V_\)FX9%AK[=CZ8\%F 'J"VP MJ9)^]]JEATCH#^+#HB>S5\[=\U^P-,L;P1I?[?!/<';@\=+\VO^* :_)*B6J M\^,[[CP??%&VF-XK 0560W\'M#F!EX $/J">-P@9+3%2Z1'_Q38)^I207P_C MWI3V^DGX:N46V&N27.0-M0!]-"?H8"$8=(;%Z[9\.W0@]W6RB=]GM['AG8*!Z$A!N[I$^("H,D8 M^S%YT@?[%B5#! 0W1#]KO1IZ)BZ0C.-,Z&4RIH_$,]4^!D8S[3&E^)1TV*_^ MZ'0>IO1#98--[4I[-+>&(?F?!(7M*+^!$VWS[9-,>408+B543G0(NS)WMAVZ5/A M14 A^)E=EMB[76("'U#["EN4]-@/030/;1#UK&(FH"CQ7(=98"Y=H0,+ G P M&0BD,8+[9PA/-C:51PO4M))8 7CV%Q VS[SB3& 0DB)PQFP(GQ&[:7T84G$FYI40'WS)$NME(X+/H(#9@Q3%_#T5$+\%_I$KR>,/OUV01#11:34 M (]<(@;M7:S\O<^2R>5Z)"\$O!8Z%IV&&VG6YN\ B2L@'=!/_EIOH[G"XVDN MNU[K";6HN$J\7Y34Q"P7\I6 L[K+BG#.EP6CQ[6P3\,M%G-UPWG=TNE-=0MZ M JENHH;GLAL,@%AST@?0> =LC#:I2/@U?ND0 M[$30%/"^F&'!4PACBY599Y[C@.!-ZI_2!T]_O%#:21<)]EV?KHM9IDPY6: E M_9'-;$$JT%^3[]?F90/R3 7&AW46W;O;I8. $15G]X/[6"&YS[WX.8M962 > MDV9F7X$.0"E-D[+RC$=;E7;XZBUE9%--![22K'"JKBE\*5@2MP7 MM+;@=^9 M\$T*1'#N: 08=L4L=-"#U &8S.R9Z=,>YYYV!2^;DF)J-U$+.[83IB;]S-Z8 MF>?,(P@2CP#D[WL[GMG4XWB>HA^L]!EB=VS]TF#G,2^PW"[M>@F60*SHD\ F M=:.8X0#/@7=9D9FJ^@2,/AY/JGU,U=_4#05#D-K]YI2WIF:<93%I!*L']#!$ M4^[V9L7D !R*HB!U/U[L(#')@+9B70' 2=M:F0NW 0*#3,^'-(,#2:U?F)N]]QGCY%4XB/%/CBUH%RVD01;]$0Z< [8 MC3A8\*%F-TRWZ83SARO,@6* MRAQG7(O('(O,L<@<\Y Y%CECD3/.-6>\*:FHKDPJ:I7UOVFN3$0V62*2>[_V M(X5\;0?X^=DGL24_+=.B*@(?!46AC?Z5&H;'A(P-X7V[$\M?&NV_S@NG#B#4NK,)/[?,PL?L%BL%\'ZK.#S M)=HV'%DF"Z*IU PM?PM"46MR:_U//WKLQ]=TN7&8Q6K;/O84.D9L/ -O;&/1 MQ!J&IZ$N3RR,_B,.H]_0Z "KCYZ&RY$F2UM8<<7"?NXDS;8E_WQCA8;OMYF> MLW&W9P4R]>"$6B#QRB)M,& MXG6I9? T7$7K8/(#![^" M6>'T>;4@S\3,:O',3/O[&*JD-_;N3BK:&7),:1LFLQ^#TC2@-*TEU1MY]8H0 M:N/T6C ^>;2,:\NXPT(#QDV0.,L>.6J7= '&GU5NE&'=__/%4 M@@M/G0OKQ7,AG:W3;$F*G)>O6@07GH YPK,7NSKW<>6-^JSF_R;RO3&14">P M\=QQX/B<<8"VR8+L[+CP]XP3H$61'.%UGR+(&RO.1O&*LP'>NM*26AI/4VM$ M;YJ5M@(&IZSE-998F)4E-2M%_7B:_!T6H.G MZE*C:90X/BNR)((+=^?"XBOZ=*725AL-"0S>$G/A"1@F/+NSJ[,D?SA>GW7U M6SR5RW\>0^1"RF\*OT^+9+)T3U^3GJB^++YH5EIUM2JR'2)?S[B 5$)6(5LK['[X%BDGQ9PZM! M<^+QV-6;SB3?BB^^TQN5MM'0)%E;MI,/,A)K.RU1GE"P2,@( ;"[ "B^BE!O M5MHM79=T71,"X*2LKO26%*[UN%4FUVD.7I[!+5)/V91>.8QOIZK5;>/'Y58> MQ5>MZK1J53,DM:677WEP9",*(I\2>?$%L[J1E&;7E\\G"2(_)959OIH8%GW* M&H%,K.2DY;D&5&!Y$6V@SBSEL_0_\X3,R1O%%NW499*^DR*JDJ666OCG2 M5\'9*2%O]9,=2CS!Z6#/4 M,QEN&4^A[6.'WK!^J!6?^YZ-5;;IJ'DV6?E/.HZ4COU=-\V4P2:>^$W\$1OU M^\$$81IZ"N"7 1W\^P4]$Y?X=(0PG0$,+_5,,_*#V1!O>(@;# @;4>O;P2\* MY@LV[1Z>[SE+8UOIT%8T]FPW9%/G 30U.K-[=D,RV/N#>;'IP%HV%WGZ_O2% M\2RE_\?>FS:WC62)HG\%H9Z>L2,@%L$==HRRYZ\ZG#A!(BFB# M N+9/:OO^><3"PDP 4D*(%DOONF6B;!1.;)LZ\",CB\%H?'\ C3NS9 M# <,\SEHR?'M_,CG[/AB'#9./Z7)3PA.OGTO'NN:;BX>_V0$@6?:-/N)EC,= M+[)P@BY^D@YKI4&XR87RX;-S)3->UZ(!R18;B\OTT\':_$IQ&JSX1SQ>/1VT M#$\S^VD3JN#K7"]4YBQ,D:!!L^$*EJ+AU3'DZ.8,ZXFO.<[,MTVW"?AC.@ / M&BJ-9Z33^,R*GVXHJZC79V(J+;YF^6?3%YN*+^G3"1WX&?;<931 O+SS2&2 MVIZ%BZZ=-]=KQ5J3/[7>/D'LC[!,C.#Z//SO:W(3^9[QXI1Z^(* MQ";0@N$O2TB\@/6;:A]H4^V+JS$0'^TJ6-X6'R^=CKRV/*)F_ #P0 E ?-&@ M>IPCSR<\ A::WA3N$"<\-O88\E>DGJ)6&@Y=Z[,MAL&O&/F'N93;CORKCR3> M8@I@3MU8'N]W@L/]VMV&IK56?GT^P_V.9;-T89VMECW&05MES,MR9ZK?!+?% MF8,XA7#+,7@[# <["H#\/0(!+F%!L/C 91"8+PRT>Y"VJ'3D9W$?&7FOZB4K M!*^!*DBNCV>1"_@8!^<=[GTGE6A3+ *&IC!AN#V+JI**X(>=RR\CL!X=1$('O-KF0M&VJ^5GH3]^ P?9RB MJ;::*2/6AEJB0R#6 !!+4[L%J5FG@UBGQ;&_^6QF@/W+?LV8&[!,VXN8 M=1>:^[(>"@E7VUU\HE;IZ,R M2]S:4/MQ&-SJ-0FWFOT3]%><*.^.A5IH_%J0:!D.7HE4.SYQOW6PKRZ%M\>Y MQDGI1QOB2HY(:;'S0^)>BT6=[!IGP*%NEK+BSM2%]*:,8M3?4)A5I!@EF6@[ MVOH]#=2B3D_M:WF]Z.TIV/D2K?H;2G(.@E8M[" P '4[/\3N)-#JM+FU\B;6 MKS-JP=MS\QWE9=C9^H[*,9P-_=77,IP]+/PV\)R6IG;T?7A.C:U[B5G]#1W( M#X59'< L35>U0;Y;[$E@UFGS;>5-UF.T7J*=&^\BH M]"TNP,2B-^71\ZQ X>6<3S920%+AV%!N-Q;I!>QQ"DBGKMU54G[(*ST7J@RQ M>NS)\+%^C]=:TCZI-)&/:>1E=YB<#4L$RAO6>&S CT=&R (U+6M3E;'/&#_. M6_&B,/)=+)Z%L_*Z4:KP2:H?18&@[2\/@@2B0+9LNY$ABNISGV301]Q9!\MT M9EY E6'OJ/X/-IQ6Y_QUL49*U/8TTY\8H\!SHG#U3U;C*4]=?R4TU9I+X,O\ M=Y)TU;@()V689FQ^-* M@)%S-V[@3G\S:K,79>*CNO$7V]3'NC&V.AUMK'6,=EN2F5L0-.H>V#-X=]^,ZZVX:6K+^9H*N,Z@X;>7/WUKO5;)9:MML #KN7E MF00/=0V_/RBWRG_^9=#2M/?*I]N[X=WU[?"SOW+\.'VZ]W^]5V%6J5 MKW?@VY!-%6V3_E5,.>U7X>Y%3 24D(_W7S[>P#5=-Y3AW8UR_^/#_>W-[?#[ M[(+!OV_[9(^"ZI*[&9U^J"1;GZV_YEZSCJN!,5KJ'\@;TQ0.M]1$4W5>VH MVP;^@NO!J @J#'9NH^!)NXKPQB.D))N@(MJAFFB-J-PR..24D&1D(-X K+ ! M@VLX\\ .XD8I$SO !A+ =$CW!E46M-6&\M_>,VBZOIK10Y,WJZB0\SY0<0.+ M^25O&9'HK:HR,6!?Z>K.7!DQ.*WM@J;[9T3) 7 V\TT":"&(X:%UT,PB$^0 M;>]AB*\,4 9X%QAJ,(*?3;T [<>?#-ZU2IF'UV#SAP0V"ZH_-SZXLLT[1'#% M7VCU*AH:R=L6UQV!IH(X,K9_,:MQ=,;:'XP;&IL,IA1'32.8*&D?G=BF27'M M"8DV0])YO[[(+U"^-8&E$&&B%A@A\D.R# T>"T!HC 9E1,6Q._ (SWZQI3W M^X&=1B9+[3X#)> <+5E^+.I/Q,_"F^3P)7@KD=&<(VN\J2?#B5C<+R<^48QL M2#?Y!D$-N 3^W"+@C SHQ-OP@J*9M43RHH<0;9:W@B'608@/BK3GD^,\!K3H MFH,D:@NS,W9#,+%KO&Y\C'B3Z**#+8G\XGTNW"F!E.^14"V^WH!?ISC2YMTG MY\3] RK"I^(:X2GL08,7NW 7<.W'2)4S S5">X8'L=T$-9$-P6T_HWLEB&+^ M'\1>@C44#'9)Z-NC"#X)$F8V%^V@TDL/F.,L-M(:,<=[5ESVZ(6\/X\#*W%/ M5:#88]P+L?R9S]@O^(JW>HD[PR2-K;+O_R\E*PMSM(8W*OK_Q.<3W!_;>%'S M'^RU)0@FLS!@V<0&='K.\(\$I0H%GH*=CQZ+B'7*PHEG'2?R&$[@";Z>-E!" M=N/!96S $V!PSX@#1I#VA\HXGP+"3+P#%WWU3MH[:D:N=]'^B?-5PCOB&W$3 MKZ094RQ-Z29YK[C@-K@HBG',L.@AA%P 8;":%=(R8S1\%>>2C]YU0'GZ'G^*WN.L80_C3_ Y3 MKAH 4:"6ELA[E.OE4ZJR&8J08GF !)B\48@Z;525<#X\*OYG'FO$Z M-2BYR' "+(ENTU"0A:R\S9@G\9-33[]8-\&7H3 V9O-+?FK<$GU];+2PSH4X M3%4N!*K ,<&&+6IGQQQ&NL7QMRIS,O M,5.I6&8A=T7"!(.T@/F]SOLU>$P0BEV#1&,D>[I-5\GQCSMOOD :NBC[7W M12MD^ 28U.S)B#'(XRI/*HP3'@2GMD/B;,\!2 D1/!,-23-]'A>#7/@OL1W. MP6W$'H!X,/-<*P!Y (N$P,D3U2VQ7K(<#KOY.4R@/.KD#04;U06P@15$;EC> MC#@^FVL/,F!-BQ=(*XVA9"64'R[9]W&@1GP*$ M658ZUH;,7I\'%;O5MFN@B/TA/X.)QH0L_N8YMCG/-TG$;@P"!,P:AN(S7&>Q M=2*M%0OV7$C^V/CX*OSR M)Y"*!*FA@N(H$V8X\ _;15O:C[64J> QBLE\:K&)]B] #=1$- QG$QL#WS?T M:NR2BE-R,XP"59>%?KC>C!Q80%5T+B$EDC:2O'_SDP%G PZ>MFPFQQTQ45B! M=YE%*TQD*Y#"RUO<+O0R%OY.#L',KE!^Q,NEML 8E+%X0CSO,.MAG)V4XEAM M3'>ZZ(TCDQ"D"? T-@TX,X]CVER!Y/JCT(J1Q2_U<5XP4.)6SW'J09!STN09 MAO)U$;3IB@#V_RB35;68']Q=3JI*WD.$2/^Y==$9N5T:52\E^-[%5:O5R$^D M58#.'-QES%[#"28K3&&7$V"LU,@XZ03(:Y_:357!]G<$U5*GU5_JM'TX;;O2 MT[;VZ6=[3UCI6]^X??6'\*MS[ISN>E#OSK7%@NE;TC8:81H?[2##'K9D\T?I MSA%]V1/$3 ,\L:8?&^?YMN)K!%:V57[B7..>U#BD4S "0#2'S_H=LKJE'62: MA8_FPK]FQ&H2_@@X=T=S9,EQX;MX(%\6;>&(0L*ND3V\$X;%+)H_I&-X K?7>)#KW7,UEMN>>?_6]+JYG&4 M[XQBC^[CC1V8CH^L2$*SL-6,9#2T'XFGAC$7F6,KDY5CN > "+S:#*U,"PC4MT?,HA@F\'ZE%>_)S++\U!,0)"P_ M]DQ;\:2T3W J16M>_D_BAQG;B#(\G,3]@S@&9-$1"A:SN._#7_,OX-6+=C.\D%3MPT:5H%QJ'3X(") #)2^/,L,C'9K7!6(<]XC:&: M'1XH+I@=8V[4M8B>\/ 16UP;IU!G$FXP< ^FGG$FK@'A^(08ESA GRS",@Q M%>M9TT?X2^+[2Y>=,,,2"8\!=X^H >0."()!&-"H)>([!%CBA+JWUQ"" \4 MQQ7#%+X0/(%+2>(8Q\%/N=LA\5/%CBOJFLTQB05ALMH;CH%O505$(+H#>3X= M&6686@,+AG.1$(>A8_BM8'J/ #F.A/A+[G44CR\\ES2)HQV0&\YE-G6-P_0C MGU'J4!+=X=WCXJ3&(F[K GY:GIA^=CW!.'(:=[D!X4#^QR_&3WC# GO*+R9< ME/$^^,LQ73T6XGMY]\T)LR*'?1TO:QP9+>'#7'R9USWZ.2WC&,@,:8&C#T\> M%>D5 47C,,'#=FPC'B&:XXOX07I-G-/Q##8$'7<5Q'>WVYB[(_="]+6&WJ[> M"W%4P^1HL^UMERWP'-1T7O9FU\[*;A'Z<8X+>Z PZQ<>9OV(:A0-45L<,;?9 M$_2ZL"\S_^HH;F7+&7:53!<['9"U#HZHKXC\M6HQ4WP%=ZDN@1J#4!-.=2K? MT6%2Y5V,2,U[A59&J]T[2]Y7.;GLI">7]3>,]A/9L9_ 7"_J@?8Q+J<>BGSY M!^-7V29H_=;%E=YKJ\UV/J7MZ#OH2[HY4;K9,/'O)>BF?7$UZ'343J==>[HY M 4%_?,UW[[UQ^"PJ8@WEGKO SZM->BF2WC!I[R5(&ON!MG6U-=A[4%&-6UQ+ M3-LP>N\E,*V+#02[ZJ!;_UE\)R \CJ_7[8,7&DY9!6([/]AIZKE;GOUDF-B& MX0\OP<-ZP,-4K=E2V_M/%"UUBS4W*B49G@\9;IAY^!)DV+^XTKM-M:57-5WS M-8BPMDI&_$B,(5UB!:\P=J::2%GM=UA;1#@-;;,X['7#9CXS14H-Y:MED\;* M!<*.+B$;K--H?&=C")3TS;*CKAR>A4_0U#RK/<"OYV&/XQ=*UAAFF5 MUJ(&F'^A=C6]]OZ8TC)P6+IMSQN3?+00:^C MG7Q7AH0'&T8#'X*$X9U7+:#@9NW#UG*DXNZ(M<$_?!#$PIG3JJ[)? AIV!6@ M;Q:UL&ZGH/PL+MSBK87B>C?^H#Y29$KMC MUH:YO ?!+!SWW%&[^MYB1%H8IVAAR,P(&9+=)S/B(#RK@\Q[D'D/IZE+KB[W+>H4(M,=ZO'D&7C% M9+K#V8=Q-Z0[)'VI^+R*SUX0E%:5>J JZ4VUHYV@NT[2Q8G2Q0:;H@JZZ -= M=%MJ=_]@J'0V'K>"*-,97B"=H0J2'0#):FJK.ZA]E%FF+QPL?:$*1-(OKEK8 MOJ&JVC7)^D_*,"L79]K:%72Z6NBYN;P'&WHW5<"C].;%50?3+/;W<9>ZI)I; M=)+*SHC*-G1ZJH+*-% I^WVUV:RJ&8>,)%462:K0%7Z@2%+==EA;1#@-;;$X MDO0];DOO/O*Y#3O%CBH,2K[P&B> =,?GG;I.4J1I"LA>K2%/2UDZZ>:7@Q6= M\ORI]>Z'F\R/2;#C&I&CM%+4P@YE;;7=/T%'FZ2,$Z6,%9W]JJ4,;/S:4_5V M_0GC!*1RG57!?>N<9$G3+B(N"]^OXZ& [FT"W"'!5BM-UAVJ:&H/ZE_9+BN: M#B(A#H5872IH:K?JWU3XZ.1%_39\+$^>RZ2581#ZAJ.,;>8 91EC%LYQ$J<] MADUF1V(&R3#22C?9;;2VV.;[F<MD=DU?S+K\-_.](H3J7P#J#%I:ZWWM4>H$1.7QV:RWJTLI(M&$>R;Y(I*,VH>U?FR[-SU,,(F+&C&*$H6^/(C[! M//04]F=D@Z$T9>'$0\?E$Z ?#4R7N>_;BX( M@]_YN[I,E08Q3+"8H713$-^T8V6S+L)4V( D1^\[MANV\5 M!\4)NM6X!-E7=)R' KBMZ+AAHW#H6IR@[YD9^79HL^"'ZS,X\;^9A7? 4V#S MY-NZN.HU6[57 J4A<7CY4 */2LJ(-JHAK8$LIY6V1@$R?PTGS-_=I72T2MZ; M@T@#@N:=YWJ+)1"[N0DZ3#N9EJAB;,.E![3:K:H@H M!<%)&0L+5YQ+S7RVK7 2LY[,KP19-=.?&",@HBA< M_9,E=,H@C\F0:U2-*5IS*U316DO R_P7=T_YGJ8^UHVQU>EH8ZUCM+OZJ*/K MO1'3=6MLZI;USS:E>-*/)DD7@)GQR"Y'/C-^7AIC..$[PWDVYL'%;XMP :"( M'>DZ;'D+^-'1\M2W&H+C<240S-6# P3Y/H"S>UQFO -6S'R>M/LWHS9[428^ M"L6_;+Y*D$0/E!L )(HRD<=SC*M%-"E[,3S=(*$>DCX %,>8!>Q=_,?[F$G; M+AV-?O1>K"](KIO/DJ87\J]3[&DT.08)XUJ\67S=H*^61"G_KC-HZ,W57S<; MVLKO*EIV@T^@I.D/U_+RG(5.^FWX_4&Y52@957NO?+J]&]Y=WPX_*[=WG[Y^ M_S)\N/UZMT7KA#7G+51%7N_ J \JVL*1MM8PVJ\B$HJ8R,75]X_W7S[>P#5= M-Y3AW8UR_^/#_>W-[?#[[#O?GA&I%EP_Z7*T$V,>05FNLAU=1MS]1>J:?^;4&) M6[+LM&P&_7TTFSETB8;SP7#@9MG]A+'PUN4V& C"!_CI!\ MFQ-F10[[.L;L'A<;R%]'O@]_D^?*+5.NDK::#7L7$0H,H1,(>99&88 M,[+!T61 6C836C:SM#P2=Q+@G03TG1W@%[ 6_FP,NH7WC+UZWM!"7@1[M8*W M[[;19SA0CD9WZ6L-O5V][J*U&LW!ZI^N6W;]=YUF[S";;;^"HO6:+:EB9F#G M@RKE#L8E7)V.=L]F(*%'S%?:3?5O(_^WJU:SU2YQRBTZ6AT50/X>N6PU+,X@ ML^2[\:R@)\H'!:YT(ZRSC ZR: IXE"W;WYK,Q/']'<.Y'$!W@LRW@M(.J1E;7 M2.&7B%66TU:(6%U K'9'U=M5V9A2J]U^2!05N:[PM,JT59FV^I+""MA(:>;1 MN[C2NP.UU3[=-%.9;B[IMM:ZP"YTVP>ZU0=J4ZNJJ/\UZ;8@*6HY?V)=.+Y4 MPL0-&S/?QSD 01A<&S,[Y%7OWWPV,VQKZ%I4#,G[/=_8@>EX0>07)%)H@UPB MA'HQ;%B@>5I/K_A6HJ'"*^8/&UHTWB"(PV2RZP!F3503 KE*H]E M!//LU+@-YI? (ZH&+*W&Z3AHJZ/V-9D?(*GK+*EK@Y&T#W6UFD!=6D=M-O6C MH*XS\)G&0G>-UU1&;3<('BQQ$'!,7 BE24,#TN@/U(Z,^Y\R!JU@KI5@$,X( M[;35YJ!.O<7/P&XA]Y0R*S+DMS3ASSY(NT&CSS@ 12U5:>)H W'T-+77JW\/ M-!GL/Y3N6@$>=5!,ZZK>JE-O]S/04WELOY#);N,ME1%$&4%\.=>3:-.Y&+K: ME>-T+ZXZG8XZV%]RU2"P*!,")#G7B)RW\W552LX](.=V7VUJ>T_NJ $Y+^8) M+'=8V%BV7RI/X)N/S9##^3?'<.-^^3-L^Y#/!&CU92: S 0XNDP CM^J0AA. MJFV"XS+Z+Z/_I^U%2]%_EJ _B]%?58R0NEK*M 9N-S9-ENA/_SN[S!;IX7# M8-564U,'^VMR,E5 4EQ=#EVI^50IQ>F17,D^97P9# +66K M],$?!C*UYD(O8;;M4*37QM8Z[;:J#ZJ*WA]#+*T:@T[2L:3C@QB#N]!Q&^D8 M5-/]NQG5@(Y?,HB6=B?'?BO6#0WWT8;W\]#FBD;E[8Z,JLFHVI%% MU7AR;HKA"D=Q10;49$#MM"VZ&_;$')"YUF\FCO6=^9X5F:$2,G/BP@X>YS*6 M)CW[*P=S#M9K&!8K4XRYAWI7.X)Z(::]B[<8$X[97!YQS)26]^;+F M:P>G2G7 ?.WMW4NJU,T=D59^MJBHO3 JMA 5VVJO6W'OY[KP]>/3W2OUI!QM MZY121NX>#+PB([>#37K:;;7;W"?C6/;GJ3.2[76-(^SH#75WFH)0W:G=GX%49M13B[ )+SSO#90[*:2#9[JRY(B3K8O@2 MF'5'YJ"\GH(M7LO>P5;MXCB/9E?5=9ES(A&Q*D:^"R*V<"ZMJO>/ P_/ M0,'FG>R]K1C[E@XL69LO^USOTV.C8I:#U?F]MMKJGT*+:]FQ7E)RC2AY0Y>- MBBFY Y3<;:GMSM[:0PTH>9\^&]E7_2L*0GL\KQI7M.8F9&DALF1:&?!1-X@@ M@1V$BC<&U-A8LA#ZAL4(:U#E\%RXH.F,A;#:H\\8-F2!S\T5 7OL"C8S0O[0 M\\0V)\HSB]V$3/$ _@HH-@H#"$W)A1@%;!PYBF./&6X0O^3;5I5'YC+?<)RY M,F+A,V.NLK:7B=[9'ME_T%L_PTL74!Y@;KZS(O\9\"Q@;HKGW8NK\-E3YLSP M@V744$)OP\:ZA]M8[^)J;(]#!$[AYAK* ^B1 %/X/]>CN4@F@MUG@6U%H&<^ M&4X$R$?W")_#6> * I;1/,5]-!)2)DK ]^ Q;3N?6!&WEJ (U05)7Z* >J<-"FF,?V2[%F#XUF+[G7@M)<_-LE>Y=)/I6V#%G=L'Q>\NV/T@UR9H7?NBU^"A0Z '.*EI M.Z);+7 F$9,#C>ZH@](HM4[ #(!BC8<;SG0'D# M/PHG7@1[LH*W[Q;!O^[P1],_J3MH:)V6[)]T7)OM5-GL::6O3^L>9X>@APDH M/,H7>&X2*!]!QEC*0A#<&I;EL->J>N4P]B,M$)JL_2= M!3/;-W!ZL7(-*LD6[:X\-K!FLZEFRO9?L-;0R!M5;[T:*M?O2#B/]XJK7;ZI:07%%'<--)7E$ M>O[3%J;/]BUN6_F>\5(5/[ K!FT-):[R4V MG2XV;2@OK90]=6K(GL[ E_7)\^&?KF)&OL]<!,RO!<@?4HC_;MCNYQWJ^'K=BZN!JG4Z]6BI(?NV5%Y]E)/K M+X]C/:P553NM?4K<))+5&,ERXO[E<:Q_<=5NJ=V"QD-E?6)\1*>)Y8F@?]U,25?'+69_L08P<&B&F,XX3O#>3;FP<5OBW !H(@=Z3IL>0OX MT='*5)>-QP>K<^'[ 'KS?$*N=T >S,>G8#M&;?:B3'QD*W_9?)5@SM,P:S0I MKY$CD2?9N-JF0F/UQ1Q-U49GT-";U4^]+K%LM8.DX5I>GK/02;\-OS\HMPK% M'+7WRJ?;N^'=]>WPLW)[]^GK]R_#A]NO=_N-E"X4#Z]WX-N0314MGUF]*)V* M*:?]*B*AN'#O^\?[+Q]OX)JN&\KP[D:Y__'A_O;F=OC]]N/]2BY0E\W?>2$L MQFLVD7]9S V8A7^1XD$5G9]LUW!-VW"4^Q ^6 R6U?5@;WZX1F39L/^W11+[ M9*I&NQ55C=ZZ3XP'0O/UEGTM7RW:U_+5HND:N2KBK>I%^9H%;VIMJQN^;N'\ M'TR9&$],87]&=CA7[!0<6/,Y\^TG(!]GSFO<0>.W3?C'A#G(R*>P7QM)<6*$ M5&L=N6:6"&$5T)Q90.78HBP4"S) !S"C((!?8DWITBL!4#\9UR7$G@)F1CXM MQ$OSUS^!&\TN:9@FV#.X';"B%%*7N$N=_W3*PHEG-;91?6IU;U\!1 M7!BU-T"%!$@D@#,;6&)M871A;-@^+XF@!(^[,\!J:(\" MXO%# (Y\V70:K$[V\1B$F&QF@)&)I?TN8A)NGG>/XCD38?PFC^_;3.3$ HJ. M1)PEF+!\M?\1H,'=!GK(ML%82=M+Y(P7[T4AP-NP8,>*Q4 D@@U';TCOG\-\ MU<6$QJ^%6Z&>&GOZ^RR(G!"YU-CWIHHW@HMYHC<2.B\4Q*.)XXC<'.Y=X=B.ITHQ M'CX(;+AZ(\OJXFA> )-L8,@8GY#^8-WG0B"C6P.S^< %8= :P8<&+=!=):< MDU,S7CXR/'C*L4-R>- 7\&_DS?R#,>S=\_%(IA.A&L$/0'ME[+_@3(DR!=P2 MH !<-NZAPM\R!8%)WP/:.)[WDW]L!!-@!\8C QW3<91'PW8Y1C@>9_X+S!Z_ MV,S= 2<=( ^+'H_<^)]J@H>/+GT-UX/O4][@N][BJPH$G '_/^&]YXHKB?O/ MP8=,_)8ZT&W U2#1,6F1&>/&^1'RDX]Y*#UC*Y71')D[:0J8?@ 2PC2PX8,[ M!DX 9*HJ(^ 8KA>2*N1[3MKU)D:DA%W@4Q3)]FT TH/E\%Z-OXMR"+^#5F6 M_?6'^,(.Q$0T0L!T.!,A M(M@:"PN_,!8I.4UTLX[L3ZU,7Y*,EDN>GP)]N;5]?Y):H^MH'NLWQ 9-@.DC M5MX_4T.@<^I.TM<:>KMZ/]?Q-?QHOX)3[C5;>'PIP/_]W'#U:U.RT).$VFSD M^I+LW8[DJ #R]\AEJV%Q#CGSB64B>SS(NM>2,7=4EU('!%*NF@A9[%,6P%65O2X*3!+>AT/Q@!$>#;-5.2X[.J@FR9+51PP&MR26W MDZP_WS$MC-/*?>(4^X.[:[]S;^U-QEF;$-%PBLZ2TJ34O;CJZ6JOLH;U-4KA ME-BV92.0E\.V'F#;0.UWZH1M9V V? ML;^N13"@-"NA0;IMM=?;NY-B#>I)9!68).D:D?0:!]D!27I 8XM[:K?=/P&2 MEB5B>Y:(=5:7B,EJ+UGM):N]9+67K/:2U5ZRVNO%JKU6UQNU+G;* ;WFF>NW M;EZK+$X)'>2*I8XA)72QU(@H-5""B?>L& 7S[2@==W'&74&B^&ZYHLCVFRED_B.P%-2;%BG@1'M.%-/#S8R\/BO]""C MY5[SKI?*\-+:K",J.?H2AGO#\..JFBP)1SDNK'_I0B3VEJ:M;6?J.K'.K!C6&L%/> RKTMG)&G'WID=9<0R(Q. UG M?V+I ;%4,09,3"^# M2OK%55OMU4K";5#YX@P7V"Q;CWWRR<4GSR X\R/I[%G<+#37&506+I=6LN-R MTS02G5;YI_ OGAFZ5DW2FY6I2;**^641J]Q@VKS&O6(T[;8HED*JU\P/ ML9*CC>N*094HVH=C32W)FHX4L0XR,WMWQM2N$6.2FG9=-.WC\UI_\SU 1"O@ MXP[8+YMW'S];_W5)#2BG6Z]@--^,.>]KZ/DQQ#\!P!=,_CR3Z5QF>/]2U-5D)P(W?9JEWB>C$VD%ZAL\"K#0IWY7BE M2[PZ4KPJZ0;(*=TK%*0=,&QC\+_;;&+P?Z!WZ^&-E/CU6NKW8;!+JQ5VG8%+ M%JPG^* ]3 M<&\O^+O-ZL*,TB]29S3;H% >&LW:$LV.%,T.I%_NCW!;* 0X84L=:#7QV$ET M>RUU\T60K5LK9#L#+^:UX?MS[(-"HU3C]BC,M2IIC"*[X1\&,K7F/N5D7?]P M9;/=9J^JD7857MYQE*Q+RI64NX%R!X>DW/YA!BE+RI64*RE7/R3E#BJ>:2@I M5U*NI-S2X^!*TVUU0]]J0+A;#^XXB<;][>YVK=7++'M\[>7E9@^UV6Z5C?M7 MNV)/N!]^:Y=^^.?3DEJVF9=MYNL"0]EF7K:9EVWFZV8!GHV-IVG- UIY&B:/ MZFI+K]C(.PG_BZ2OLZ"O XYQZ,+B5[JJ]8ZC3:\D+TE>E9/7 :;Y&.FSR&PM M)XK6Q,NJZ\;;U3H75QTPJ?8.>,LTZ3HC4Q7#"];6=VBR9\]Y8-*A)Q=T-=FH MYQPP:8TN6*5XZ]=/O,F^/2?2M^>U=.K=.\Z75[:/MFM!)\]ZSO7-)^4?#5EH%PU9DOY6Z(E@E^OC!.%=+3LPX5L0JQ;ER^OF+ M\JV65BN^)57VUU'9Z[?A8WGR#'I/O4 /T[/PQ&RT?BKN-=EMR993YX%7+]L; MM]N2/::.%:]*&M7;#G,[2)?)%HXZ49NM?!Z/;"IU$OBUK>ES&.SJU@J[SJ#L M07:1DG7QKZHFK1GAOG< M-6[N.JTU>Y =K20E"LIMV+*/63_MU;_XJJK#@85 M5V-(PI6$*PGWD.W?6H.+J[XZJ+I*41*N)-QS)]SV(2M(6CH(W+[:[IY"P]6" M'E+B4'?1%.[)+-U3JE+4T)J;<*-%K558"/BPG.WF,]-[=.D3N.$XY).)]<#? MBKO8E<4 <[ZP28LR88ZE).NE\P^];M+]ITUO0$1!2LYRI1\URV&*SG*6? M/#.?*?^Q>ROS[DJO$\?S--C^Z>G.WC7@WDN0O]V\N&HV>CG,5^!6'?BCH=3B M+EKE[Z*UPUWHKWL7F/S0:*^^BZ5\3G@,MV^[$;6PYY2-:]FF/M:-L=7I:&.M M8[2[^JBCZ[T1TW5K;.J6]<].[^)J;8LY(E3!D"Y1FK[3!H4<@G]DPT6XX;M+ M?.C@/"/7NH5XQIO>6W[_^?_^;8$#YNEO:4*L[UF1&?YA^+[AAO,;.S !Z2.? M/<"//CB>^3.]L1;'(+@"9@U#\1DNR>!V9[!HZ$>,)MCCDHI8DU)SE[CRPM4N MW6SZ.ECZJMQI[LT)LR*'?1TOG>NS;8QL!]#X :FQX&SMY5,<@^2XGACN(R/N M@]S"B0])_.-9'!U@%H2!JCQ/;'.BV/BTZ43(2N!GAFG":2V%_9HQ-^!+>9&/ M<+;P ]2,79+:1@C_&(GF.<&$,5S3 )X#G&SL.8[W'"AO:"->!&>R@K?O%J]Y M)3P!>$?3RK&O-?3VZJ_/I^%@^T4:#NJGTF_P;R/_MZN%GH.RW> Z"*)Z*;NY ME059J1Z6IQ#5E,W<9+N._9PM&[*WEM3((:I+:,Z4<[JT,9FFK_:JGI5Q$OY0 M269G0&:KNN)43&>85H3A1/THZ.P,TM?C"^6&)EQ^XMHJ%LVGG:"WU]#';0@F M=;GQJ-SL'?82:9][L1_R0F( MKC^X"=7 9[Y47+@N,:8]-.O'=G;-*1 MY_:T5CVPZ0S473%R6S'%S&TE3(=N*T8Z=?N\U-XJ^>U]:+B6X5M#U_KX*Z20 M>#'1K)Y^GD:L&Z"?;Q=C$-4*3!YG".Q86$<7@XDK/)^O)<.5) M8,N&VH3RV*(#MLB6BZ]DF:B*RT)IG4CU:4?AD*A0'V)Q6UJ'ZC9I.'?S.*8' M2PM%DMC+5OM506(:)[%\(D\=24Q(X7@724R"APXJ5NBV6*.:>NX:[? ,U)S/ MGON8:CG[)!:?)H\]34ZZT9(=A;=N$/H1YCO'S<>'4X!/6)JEMC WLMWM5NC\ M.2+]1%)(?8Y6J?5>(86TD4(Z[;I1B'2"2K=6)4[0.X\7+@K/5DGJZ."8Q4Y! M4P#I)ST)A-K!3[H?0G41H?J]?'*U=*6^A(TA/:G2S;./A$%LBF/1I6F_QXT1 M3>UJLIN3I*^SI*\- GXON4EE4=1C( MG Q'V<*=B%P%5<"A:U&*^UH]MD0+*\!_Q&V[M0LL)K?67+4M*T MI.D7@*9UTA\ZFJJU3X&F=RZ=7 SI=K!\:^8%-C[PSF?8K>*)I55;?UVL MDQ-';:8_,49PL"A<_9/5I76\:.:5*NNT[M(V8\LLN1SXR?E\88 M-OO.<)Z->7#QV^(1X7QB<5V'MV\!"MIEF3+#\?A@5:5\'T ZGD]X\@XPG?GX M%&S'J,U>E(F/_.,OF^M^P52@*E"LE[Q&UD.=E8RENM2R%W,T%9.=04-O5E\Q M66+9+8L0MQ3U<"TOSR3HI-^&WQ^46^4__S)H:=I[Y=/MW?#N^G;X6;F]^_3U M^Y?AP^W7NQ(UAMLZV%_OP+P#5= M-Y3AW8UR_^/#_>W-[?#[[_/#-2++AOV_+1*^JQL%% R8@D_;=:OA+S[UM<_@S,HGPZ09 M3%N6Z->G!\%75\%B8JXBMW0^5DY5GK$W%N 2S8L"9#5PE!T@JP+*/ VDPT%W M/@M"PE>3 \%X]!DAJ_(&D1L9:ZOY_CM[\IPG#)$+6 WCQ^@![?U;%:=)\4@Z M\^'==CA1''R-'RA??GSZ7?GA(L9\,-R?JG+7&#;H!X8%FID=A#XIM?!R6%%5 M_N7!?N'7!FP16[$\XHI 60Q>X/U4_,AUZ1.*V2,XQ)OH0 Y#6P05"W$B&[L> MP^-_P$EGADE;H)-X_DSH,+278.Y:P.)YPT?<""U7N)?_OO]P3>LH/^Z'#*A5*UN>2=DGF;4;R@-*+80Q1U959K[W9!,R '; %?E@&-+$0X:X$:\E0#D6%(+0+3<\4EMHO0/" M.>=YAFO\.N9[C@GQB_'+GD9I2N^U ?<'GY<=6-AKHF7917UMY=!"@;(&GL/T MIE,[I'8>,SH:$(_M @R,@!'+7PV8T1R70&U"7)Q!MC .GH1_"(D!-V(('"T' MQ59S!12Q4/-'NN^OM.T'[U9L>A&LI<%''0Z;:\&G .*L/ J\8@0B;6NF?/$:%S7%S@H8"T^_8W: "8G::8G MP7S$HE.$Q([Q;OB;E#=(8VR,WHQX1M]JRGJ;3OT4^U)"VM@ES?]4ING61(O" M3;3*6720Y="X/2-43%!$#=C1,,/#O\<\/$_R7!?A(TN',]]V%*V/\D$;Q.P M?OR%6>HJ)KV&:]*[:7JAX/,SPP<20/;"0J]Q=&)TF%"M,U<5KUBH"UFZ(+I+0?7W0AB@;ABSB\R%NZ@R^D&X^$,D:C=A)K]'!N\) M/RR4TABY>RT!G9%L"T*:R[62DK?4&_AT3$$P"S2R'N*K28-39R$TUPK1H @[ M"N0JI3?Z M[X,5^RI$U((M15R>[+*SS?(*?EZ\#\1:?)T)MPJWX^- BR<&MC%.H>4#;6%% M_%-A!A"R"?H* $(9)_9S_#PG;A]G>/NQ. 0;9PJKTQL,^).P&_C&$_.!DRC$ M9/"DXXBD)?49 K:ZBY1??4;.*6FH60/$(VOC._(D1!Z@/^$[)"-;"O M' 890HP06KT&?ZJH0P%2RBXI^+=/8-6.Q&>/WZ_%+@/]S+U.9LZ0DO(UYZP=T\N ;=] .MI5WNUY[]Y"P M[..U%X%REUOO'7*G ]QI-;<.+#A4DM:DG,NWF\3EVUP-2#@ $3]7.M&29J2Y M34#\1<+U,2.=I_1A!CM8K-?):S^Q#4?I-PF%*V-=N_BLRVQ7P^UJ%;$O M^@J51OYXY$88DIRA]//54OYI(CK78E?8+U-S&LDBI.NUE> MQ1'-N?9VF_1;%U>#UEHEQW@"\X1N&)W*EF\\@Y7P[&8TP]67>'1:^A^,_!2) M&@=4:O&6]SS0 J::KSP93D3\)G4)V G'XV.)N0^0@GW >!&DG$A@/>"&GB6! P<")#(C)_96%FBJ!Z'I&!E!#L<2?B:\:',*5%C62D;Z1RI890A2;H)%'4EJ5+;0)69 MRI1/L,E_X!Y+DU\;R*^WGOS5EM MCMW4996WDF?**LZ4KV5MT-W \FPW6ODZM[_&X1Z7XI/[+75*Y,Y6^I %>4J?('-A\2;KR!E.&8X8*W%6T"T%:YN)6A%VS MC"N.MC:4U7&D57P@]B!DUR-E),H&@1T>'[!]5 -1RYE7$'GB3C&7A1C*-&$A MT 1\;XH!SH!/PA4W^LQP/P$'P\R8<]TTZ:!"Y@>^=;6C9$E)E240ZTH@>K($ M0I9 R!((60(A2R!D"42M*@5D"<1R"42[L 2B4[<2B&)-XT>BG6+H.\DE6*&J MDG5+IBGI@06I/6EF#[=4A6\"GT;UT!09@& C_\+!B6"_JED],Q#1Z_'8=C!7 M1:1&39G_B-8Q_LTS\ !^O@%B#C -7I]=H:&@!2UHXAA^\O-&"JA&!QG,=!EZQO.*D-"L]X4R#>>9$Q.L BA*)0C[#3 M%C H--Q'&S4Y(P@89@=9C*>D)!FK(6686?&OIUY #FO8"!B$/#5\\3+0Q -C MCF/SDE10^H\@1QC$INR/C95]GPB;)>1%=A<4<,-3\C.,^2 2!"L]0 MICS/9XJ<-#-.:Q$TX,HIQ8DGT8M]B* 8L0=*]EC>J0R"U"H(LCI\MS*$D/.! M8(S/R,4ORKHYV^O=]/R-],*R'K.!MD][C4IWTKJX*JYS6A,W (8I1+6UHB4N M9^28&BKPR%I"RI*NS.X+1$P&[8NK3E=K]"N-]?1>8N>@,W9ZK49^$,6J6,__ M1A[>"3"XG^3"LTU&.:@&SQ'EGW,F$8#2XQ@^*#_&" 49"LV1$9"*,HO@H3>? M@3$X2NOMHJ\OX2#IQ9?QY-65]Z[1Y^$6UN4&H::( **PS'0&\$3.1W*)W*Y\ M+GBL#@O?+CR_0VBTOQ[IJFS'D\'"+F^QM39:FDUXVB;%6%U5K #@R;+\1AZ; M"@*:N-/-CC8<0K#9FR;<'Y?HVWFG#6(O99 .WG+?#1\%WWTH+#>3T"^/\"S'QS/_)G>>2]OPPYZN!(#_)BAE>X#/[N* M5U)@*876RK=0!=Z(ZB85O@G4M41R%S=64,32^T1- M0/K[+ 4VE$] /[,(3.M /"ET?)+MMD.[S!^":UR YQ[EO'M^7#B!>>DBRKS7 MQI+(5OHCV@W*IH7?I/DH 5?NL3B0K\8-]*0@%G ,=\._1.X9U#KC876-PAK M9B&X+11(9Q?79Z4Z.F*H$2<"KL8$+M%6"B=^TVLMYWRSN"'0?7S;]VC%D\[Q M\1??XB??0SD5;^_K>)E)[=9+;M '%4KK@_C*1^@)>B7/J-?QC-@#4VNK6J] MQ4T*TB<@8KD%'0BWP#ISC-^+*6.@05PP8*@7T.5^'^+ M28!CSW&\9U#6;6["PQ:L0#@R,S\$J]QX^VY+OGA,T<.^UM#;U44A!_(=A::^CLDK'WQ-84QW4EH> M83/>3E\MZM=1-WDD9SSO@V4;M)K#8ED;L:R'#FR<@ MJX[/BEE5(K'CR.YUKOG3C6IN>_CCY'A18,4YW6M%ZA#RPJD**P9!EM MSI.Y50J:DV-]Y70)@:EYYM=K-JO1)JJ\K5P9K@5ICC)L;%"R$;BX3,8L=52O$!#^6-B.RS?4= .L@N8AHM- M,D8XFI=9/,N"VC:)QODX9_<9NQLX-GL2$]]@29NW,70PMY1ZNL1]+57JJ_]D M6Q$UYZ?V*8KQ^.@#XH9,Y;T2<#9Q"'##D0D6,/\@::@@&N8O-AHA,9/ M[+< 2*\\3SQGN=G"$6# 5SY+56E1QPE-I77_S_-_XNQY! KV_7QS M @P*;&"H\&]CR,1V[?NF9#I2'!<*\-17O7TB[-I\MFN>]HJM:#3N##.PME=D;TS8=0\+9RP3P M_ Y$=]]PXEF\39UE&X^N%]BB!.CP&%LAG_((1+;#Y'HRR$25[\'B4#" B>J^;SG)-@X M.#B7*V[B L9\!]JAC(0YQL(RI\2AL>P/DA.^R>3(<=O3'[*YOW9>3_).&:-LN]C\ ,G3)NI]!./S$+YPHHU[9O M1C;VAU>NN"'6?RB^9M"W$?PM)YX)8VO'4X MFS$XK_+!,WQ+>2-&]GU[&'Z(1_7%1Q _I0&]OF$Q[)JM?!V/X: )=-%2CS># M[@GV9 /IB*;ZMH7VJUA-&&C"-DW0)P#2$KUBT2R*#= H,^*!MX_E5\([S!KP M(B/P7#[WVP; V1//$Q<73RP!+,$FLQQ'XO,1<+G;XMFW 35=\K8'5&DB,'UY MY\D>XR-@8\$9M]A@VUF@MQL*V/1#N#U'3#Z-^_=;L;G-<6H%_( ?S%,\BP>> MA\L'B+>\:L) :(!>"$8XL)5@N>D^9>NP>= -B%D[/?;S[\PP3(HFUAQ*@)/,N8,A46?\*N\,*M=N*,:9@_D9!Q3$O_&R&N.LH?-ACY#!C9/9KM=+9KKP%O"ZWW0"0&'O+F M]EX9PO_]N!_2-M3E+VY8% ;FQ,'M_3X=_3?\$J@O+%A<%>XC_OT24+_ATM>& M,YS.&O"=/X,'_Y_M/WKPN#EQ ;$>;1QR1%N@&S)LGQ0AFO?[9*-3$MOQL3DC0J1,AI7$&VDR1GNN!)@UJXN$ ;):^RK<<,Q72\8#KT8@40$@^XFRC MWSGIPUSD?DY?KM\2 M%9.RS?5FE2/DOR+7Y-1.>C2"!Y@]OQXQVC=6^ 3.9^9P\2$?&:4#UW ]]Q+G M$OFV:!(S3Y1 FN06'W4-Q?+91!PUJ"]\!KJ%/"<#;HXW2WH%OSSJ6HZZ!%Q# M5HD MBBX1Z(/7!IS$HI!O[+(Q\ESNG"Q09/.08_D!-=F&A/T3S=,)0 M6G(>+U' @6DN&DN&+"W]H.B0($\C4O8"1LI>E@ECT[QXGEXQZ\;93<2N8J0M M> 4'!C $O!"?#Y@2@Z$XF&V4&!P$P^@15"1%XY&<3N-(M2P,1FD)<[QVBPJO(\8333AH;'+(1&XQ]A7W$%-+L0JXM(5?P- MS3=O'/*]I>&GH>W_ T43[@=^?&\:KEHZH MO7:?>-#4>THFR"56O !G[*_('X#T&!KSX7NP>7'+R+Q1[Z0(W.**R23Y>, C MZ!Q+2(^:G6!"H)?DWKF@K;6RIN.BQ0AXAN/]4A;.W1]JO!T2(\ 1\X<2YNN8 M O(;MJL*?XGI$,X+X1$NOI.V_,7PS8F">TW&0,6>I1D+*5+(268+;\06CH=8 MN L-3_PB:P#G#Y[%O13MT!K^FO6. =9EH(X&-U@ S .]Q?O''Q)D/(NZ-,J%C&1T&[ M9&-FA9. Z;T7H>[B+@@5,$QM(!/7-C)BI=7F0J7;;%X^_/']\N^?/Z@).B[J MDUP)"3.7$#-X0D5Q^6*P#3"L'C"PUJ"3SBL5EA1@60&?R"/X!)-@@I^)\Q>1 M8HE!I4?B)T)1ZA%WQ(W"GPERP3?I&V*1"X+F"9VG.-(M<3*1ELB=S_B[&68& MQ+XZX=1J'*7#Z4-LCIN1[_,;20=6P5V2X"2F*W36R(UG64V-GVS1/YD,"@2X M.1Y/EC\@&J&#;9O,!U?9M@2!8)]YT',4!Q!#- F;EUILOB\$^2I!@J M7T>.'(C81;8J*P+7SO M8GD/JPLL"G$0LW-F% M[R!_%WSU"ZU48TY:$NC0+A_;%A^UZ%BXI$QXVC[A:2 3GF3"DTQXD@E/,N%) M)CS5*B]()CPM)SP=26I3K.4EX2:T7>TGDALCPZ'9WW; /3^./26OKA\K^L\8 M)1O-8^N)1VL#&W^+6B_IC;$3)54=>8AJK@03&KFYH-A:;&Q$#D_IP=?XO%(B ML3IFL6F!WES;G% 2AS#,K#3\.K%A/9]L:K$BA7(H+F*3P]^8S1R;F^;IB3'N MZ C/<')(U)3M0.R&ARL-T_31KL?T$<#SH,Z&7/&UW_ \MATFJ19_1\-5B\"8 MQQD,)I6;$U\\)1Y]X=_3=][#*_^ -W[F+XR-T9+3X7M-[(+:;Q1,GHU'PR,0 M2NU??]']=R^NVGHC7]L?[W]Q"BZ(&G(DKKAQ;J)-C5_V-)HBNE/-(R_M2FQ=7K<$: )='D!4(ON(80V0^AI,X64H? $R-9B,_*F<]@F!(\4"X41$R=%X# M&09 ;:U&OM_E'LC07L$O#H4..J+#ZA,LH<,V[IHMJ^ '&ZK@ZUYGKC4K*C2_ M@8>>R(EUZP:A'\4EY__-+(Q!#7FBW(:RFRG8)-59 T[#%JFLX<*0\6,9_)':#WE]BU^BPA1-%W*>*6X87B."0 MY5$,#"-"-H\OQ6D^XB/2IF<.LVALD8-#W3'=/W: 9X"9 6&==>=BPO^$.63_ M,)R(BR^<[LDSALGS+8BHQJ=:&7*]\YX6D@M;%!=COP ?PBS6%F WEN^[-.8T M <0$\4 @,4+LB2 F/K4Q7S^ U4@=G C&PWWY0 ,33&@D38'9E))&%J1XOQ6/ MP*>#ZT'%RE)*8?T:8 M/0[\7NR0%@MXA;QC&R/;L4/0GJZ-8$*5[T%6_Z6C%=,#O6T&,I>YF>182M$T MX;>/F)XH$AL76BMD&BJ NF9F7[M\Q#J37#%R/DP27I34H11A85!QSO-JL9U!2J (5_Y&PS0QFQ:H540)"48(HLRJXHJR"+[H0$E0 M&J^:<+( 357%0\I2DP M N2+P!8G>G0!C=,S%6]#1&D-T14"/C3Y.)RXY(5WB%" _W+\A7M(H!@SQY1' MQ"ZI!2Y!^(>I76^$5^JMF#E-\ .FAF@IRA9-EB#GXATNT4YF!WM *K'_*0][ M&6Q)(\TLBE SF.2%!$QBLOB1SR9P/,XU\7S'F9I2EJ,5"=>*N5K\FF5YRM,4 MXL7'(O^>LBM'@6W9AF_'G*58!7AI[F)&TUB!I:P&4;QA).-J"!"8A%. 5)3: MPV=5F0Z M,L+%[ODZ J)1)GN-72L>U$*2"/!^K4 *G0H)H!!ZL+0%TFOK6. M/Y6@MR)A0+63([9$;9NXQ%'2D>L)A$Q@E_5 K55;L<*GG'NFTUSOGDGMZSNQ MK2'QO;)^&0W[/JI-K;/&5;>#=ZFSP=E8V?9;M/U.;ZUS+%P;:BCR.2[Z)A]X M%4=B&T^I(16N&W>/LHB[\3)LRHX4]5-M7KNFUUD77A5J=2]O4N;YW\1C:WR* ME4Z6..,LZ7.'#"J^MR591D6D:16"$2?= JU/C7_!W7Z,?-"WC.P/4(MXQJ(B MH5H.(ZP!!-N,T\T]+&3,L$+#XOZ6M(] 3I F?I9PXF-EHC("T4%B<>6B *%H M#*?C@38C<:GQC'Q[H>(YH-+9NV>U"]&>@.L&EN_<1_+14BDEBD7?E@E24I&$)F3U2=, MM\4[R*$<%0XID(X,-K+>Y]K)M>!-.=T#;.'K^%J\(5]08T5^4E 3L[?VQ14/ MG,Y!*\CY247]75:_LX/<;7'U#>0S0I-[$ %6. 8M$S!'AR-/_8=E5B)FL&"+ M8H8Q9I^[1!8"Y3:C?YQ_2J8%;9%H#G.@N5\%V+WXA^TN*(7)?K;&#%5DH/I3 MJNP3?4ZY\P,3TGG+R?&85-&Y0I5F]!.>:1WKJWGC:,%7F2B9PN;.TT."5D8@ MU%7N_\&,>KZEE691;K%E+TZBDV;5355HBW%SS+76+!%&;.;(3-GM,V5UF2DK M,V5EIJS,E)69LC)3ME8)I3)3=CE9H* U('QZ)/FSQ?XGO-NL#XI:C"S&.]E. MSJ<-&6^5>6\ZZ+UI]]J-_-R1?9Q/&W*T*MM^]^)*[W;69G&^N.N)"IKYFAJO M4.]NZWQZ]42'@+?H*,PSQ%C&D(Q:D2?66$Z*.A$6V =5N/J)K7'0&%;;JFEAK7!803!B^\PT]#0@/+P_>OMO+$WD\ M6GBST>WU*M?"-?BRM?JGZY9=_UVG>>:;;6N-_J!2^V;E'/BM3 .NJKW.D+,< MMR<:6&@O_+>1_]L5BKT2!M"I 82Z:+T*+%YO)F Q)#X(CG^/'%^Y-F8+%AA4>LKE6>^P-(HNC2>O!XK2 M@N_L$%YF;N'R 3M*R02+P>",D_PS:O9.B+QA>+M<8Q_4*^:.-'.S_^HHN!;A M/JT*X-JK\:T,&+:>H3NU+W5_AXN4;?S M\[138[Y_<=56>YI6T7#IHXH&'QJNB3?27'W#;AMVVI."?($BP9EW M/Q1.P@0!%O^G0A7Y5/64!"2M)B)Y M:-9Q2FNOJ/X_*?Y(>WI10?4^?H43"\<4G?"$/%3ZMEI:1I:65M7Z%U>Z M.ACDD^F/WHLE">-$":/;? G"&&"MKMKOG"!EG*E_=W.TLMV\N/I*WES'S6DN6T6CMDTJ.7*6IKT 2VMCWZ:^VN[M'=FL7P*& M3$HZ56'?>@G*:%U<=9KJH+FWL*\?99QH:M(V8OITO*HRM_X(USA'G;#JG+4S M4?^V#GCO(^3:%U>MKMJL+"Q71R$G<:F[=7!W'USJH-NPVZTJ@Z*.J'1:^M(F MST=W\R.]BZOATGA!F;$M,[;WYUA;UV(M<*P\4^I?7'7UU@G[:R6N=+>N4=J M*P/$E;TUH1KCRFGY]@]F[I]28O4JH&R?8B=Z%"WG*E[E\:=#OU6DQ:YV YY M>0)N?9MT\OB_\CN-2GCSF>8D++7BW;L[9R:R@>_!E]RZ29O.XBZ=^2:EBNDOZY,:V[^8=?EOYGM%=-F^N**RA-;[(Z;-$U!5CB_JN$)5\0J+ M7S8/,5?>�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